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Summary 
The beta 2 adrenergic receptor (β2AR) is a GPCR that is susceptible to multiple 
post-translational modifications (PTMs) including phosphorylation, ubiquitination, 
palmitoylation and glycosylation, which can alter how the β2AR orchestrates 
downstream intracellular signals. Following the discovery of SUMOylation of the 
cardiac signalling protein SERCA2a, we hypothesised that the β2AR, which is also 
involved in cardiac signalling, may be a substrate for SUMOylation. This notion was 
supported by previous findings that five different GPCRs have been identified as 
susceptible to SUMOylation, including metabotropic glutamate receptors (mGluR), 
a cannabinoid receptor, a serotonin receptor and a receptor involved in basal cell 
carcinoma known as smo.  
For the first time, we confirm the susceptibility of the β2AR to SUMOylation by 
identifying SUMO accepting lysines, interaction sites between the β2AR and the 
enzymes of the SUMOylation cascade, and the traditional “ghost” band, which is 
indicative of protein SUMOylation. SUMOylation has been shown to influence 
receptor signalling, and we now uncover a possible role for SUMOylation in β2AR 
signalling. I report that SUMOylation of the β2AR (mediated via overexpression of 
the E3 ligase PIASγ) reduces β2AR phosphorylation by PKA altering the receptor 
driven phospho-ERK response, inhibits β2AR ubiquitination and degradation, and 
delays β2AR internalisation. These changes could be associated with steric effects 
of the bulky SUMO modification and ubiquitin-SUMOylation competition for 
available surface associated lysines. 
With the importance of SUMOylation in multiple disease states (including 
cardiovascular disease, neurodegenerative disease and cancer), we worked in 
conjunction with the antibody production company Badrilla ® to produce a SUMO-
substrate specific antibody for a site within the third intracellular loop of the β2AR. 
The antibody we have produced is successful in recognising the SUMOylated form 
of the receptor in both cell and tissue lysate, making it the first antibody of its 
kind to be generated. In conjunction with the Hajjar group at Mount Sinai 
Cardiovascular Research Centre (New York, USA) we used the SUMO-β2AR specific 
antibody to assess the influence of the SUMO modification in two animal models 
of heart failure (HF); transverse aortic constriction (TAC) pressure overload HF 
model in mice and the left anterior descending (LAD) artery balloon occlusion 
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ischemic HF model in pigs. Prior work within the Hajjar group has revealed that 
SUMOylation of SERCA2a is reduced in HF, and restoring this modification to 
SERCA2a via SUMO-1 adeno-associated viral-mediated gene delivery is beneficial 
in restoring cardiac function. We hypothesised that SUMOylation of the β2AR would 
also be reduced in HF, however unexpectedly; the SUMOylated form of the β2AR 
was increased in the LAD artery balloon occlusion ischemic HF model in pigs.   
The role of the β2AR in HF is unclear. There are studies which both report a cardio-
protective and a cardio-toxic role of the receptor. To ascertain the role 
SUMOylation of the β2AR plays, in vivo studies promoting SUMOylation of the β2AR 
in the HF models described above will help to determine if enhanced SUMOylation 
of the receptor worsens the HF phenotype or prevents its development. 
To conclude, we present the first evidence that the β2AR can be modified by 
SUMOylation, which acts to influence the receptors downstream signalling, 
desensitisation and degradation. We have designed a first-in-class SUMO-β2AR 
antibody – which paves the way for a panel of SUMO specific antibodies – and 
utilised it to assess SUMOylation of the β2AR in model cellular systems and animal 
models of HF. Similarly, to SERCA2a, SUMOylation does influence β2AR in the HF 
phenotype, although not a decrease in SUMOylation as was expected, but an 
increase. Future work in animal models promoting SUMOylation of the receptor is 
vital to assess the role of this highly novel post-translational modification of the 
β2AR.   
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Chapter 1 Introduction 
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1.1 The Cardiovascular System  
The cardiovascular system - composed of the heart, veins and arteries – is 
responsible for providing the organs and tissues of the body with oxygenated 
blood. Following cardiac contraction, the heart expels blood into two vital 
circuits; the pulmonary and the systemic circuit (Campbell, et al., 2008).  
1.1.1 Pulmonary and Systemic Circulation  
The pulmonary circuit begins at the right ventricle with de-oxygenated blood 
being ejected into the pulmonary artery, where it passes to the lungs. Within the 
lungs, blood flows through the capillary beds, allowing gaseous exchange between 
the blood and the lungs – oxygen diffusing into the blood and carbon dioxide 
diffusing out of the blood. Oxygen-rich blood now returns to the left atrium via 
the pulmonary veins, where it will be sent to the systemic circuit. The systemic 
circuit begins with blood flowing from the left atrium into the left ventricle, where 
it is then ejected into the aorta. The aorta then branches off into smaller vessels 
providing blood supply to the heart itself, the upper body – head and arms - and 
the lower body - abdomen and lower limbs. Blood passes through the capillary 
beds of organs and tissues, allowing gaseous exchange. Within the systemic 
circuit, oxygen diffuses from the blood into organs and tissues, whereas carbon 
dioxide from metabolising organs and tissues diffuses into the blood. The oxygen-
poor blood now returns to the right side of the heart via the superior and inferior 
vena cava, draining into the right atrium. This blood can pass to the right ventricle 
– beginning the pulmonary circuit once again  (Campbell, et al., 2008).  
1.1.2 The Anatomy of the Heart 
The heart is composed of four chambers; two smaller chambers with relatively 
thin walls known as the atria, and two larger chambers with thicker walls known 
as the ventricles. In addition to the chambers, there are four valves present in the 
heart to prevent the back flow of blood; two atrioventricular valves which are 
located at the junction between the atria and the ventricle, and two semilunar 
valves, which are located at the junction between the ventricles and the arteries 
(Campbell, et al., 2008). 
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1.1.3 Cardiac Cycle  
The cardiac cycle is a rhythmic cycle of contraction (systole) and relaxation 
(diastole), with contraction pumping blood from the heart and relaxation allowing 
chambers to fill. During relaxation, blood returning to the heart from the vena 
cava passes easily from the atria to the ventricles, through the atrioventricular 
valves, allowing ventricular filling. During systole, the remaining blood within the 
atria is pumped into the ventricles, immediately followed by the ventricles 
pumping blood through the semilunar valves, into both the pulmonary and 
systemic circulation  (Campbell, et al., 2008).  
1.1.4 Cardiac Conduction System 
An organised rhythmic contraction of the heart requires adequate propagation of 
electrical impulses along the conduction pathway. To generate cardiac 
contraction, an electrical signal comes from the sinoatrial (SA) node – which is 
located in the wall of the right atrium – and travels through the heart via the 
electrical conduction system. Due to the location of the node, the signal first 
passes to the right atrium where it passes through the Bachman’s bundle to the 
left atrium. From the right atrium, the signal passes to a second node known as 
the atrioventricular (AV) node. From this node, the electrical signal passes through 
the bundle of His and down the bundle branches, the right bundle branch 
depolarising the right ventricle and the left bundle branch depolarising both the 
left ventricle and the interventricular septum  (Annderson, et al., 2009) (Renwick, 
et al., 1993). 
1.1.5 Excitation Contraction (EC) Coupling 
The sarcomere is the basic functional unit of the muscle within a myocyte. The 
contractile elements are firstly myosin, thick filaments with globular heads which 
have ATPase activity (enzymatic activity to catalyse the degradation of adenosine 
triphosphate (ATP) to adenosine diphosphate (ADP)), and secondly, actin, the thin 
filaments arranged as an alpha helix woven between myosin filaments. Regulatory 
elements include tropomyosin and troponin. Tropomyosin prevents the interaction 
between myosin globular heads and actin in the resting state. Troponin is a 
complex of three subunits (T, I and C) that sits along the actin filaments: troponin 
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T is responsible for mediating the interaction between troponin and the other 
contractile proteins tropomyosin and actin; troponin I is responsible for inhibiting 
the enzymatic capacity of myosin in the actin-myosin interaction; troponin C is 
the regulatory component which binds Ca2+ to allow regulation of contraction 
(Bers, 2002).  
When electrical impulses pass through the conduction pathway this leads to 
depolarisation of the cardiomyocyte membrane. Following depolarisation, the L-
type Ca2+ channels (LTCC) on the myocyte membrane open, allowing an initial 
influx of Ca2+ into the myocyte. This Ca2+ influx induces the opening of ryanodine 
receptors (RyRs) which are located on the surface of the sarcoplasmic reticulum 
(SR) – an intracellular Ca2+ store – allowing a much greater influx of Ca2+ into the 
cell interior. This is known as Ca2+-induced-Ca2+-release (Pathak, et al., 2005). The 
free Ca2+ is responsible for mediating cardiomyocyte contraction via the 
contractile proteins. The free Ca2+ binds to troponin C and induces a 
conformational change in troponin, such that troponin I exposes a site on actin 
that can now interact with the myosin ATPase of the myosin globular head. This 
interaction leads to ATP hydrolysis, which supplies the energy for the 
conformational change that occurs in the actin-myosin complex. This change 
promotes movement between the myosin globular heads and actin, such that the 
filaments slide past each other, shortening the length of the sarcomere. This leads 
to cardiomyocyte contraction (Ikonnikov & Yelle, 2016). Relaxation occurs when 
Ca2+ is released from troponin C, and the contractile proteins return to their 
resting state. Ca2+ is then either returned to the SR via the sarcoplasmic reticulum 
Ca2+ ATPase (SERCA2a) or expelled from the cell via membrane protein Na+/Ca2+ 
exchanger (NCX) (Figure 1.1) (Kawase & Hajjar, 2008). 
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Figure 1.1 Excitation contraction (EC) coupling. Ca2+ enters the cell via the 
LTCC. This Ca2+ is responsible for inducing a conformational change in the RyR to 
induce Ca2+ release from the SR. This Ca2+ interacts with the contractile proteins 
to mediate cellular contraction. Following contraction relaxation occurs and Ca2+ 
is removed from the contractile proteins and removed from the cell interior either 
via SERCA2a or the NCX exchanger  (Kawase & Hajjar, 2008). L-type Ca2+ channels 
(LTCC), ryanodine receptor (RyR), sarcoplasmic reticulum (SR), sarcoplasmic 
reticulum Ca2+ ATPase (SERCA2a), Na+/Ca2+ exchanger (NCX), Na+/K+ ATPase 
exchanger (ATPase), phospholamban (PLB).  
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1.2 Heart Failure (HF) 
1.2.1 Definition of HF 
Heart failure (HF) is often regarded as the inadequacy of cardiac output resulting 
in the metabolic needs of organs and tissues being unmet. This definition is mostly 
suited to describe patients who are admitted to hospital with salt and water 
retention or pulmonary oedema, but is less suited to patients suffering with 
chronic HF (Denolin, et al., 1983). When patients suffering from chronic HF are 
adequately treated they can have a normal resting cardiac output, as well as a 
normal left ventricular pressure, therefore their tissues’ metabolic needs are met. 
At rest, these patients are described asymptomatic, however they will experience 
symptoms during exercise leading to their exercise capabilities being limited 
(Denolin, et al., 1983). The animal models that are utilised in this thesis (Chapter 
5 - Analysis of β2AR SUMOylation in Animal Models of Heart Failure (HF)) were 
designed to resemble chronic HF; therefore, SUMOylation of the β2AR will be 
assessed in this disease state. 
1.2.2 Diagnosis and Classification of HF 
The characteristic symptoms of HF are not limited to this disease state. They 
include dyspnoea (shortness of breath), fatigue, oedema (water retention) in the 
legs/ankles/feet, irregular or fast heartbeat, and exercise limitation. The origin 
of these symptoms is not fully understood, but the severity of these symptoms 
correlates accurately with the extent of cardiac dysfunction (Cleland, et al., 2003) 
(Marantz, et al., 1988). The severity of symptoms allows HF patients to be 
classified on two specialised scales derived by two independent associations; the 
New York Heart Association (NYHA) and the American Heart Association (AHA). 
The NYHA scale originated in 1928 and was revised and widely accepted in 1964, 
categorising patients in groups I-IV (Table 1.1) (Marvin, 1964) (Miller-Davis, et al., 
2006). The AHA scale originated in 1995 and proposed an additional classification 
which would complement the NYHA classification, categorising patients in groups 
A-D (Table 1.2) (Hunt, et al., 2005)  (Williams, et al., 1995). 
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Table 1.1 NYHA HF classification scale  
 
Class Description 
I The patient suffers from cardiac disease but experiences no symptoms 
and no limitation to general physical activity.  
II The patient suffers from cardiac disease and experiences mild symptoms 
and slight limitation to general physical activity 
III The patient suffers from cardiac disease and experiences limitation in 
both minimal and general physical activity. The patient is only 
comfortable at rest.  
IV The patient suffers from cardiac disease and experiences severe 
physical activity limitation. The patient experiences symptoms even at 
rest and is mostly bedbound.  
(Marvin, 1964). 
 
 
Table 1.2 AHA HF classification scale  
 
Class Description 
A The patient displays no objective evidence of cardiovascular disease 
and experiences no symptoms or limitation to general physical activity 
B The patient displays objective evidence of cardiovascular disease and 
experiences mild symptoms and slight limitation to general physical 
activity. The patient is comfortable at rest.  
C The patient displays objective evidence of moderate cardiovascular 
disease and experiences marked limitation in minimal and general 
physical activity due to symptoms. The patient is only comfortable at 
rest. 
D The patient displays objective evidence of severe cardiovascular 
disease and experiences severe limitations in physical activity. The 
patient experiences symptoms even at rest.  
 (Williams, et al., 1995) 
 
 
1.2.3 The Cause of HF 
The classical causes of HF are the cardiovascular conditions which precede HF 
initiation. In Western countries, the most common cause of HF is coronary heart 
disease, which begins when plaque – a combination of fat, cholesterol and cellular 
waste products - builds up within the vasculature. When plaques become large 
enough, fragments can break off and these broken fragments are known as 
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thrombi. Thrombi can become lodged within the vasculature, and if this occurs in 
a coronary artery, it can lead to a myocardial infarction (MI) (Thygesen, et al., 
2007). A blockage within a coronary artery will inhibit the artery from supplying 
the blood flow to the heart, with the extent of the inhibition being dependent 
upon the size of the thrombus. If the thrombus is large enough, then a healthy 
ventricle can become severely dysfunctional almost instantaneously due to 
massive myocardial ischaemia and subsequent necrosis of the myocardial tissue. 
If the blockage is successfully removed the tissue will be re-perfused, but this in 
itself can promote problems, as although re-perfusion saves viable myocytes it 
also accelerates the necrosis of injured myocytes and permits infarct scar growth 
(Simonis, et al., 2012). Those who have an elevated chance of plaque formation, 
have an elevated risk of MI, and consequently an elevated risk of HF. This includes 
individuals who suffer from hypertension, high cholesterol levels, high triglyceride 
levels, obesity, diabetes and high blood sugar levels, as well as the more 
traditional factors of age, smoking and genetics (Macon, et al., 2015).  
Following an MI, the heart will attempt to function in the same manner as it did 
before the MI occurred, but with the scar tissue which was once viable 
myocardium inhibiting the function, the remaining myocardium must remodel to 
compensate for the loss of functional tissue. The left ventricle (LV) is the chamber 
which expels oxygenated blood to the body; hence, this chamber undergoes 
remodelling to maintain the cardiac output. Remodelling of the LV following an 
MI involves LV wall thinning at the infarct area, chamber dilation and 
compensatory hypertrophy via the lengthening of the non-infarcted areas. This 
remodelling will initially maintain the stroke volume – volume of blood pumped 
from the LV per heart beat – but over time these compensatory changes will 
become maladaptive, leading to increased wall stress and oxygen demand along 
with interstitial fibrosis, which results from elevated cardiac fibroblast 
proliferation and collagen synthesis in response to the growing myocardium (Diez, 
et al., 2007). With the build-up of collagen, the LV becomes stiffer, leading to 
decreased contractility which results in diastolic dysfunction (Cowie, et al., 2005)  
(Krayenbuehl, et al., 1989) (Heyman, et al., 2005) (Monrad, et al., 1988). This 
leads to the manifestation of HF symptoms where the heart is in a state of both 
LV systolic and diastolic dysfunction (Houser, et al., 2012) (Peske, 2004). 
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1.2.4 Prevalence and Prognosis of HF 
HF impacts on healthcare systems worldwide. In 2015 the British Heart Foundation 
(BHF) estimated that over half a million people in the UK (about 1% of the UK 
population) were affected by HF (BHF, 2015), with more than 23-26 million people 
worldwide suffering from the disease. Furthermore, HF prevalence is rising 
(Roger, 2013) (Ambrosy, et al., 2014). Even although HF can be managed by 
multiple approaches, the prognosis is poor with average life expectancy 
approximately 3 years post diagnosis (Dickstein, et al., 2008). For patients with 
severe HF, more than half will die within a year (Clevland, et al., 1999) (Stewart, 
et al., 2001).  
1.2.5 Management of HF 
Although there is no cure for HF, it can be managed by a number of multiple 
approaches ranging from lifestyle changes and pharmacological therapies to more 
extreme approaches such as implantable devices and cardiac surgery. These forms 
of management are summarised in Table 1.3.   
1.2.5.1 Life Style Changes  
Positive lifestyle changes concern diet and exercise. Patients suffering from HF 
are advised to participate in light exercise rather than heavy exercise. In 2012, a 
meta-analysis study identified that aerobic exercise training can reverse the LV 
remodelling that occurs in HF (Chen, et al., 2012). In relation to changes to diet, 
HF patients are often restricted to 2-3g of sodium per day. This dietary change is 
beneficial as HF causes patients to absorb an unnecessarily high level of sodium 
at the kidneys, and subsequently retain excessive water. This additional water 
retention will exacerbate the existing HF symptoms (Konerman & Hummel, 2014). 
1.2.5.2 Pharmacological Therapies 
Various pharmacological interventions are available for HF patients and the 
medications outlined here are by no means an exhaustive list (Table 1.3). 
Diuretics promote the loss of fluid from the vasculature through urine. This 
counteracts the excessive water retention in HF patients and relieves the 
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associated symptoms, such as oedema in the legs/ankles/feet  (Beckerman, 2016). 
Furthermore, if there is less volume within the vasculature then the pressure is 
lower. This leads to a lower LV afterload, i.e. the pressure the LV must develop 
to force blood out of the chamber – therefore lessening the stress on the LV walls  
(Houser, et al., 2012).  
The elevated water retention in HF patients is partly due to excessive activation 
of the renin-angiotensin-aldosterone system (RAAS). This is a system which 
regulates plasma sodium concentration and arterial blood pressure  (Selektor & 
Weber, 2008) (Schrier, 1990). When the volume of blood in the vasculature is low, 
the RAAS system is activated to promote reabsorption of sodium at the kidney, 
which leads to reabsorption of water. In patients with HF, the excessive activation 
of this system leads to heightened water reabsorption; therefore, medications 
which inhibit this system are beneficial. Angiotensin converting enzyme inhibitors 
(ACEi), angiotensin receptor blockers (ARBs) and aldosterone antagonists are all 
pharmacological interventions that inhibit the RAAS, and therefore reduce water 
reabsorption. As mentioned before for diuretics, less volume within the 
vasculature will lower the LV afterload. Both ACEi and ARBs can lower this further 
by promoting vessel dilation. This is another way of reducing the LV afterload, by 
reducing pressure in the vasculature (Dumitru, 2016). 
In a similar fashion to the RAAS, the sympathetic nervous system activation is 
markedly higher in HF patients. This is one of two branches of the autonomic 
nervous system – parasympathetic and sympathetic – that is responsible for the 
“fight or flight” response mediated by the catecholamines adrenaline and 
noradrenaline  (Selektor & Weber, 2008) (Schrier, 1990). The traditional response 
of the sympathetic nervous system begins with a stressful situation causing the 
hypothalamus in the brain to promote increased production of the catecholamines 
in the adrenal glands. Adrenaline and noradrenaline are released into the 
bloodstream where they travel in the blood to the adrenergic receptors (described 
further in section 1.3.1 – Adrenergic Receptors). Through these receptors 
catecholamines mediate their effects including increased heart rate and force, 
increased blood pressure, and an increased uptake/production of glucose to 
provide energy for metabolising muscles (Tank & Wong, 2015) (Chistiakov, 
Ashwell, Orekhov, & Bobryshev, 2015) (Thorp & Schlaich, 2015) (Konturek, 
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Konteruk, Pawlik, & Brzozowski, 2004). The symptoms of HF can be worsened by 
catecholamines and therefore it is beneficial to inhibit the body’s response to 
these hormones. This can be done by inhibiting beta adrenoceptors (βAR) – a type 
of adrenergic receptor – using beta-blocker drugs. These drugs act antagonistically 
at these receptors and were first synthesized in 1958 by James Black (Black, et 
al., 1964). Although the initial increase in sympathetic nervous system activity 
during HF is beneficial as it compensates for left ventricular dysfunction, chronic 
adrenergic stimulation causes myocardial damage due to left ventricular 
remodeling and cardiomyocyte necrosis. Attenuation of this adrenergic 
stimulation is associated with improvement in survival  (Manurung & Trisnohadi, 
2007). Furthermore, these drugs can slow the heart rate giving the LV more time 
to fill correctly in an attempt to maintain an appropriate stroke volume (Pai & 
Hetherington, 2015). 
A combination therapy of nitrate and the drug hydralazine can change vessel 
dilation and subsequently alter blood pressure. This method mediates both venous 
and arterial dilation, therefore reducing both cardiac preload – the degree of 
myocardial distension prior to contraction - and LV afterload. This reduction in 
pressure within the heart may reduce adverse cardiac remodelling by lowering 
cardiac wall stress  (Colucci, 2016). 
There are certain drugs which can also be administered in conjunction to the 
standard pharmacological therapies; two examples are digoxin and 
anticoagulants.  
Digoxin is a cardiac glycoside which inhibits the Na+ K+ ATPase pump on 
cardiomyocytes leading to elevated Na+ concentration within the cell. This rise 
impacts the Na+ Ca2+ exchanger pump causing Ca2+ to rise as the elevated Na+ is 
pumped out of the cell. The additional Ca2+ is now available to bind to troponin C 
mediating stronger contractions. In addition to this, digoxin can also promote 
parasympathetic nervous system activity. This system works in opposition to the 
sympathetic nervous system and, rather than increasing heart rate, the 
parasympathetic system acts to reduce heart rate (Campbell & MacDonald, 2003). 
Therefore, digoxin both increases the strength of the heart contraction, while 
lowering the heart rate, allowing additional filling time for the LV.  
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Anticoagulants are drugs which act to prevent the coagulation cascade. Activation 
of the coagulation cascade leads to the formation of blood clots, also known as 
thrombi when they form within the veins or arteries. As described above, a 
thrombus can be an initiating event which leads to MI and subsequent 
development of HF. In light of this, patients can be given anticoagulant drugs to 
reduce the risk of further thrombotic events  (Dumitru, 2016). 
1.2.5.3 Surgical Intervention 
Often pharmacological and lifestyle changes are not enough to counteract the 
symptoms of HF and surgical intervention is necessary (Table 1.3).  
HF is a dynamic process in which the myocardium is continuously adapting to try 
to maintain perfusion of the other organs and tissues in the body. The alterations 
to the myocardium can lead to discrepancies in the electrical conducting system 
of the heart. The SA node is the natural pacemaker of the heart. Cardiac 
contraction is initiated at this node and electrical signal passes through the 
remaining electrical conducting system (NIH, 2011). Any of these components can 
be damaged by HF. In these circumstances, electrophysiological intervention is 
available through the following implantable devices; pacemakers, cardiac 
resynchronisation therapy (CRT), implantable cardioverter defibrillators (ICDs), 
and a combination of both CRT and ICDs known as CRT-Ds (NHS, 2016). Pacemakers 
encourage the heart to beat at regular intervals if the origin of cardiac contraction 
is damaged by HF remodelling. CRT can be used to synchronise contractions 
between the right and left ventricle, as the remodelling process can result in 
deleterious alternate chamber contraction times. ICDs can be implanted as a pre-
emptive measure, if the failing heart enters a state of fatal arrhythmia - which is 
possible if the conducting system is damaged by remodelling - the ICD can be 
triggered to restore normal rhythm. A combination of both ICDs and CRT is known 
as CRT-Ds, a device which can both synchronise ventricular contraction and 
restore normal rhythm if arrhythmia arises (AHA, 2016).  
Surgical intervention can also be performed to restore the physical damage caused 
to the heart during the cardiac remodelling in HF. The development of HF can be 
initiated by a blockage in the arteries which supply the heart, and therefore 
revascularisation procedures can be used to restore the cardiac blood supply. 
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Coronary artery bypass graft (CABG) is an option if HF is initiated by coronary 
artery disease, in which a thrombus is lodged within a coronary artery and 
therefore the heart has a reduced blood supply and reduced function. Using 
arteries or veins taken from other parts of the body, the blood flow is re-routed 
around the blocked arteries, restoring cardiac perfusion. The valves of the heart 
can also be damaged by HF. These valves normally control the unidirectional flow 
of blood through the heart but in HF they can become leaky, as the muscles which 
normally tightly close them have become weakened. In other cases, the valves 
can become stiff and do not open properly. These valves can be replaced or 
repaired by prosthetic components to restore function  (AHA, 2016). A more novel 
technique is ventricular restoration, in which a plastic model is used to reshape 
the heart. During HF, the shape of the heart can be lost due to remodelling and 
this alters the LV volume, which will directly impact on stroke volume. Ventricular 
restoration helps return the heart to its original shape. (Castelvecchio, et al., 
2010) (BCBST, 2016). The final surgical intervention for end-stage HF is complete 
heart transplantation as the damaged heart is beyond repair by any other method.  
Table 1.3 Management of HF 
 
Lifestyle 
Changes 
Pharmacological  
Intervention 
Surgical  
Intervention 
Electrical  Non-Electrical 
Diet 
Exercise 
Diuretics 
RAAS Drugs 
Beta Blockers 
Hydazaline & Nitrate Therapy 
Digoxin 
Anticoagulants 
Pacemaker 
ICD 
CRT 
CRT-D 
CABG 
Valve 
Repair/Replacement 
Ventricular Restoration 
Heart Transplant  
 
1.2.6 The Importance of Novel Cardiovascular Research to 
HF 
With the prognosis of HF being poor, research has been aimed at discovering 
alternate methods to tackle HF in terms of both new diagnostics and treatments. 
Cardiac function is assessed at a molecular level in both healthy and diseased 
states to identify essential cardiac contractile and signalling proteins which are 
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defective in HF and therefore could be novel therapeutic targets (Gomez, et al., 
1997). One molecular mechanism which can compensate for loss of functionality 
during HF is modulation of protein activity via post-translational modification 
(PTM). Proteins can be modified in this manner at any point in their life cycle, 
ranging from directly after ribosomal translation, up until the protein relocates to 
a specific cellular compartment or tissue. This type of modulation can occur 
naturally to control heart rate, for example in the cardiomyocyte, beta 
adrenoceptor (βAR) activation by catecholamines promotes phosphorylation – a 
PTM in which a phosphate group is covalently linked to the target protein - of the 
L-type Ca2+ channel (LTCC), TNI and phospholamban (PLB). This causes increased 
Ca2+ entry into the cell via the LTCC allowing further Ca2+ release from the SR to 
promote contraction, desensitization of TNI to Ca2+ ions making the cell less 
susceptible to Ca2+-mediated contraction (Bodor, et al., 2001), and reduced 
inhibitory action of PLB on SERCA2a resulting in more Ca2+ being removed from 
the cell cytosol and further inhibiting cardiac contraction. These actions on TNI 
and PLB combine to improve cardiac relaxation, which can often be inhibited in 
HF (MacLannan & Kranias, 2003). Therefore, catecholamine levels are elevated in 
HF to promote βAR stimulation, promote protein phosphorylation, and promote 
optimum relaxation following an enhanced contraction (Figure 1.2) (Kaumann, et 
al., 1999).  
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Figure 1.2 βAR-mediated PTMs of LTCC, troponin I and phospholamban. 
Activation of βAR by ligand mediates phosphorylation of LTCC, TNI and PLB by 
PKA. This causes an increased Ca2+ entry into the cell via LTCC,  desensitization 
of TNI to Ca2+ ions and reduced inhibitory action of PLB on SERCA2a. βAR (beta 
adrenoceptor), RyR (ryanodine receptor), SR (sarcoplasmic reticulum), SERCA 
(sarcoplasmic reticulum Ca2+ ATPase), PLB (phospholamban), P (phosphate group) 
L (ligand), PKA (protein kinase A) LTCC (L-type Ca2+ channel).  
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1.3 The β2 Adrenergic Receptor (β2AR) 
1.3.1 Adrenergic Receptors 
Raymond Alquist believed that the cardiovascular effects of catecholamines - 
increased blood pressure and heart rate - were explained by two distinct sets of 
receptors, the α and β receptors (Wenger & Greenbaum, 1984). It is now accepted 
that there are three types of adrenergic receptor: α1, α2 and β. All adrenergic 
receptor subtypes are G protein-coupled receptors (GPCRs): the α1 family (α1A, 
α1B) couple to the Go protein to modulate phospholipase C; the α2 family (α2A, α2B, 
and α2C) couple to the Gi protein to inhibit adenylyl cyclase; and the β family (β1, 
β2, and β3) couple to the Gs protein to stimulate adenylyl cyclase. The receptors 
share similar features including a single polypeptide chain ranging from 400 to 
greater than 500 residues in length, amino- and carboxy-terminal regions, three 
extracellular and three intracellular loops, and seven transmembrane stretches. 
The carboxy-terminal differs between families to allow interaction with the 
respective G proteins - the α2 and β families have shorter C-termini than the α1 
family, which requires a longer sequence to interact with Go (Strosberg, 1993). 
The adrenergic receptors are located throughout the body however, they can be 
found abundantly in specific tissue types:  α1A in the arteries, α1B in the heart, α2 
family in the brain, β1 in the heart, β2 in the heart and the lungs, and β3 in fat 
tissue (Molinoff, 1984). The focus of this thesis is the β2 adrenergic receptor (β2AR) 
in the heart.  
In addition to both the β1AR and β2AR being located in the heart, they also share 
other similarities with approximately 54% structural homology: their N-terminals 
are susceptible to glycosylation; their C-terminals can be phosphorylated by two 
kinases, namely PKA and GRK; and a disulphide bond between their second and 
third extracellular loop  is essential for receptor activity. These properties will be 
discussed further for the β2AR, the focus of this thesis (Coman, et al., 2009).  
1.3.2 Crystal Structure of the β2AR 
The gene for the human β2AR, ADRB2 is located on the long arm of chromosome 
5q31 and codes for a gene of approximately 1200 base pairs. This gene codes for 
the β2AR which is composed of 413 amino acid residues totalling approximately 
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46500 Daltons in weight (Kobilka, et al., 1987).  The receptor belongs to a family 
known as G protein-coupled receptors (GPCRs), which consist of seven 
transmembrane spanning alpha helices, with three extracellular loops, and three 
intracellular loops, with one being the amino-terminus and carboxy-terminus, 
respectively (Qing, et al., 1997) (Figure 1.3).  
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Figure 1.3 Schematic diagram of the β2AR. β2AR consists of seven 
transmembrane spanning alpha helices, with three extracellular loops, and three 
intracellular loops, with one being the amino-terminus and carboxy-terminus, 
respectively. Image from   (Rasmussen, et al., 2007). The differing amino acid 
colouring represents a key for the crystallography studies described by Rasmussen 
et al (2007) but as this diagram is being used here to illustrate general modular 
structure the specifics are not required in this instance. TM (transmembrane 
domain). Amino acid abbreviations in appendix.  
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The amino acid sequence of a protein is not enough to relate shape to definitive 
function – for this, high-resolution crystal structures are vital. The three-
dimensional (3D) structure allows visualisation of the spatial characteristics of 
each individual amino acid, and therefore can be used to predict sites of protein-
protein interactions, in addition to assessing ligand binding pockets for 
pharmacological intervention. In the GPCR field, rhodopsin – a light sensitive 
receptor found within the retina - was the first receptor to be crystallised 
(Palczewski, et al., 2000). The elucidation of the crystal structure of rhodopsin 
made it feasible to predict the structures of other similar GPCRs, such as the β2AR, 
by using the rhodopsin coordinates as a template. It is prudent to note that 
although the template is useful to predict related GPCR structures, it is difficult 
to assess the changes of predicted structures such as the β2AR when bound to its 
agonist, as rhodopsin covalently binds it’s ligand 11-cis-retinal (Cherevoz, et al., 
2007) (Rasmussen, et al., 2007) (Rosenbaum, et al., 2007) and this is markedly 
different to the ligand binding mode of the β2AR.  
The crystal structure of the β2AR revealed that the receptor is composed of seven 
transmembrane helices, in addition to two additional helical segments. One of 
these segments is known as helix 8 and exists in other rhodopsin-like GPCRs 
(Katragadda, et al., 2004), whereas the other is a shorter helix – not present in 
the rhodopsin template - which is found in the middle of the second extracellular 
loop. Helix 8 has been shown to interact with transmembrane domain 1 to play a 
role in β2AR homodimer formation and in the delivery of functional β2AR 
complexes to the plasma membrane (Parmar, et al., 2016). The shorter helix has 
been shown to work in conjunction with a pair of disulphide bridges to promote 
ligand binding (Warne, et al., 2008). The crystal structure also revealed that the 
N-terminus (residues 1-28), the majority of the C-terminus (residues 343-365), and 
a stretch of 26 amino acids in the third intracellular loop are disordered 
(Cherevoz, et al., 2007) (Rasmussen, et al., 2011). It is thought that disordered 
areas must be unfolded to perform their functions, or they only fold when the 
β2AR interacts with other proteins or become post-translationally modified 
(Gunasekaran, et al., 2003) (Wright & Dyson, 2015).  
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1.3.2.1 β2AR Ligand Binding Pocket   
The ligand binding site on the receptor is a narrow and deep cleft, located 
approximately one third of the way into the hydrophobic core of the β2AR. At this 
site, interactions between the amino acid residues on the β2AR and functional 
groups on the ligand promote ligand binding. These interactions were assessed 
using the ligand isoprenaline - the agonist used within this thesis to stimulate the 
β2AR - but other ligands will interact with the β2AR slightly differently dependent 
upon their molecular structure  (Bang & Choi, 2015). There are specific residues 
which are important for ligand binding including aspartate residue 113 in domain 
III; serine residues 203 and 207 in domain V and asparagine residue 293 in domain 
VI (Liggett, 2002) (Strader, et al., 1988) (Strader, et al., 1989) (Wieland, et al., 
1996) (Figure 1.4). Aspartate 113 forms an ion pair with the amino nitrogen on the 
ligand (Strader, et al., 1988); serines 203 and 207 interact with the hydroxyl 
groups on the phenyl ring of the ligand (Strader, et al., 1989); the asparagine 293 
binds to the β-hydroxy group in the ligand  (Wieland, et al., 1996). Following 
agonist binding, the receptor undergoes a conformational change. Initially 
transmembrane domain (TM) 5 moves inwards, resulting in TM6 to move outwards. 
This outwards swing is the largest change in receptor confirmation. The movement 
by TM6 mediates an outward movement of TM5, and an inward movement of both 
TM3 and TM7 to accommodate the β2AR-Gs protein interaction (Rasmussen, et al., 
2011) (Rasmussen, et al., 2011) (Bang & Choi, 2015).  
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Figure 1.4 β2AR Ligand Binding Pocket. Residues which are important for ligand 
binding (highlighted by yellow star) include aspartate 113 (domain III), serines 203 
and 207 (domain V) and asparagine 293 (domain VI). Aspartate 113 forms an ion 
pair with the amino nitrogen on the ligand, serines 203 and 207 interact with the 
hydroxyl groups on the phenyl ring of the ligand, and asparagine 293 binds to the 
β-hydroxy group in the ligand. Protein model shown as grey backbone, flexible 
backbone shown as green, extracellular portion shown as red, rigid side chains are 
grey sticks with grey carbon atom ball, flexible side chains are green sticks with 
green carbon atom ball, predicted ligand positioning in yellow with yellow carbon 
atom ball, hydrogen bonds between ligand and receptor represented by chain of 
cyan balls, intracellular hydrogen bonds imperative in formation of binding site 
represented by chain of green balls, hydrogen acceptors are blue sticks with blue 
ball. Amino acid abbreviations in appendix (Katritch, et al., 2009).  
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1.3.3 G Protein-Coupled Receptor (GPCR) Signal 
Transduction 
The β2AR is a GPCR and following activation by agonist, GPCRs mediate signal 
transduction via G proteins. These proteins are part of the GTPase super family of 
enzymes which have intrinsic ability to hydrolyse the guanyl nucleotide guanine 
diphosphate (GDP) to guanine triphosphate (GTP). The G proteins can be divided 
into four subfamilies; Gs, Gi/o, Gq/11 and G12/13 (Table 1.4). G proteins have three 
subunits; α, β, γ which are each encoded by a separate gene selected from 16 Gα, 
6 Gβ and 12 Gγ genes, respectively (Downes & Gautam, 1999). The Gα subunit is 
receptor specific, with the C-terminus of the subunit containing the receptor 
recognition domain. This Gα subunit can switch between an inactive and active 
conformation to mediate the signal transduction of GPCRs (Tesmer, et al., 1997). 
The β2AR mediates signal transduction via the Gs protein, with the capability to 
switch to the Gi protein (Daaka, et al., 1997). 
Table 1.4 G protein families  
 
Family Members Function 
Gs Gs and Golf Activate adenylyl cyclase (AC) 
Gi/o Gi1, Gi2, Gi3, Go1, Go2, 
Gz, Gt1, Gt2, and Ggust 
Inhibit adenylyl cyclase (AC) 
Gq/11 Gq, G11, G14, and 
G15/16 
Activate phospholipase C 
G12/13 G12 and G13 Activate Rho guanine nucleotide exchange 
factors, Na+ - H+ exchanges and 
phospholipase-ε  
 (Riobi & Manning, 2005).  
1.3.3.1 G Protein Cycling 
When the GPCR is inactive, it is coupled to the inactive GDP-bound Gα subunit of 
the G protein. In this state, it has a high affinity for agonist. Upon agonist binding, 
the GPCR undergoes a conformational change which causes the Gα subunit to 
exchange GDP for GTP. This guanyl nucleotide change from GDP to GTP reduces 
the affinity of the receptor for the agonist, therefore increasing the probability of 
agonist dissociation. This results in a limitation in G protein activation. Another 
action mediated by the switch from GDP to GTP is the Gα subunit dissociating from 
the Gβ and Gγ subunits.  These subunits - Gβ and Gγ - remain associated with the 
plasma membrane via prenylation at the Gγ subunit. Gα subunit and Gβ Gγ subunit 
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complex are capable of activating effectors to generate an intracellular second 
messenger and a physiological response. To return the system to the resting state, 
the intrinsic GTPase activity of the G protein is activated by a GTPase activating 
protein (GAPs). GAPs can be part of the signal transduction pathway which has 
been activated by initial agonist binding to the GPCR. The intrinsic GTPase activity 
means the G protein mediates the hydrolysis of the γ phosphate of GTP into GDP 
and an inorganic phosphate. The system is now reset with Gβ Gγ subunit complex 
binding to the Gα subunit-GDP to allow for further agonist activation (Figure 1.5)  
(Billington & Penn, 2003) (Hamm, 1998) (Tuteja, 2009).  
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Figure 1.5 G protein cycling. Upon agonist binding to GPCR it undergoes a 
conformational change and the Gα subunit switches GDP for GTP. The Gα subunit 
now dissociates from Gβ Gγ subunit complex. Gβ Gγ complex remains associated 
with the plasma membrane via prenylation at the Gγ subunit. The free subunits 
can activate effectors to mediate intracellular effects. The system returns to its 
original state when the intrinsic GTPase activity of the G protein is activated by 
GAPs resulting in the hydrolysis of the γ phosphate of GTP into GDP and an 
inorganic phosphate. GPCR (G protein-coupled receptor), GTP (guanosine 
triphosphate), GDP (guanosine diphosphate), E1/2 (effector 1/2), GAPs (GTPase 
activating protein), Pi (inorganic phosphate) (Tuteja, 2009).   
 
Figure 3.
GAPs
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1.3.4 β2AR Signalling  
1.3.4.1 Agonist-Mediated β2AR Activation 
Upon agonist binding, the β2AR mediates activation of adenylyl cyclase (AC) via 
the stimulatory G protein (Gs) (Figure 1.6). The ratio β2AR : Gs : AC is 
approximately 1 : 100 : 3 therefore receptor activation of Gs is considered the 
most critical event for signal amplification (Alousi, et al., 1991) (Ostrom, et al., 
2000).  
The majority of AC isoforms are membrane bound, however a soluble isoform also 
exists. The AC enzyme contains two cytosolic catalytic and two integral membrane 
domains, with each domain containing six transmembrane alpha helices (Tang & 
Gilman, 1992) (Tesmer, et al., 1997). The cytosolic catalytic domains possess 
specific binding sites for G protein subunits and when the Gα subunit of the Gs 
protein stimulates the catalytic domains, this initiates the conversion of ATP to 
cyclic adenosine monophosphate (cAMP) - the intracellular second messenger 
which can go on to activate multiple targets, one of which is protein kinase A 
(PKA) (Figure 1.6). This occurs within milliseconds/seconds of receptor stimulation 
(Hein, et al., 2006)  (Violin, et al., 2008).  
PKA is a cAMP-dependent kinase that can phosphorylate a large number of proteins 
- on serine or threonine residues - leading to tailored physiological responses. PKA 
is a cytosolic protein therefore, it must be localised to the vicinity of the β2AR. 
Spatial compartmentation of the β2AR and PKA is achieved by PKA anchoring to 
scaffold proteins known as A-kinase anchoring proteins (AKAPs) (Chen & Malbon, 
2009) (Fan, et al., 2001). AKAPs bind to the regulatory subunits of PKA and limit 
the pool of PKA to the vicinity of the β2AR (Wang, et al., 2006). PKA activation is 
the most common mechanism by which the β2AR signals, but it can also mediate 
effects via Gi proteins, which oppose Gs and acts to inhibit AC (Figure 1.6) (Daaka, 
et al., 1997). This occurs because the β2AR itself is a target for PKA 
phosphorylation. The consensus sequences for PKA-mediated phosphorylation fall 
within the C-terminus of intracellular loop 3 (serines 261 and 262) and in the 
proximal cytoplasmic tail (serines 345 and 346), but the former is the preferred 
substrate (Bouvier, et al., 1989). Direct phosphorylation of the β2AR by PKA results 
in reduced coupling between the β2AR and Gs, switching it to Gi, with a mutant 
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β2AR lacking these phospho-sites incapable of signalling via Gi (Hausdorff, et al., 
1989) (Strulovici, et al., 1984) (Daaka, et al., 1997). In the active state the Gα-
GTP subunit of Gi dissociates from the Gβ Gγ subunit complex and these free Gβ Gγ 
subunits mediate activation of the mitogen-activated protein kinase (MAPK) 
signalling pathways, such as extracellular signal regulated kinase (ERK) (Figure 
1.6).  
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Figure 1.6 Agonist-mediated β2AR activation. Upon agonist binding (1) the β2AR 
activates AC via the Gs protein (2). AC initiates the conversion of ATP to cAMP (3). 
cAMP is the intracellular second messenger which can go on to activate multiple 
targets, one of which is PKA. The β2AR is a target for PKA (4). This PTM of the β2AR 
results in reduced coupling between the β2AR and Gs, and switches it to Gi (5). In 
the active state, the Gα-GTP subunit of Gi dissociates from the Gβ Gγ subunits. Gα 
mediates inhibition of AC (6&7) and the free Gβ Gγ subunits mediate activation of 
the MAPK signalling pathway such as ERK (7). β2AR (beta 2 adrenergic receptor), 
Adr (adrenaline), GDP (guanosine diphosphate), GTP (guanosine triphosphate), AC 
(adenylyl cyclase), PKA (protein kinase A), cAMP (cyclic adenosine 
monophosphate), P (phosphate), ERK MAPK (extracellular signal regulated kinase 
mitogen-activated protein kinase).  
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1.3.5 β2AR Signalling Regulation 
Receptor signalling is subject to regulatory mechanisms to prevent constant 
signalling in response to continuous agonist exposure. Cells mediate this by 
regulating the expression, localisation and activity of all signalling molecules 
involved. Common mechanisms directly related to the receptor include 
desensitisation, resensitisation and down-regulation.  
1.3.5.1 β2AR Desensitisation  
Desensitisation acts as a safety device to prevent the over stimulation of receptors 
by excessive agonist stimulation. The extent of desensitisation depends upon the 
degree and duration of the β2AR agonist response. There are two types of 
desensitisation; homologous and heterologous. Homologous desensitisation occurs 
via direct agonist stimulation of the β2AR, whereas heterologous desensitisation 
occurs when the receptor becomes desensitised even without agonist occupancy 
(Litalien & Beaulieu, 2011).  
For homologous desensitisation, the β2AR is agonist-occupied leading to the 
following: phosphorylation of the receptor by both G protein receptor kinases 
(GRK) family members and PKA; β-arrestin recruitment, and uncoupling of 
receptors from the Gs protein. As mentioned above, PKA can phosphorylate the 
receptor leading to a switch from Gs to Gi signalling (Figure 1.6). This occurs within 
seconds of agonist binding (Yuan, et al., 1994). This acts as a method of 
desensitisation as regardless of agonist occupancy, the receptor will not allow 
further cAMP production via the Gs pathway. Additionally, as the Gs pathway 
stimulates AC, the Gi pathway inhibits AC; therefore the combination of both AC 
inhibition and functional uncoupling from Gs will inhibit the β2AR-mediated cAMP 
signal (Daaka, et al., 1997).  
The β2AR can be phosphorylated by GRKs and, similarly to PKA phosphorylation of 
the receptor, this also occurs within seconds of agonist binding (Figure 1.7). The 
first of these kinases was discovered during the studies comparing the β2AR with 
the rhodopsin receptor, and was initially named βARK (Benovic, et al., 1987). 
After this, other GRKs were identified and βARK was renamed GRK2. GRK isoforms 
are capable of phosphorylating the β2AR at multiple residues within the C-terminus 
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of the receptor including serines 355, 356, 364 and threonine 360  (Vaughan, et 
al., 2006) (Nobles, et al., 2011). This phosphorylation initiates the recruitment of 
the scaffold protein β-arrestin1/2 to the membrane (Krasel, et al., 2005) (Figure 
1.6). A scaffold protein often acts to bring other proteins into close proximity 
allowing specific protein-protein interactions to occur. Although PKA 
phosphorylation of the β2AR reduces coupling between the receptor and Gs – it 
does not promote β-arrestin binding or internalisation, unlike GRK phosphorylation 
(Billington & Penn, 2003). Another difference between PKA and GRK-mediated 
phosphorylation is that PKA-mediated phosphorylation does not require agonist 
occupancy, whereas GRK-mediated phosphorylation is agonist-dependent (Nobles, 
et al., 2011).  
The scaffold protein β-arrestin binding to the receptor sterically uncouples the 
β2AR from the Gα subunit of Gs protein therefore preventing further cAMP 
production via the agonist-dependent Gs pathway. This occurs within a minute 
following agonist treatment (Violin, et al., 2008) (Oakley, et al., 2000). Krasel et 
al (2005) identified that both subtypes of β-arrestins (1 and 2) are capable of 
binding to the β2AR but studies in knockout mice have identified that β-arrestin 2 
has a higher affinity for the receptor than β-arrestin 1 (Kohout, et al., 2001). The 
affinity of β-arrestin for the receptor is dependent upon two factors; agonist 
occupancy and phosphorylation (Violin, et al., 2006). Phosphorylation of serines 
355, 356 and 364 – which are susceptible to GRK agonist-mediated phosphorylation 
- in the cytoplasmic tail of the β2AR are crucial for β-arrestin-β2AR interaction 
(Vaughan, et al., 2006). β-arrestin also plays an additional role in β2AR 
desensitisation by acting as a protein scaffold to either mediate arrestin-biased 
signalling pathways, or to inhibit the existent Gs signal.  
In addition to sterically uncoupling the β2AR from the Gα subunit of Gs protein, 
another desensitising function of β-arrestin is that it recruits phosphodiesterase 4 
(PDE4) to activated receptors (Perry, et al., 2002) (Figure 1.7). This enzyme acts 
to hydrolyse locally generated cAMP to 5’-AMP. Hence, the recruitment of 
arrestin-PDE4 complex dually desensitises by concomitantly uncoupling Gs 
signalling and promoting degradation of the second messenger cAMP. Multiple 
isoforms of cAMP PDEs have been identified (Rabe, et al., 1993) and are known to 
degrade cAMP to 5’-AMP. The expression of specific isoforms of cAMP PDEs is 
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induced by an increase in intracellular cAMP, which is initiated by β2AR activation 
and serves as a means of termination of signal, by reducing cAMP and therefore 
reducing PKA activity.  
Furthermore, in addition to inhibiting Gs signalling, β-arrestin can initiate 
alternate signalling cascades by selectively scaffolding signalling cascade 
components including small GTP binding proteins and members of the MAPK 
cascade (Lefkowitz, et al., 2006) (Lefkowitz & Shenoy, 2005). This was first 
observed for the non-receptor tyrosine kinase Src. Following agonist stimulation 
of the β2AR, arrestin mediates the formation of a complex which consists of 
arrestin, β2AR and Src. This complex has been shown to be essential in β2AR-
mediated ERK1/2 activation (Luttrell, et al., 1999). 
Heterologous desensitisation occurs when the receptor becomes desensitised 
without agonist occupancy. This can occur via other GPCRs signalling pathways 
stimulating proteins that are involved in the β2AR signalling pathway. For example, 
other GPCRs which mediate their effects via Gs, such as the histamine H2 receptor, 
can go on to mediate phosphorylation of the β2AR via cAMP elevation and 
subsequent increase in PKA activity (Johnson, 1998) (Hill, et al., 1997). This type 
of modulation means the β2AR can be influenced by steroid hormones, 
inflammatory mediators and other agents (Pelaia & Marsico, 1994). 
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Figure 1.7. β2AR desensitisation. β2AR is susceptible to phosphorylation by both 
GRK and PKA. Phosphorylation functionally uncouples the receptor from Gs (1). 
GRK sites of phosphorylation have been shown to be vital for β-arrestin-β2AR 
interaction (2).  β-arrestin brings phosphodiesterase 4 (PDE4) into the receptors 
environment to metabolise locally generated cAMP and terminate the effects of 
receptor signalling via the Gs protein (3).  β-arrestin can mediate biased signalling 
(4). Adr (adrenaline), PKA (protein kinase A), P (phosphate), GRK2 (G protein-
coupled receptor kinase), PDE4 (phosphodiesterase 4).  
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1.3.5.2 β2AR Internalisation  
When the β2AR is either phosphorylated by PKA or interacting with β-arrestin 
following GRK phosphorylation, the receptor is functionally uncoupled from Gs. 
The next step is for the cell to physically remove the β2AR from the cell surface. 
This is termed internalisation and occurs within approximately three minutes of 
receptor agonist stimulation (Morrison, et al., 1996). When the receptor is 
internalised, it is moved away from the cell surface and localised within 
endosomal compartments, which are formed from endocytosis of plasma 
membrane fragments that contain the embedded β2AR (Kallal, et al., 1998) (Figure 
1.8). When β-arrestin translocates to the receptor in response to agonist 
stimulation and subsequent GRK phosphorylation, it not only co-localises with the 
β2AR, but also with clathrin - the major structural component of the coated pits 
formed during membrane endocytosis (Goodman, et al., 1996) (Figure 1.8). The 
arrestin-receptor complex then interacts with the adaptor protein 2 (AP-2) of 
clathrin, initiating the formation of the clathrin coated endosome (Laporte, et al., 
2000) in which the receptor is contained. The interaction between β-arrestin and 
the β2AR is a prerequisite for the receptor internalisation, as internalisation was 
prevented in β-arrestin knockout mouse embryonic fibroblast cells (Kohout, et al., 
2001). An additional requirement for internalisation is β-arrestin ubiquitination – 
a PTM in which a small ubiquitin protein is covalently attached to a lysine on the 
target protein (Shenoy, et al., 2001) (Figure 1.8). Ubiquitination of arrestin is 
encouraged by the scaffold forming a complex with mouse double minute 2 
homolog (MDM2) – an ubiquitin E3 ligase (Ferguson, et al., 1996) (Wang, et al., 
2003). The ubiquitin E3 ligase is the final enzyme in the ubiquitination pathway 
which underpins the specificity of ubiquitin ligation to a specific lysine residue on 
the target protein. Although the MDM2-β-arrestin interaction occurs prior to 
membrane co-localisation with the β2AR, it is thought the arrestin only becomes 
ubiquitinated when it interacts with the β2AR, as this changes arrestin 
conformation exposing the susceptible lysine residues (Shenoy, et al., 2008).  
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Figure 1.8 β2AR internalisation. β2AR is phosphorylated by PKA/GRK (1) and 
interacts with β-arrestin to functionally uncouple the receptor from Gs (2). β-
arrestin is associated with scaffold proteins such as E3 ligase MDM2 and clathrin. 
β-arrestin ubiquitination occurs when the interaction between β2AR-β-arrestin 
changes the confirmation of β-arrestin making it susceptible to ubiquitination (2). 
β-arrestin also interacts with clathrin, initiating the formation of the clathrin 
coated endosome in which the receptor is contained (3&4). β2AR (beta 2 
adrenergic receptor), Adr (adrenaline), PKA (protein kinase A), P (phosphate), 
GRK2 (G protein-coupled receptor kinase), MDM2 (mouse double minute 2 
homolog), U (ubiquitin). 
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1.3.5.3 β2AR Resensitisation  
Internalisation of the receptor is vital for preventing excessive receptor response 
via Gs (Freedman & Lefkowitz, 1996) in the presence of prolonged agonist 
exposure, but this is not its only purpose. Within the endosomal compartments 
the receptor can be dephosphorylated by the phosphatase 2A enzyme, and 
recycled back to the plasma membrane where the receptor appears in a 
resensitised state capable of signalling once again in response to agonist (Pipping, 
et al., 1995) (Barak, et al., 1997) (Krueger, et al., 1997) (Figure 1.9). 
Internalisation is therefore vital for resensitisation as otherwise phosphatase 2A 
would not have access to the receptor. An additional protein which is important 
to this process is N-ethylmaleimide-sensitive factor (NSF) (Figure 1.9). This is an 
enzyme which is involved in membrane fusion processes (Furst, et al., 2003). The 
β2AR has been shown to interact with NSF, and this interaction is vital for recycling 
of the receptor to the cell surface (Cong, et al., 2001). This resensitisation is a 
rapid process with receptors being rapidly recycled to the surface within 
approximately 8 minutes of being internalised (Pipping, et al., 1995) (Zhang, et 
al., 1997) (Morrison, et al., 1996) (Hertel & Staehelin, 1983).  
A novel role for internalisation is now known; namely endosomal signalling. 
Traditionally GPCRs signalling via Gs produced cAMP via activation of AC at the cell 
membrane, however it is now known that Gs-GPCRs can also initiate cAMP 
generation from within the endosomal compartments. This has been studied for 
the thyroid stimulating hormone (TSH) receptor in which a complex of Gs, AC and 
the receptor itself was internalised allowing continuation of cAMP production. 
Additionally, the signals generated by cAMP produced at the endosome differed 
from those generated by cAMP at the cell membrane (Calebiro, et al., 2009). A 
similar situation has been observed for the GPCR parathyroid hormone receptor 
(PTHR), in which alternate agonists mediate either signalling from the endosomal 
compartment or at the membrane surface. This can explain how different 
agonists, with a common receptor, can mediate distinct cellular outcomes  
(Ferrandon, et al., 2009). There is now evidence for endosomal signalling by the 
β2AR. Irranejad et al (2013) revealed that in HEK293 cells isoprenaline promoted 
cAMP production at the plasma membrane via the β2AR as expected, but also in 
the early endosome. Furthermore, inhibition of endocytosis led to a reduction in 
cAMP production mediated via the β2AR (Irannejad, et al., 2013). This group 
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propose that β2AR-Gs coupling occurs in the early endosome, promoting a discrete 
phase of cAMP production (Irannejad & Von Zastrow, 2014). 
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Figure 1.9 β2AR resensitisation. Within endosomal compartments the β2AR can 
be dephosphorylated by PP2A and recycled back to the plasma membrane where 
it appears in a resensitised state capable to respond to agonist again. The β2AR 
has been show to interact with NSF for recycling of the β2AR to the cell surface. 
PP2A (phosphatase 2A), β2AR (beta 2 adrenergic receptor), NSF (N-
ethylmaleimide-sensitive factor), U (ubiquitin), MDM2 (mouse double minute 2 
homolog). 
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1.3.5.4 β2AR Down-Regulation 
Although internalisation of the β2AR is necessary for recycling of the receptor back 
to the plasma membrane, this is not the only fate for internalised β2AR.  These 
receptors can be degraded leading to a permanent reduction in receptor density, 
thus diminishing β2AR responsiveness to subsequent exposure of ligand (Moore, et 
al., 1999) (Futter, et al., 1996). The two common methods of protein degradation 
are via lysosomal or proteasomal degradation. Lysosomes are membrane-enclosed 
organelles that contain an array of digestive enzymes including several proteases. 
These act to degrade all kinds of biomolecules including proteins, carbohydrates, 
nucleic acids, lipids and cellular debris (Cooper, 2000). In contrast, proteasomes 
are cylindrical protein complexes that only degrade proteins which have been 
marked for degradation by the PTM ubiquitination (Naujokat & Hoffman, 2002). 
In the presence of a proteasomal inhibitor (MG132), ubiquitinated proteins 
accumulate, indicative of a lack of protein degradation at the proteasome. Shenoy 
et al (2001) identified that in the presence of MG132, the degradation of the β2AR-
mediated by isoprenaline was inhibited. However, even without proteasomal 
inhibition, the ubiquitinated form of the β2AR was identified, suggesting that the 
ubiquitinated β2AR was not an immediate target for proteasomal proteases 
(Shenoy, et al., 2001). Although 26S proteasomes often degrade ubiquitinated 
substrates, it has recently become clear that they also play roles in targeting 
ubiquitinated membrane proteins to lysosomes (Yu & Malek, 2000). In support of 
this, Moore et al (1999) showed that the internalised β2AR can be targeted to 
lysosomes via transport by the endosomal compartments. Ubiquitination of the 
receptor still plays a role in mediating degradation at lysosomes as a β2AR mutant 
which lacked lysine residues could be internalised but was not degraded. The 
enzyme MDM2 which mediates β-arrestin ubiquitination can also mediate receptor 
ubiquitination. However, ubiquitination of the receptor and subsequent 
degradation can occur in the absence of MDM2. This implied that the receptor 
could be ubiquitinated by an alternative E3 ligase, namely neural precursor cell 
expressed developmentally down-regulated protein 4 (NEDD4) (Shenoy, et al., 
2008). Shenoy et al (2008) identified that β-arrestin2 recruits NEDD4 to the 
receptor-β-arrestin complex within the endosome, dependent upon specific 
conformational changes in β-arrestin2 when held by the activated β2AR. The 
Shenoy group hypothesised that NEDD4 displaces MDM2 (Figure 1.10). Thus β-
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arrestin binds at least two E3 ubiquitin ligases; MDM2 which mediates β-arrestin 
ubiquitination and regulates the initial step of receptor endocytosis, and NEDD4 
which mediates receptor ubiquitination, within the endosome, that targets 
receptors to lysosomal compartments. The process of down-regulation occurs 
after approximately 6 hours of agonist stimulation (Moore, et al., 1999).  
Following down-regulation of the β2AR, transcription at the gene level and post-
translational conversion of mRNA (molecules which direct ribosomal production of 
the protein) to protein is now required to restore the membrane complement of 
β2AR. In addition to prolonged agonist stimulation mediating down-regulation of 
the β2AR receptor protein from the membrane surface, a decrease in the 
expression of β2AR mRNA levels has also been reported in several cell lines, 
therefore inhibiting the synthesis of further receptors during periods of high 
agonist exposure (Bouvier, et al., 1989) (Hadcock, et al., 1989). However, even 
with reduced synthesis, the existent β2ARs have a half-life of up to approximately 
30 hours (Mahan & Insel, 1986) (Fraser & Venter, 1980) therefore receptor 
degradation is imperative during high levels of agonist exposure.  
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Figure 1.10 β2AR down-regulation. For down-regulation β-arrestin2 recruits 
NEDD4 to the receptor-β-arrestin complex within the endosome. NEDD4 displaces 
MDM2 and acts to ubiquitinate the receptor within the endosome. This targets 
receptors to lysosomal compartments for down-regulation. β2AR (beta 2 
adrenergic receptor), U (ubiquitin), NEDD4 (neural precursor cell expressed 
developmentally down regulated protein 4).  
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1.3.6 β2AR Dimerisation 
The capability of β2AR to form dimers (a complex of two proteins) and oligomers 
(complex of three proteins or more) is uncertain. Conflicting reports both support 
(Calebiro, et al., 2013) (Angers, et al., 2000) (Mercier, et al., 2002) and refute 
(Kawano, et al., 2013) (Felce, et al., 2014) this notion.  The uncertainty is 
believed to come from the methods used to study interactions between integral 
membrane proteins, as biochemical methods are not appropriate to assess 
interactions between transmembrane proteins. For this reason, biophysical 
methods that can be applied to receptors in living cells have been utilised such 
as BRET (see Chapter 2 – General Materials and Methods). The following 
discusses dimer relationships that have been reported to occur (Lan, et al., 
2015). 
1.3.6.1 Homodimerisation 
Homodimerisation occurs when two identical receptors form a complex. It has 
been identified that the β2AR forms a homodimer in HEK293 cells and agonists can 
interact with the homodimers at the cell surface (Angres, et al., 2000). It is 
believed these homodimers are formed during endoplasmic reticulum processing 
or trafficking to cell surfaces (Salahpour, et al., 2004). It has been reported that 
prevention of homodimerisation results in reduced β2AR signalling, suggesting that 
dimer formation is important for normal function (Hebert, et al., 1996).   
1.3.6.2 Heterodimerisation 
Heterodimerisation occurs when two distinct receptor types form a complex. The 
β2AR has been shown to form heterodimers with both the β1AR and α1A adrenergic 
receptor (α1A AR) (Mercier, et al., 2002) (Lavoie, et al., 2002) (Uberti, et al., 
2005). These dimers mediate different receptor characteristics. The formation of 
the α1AAR-β2AR dimer promotes cell surface expression of the α1AAR, whereas 
formation of the β1AR-β2AR dimer inhibits β2AR internalisation. This reduction in 
internalisation results in the β2AR behaving in a manner characteristic of the β1AR. 
In addition, the β1AR-β2AR dimer inhibits the β2AR from activating the Gi pathway 
(Lavoie, et al., 2002).  A third dimer has also been identified to exist between the 
β2AR and the prostanoid EP1 receptor (McGraw, et al., 2006). Formation of this 
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dimer allows the EP1 receptor to influence β2AR signalling – activation of EP1 
receptor results in a loss of isoproterenol-mediated relaxation in murine airway 
smooth muscle cells. It is believed this effect is steric, and influences the β2AR 
coupling to Gs. Activation of the prostanoid EP1 receptor had no direct 
physiological action itself, thus it was suggested that the EP1 receptor only 
functions in conjunction with the β2AR to form a signalling unit in airway smooth 
muscle cells (McGraw, et al., 2006). 
1.3.7 β2AR Gene Polymorphisms 
The β2AR gene is polymorphic which means it can exhibit multiple genetic 
variants. Initially 9 polymorphisms were identified (Reihause, et al., 1993), but it 
has now been discovered that 49 polymorphisms exist (Hawkins, et al., 2006). Only 
4 single nucleotide polymorphisms in the coding region of the receptor - at codons 
16, 27, 34 and 164 - result in amino acid changes and therefore may influence 
function. Several mechanisms by which polymorphisms of the β2AR might influence 
the function of the receptor were proposed. Polymorphisms at codon 34 may 
influence receptor expression at the translational level (McGraw, et al., 1998). A 
rare polymorphism at amino acid position 164 (Thr to Ile) influences the ability of 
the receptor to bind agonist and couple to G protein (Green, et al., 1993). N 
terminal polymorphisms at amino acid positions 16 and 27 are thought to affect 
receptor down-regulation (Green, et al., 1995) (Green, et al., 1994).  
1.3.8 Post-Translational Modifications (PTMs) of the β2AR 
PTMs play an important role in the function of the β2AR such as phosphorylation 
initiating the switch from Gs to Gi, as well as β-arrestin binding, and ubiquitination 
being vital for receptor down-regulation. However, there are other PTMs which 
are also of importance.  
1.3.8.1 Glycosylation of the β2AR 
The β2AR has been shown to undergo both N- and O- linked glycosylation, a PTM 
in which a carbohydrate group is attached to a hydroxyl or another functional 
group on a protein (Rands, et al., 1990) (Benya, et al., 2000) (Sadeghi & 
Birnbaumer, 1999). There are three sites on the human β2AR which are susceptible 
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to glycosylation; asparagines 6, 15 (found within the N-terminus) and 187 (found 
within extracellular loop 2) (Rands, et al., 1990)  (Li, et al., 2017) (Mialet-Perez, 
et al., 2004). In 1990, Rands et al identified that mutagenesis of sites 6 and 15 
resulted in impaired β2AR membrane insertion, while Mialet-Perez et al (2004) 
identified that lack of glycosylation at site 187 results in receptors which do not 
down regulate due to the lack of lysosomal sorting. This is in conflict with reports 
from Li et al (2017) who found that N-glycosylation of the β2AR does not affect 
membrane insertion. The Li group report that deletion of sites 6 and 15 resulted 
in decreased cAMP accumulation, β-arrestin2 recruitment, receptor 
internalisation and receptor dimer formation. They did not find any impact of site 
187 deletion on receptor expression, G protein-dependent signalling, β-arrestin 
recruitment, receptor internalisation or receptor dimerisation (Li, et al., 2017). 
Further work is needed to confirm the role of β2AR glycosylation.  
1.3.8.2 Palmitoylation of the β2AR 
The β2AR has been shown to undergo palmitoylation at cysteine 341 (Ovchinnikov, 
et al., 1988). This is a PTM in which fatty acids such as palmitic acid are attached 
to cysteine residues. If this cysteine is mutated to a serine it results in a reduced 
ability of the β2AR to stimulate AC in an agonist-dependent manner – suggesting 
palmitoylation at this site may be required for adequate Gs-β2AR coupling. This 
mutated form of the receptor also has an impaired ability to form a high affinity 
state for agonist – characteristic of an uncoupled form of the receptor (De Lean, 
et al., 1980) (O'Dowd, et al., 1988). Palmitoylation at this site has also been shown 
to influence phosphorylation and desensitisation of the β2AR (Moffett, et al., 
2001). Moffett et al (2001) propose that agonist stimulation of the β2AR mediates 
depalmitoylation of cysteine 341 which releases the cytoplasmic tail of the β2AR 
from the plasma membrane. Serines 345 and 346 are now exposed for 
phosphorylation by PKA which initiates phosphorylation of the downstream serines 
by GRK2.  
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1.4 SUMOylation 
SUMOylation is a PTM in which a small SUMO (small ubiquitin-like modifier) protein 
is covalently linked to a lysine residue on the substrate protein. Much like other 
PTMs, this SUMO modification can act to regulate protein-protein interactions, 
intracellular localisation or directly change the activity of the target protein  
(Gareau & Lima, 2010). 
1.4.1 The SUMO Paralogues 
The SUMO protein family was discovered approximately 15 years ago with 
mammalian cells expressing three main isoforms; SUMO-1, SUMO-2 and SUMO-3. 
SUMO-2 and SUMO-3 share 97% similarity, only differing at 3 residues in the N-
terminus, and therefore are often termed SUMO-2/3 as biological applications 
such as antibodies cannot distinguish between them (Varadaraj, et al., 2014). In 
contrast, the SUMO-1 isoform shares only 50% sequence identity with the SUMO-
2/3 isoform  (Hay, 2013). The presence of a SUMO-4 isoform has been identified 
but the mRNA for this molecule is only found within the kidneys, dendritic cells 
and macrophages, whereas SUMO-1 and SUMO-2/3 exist universally in all human 
tissue (Varadaraj, et al., 2014) (Bohren, et al., 2004). 
There are important differences between the SUMO paralogues, including isoform 
preference, abundance, subcellular localisation and chain formation.  Certain 
target proteins display preference for a specific SUMO isoform, whereas other 
proteins will form covalent linkage with any SUMO isoform (Vertegaal, et al., 
2006). However, since SUMO-2/3 is more abundant in cells than SUMO-1, it is 
probable the majority of protein SUMOylation is mediated via SUMO-2/3  (Saitoh 
& Hinchey, 2000). The SUMO isoforms can also show different subcellular 
localisation patterns. Compartmentalisation of proteins can define which isoform 
will be available for SUMOylation, for example SUMO-1 has been shown to uniquely 
localise to the nucleoli, nuclear envelope and cytoplasmic foci, and therefore 
would be the dominant paralogue mediating substrate SUMOylation within these 
locations. Additionally, compartmentalisation of the SUMO paralogues has been 
shown to be influenced by cell cycle – with SUMO-1 and SUMO-2/3 co-localising 
with chromosomes at different points of the cycle  (Ayaydin & Dasso, 2004) 
(Zhang, et al., 2008). SUMOylation mimics ubiquitination in two ways; firstly, the 
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conjugation of both SUMO and ubiquitin occurs on a lysine residue, and secondly 
much like poly-ubiquitination, in which a target protein is ubiquitinated by 
multiple ubiquitin molecules, poly-SUMOylation can also occur. This can either 
involve multiple individual lysines within a protein being conjugated to one SUMO 
protein, or individual lysines being SUMOylated by a chain of SUMO proteins. Chain 
formation is only possible for the SUMO-2/3 paralogue as both isoforms 2 and 3 
contain a single conserved acceptor lysine at position 11 which allows linkage to 
a second SUMO protein  (Bylebyl, et al., 2003) (Tatham, et al., 2001) (Ulrich, 
2008). As SUMO-1 does not have this lysine residue it cannot act as a link in a SUMO 
chain, however it may act as a chain terminator at the end of a series of SUMO-
2/3 proteins  (Matic, et al., 2008). It is possible, that in a similar manner to poly-
ubiquitination, the differing chain lengths in poly-SUMOylation may alter the fate 
of the protein  (Wang & Dasso, 2009).  
1.4.2 The SUMOylation Cascade 
SUMOylation of proteins occurs via an enzymatic cascade which terminates with 
the covalent linkage of SUMO to a target protein via an isopeptide bond (Figure 
1.11).  
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Figure 1.11 The SUMOylation pathway. The immature SUMO is processed into 
the mature form by SENPs, which cleave the SUMO carboxyl-terminus to reveal a 
Gly-Gly motif, which is essential for all subsequent steps of the SUMO cycle (1). 
Mature SUMO is activated by SAE1–SAE2 heterodimer (2). Activated SUMO is 
transferred to the catalytic cysteine of UBC9 (3). UBC9 catalyses the conjugation 
of SUMO to lysine residues in target proteins, either independently or in 
conjunction with a SUMO E3 ligase (4). SENPs can cleave SUMO from target 
substrates, thus releasing an unmodified target and free SUMO, which can re-enter 
the SUMOylation cycle (5). S (SUMO), SENPs (sentrin specific proteases), SAE1-
SAE2 (SUMO-1 activating enzyme subunits 1 and 2), UBC9 (ubiquitin carrier protein 
9), E3 (SUMO E3 ligase). Amino acid abbreviations in appendix. 
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1.4.2.1 SUMO Specific Proteases 
The SUMO cascade begins with SUMO proteins which are translated as immature 
precursors being converted to the mature form. The proteases responsible for this 
are known as SENPs (sentrin specific proteases) and they act to expose a C-
terminal glycine-glycine on the SUMO isoform that is essential for the formation 
of the isopeptide bond between the acceptor lysine on the substrate and SUMO. 
Furthermore, the conversion to the mature form means the SUMO protein can 
interact with the next enzyme of the cascade; the E1 SUMO activating enzyme  
(Hannoun, et al., 2010).  
1.4.2.2 The SUMO E1 Activating Enzyme 
The E1 SUMO activating enzyme is a complex formed by a heterodimer of SUMO-1 
activating enzyme subunits 1 and 2 (SAE1 and SAE2). This complex is responsible 
for promoting the adenylation of the SUMO protein. This is the process by which 
an AMP molecule is added to the side chain on the SUMO protein in an ATP-
dependent manner. This results in the formation of a thioester conjugate between 
the E1 SUMO activating enzyme and SUMO, in which the thiol group at cysteine 
173 on the E1 SUMO activating enzyme, conjugates to the C-terminus of the SUMO 
protein (Desterro, et al., 1999). In this complex, adenylated SUMO can be 
transferred to ubiquitin carrier 9 (UBC9), the SUMO E2 conjugating enzyme.  
1.4.2.3 UBC9 
UBC9 is the only E2 conjugating enzyme that exists for SUMOylation and is highly 
related to the E2 conjugating enzymes of the ubiquitin pathway (Johnson & Blobel, 
1997) (Hayashi, et al., 2002) (Jones, et al., 2002) (Desterro, et al., 1997). A second 
thioester conjugate is now formed between SUMO and UBC9, which is capable of 
interacting directly with certain SUMO target proteins to transfer SUMO to the 
substrate protein’s acceptor lysine residue via an isopeptide bond. However, in 
many cases UBC9-mediated transfer is not capable of promoting substrate 
SUMOylation. This can be due to a lack of interaction between the target protein 
and UBC9. In these cases, a further step is required which is mediated by E3 ligases 
which act as a bridge to bring UBC9 and SUMO substrate proteins together (Henley, 
et al., 2014).  
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1.4.2.4 E3 Ligases 
SUMO E3 ligases facilitate the conjugation of most substrates to SUMO under 
physiological conditions (Meulmeester, et al., 2008). These E3 ligases can act via 
two mechanisms. One mechanism is via recruiting the E2-SUMO thioester and the 
SUMO target protein into a complex to promote interaction, whereas the second 
mechanism involves stimulating the ability of UBC9 to discharge the SUMO protein 
(Gareau & Lima, 2010). SUMO E3 ligases which have been identified include SP-
RING type, IR E3 ligases and a number of other proteins which have potential E3 
SUMO ligase activity. These four other potential E3 ligases include: histone 
deacetylase 4 (HDAC4), an enzyme which is involved in removing acetyl groups 
from histones (Haberland, et al., 2009); proprotein convertase 2 (Pc2), an enzyme 
which converts immature proteins of neuroendocrine peptides to the mature form 
(Seidah & Prat, 2012);  KRAB associated protein 1 (KPA1), a scaffold protein 
involved in chromatin remodelling (Chang, et al., 2009); and topoisomerase I- 
binding arginine/serine-rich protein (topors), a E3 ligase of the ubiquitin system 
(Hartz, 2005). In this thesis, the focus will be on the E3 ligase PIASγ and therefore 
the HDAC4, Pc2, KPA1 and topors will not be further discussed. 
The first type of E3 ligase is the SP-RING type ligases. These are named for 
containing a Siz/PIAS (SP)-RING (really interesting new gene) finger-like domain. 
Siz proteins are found within yeast whereas PIAS proteins are found within 
mammals.  The RING domain is characteristic of the E3 ligase enzymes of the 
ubiquitin pathway, that function by binding a pair of zinc atoms in a distinctive 
cross arrangement involving cysteine and histidine residues. The SP-RING type of 
the SUMO pathway E3 ligases is believed to function in the same manner as those 
of the ubiquitin pathway; however, it lacks two of the cysteines which are 
conserved in the classic RING domain (Hochstrasser, 2001).  
In mammalian cells, there are five members of the PIAS (protein inhibitor 
activated STAT) family of E3 ligases; PIAS1, PIASxα, PIASxβ, PIAS3 and PIASγ. 
These proteins display a high similarity in amino acid sequence (Shuai & Liu, 2005). 
Originally these PIAS proteins were identified to be involved in transcription 
regulation as they are inhibitors of STAT (signal transduce and activator of 
transcription) proteins, but later they were found to function as SUMO E3 ligases 
(Nishida & Yasuda, 2002) (Rogers, et al., 2003) (Kotaja, et al., 2002). The PIAS 
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proteins have shown SUMO substrate preference. Gocke et al (2005) reported that 
PIAS1 and PIASxβ can facilitate SUMOylation of a broader range of substrates than 
PIASγ (Gocke, et al., 2005). Additionally, the PIAS proteins also display isoform 
preference. PIASγ prefers to facilitate the modification of LEF1 (lymphoid 
enhancer factor 1) and GATA-2 by SUMO-2, not SUMO-1, even though the proteins 
can be modified by both isoforms (Sachdev, et al., 2001) (Chun, et al., 2003). 
Facilitation of SUMOylation by the PIAS proteins requires three domains to recruit 
UBC9-SUMO thioester and the substrate into a complex; the C-terminal domain 
which interacts with the SUMO protein; the SP-RING domain which interacts with 
UBC9; and an area within the N-terminal known as the PINIT domain that interacts 
with the substrate (Duval, et al., 2003) (Yunus & Lima, 2009) (Hochstrasser, 2001).  
The second type of E3 ligase is the IR E3 ligase. To date the only ligase of this type 
identified is the RAN binding protein 2 (RanBP2), a member of the nucleoporin 
family which form the nuclear pore. This ligase contains two internal repeater (IR) 
domains, named IR1 and IR2, and both are required for SUMO E3 ligase activity 
(Gareau, et al., 2012). RanBP2 binds to the UBC9-SUMO thioester, altering the 
thioester conformation to promote the discharge of SUMO (Reverter & Lima, 
2005). 
1.4.2.5 The SUMO Deconjugation System 
Much like other PTMs SUMOylation can be reversed – a process termed 
deSUMOylation. This results in an unmodified substrate protein and a free SUMO 
protein which can be utilised for further protein SUMOylation. As SUMO is linked 
to the substrate via an isopeptide bond, enzymes with isopeptidase activity are 
essential to this process (Wang & Dasso, 2009) (Doerks, et al., 2002) (Seeler & 
Dejean, 2003). In mammals, there are 9 enzymes capable of mediating 
deconjugation of SUMO; 6 types of sentrin specific proteases (SENPs) (SENPS 1, 2, 
3, 5, 6, and 7), 2 types of deSUMOylation isopeptidases (DESI1 and DESI2), and 
ubiquitin specific protease-like 1 (USPL1) (Henley, et al., 2014) (Hickey, et al., 
2012). In a similar fashion to the SUMO paralogues, the SENP members can be 
distinct in their subcellular localisation as well as with which SUMO isoform they 
would prefer to deconjugate from the target protein  (Gareau & Lima, 2010). For 
example SENP1 has been shown to be mostly present in the nucleoplasm (Gong, 
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et al., 2000) (Mukhopadhyay, et al., 2006) (Shen, et al., 2009), as well as showing 
slight preference for deconjugating SUMO-1  (Shen, et al., 2006). 
1.4.3 The SUMO Consensus Motif 
Unlike ubiquitination where any surface associated lysine can be modified, the 
acceptor lysine of the SUMOylation motif is found within a consensus motif γKxE/D 
(where γ is a large hydrophobic residue often consisting of 3-4 aliphatic (straight 
chains of carbon atoms) residues, K is the lysine SUMO acceptor, x is any residue, 
and D/E an acidic residue) (Hay, 2005)  (Rodriguez, et al., 2001) (Bernier-Villamor, 
et al., 2002). These residues directly interact with UBC9 and thus play a crucial 
role in regulating the stability of interactions between the enzyme and the target 
protein  (Sampson, et al., 2001). The acceptor lysine within the motif slots into a 
hydrophobic groove on UBC9, while electrostatic interactions and hydrogen 
bonding occur between the residues surrounding the lysine and UBC9  (Lin, et al., 
2002) (Bernier-Villamor, et al., 2002). The consensus motif is believed to play a 
role in the preference of proteins to certain SUMO isoforms. It is believed this 
could be down to the arrangement of hydrophobic and acidic residues. For 
example, protein conjugation to SUMO-1 and not with SUMO-2 can be attributed 
to the clusters of negatively charged amino acids at the C-terminus to the 
hydrophobic core (Kerscher, 2007).  
1.4.3.1 Additional Elements of the SUMO Consensus Motif 
In addition to this canonical consensus motif, longer sequences that include both 
SUMO consensus motifs and additional elements have been identified in certain 
SUMO substrates. These include phosphorylation-dependent SUMO motifs (PDSMs), 
negatively charged amino acid-dependent SUMO motifs (NDSMs), hydrophobic 
cluster-dependent SUMO motifs (HCSMs) and inverted SUMO motifs.  
For PDSMs, substrates have a phosphorylation site adjacent to the SUMO site which 
can influence substrate susceptibility to SUMOylation. This was first identified in 
heat shock factors, in which stress-induced phosphorylation, resulted in increased 
levels of SUMO modification  (Hietakangas, et al., 2003). In contrast, 
phosphorylation can also negatively regulate SUMO modification. For example, 
phosphorylation of ELK1 (transcription factor which regulates early gene 
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expression) results in a reduction in ELK1 SUMO modification (Yang, et al., 2003). 
NDSMs occur where negatively charged amino acid residues are located 
immediately downstream of the SUMO consensus motif (Yang, et al., 2006). ELK1 
SUMOylation is also subject to control by NDSMs, since mutation of the negatively 
charged residues C-terminal to the consensus sequence inhibited the SUMOylation 
of the protein (Yang, et al., 2006). Both NDSM and PDSM SUMO consensus motifs 
are believed to mediate their effects by interacting with lysine residues on UBC9 
(Mohideen, et al., 2009) (Yang, et al., 2006). In HCSMs, the hydrophobic cluster 
N-terminal to the SUMO consensus motif acts to enhance SUMOylation via 
promotion of interactions with UBC9. This has been demonstrated for RanGAP1 
(GTPase activator) and ZBTB1 (transcriptional repressor) (Matic, et al., 2010). For 
inverted motifs, the consensus motif is reversed (Impens, et al., 2014). 
1.4.3.2 SUMO Interacting Motifs (SIMs) 
On SUMO substrates, SUMO interacting motifs (SIMs) are important in mediating 
non-covalent interactions with SUMO (Kerscher, 2007). SIMs contain a short stretch 
of hydrophobic amino acids which are flanked by acidic residues. When the target 
interacts with SUMO, the SIM adopts a conformation that promotes this interaction 
using a hydrophobic pocket on the SUMO surface  (Reverter & Lima, 2005) (Song, 
et al., 2005). SIMs can be found in a wide variety of proteins including those of 
the SUMO pathway such as the PIAS family members  (Kerscher, 2007) (Perry, et 
al., 2008). Three SIMs have been identified in the PIASγ C terminus and are 
required for full E3 ligase activity of the enzyme (Kaur, et al., 2017).  
1.4.3.3 Alternative Lysine Modifications 
The PTMs SUMOylation and ubiquitination both occur on lysine residues and this 
can sometimes be observed on the same lysine residue of a substrate. IĸBα – a 
protein involved in DNA transcription - can be modified by ubiquitin and SUMO on 
the same lysine residue (Desterro, et al., 1998). In this case, SUMO modification 
was shown to inhibit phosphorylation-induced ubiquitination and subsequent 
proteasomal degradation of the protein  (Desterro, et al., 1998). This has also 
been identified for other proteins: MDM2 (an E3 ubiquitin ligase) is stabilised by 
SUMOylation at lysine 446 but ubiquitination at this same lysine mediates 
degradation (Meek & Knippschild, 2003); NEMO (an inhibitor of nuclear factor 
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kappa B) accumulates in the nucleus when SUMOylated at lysines 277 and 309, 
whereas ubiquitination at these sites mediates translocation to the cytoplasm 
(Huang, et al., 2003); axin (a signalling component of the Wnt pathway) and RNA 
helicases p68 and p72 (involved in RNA metabolism) have increased stability when 
they are SUMOylated due to the inhibition of ubiquitination (Kim, et al., 2008) 
(Mooney, et al., 2010). 
1.4.4 Variation in the SUMO System 
The SUMO system can vary dependent on the expression levels or activities of 
enzymes within the pathways, as well as in response to altered intercellular 
environment. For example, there is an overall increase in SUMO conjugation in 
response to heat shock and both high levels of oxidative stress and ethanol stress  
(Saitoh & Hinchey, 2000) (Zhou, et al., 2004).  
1.4.5 The Role of SUMOylation 
SUMOylation was initially identified as having a role in nuclear biology. SUMO was 
shown to mediate subcellular targetting including nucleocytoplasmic trafficking 
(Pichler & Melchior, 2002) and orientating substrates to mitotic spindles and 
kinetochores in dividing cells (Joseph, et al., 2002). SUMO has also been shown to 
play a role in the regulation of transcription factor activity by trafficking the 
modified factor to the appropriate subcellular compartment, and directly 
influencing transcriptional activity (Seeler & Dejean, 2003). Further biological 
roles for SUMO include DNA repair and replication regulation (Hoege, et al., 2002), 
and regulation of chromosome dynamics (Apionishev, et al., 2001) (Bachant, et 
al., 2002). There is a large and growing number of SUMO substrates, and this 
demonstrates a previously unexpected diversity of physiological processes 
affected by this modification (Hay, 2013) (Hay, 2005). 
A role for SUMO in the gastrointestinal (GI) tract is supported by the discovery that 
a UBC9 knockout in the GI tract of adult mice leads to disruption of the intestinal 
stem cells causing death within six days (Demarque, et al., 2011). SUMOylation 
has also been implicated in cancer as increased levels of SUMO-E1 activating 
enzyme, UBC9 and SUMO isopeptidases correlate with tumour development, 
tumour grade and metastasis (Bettermann, et al., 2012) (Bawa-Khalfe & Yeh, 
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2010). SUMO has also been shown to play a role in cardiovascular disease with 
SUMO-1 levels being reduced in HF, and SUMO-1 overexpression markedly 
improving cardiac function (Kho, et al., 2011). Neurodegenerative diseases such 
as Huntington’s Disease and Alzheimer’s Disease (Henley, et al., 2014) 
(Subramaniam, et al., 2009) (Dorval & Fraser, 2006) can also be influenced by 
SUMOylation, as SUMO can modulate synapse formation, spine morphogenesis, 
neurotransmission and synaptic plasticity. Some infections have also been shown 
to impact the SUMO system, for example Listeria monocytogenes - a pathogen 
responsible for the human food-borne disease listeriosis - affects the stability of 
the SUMO E1 activating enzyme and UBC9, therefore altering the SUMO pathway 
(Ribet, et al., 2010). 
1.4.6 SUMOylation of GPCRs 
To date there are only 5 GPCRs which are identified as substrates for SUMOylation; 
these include metabotropic glutamate receptors (mGluR), a cannabinoid receptor, 
a serotonin receptor and a receptor involved in basal cell carcinoma known as 
smo. mGluR8b was identified to have affinity with PIAS1 and PIAS3 in vitro, with 
PIAS1 enhancing the SUMOylation of the receptor in HEK293 cells with no function 
defined as of yet (Tang, et al., 2005) (Dutting, et al., 2011). mGluR7 is conjugated 
to SUMO-2 in vitro, with deSUMOylation shown to promote receptor internalisation 
(Wilkinson & Henley, 2011) (Choi, et al., 2015). For the cannabinoid receptor 1 
(CB1) (Gowran, et al., 2009) and the 5-HT1A serotonin receptor (Li & Muma, 2013) 
SUMOylation influenced receptor trafficking. For the most recently discovered 
GPCR shown to be susceptible to SUMOylation, smo, SUMOylation was shown to 
stabilise the protein preventing degradation (Zhang, et al., 2017).  
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1.5 SUMOylation of SR Ca2+ ATPase 2a (SERCA2a) 
1.5.1 SERCA2a 
SERCA2a is a protein pump which is found on the surface of the SR within cardiac 
myocytes that plays a vital role in cardiac contraction. Cardiac contraction is 
triggered via a depolarisation event which leads to the opening of the LTCC 
allowing Ca2+ to enter the cell and stimulate the RyR on the surface of the SR. 
Activation of the RyR leads to a release of Ca2+ from the SR into the cytosol  (Bers, 
2002), which initiates cardiac contraction via binding to troponin C. 
Cardiomyocyte contraction cannot continue indefinitely, and must be terminated 
–  this is pertinent to the role of SERCA2a. SERCA2a removes Ca2+ transporting it 
back to the SR to lower cytosolic Ca2+ levels, and therefore terminate contraction 
(Shannon & Bers, 2004). 
SERCA2a exists in two structural states dependent upon the protein’s affinity for 
Ca2+; E1 and E2 (Figure 1.12). In the E1 state the Ca2+ binding sites have high Ca2+ 
affinity and are open to the cytoplasm, whereas in the E2 state the binding affinity 
for Ca2+ is lower, with the sites facing in towards the SR lumen  (Toyoshima & 
Mizutani, 2004) (Toyoshima, et al., 2000). In the E1 confirmation, two cytosolic 
Ca2+ bind to the separate high affinity sites within the transmembrane domain, 
followed by ATP binding to the cytosolic domain. When ATP is hydrolysed to ADP, 
this leads to the phosphorylation of Asp351 residue of SERCA2a  (Toyoshima & 
Mizutani, 2004). As this occurs, the pump changes confirmation from E1 to E2 
resulting in the Ca2+ being transported across the membrane and released into the 
lumen of the SR. As the Ca2+ ions are deposited in the SR, there is partial exchange 
of protons at these residues. This leads to a favourable environment for 
dephosphorylation of SERCA2a. This deactivates the lumenal Ca2+ binding sites and 
reactivates the cytosolic Ca2+ binding sites, while shifting the confirmation of the 
protein back to E1 (Olesen, et al., 2004). 
 
73 
 
 
Figure 1.12 SERCA2a affinity states. SERCA2a exists in two structural states; high 
and low affinity. The high affinity binding state Ca2+ sites are open to the 
cytoplasm (1). High affinity state binds Ca2+ and ATP (2). When ATP binds and is 
hydrolysed to ADP this leads to phosphorylation of SERCA2a. This changes 
conformation of SERCA2a passing Ca2+ through to the lumen of the SR with low 
affinity binding sites and Ca2+ is released (3). The cycle is complete when SERCA2a 
is dephosphorylated shifting confirmation back to high affinity for Ca2+ (4). SR 
(sarcoplasmic reticulum), ADP (adenosine diphosphate), ATP (adenosine 
triphosphate), P (phosphate) SERCA (sarcoplasmic reticulum Ca2+ ATPase).    
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1.5.2 SERCA2a Regulation 
SERCA2a is the most abundant isoform within the heart. The activity of the pump 
is specifically regulated by the integral SR membrane protein phospholamban 
(PLB). PLB is susceptible to phosphorylation by multiple different kinases including 
PKA, Ca2+ calmodulin-dependent kinase and Ca2+ phospholipid-dependent protein 
kinase (Kranias & Solaro, 1982) (Le Peuch, et al., 1980) (Simmerman, et al., 1986), 
however it interacts with SERCA2a in the unphosphorylated form. This interaction 
lowers the affinity of SERCA2a for Ca2+ by structurally altering the Ca2+ transport 
site in the E1 state, therefore reducing transport of Ca2+ to the SR pump (Asahi, 
et al., 2003) (Chen, et al., 2005) (Koss & Kranias, 1996) (Espinoza-Fonesca, et al., 
2015). Phosphorylation of PLB acts to release the inhibitory effect of PLB on 
SERCA2a leading to an increase in SERCA2a activity (Kadambi & Kranias, 1997). 
The inhibitory effects of PLB are restored through dephosphorylation by SR 
associated phosphatases (Kranias, 1985). Although PLB is the main mechanism by 
which SERCA2a is regulated, other mechanisms do exist including sarcolipin-
mediated inhibition. This protein acts in the same manner as PLB to mediate 
SERCA2a inhibition at the Ca2+ transport site in the E1 state (Espinoza-Fonesca, et 
al., 2015).  
1.5.3 SERCA2a in HF 
A decrease in SERCA2a protein expression has been described by many groups in 
the pathogenesis of HF. As a consequence, there is a limitation to cardiac 
relaxation as Ca2+ remains elevated within the cytosol, and subsequent 
contractions are weaker due to the depleted SR Ca2+ store (Beuckelmann, et al., 
1995) (Hasenfuss, et al., 1999) (Schmidt, et al., 1998) (Schwinger, et al., 1995). 
An increase in SERCA2a expression in rat neonatal cardiomyocytes was shown to 
promote cardiac contraction (Hajjar, et al., 1997). The results obtained with 
reconstitution of SERCA2a in vitro have been reproduced in vivo and have 
demonstrated a significant improvement of cardiac contractility in an aortic 
banding model of HF (Miyamoto, et al., 2000). The first clinical trial of SERCA2a 
gene therapy in humans; the CUPID (calcium upregulation by percutaneous 
administration of gene therapy in cardiac disease) trial was conducted to examine 
the effect of restoring SERCA2a expression in HF patients via AAV1 (adeno-
associated virus 1)-SERCA2a. This demonstrated improvements in patients with HF 
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resulting in reduced HF symptoms, increased exercise capacity, reduced HF 
biomarker expression and improved LV function (Jaski, et al., 2009). These 
findings supported the initiation of the phase-2 double-blind, placebo controlled 
portion of this study, but unfortunately restoring SERCA2a via AAV1-SERCA2a did 
not improve the clinical outcomes for patients with HF in comparison to placebo 
control. Patients receiving AAV1-SERCA2a did not demonstrate a prolonged time 
to recurrent events – regarded as hospital admission or ambulatory treatment 
relating to HF – in comparison to placebo control  (Greenberg, et al., 2014) 
(Greenberg, et al., 2016).  
1.5.4 SERCA2a SUMOylation 
In 2011, Kho et al discovered that the cardiac signalling protein SERCA2a is 
modified by SUMO-1. The group identified that as well as SERCA2a being decreased 
in the pathogenesis of HF that also SUMO-1 and SUMO-SERCA2a was also reduced. 
The group went on to prove that restoring SUMO-1 expression via adenoviral gene 
transfer is beneficial as it improves cardiac function and also stabilizes heart 
weight to body weight ratio – indicative of reduced hypertrophic response. 
Furthermore, this transfer causes SERCA2a levels, which are normally reduced in 
HF, to remain elevated in the animal model (Kho, et al., 2011) (Tilemann, et al., 
2013).  
Multiple reasons have been speculated as to why SUMO-1 restoration is beneficial 
in HF. Firstly, SUMO-1 prevented poly-ubiquitination of SERCA2a as SUMO-1 
modification and ubiquitination appear to occur at the same lysine residues 480 
and 585 (Kho, et al., 2011). This therefore prevents SERCA2a from being targetted 
to the 26S proteasome for degradation. This competitive relationship between 
ubiquitination and SUMOylation has been observed for other proteins described in 
section 1.4.3.3 - Alternative Lys Modifications. Secondly, SUMOylation can act to 
influence cardiac transcription factors, such as serum response factor (SRF) 
(Matsuzaki, et al., 2003) and specificity protein 1 (Sp1) which is associated with 
SERCA2a promoters  (Tilemann, et al., 2013).  SUMOylation of SRF can lead to an 
activation of genes for contractile proteins, such as SERCA2a, therefore promoting 
SERCA2a expression (Wang & Schwartz, 2010), whereas Sp1 levels which are 
normally reduced in HF were restored following SUMO-1 gene transfer, also 
promoting SERCA2a expression  (Tilemann, et al., 2013). Thirdly, SUMO-1 has been 
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shown to abrogate the damage of reactive oxygen species (ROS) formation, which 
is often elevated in HF (Lee, et al., 2014) by inhibiting nitric oxidase activity – an 
enzyme responsible for ROS production (Pandey, et al., 2011). 
Recently the Hajjar group have identified a small molecule, N106, which promotes 
SUMOylation of SERCA2a by directly activating the SUMO E1 activating enzyme 
(Kho, et al., 2015). In a mouse model of HF, this molecule improves ventricular 
function. Additionally, although the enhancement in the SUMOylation pathway is 
often associated with cancer (Lee & Thorgeirsson, 2004) (Kessler, et al., 2012) the 
small molecule N106 mediated no such effects and may serve as a potential 
therapeutic strategy for HF treatment (Kho, et al., 2015).  
1.5.5 Other SUMO-Susceptible Cardiac Signalling Proteins 
in HF 
There are more than 1000 SUMO substrates known in nature (Hay, 2013) – 
supporting the notion, that SERCA2a may not be the only cardiac protein 
susceptible to SUMOylation. Using sp2.0 SUMOylation site identification software 
(GPS-SUMO, Guangzhou, China) the Baillie group (University of Glasgow, 
unpublished work) identified putative SUMOylation sites on the β2AR, RyR, LTCC, 
cTNI and myosin binding protein C (Figure 1.13). This software identifies possible 
SUMOylation sites by examining lysines residues and their surrounding amino acids. 
To validate these putative SUMOylation sites 15 mer peptides which contained 
potential SUMO conjugation motifs were synthesized as peptide arrays (Frank, 
2002) and then SUMOylated using an in vitro assay (described in Chapter 2 – 
General Materials and Methods) (Figure 1.13). This confirmed that SERCA2a is not 
the only cardiac signalling protein susceptible to SUMOylation and therefore 
modification of the other proteins by SUMOylation may also be important in HF. 
The following proteins are speculated to have SUMOylation sites: RyR (positions 
833, 841, 1572, 3413, 4385, 4265, 4601), β2AR (positions 60, 227 and 235), LTCC 
(position 1621), myosin binding protein C (position 543 and 1816), and cTNI 
(position 177 and 178) (Figure 1.13).  
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Figure 1.13 SUMOylation of cardiac signalling proteins. Using sequence analysis, 
the Baillie group have identified putative SUMOylation sites on the β2AR, RyR, 
LTCC, cTNI and myosin binding protein C. To validate these putative SUMOylation 
sites 15 mer peptides which contained potential SUMO conjugation motifs were 
synthesized as peptide arrays (Frank, 2002) and then SUMOylated using an in vitro 
assay. β2AR (beta 2 adrenergic receptor), RyR (ryanodine receptor), LTCC (L-type 
Ca2+channel), cTNI (cardiac troponin I). Amino acid abbreviations in appendix. 
 
 
 
SLTSAQKEEEEEKE (position 767) 
ARTASPEKKQELVE (position 786) 
RTASPEKKQELVEKP (position 787) 
VGESKEEKIELKSIT (position 803) 
VRTALRIKTEGNLEQ (position 1621) 
LTLPEEDKRDIRQSP (position 1959) 
VRTALRIRTEGNLEQ (control)
L type Ca2+ channel (subunit 1c)
cTnI 
TLLLQIAKQELEREA (position 58) 
RAHLKQVKKEDTEKE (position 177) 
AHLKQVKKEDTEKEN (position 178)
RAHLKQVRKEDTEKE (control) 
LVITAIAKFERLQTV (position 60)
SRVFQEAKRQLQKID (position 227) 
EAKRQLQKIDKSEGR (position 232) 
RQLQKIDKSEGRFHV (position 235) 
LVITAIARFERLQTV (control)
β2AR
LKVIEAEKAEPMLAP (position 99) 
ELIVQEKKLEVYQSI (position 543)
AKDQAVFKCEVSDEN (position 564) 
LWGYTVQKADKKTME (position 1103)
LKVIEAEKAEPMLAP (position 1372) 
ELIVQEKKLEVYQSI (position 1816) 
AKDQAVFKCEVSDEN (position 1837) 
LWGYTVQKADKKTME (position 2376)
AKDQAVFRCEVSDEN (control)
Myosin Binding Protein C
QWEKPQVKESKRQFI (position 4166) 
LNERSANKEESEKER (position 4218)
MLSLKSLKKQMKKVK (position 4265)
KSLKKQMKKVKKMTV (position 4269)
DIFGLDLKREGGQYK (position 4385) 
KFQEQKAKEEEKEEK (position 4425) 
QKAKEEEKEEKEETK (position  4429)
KEEEKEEKEETKSEP (position 4432)
KEEKEETKSEPEKAE (position 4436)
MLANTVEKSEGQVDV (position 88) 
VLPKEKLKVEHSREY (position 833) 
VEHSREYKQERTYTR (position 841) 
KVPLVIFKREKEVAR (position 4601) 
FSDAREKKKPKKDSS (position 4686)
AREKKKPKKDSSLSA (position 4689)
DGDTPDMKCDDMLTC (position 4805)
RDQQEQVKEDMETKC (position 4881)
FLMYLINKDETEHTG (position 4928)
VLPKEKLRVEHSREY(control)
Ryr2
PLSAGLFKSEHKNPV (position 1572)  
LLSVRMGKEEEKLMI (position 2136) 
FDALSQKKYEQELFK (position 2656) 
NYVSMMEKQSSMDSE (position 2691) 
NIWAKKKKMELESKG (position 2857)
VSEEDHLKAEARGDM (position 3341) 
WSKSHNFKREEQNFV (position 3413) 
R
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1.5.5.1 RyR 
The RyR protein mediates the release of Ca2+ from the SR and this Ca2+ is vital for 
mediating cardiomyocyte contraction. The receptor is susceptible to 
phosphorylation (Lokuta, et al., 1995) and it has been suggested that in HF the 
receptor can become hyper-phosphorylated resulting in it leaking Ca2+ ions 
continuously (Marks, 2000). This leads to depletion of the SR Ca2+ store and 
therefore subsequent cardiac contractions are weaker (Eisner & Trafford, 2002).  
1.5.5.2 LTCC 
The LTCC allows for the initial Ca2+ influx following the initiation of cardiac 
contraction. This small influx of Ca2+ stimulates the RyR to release a much greater 
volume of Ca2+ from the SR which mediates contraction at the myofilament. In HF, 
single LTCC’s display elevated activity, but this was not observed when the current 
through the channels was measured from whole cell preparations (Schroder, et 
al., 1998). This discrepancy could be explained if the cardiomyocytes displayed 
fewer channels in HF but no changes were observed in channel density. Schroder 
et al (1998) proposed that the increased channel activity in HF could be caused by 
increased PKA-mediated phosphorylation of the α1C subunit of LTCC (Bodi, et al., 
2005).  
1.5.5.3 Myosin binding protein C 
Myosin binding protein C is a thick filament accessory protein that inhibits the 
cross-bridge cycling of actin and myosin, therefore inhibiting contraction. Upon 
phosphorylation, myosin binding protein C releases the inhibitory effect, and 
therefore the rate of cross-bridge cycling is accelerated (Tong, et al., 2008). Rosas 
et al (2015) identified that inhibition of the PKA-mediated phosphorylation of 
myosin binding protein C led to reduced myocardial relaxation – a phenotype 
associated with HF (Rosas, et al., 2015).  
1.5.5.4 cTNI 
Troponin is the protein within cardiac myocytes which regulates Ca2+-mediated 
contraction. It has been shown that elevation of troponin within serum correlates 
with adverse outcomes in HF (Kociol, et al., 2010). It is not fully understood why 
79 
 
troponin levels are elevated in HF but the cardiac conditions such as 
volume/pressure overload, increased wall stress and elevated inflammation lead 
to an increase in myocyte apoptosis, autophagy, proteolysis and membrane 
permeability. The enhanced membrane permeability leads to an increased volume 
of circulating cTNI (Wettersten & Maisel, 2015) (Francis, et al., 1995) (Januzzi, et 
al., 2012). In addition to acting as a biomarker, troponin I also has a functional 
role in HF. When intracellular Ca2+ concentration is low, troponin I  binds to actin, 
mediating an interaction between tropomyosin and actin which sterically hinders 
cross-bridge attachment of actin and myosin. A rise in Ca2+ allows troponin C and 
troponin I to bind, allowing tropomyosin to interact further with the actin 
filaments, leading to actin and myosin cross-bridge cycling (Day, et al., 2007). 
During HF, the sensitivity of troponin C to Ca2+ is increased – believed in part to 
be due to decreased phosphorylation of troponin I, the regulatory subunit  (Day, 
et al., 2007). In HF, the density of β1AR (Bristow, et al., 1993) (Daaka, et al., 
1997) is reduced, and this is believed to be responsible for less PKA-mediated 
phosphorylation on troponin I (Metzger & Westfall, 2004).  
1.5.5.5 β2AR  
In ventricular myocytes both β1AR and β2AR mediate cAMP signalling, however only 
the β1AR is capable of initiating PKA-mediated phosphorylation of phospholamban 
and troponin I (Xiao, 2001), inducing cardiomyocyte hypertrophy (Engelhardt, et 
al., 1999) and promoting cardiomyocyte apoptosis (Communal, et al., 1999). The 
difference in the outcome following receptor stimulation can in part be attributed 
to receptor localisation. The surface of cardiomyocytes consists of domes and 
troughs with the T tubules found in the base of the troughs stretching into the 
myocyte centre (Ibrahaim, et al., 2010). Nikolaev et al (2010) identified that in 
healthy cardiomyocytes, β2AR are exclusively localised to T-tubules whereas β1AR 
are present in both the domes and T-tubules (Nikolaev, et al., 2010). In addition 
to receptor location, spatial compartmentation within the cell can influence the 
outcome of receptor stimulation. Following β1AR stimulation for example, cAMP 
is propagated throughout the entire cell whereas β2AR stimulation leads to locally 
confined cAMP production at the T-tubules (Nikolaev, et al., 2006). This cAMP 
confinement is mediated by PKA-stimulated PDE4 activity which degrades cAMP 
before it can spread throughout the cytosol, and AKAP anchoring of PKA subunits 
to within the direct vicinity of the β2AR (Fischmeister, et al., 2006). 
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Cardiac disease can act to influence both receptor localisation and spatial 
compartmentation within the cell. In HF, myocytes display an extensive loss of T-
tubules (Lyon, et al., 2009) which encourages the β2AR to redistribute to non-
tubular areas such as the domes, which in healthy cells are predominantly 
occupied by β1AR (Nikolaev, et al., 2010). With this positioning, the β2AR can now 
stimulate cAMP production, which is capable of propagating throughout the 
cytosol (Nikolaev, et al., 2010). In addition to alternate localisation of the β2AR, 
spatial compartmentation of PKA is also abolished due to the lack of AKAP-PKA 
interaction during HF (Zakhary, et al., 2000). This further encourages cAMP 
propagation throughout the cell, as PDE4 is not activated by PKA to degrade local 
cAMP pools. Therefore in HF, the β2AR signals would be expected to manifest in a 
similar manner to that of the β1AR, contributing to initiating PKA-mediated 
phosphorylation of phospholamban and troponin I (Xiao, 2001), inducing 
cardiomyocyte hypertrophy (Engelhardt, et al., 1999) and promoting 
cardiomyocyte apoptosis (Communal, et al., 1999). This would contribute to the 
HF phenotype (del Monte, et al., 1993) (Dorn, et al., 1999). 
In contrast, numerous studies indicate a cardio-protective role for the β2AR: in 
isolated myocytes β2AR stimulation protects against stress-induced apoptosis 
(Chelsey, et al., 2000); in a rat model of myocardial infarction-induced HF, 
selective activation of the β2AR improves cardiac performance and reduces 
apoptosis (Ahmet, et al., 2004); and in HF there is enhanced signalling of β2AR via 
the inhibitory Gi protein, which attenuates the positive inotropic effects of β1AR 
stimulation and activates cardio-protective signalling pathways (Bohm, et al., 
1994) (Chelsey, et al., 2000) (Feldman, et al., 1988) (Zhu, et al., 2001).  
1.5.6 Inducing Protein SUMOylation 
Kho et al (2011) identified that SERCA2a is a substrate for SUMOylation. To 
SUMOylate this protein in vitro they used the HEK293 cell line to overexpress 
SERCA2a in conjunction with SUMO-1 and UBC9. This approach of upregulating 
SUMOylation cascade components has been utilised by other groups. For LIN-1, – 
a DNA binding transcription factor - SUMOylation was promoted in yeast cells via 
overexpression of SUMO-1 (Leight, et al., 2005). For LEF1, – a nuclear mediator of 
Wnt signalling – SUMOylation was promoted by overexpression of PIASγ in HEK293T 
cells (Sachdev, et al., 2001).  
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1.6 Aims and Hypothesis  
1.6.1 Hypothesis 
This thesis focuses on the SUMOylation of the β2AR, a modification that has not 
previously been described. It is hypothesised that SUMOylation of the β2AR can 
occur and that this modification may alter downstream signalling of the receptor. 
We also hypothesise that as in the case of SUMO-SERCA2a, that SUMOylation of 
the receptor protects it from degradation during HF.  
1.6.2 Aims 
The aims for this thesis are as follows; 
1. Validation of SUMO sites in the β2AR using peptide array 
2. Design, generation and validation of a SUMO-β2AR specific polyclonal 
antibody 
3. Promotion of β2AR SUMOylation in the HEKβ2 cell line to assess the influence 
of receptor SUMOylation on downstream signalling  
4. Assessment of β2AR SUMOylation in small and large animal models of HF 
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Chapter 2 General Materials and Methods 
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2.1 General Laboratory Practise 
Laboratory equipment and reagents were of the highest commercially available 
grades purchased from Sigma-Aldrich (Sigma-Aldrich, Dorset, UK) unless otherwise 
stated. Hazardous reagents were handled as described in the Control of 
Substances Hazardous to Health regulations. A laboratory coat and non-latex 
powder-free gloves were worn during all procedures.  
 
Laboratory glassware was cleaned in Decon 75 detergent (Decon Laboratories Ltd, 
East Sussex, UK), rinsed with distilled water (dH2O) and dried at 37°C. Otherwise, 
sterile disposable plastic ware was used, including 0.5 and 1.5ml microcentrifuge 
tubes (Greiner Bio-one, Stonehouse, UK), 15 and 50ml centrifuge tubes (Corning, 
Birmingham, UK), and also 5 and 20ml 'universal' containers (Sterilin, Newport, 
UK). Laboratory-ware and liquids requiring sterilisation were autoclaved in a 
Classic Prestige Medical autoclave (Prestige Medical, Blackburn, UK). Reagents 
were weighed using a Mettler Toledo balance (sensitive to 0.01g) (Mettler Toledo, 
Ohio, USA), or a Sartorius CP124S balance (sensitive to 0.0001g) (Sartorius, 
Bradford, UK). Solutions were pH'd using a Mettler Toledo Seven Easy digital pH 
meter (Mettler Toledo, Ohio, USA) calibrated with pH 4.0, 7.0 and 10.0 prepared 
from buffer tablets (Sigma-Aldrich, Dorset, UK). Volumes from 0.1 to 1000µl were 
dispensed with Gilson Medical Instruments pipettes. Volumes from 1 to 25ml were 
measured with sterile disposable pipettes (Corning, Birmingham, UK) and a Gilson 
battery-powered pipetting aid (Gilson Medical Instruments, Wisconsin, USA). 
Autoclaved dH2O was used to prepare aqueous solutions unless otherwise 
indicated, and a Stuart Scientific hotplate/stirrer (Stuart Scientific, Staffordshire, 
UK) was used to aid dissolving and mixing. Vortexing was carried out using a Fisons 
Scientific Equipment Whirlimixer (Fisons Scientific, London, UK). Centrifugation 
for samples up to 1.5ml was performed at 4-20°C in a table top Sigma-Aldrich 1-
14K microcentrifuge (Sigma-Aldrich, Dorset, UK), while larger sample volumes 
were centrifuged in a ThermoFisher Scientific Cl31 multispeed (ThermoFisher 
Scientific, Paisley, UK), compatible with 15 and 50ml centrifuge tubes, and 20ml 
'universal' tubes. For ultracentrifugation, a Beckman Coulter Optima L-80 XP 
ultracentrifuge (Beckman Coulter, High Wycombe, UK) was used. A Grant OLS200 
water bath (Grant Instruments, Cambridgeshire, UK) was used for experiments 
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requiring incubations from 37 to 90°C, and a Techne DRI-BLOCK DB2A heating 
block (Teche, Staffordshire, UK) was used for temperatures up to 100°C.  
 
2.2 Cell Culture  
All cell culture procedures were carried out in a class II hoods (ThermoFisher 
Scientific, Paisley, UK) using standard aseptic techniques and sterile instruments 
via autoclaving. All culture reagents were supplied by Gibco (ThermoFisher 
Scientific, Paisley, UK) unless stated otherwise. The tissue culture flasks, dishes 
and pipettes were supplied by Corning (Sigma-Aldrich, Dorset, UK). All cultures 
were examined regularly under a phase contrast inverted microscope (Leitz 
Diavert, Berlin, Germany).  
 
2.2.1 HEK293 Cells  
HEK293 cells were originally derived from human embryonic kidney (HEK) cells 
and are used for their ease of culture and transfection. HEK293 cells were cultured 
in growth medium consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (PS), 
1% L-glutamine (LG) and 1% non-essential amimo acids (NEAA) at 37°C in 
humidified air with 5% CO2.  
 
HEK293 cells were used in two results chapters of this thesis;  
 
• Chapter 3 – Production of a SUMO-β2AR Specific Polyclonal Antibody. These 
cells were used in the antibody testing phase to prove the SUMO-β2AR 
antibody could detect the β2AR overexpressed in HEKβ2 cells, with HEK293 
cells which lack the overexpressed β2AR used as control.   
 
• Chapter 4 – In Vitro SUMOylation of the β2AR. These cells were used in BRET 
(bioluminescence resonance energy transfer) and SPASM (systemic protein 
affinity strength modulation) sensor experiments to determine the 
influence of β2AR SUMOylation on receptor function. These cells were also 
used as a control to HEKβ2 cells, as they contain no overexpressed β2AR.  
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2.2.2 HEKβ2 Cells  
HEKβ2 cells are a stable HEK293 cell line which overexpresses the GFP/FLAG-
tagged form of the β2AR. GFP is a green fluorescent protein meaning the receptor 
can be visualised in these cells using fluorescent microscopy. FLAG is an 8 amino 
acid tag commonly used to tag proteins. Generation and maintenance of this cell 
line is described elsewhere (McLean & Milligan, 2000) (Mclean, et al., 1999). These 
cells were maintained and passaged in the same manner as HEK293 cells. HEKβ2 
cells contain an extra component of geneticin G418 (Sigma-Aldrich, Dorset, UK) in 
the growth medium at 0.5mg/ml. This antibiotic prevents growth of HEK293 cells, 
which do not express the GFP/FLAG-tagged β2AR.  
 
HEKβ2 cells were used in all results chapters of this thesis;  
 
• Chapter 3 – Production of a SUMO-β2AR Specific Polyclonal Antibody. HEKβ2 
cells were used in the antibody testing phase to prove the SUMO-β2AR 
antibody could detect the β2AR stably transfected in the HEKβ2 cell line.  
 
• Chapter 4 – In Vitro SUMOylation of the β2AR. HEKβ2 cells were used to 
determine the influence of β2AR SUMOylation on receptor function in a 
range of techniques including drug stimulation and subsequent 
immunoblotting, immunoprecipitation, peptide array overlay, ArrayScan 
internalisation assay, FRET (fluorescence resonance energy transfer) and 
radioligand binding studies. 
 
• Chapter 5 –Analysis of β2AR SUMOylation in Animal Models of HF. HEKβ2 cell 
lysate was used as an antibody positive control for immunoblotting when 
protein detection proved problematic in animal tissue lysate.   
 
2.2.3 Cell Sub Culture  
The cells were passaged at approximately 90% confluency. For cell passage, 
growth medium was removed and the cells were washed in sterile phosphate 
buffered saline (PBS) to remove traces of media. The PBS was then removed and 
the cells were treated with 5ml trypsin-EDTA solution per 75cm2 culture flasks of 
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cells to dissociate the cell monolayer for 5 minutes at 37°C. Growth medium was 
added to neutralise the trypsin-EDTA solution, and then cells and media were 
collected and subject to centrifugation at 10,000rpm for 3 minutes at room 
temperature to isolate the cell pellet. The supernatant was removed, without 
disturbing the cell pellet, which was then resuspended in fresh growth media and 
re-plated according to the requirement.  
 
2.2.4 Cell Counting 
Cells were counted with a Bright Line Haemocytometer (Sigma-Aldrich, Dorset, 
UK). 10µl of a cell suspension was pipetted under a cover slip onto the grid, using 
a light microscope; the number of viable cells in each 1mm corner square was 
counted and averaged. Cells crossing the bottom or right-hand edge of any square 
were not counted. The average number of cells in each 1mm square was derived, 
and then multiplied by 104 to give the number of cells per ml in the suspension. 
The subsequent concentration of cells per ml can be determined using the 
following calculation:  
 
Cell number / ml = average cell count per square x 104 x original volume 
 
The calculated cell concentration (cells/ml) was then used for seeding cells at the 
desired density. 
 
2.2.5 Cryopreservation  
For cryopreserving the cells, the cell pellet was prepared as described in 2.2.3 -  
Cell Subculture. The pellet was resuspended in 10% dimethyl sulfoxide (DMSO) 
diluted in a 50/50 mix of growth medium and FBS. DMSO is a cryoprotectant which 
protects the cells from damage during the freezing procedure. The cell containing 
media was aliquoted into cryovials – small tubes designed for cryopreservation - 
which were placed into a freezing container filled with 100% isopropanol and 
placed into a -80°C freezer for 24 hours. This method allowed cells to freeze 
slowly, preventing rupture initiated by rapid freezing. After 24 hours, frozen cells 
were transferred to liquid nitrogen tanks for long term storage.   
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To recover cells from liquid nitrogen, cells were defrosted within the cryovial in 
a water bath at 37°C. The cell suspension was then mixed with approximately 
10ml of appropriate cell culture medium and centrifuged at 10,000rpm for 3 
minutes at room temperature to remove residual DMSO. This ensures successful 
cell growth, as cells do not grow well in media containing DMSO. The cell pellet 
was then resuspended in cell culture medium and incubated at 37°C and 5% CO2 
for further culturing.  
 
2.3 Isolation of Plasmid DNA and Transient Transfection  
Transient transfection is a method of introducing a foreign gene into a cell. The 
transiently transfected cells will express the foreign gene but will not incorporate 
it into their genome, therefore it will not be replicated. These cells will express 
the transfected gene for several days, but after which the foreign gene is lost 
through cell division (Smith, 2013). Transient transfection can be encouraged by 
the use of chemical reagents – one such reagent is Lipofectamine LTX 
(ThermoFisher Scientific, Paisley, UK). Lipofectamine LTX is a liposomal 
transfection reagent, which means it processes the DNA of the foreign gene into 
liposomes which fuse with cell membranes and release DNA into the cell interior 
by endocytosis (Felgner, et al., 1987). This method is necessary to allow the 
negatively charged nucleic acids to pass through the negatively charged plasma 
membrane, as the membrane would normally repel the negative charge. 
Isolation of PIASγ HA-tagged DNA and transient transfection was used in this thesis 
to promote SUMOylation of the β2AR in both Chapter 3 - Production of a SUMO-
β2AR Specific Polyclonal Antibody and Chapter 4 – In Vitro SUMOylation of the 
β2AR. For control, cells were treated with empty transfection reagent. These are 
known as mock transfected cells.  
2.3.1 Isolation of Plasmid DNA From E. coli 
The only plasmid DNA used in multiple chapters (Chapter 3 - Production of a SUMO-
β2AR Specific Polyclonal Antibody and Chapter 4 – In Vitro SUMOylation of the 
β2AR) of this thesis was PIASγ with an HA tag. The HA (hemagglutinin) tag is 
derived from the human influenza virus HA protein (ThermofisherScientific, 2017). 
88 
 
This tag allows determination of PIASγ HA transfection success by immunoblotting 
for the HA tag.  
 
A scraping was taken from a PIASγ HA tag E. coli bacterial glycerol stock (a stock 
of bacterial cells which express the PIASγ HA plasmid vector) using a sterile 
pipette and grown in 250ml of sterile lysogeny broth (LB) media (2.5g tryptone, 
1.25g yeast extract, 2.5g NaCl, 250ml of dH2O, sterilised via autoclave and cooled 
before use) containing appropriate antibiotic overnight at 37°C in an orbital 
shaker (Cole Parmer, London, UK). The antibiotic for PIASγ HA was ampicillin 
500μg/ml. This means that all bacterial cells which did not display the resistance 
gene for ampicillin - which is encoded within the PIASγ HA plasmid vector – were 
unable to grow. This allowed bacterial cells which expressed the PIASγ HA tag 
plasmid vector to multiply uninhibited.  
 
Plasmid DNA was isolated using the QIAgen Maxiprep Kit (QIAgen, Manchester, UK) 
according to the manufacturers’ instructions. The DNA was then eluted with 
sterile dH2O and stored at -20°C for long term storage. Plasmid DNA other than 
PIASγ which was used within this thesis was provided by the laboratory of Professor 
Graeme Milligan at the University of Glasgow.  
 
2.3.1.1 Storage of Plasmid DNA as Glycerol Stocks 
For plasmid storage, 900µl of bacterial cell culture was mixed with 900µl of 30% 
glycerol solution, to give a final glycerol concentration of 15%. The glycerol was 
sterilised by autoclaving, prior to use. The glycerol stock was snap frozen using 
dry ice and stored at -80°C. Glycerol stocks were never unfrozen and remained on 
dry ice throughout use. Scrapings from the frozen stock were enough for isolation 
of plasmid DNA via Maxiprep. 
 
2.3.1.2 Quantification of DNA Concentration 
The concentration of purified DNA was determined using Nanodrop 3300 
spectrophotometer (ThermoFisher Scientific, Paisley, UK) following manufacturer 
instruction. Absorbance wavelength was set at 260nm and 280nm, and the A260 : 
A280 ratio determines the purity of the nucleic acid extract. The ratio of A260 : 
A280 ideally should be between 2 – 2.3 and a lower reading may indicate organic 
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solvent contamination in the preparation. Values above 400ng/μl were deemed 
suitable for future transient transfection experiments.  
 
2.3.2 Transient Transfection of Plasmid DNA 
Cells were plated the day before transient transfection for 60-80% confluency on 
day of transfection. Plasmid DNA used in the present study was transiently 
transfected into cells using Lipofectamine LTX according to manufacturers’ 
instructions and OPTIMEM (ThermoFisher Scientific, Paisley, UK). OPTIMEM is 
reduced serum media which is used during liposomal transfection methods, as 
serum can reduce transfection efficiency. Cells were incubated for a minimum of 
24 hours to allow sufficient protein expression. As control, mock transfected cells 
were treated with empty transfection reagent.  
 
2.4 Preparation of Cell Lysate 
To assess cellular contents, it is essential to lyse the cells – a process in which 
individual cellular proteins are isolated from the intact cells. Using detergent-
based lysis buffers the cell membranes are disrupted allowing cell contents to leak 
free. 3T3 lysis buffer (25mM HEPES-OH, pH 7.5, 50mM NaCl, 10% glycerol, 1% 
triton, 50mM NaF, 30mM Na4P2O7, 5mM EDTA) was used for cell lysates, unless 
stated otherwise in chapter specific methods. This buffer contains triton which is 
a detergent for disrupting the membranes. The buffer was supplemented with 
protease cocktail inhibitor tablets (Roche, West Sussex, UK), phos-stop tablets 
(Roche, West Sussex, UK) and 25mM NEM (N-ethylmaleimide) (Sigma-Aldrich, 
Dorset, UK). The protease cocktail inhibitor tablets inhibit a broad spectrum of 
proteases which would normally break down proteins, phos-stop tablets inhibit 
phosphatases which prevents phosphorylated proteins from becoming de-
phosphorylated, and NEM inhibits enzymes which promote de-SUMOylation.  
Lysates were obtained by harvesting cells at 4°C. Cells were first washed in ice 
cold PBS then lysed using 250µl of supplemented 3T3 lysis buffer. The cell lysate 
was centrifuged at 13,000rpm for 10 minutes at 4°C. The supernatant lysate was 
removed and kept. The cell lysates were snap frozen on dry ice and stored at -
80°C until required. The protein concentration in the supernatant was analysed 
by the Bradford method (Bradford, 1976).  
90 
 
2.5 Protein Quantification by the Bradford Assay 
The concentration of protein in cell lysates was determined using the Bradford 
method (Bradford, 1976). The Bradford assay determines the concentration of a 
protein sample based on an absorbance shift of the dye Coomassie Brilliant Blue 
G-250. Protein assays were performed in clear 96 well plates. Each protein sample 
of unknown concentration was diluted 1 : 100 in sterile dH2O, 2μl sample 198μl 
dH2O. 50μl of each sample was added to 3 consecutive wells in a clear 96 well 
plate for testing in triplicate. Known BSA concentrations between 0 and 5μg were 
prepared and also tested in triplicate to generate a standard curve. Bradford 
reagent (Bio-Rad, Hertfordshire, UK) was diluted 1 : 5 in sterile dH2O, and 200μl 
of diluted reagent was added per well. Samples and standards were analysed with 
a 595nm filter on an Anthos 2010 plate reader (Biochrom, Cambridge, UK) using 
ADAP software (Biochrom, Cambridge, UK). Protein concentrations were 
calculated using a curve derived from the BSA standard values, and adjusted for 
sample dilution. 
 
2.6 Immunoblotting  
Immunoblotting is a technique widely used to assess proteins which are present 
within cell lysate. Cell lysates are prepared for separation by gel electrophoresis, 
followed by transfer to nitrocellulose membranes. Once the proteins which were 
present in cell lysate are captured within membranes, the membranes are 
incubated overnight with a primary antibody. This antibody has been designed to 
recognise the desired target protein, and therefore will bind like an antibody-to-
antigen. With the primary antibody bound to the target protein, a secondary 
antibody incubation step is required. This secondary antibody is designed to 
recognise the primary antibody based upon the animal in which the primary 
antibody was raised. For example, if the primary antibody was raised in a rabbit, 
then a rabbit secondary antibody would be required. The secondary antibody can 
then be detected by various visualisation methods allowing quantification of the 
target protein.   
Immunoblotting was used in all results chapters of this thesis; 
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• Chapter 3 – Production of a SUMO-β2AR Specific Polyclonal Antibody. 
Immunoblotting was used to assess the function of the novel SUMO-β2AR 
antibody.  
 
• Chapter 4 – In Vitro SUMOylation of the β2AR. Immunoblotting was used in 
multiple experiments including assessment of protein content in cellular 
lysates following drug treatments, assessment of immunoprecipitation 
experiments, and assessment of successful PIASγ HA transfection.  
 
• Chapter 5 – Analysis of β2AR SUMOylation in Animal Models of HF. 
Immunoblotting was used to assess protein content of heart tissue lysates.  
 
2.6.1 Sample Preparation 
Protein samples were denatured and reduced for gel electrophoresis by diluting 
in 5x laemmli protein sample buffer (Bio-Rad, Hertfordshire, UK) and boiling for 5 
minutes to denature the protein. Denaturing is the process by which proteins lose 
their higher structure which exists in their native state. This higher structure 
includes hydrogen bonding, three-dimensional shape and protein subunit 
arrangement. The negative charge on the amino acids is not neutralised in 
denaturing, and therefore allows the protein to be separated by gel 
electrophoresis (Mahmood & Yang, 2012). Tracking dye bromophenol blue was also 
present in the sample buffer to visualise samples passing through the gel.  
 
2.6.2 SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) 
From protein samples, 15μg of protein per well was loaded directly onto SDS-PAGE 
precast gels (NuPAGE ® 4-12% Bis-Tris gel, ThermoFisher Scientific, Paisley, UK). 
These gels consist of a 4% low acrylamide density stacker gel and a 4-12% 
acrylamide gradient running gel. The stacker gel is porous and therefore separates 
proteins poorly, but as the samples progress to the running section of the gel, the 
pores become much narrower. This leads to protein separation dependent on size, 
as the smaller proteins will travel easily and hence more quickly through the gel 
versus the larger proteins (Mahmood & Yang, 2012). Gels were immersed in 
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NuPAGE ® MES (for <50kDa proteins) or MOPS (for >50kDa proteins) SDS Running 
Buffer (ThermoFisher Scientific, Paisley, UK) in the Xcell ® SureLock  MiniCell 
system (ThermoFisher Scientific, Paisley, UK). 1.5μl of Bio-Rad Precision Plus 
Protein Standard (Bio-Rad, Hertfordshire, UK) was added to the first well of each 
gel. This is a pre-stained marker which gives a scale to aid analysis of protein 
molecular weight. Gels were ran at 200V until the samples reached gel bottom, 
indicative by the blue bromophenol dye colouring, allowing maximum protein 
separation.  
 
2.6.3 Transfer 
Following electrophoresis, the gel was transferred onto a 0.2μm pore size 
nitrocellulose membrane (ThermoFisher Scientific, Paisley, UK). Transfer buffer 
was prepared by diluting 20X NuPAGE ® Transfer Buffer (ThermoFisher Scientific, 
Paisley, UK) in 20% methanol in dH2O. The membrane was soaked in transfer buffer 
briefly along with sponges and filter papers. The gel was removed from 
electrophoresis cassette and placed on top of two sponges and two pieces of filter 
paper within an Xcell ® II Blot Module (ThermoFisher Scientific, Paisley, UK). The 
membrane was placed on top of the gel with care taken to avoid bubbles. Then a 
further two pieces of filter paper and two sponges were added on top of the gel. 
The blot module was then placed into the transfer tank and filled with transfer 
buffer. The membrane must face the anode to allow proteins to migrate from the 
gel to the membrane. Current was applied at 30V for 90 minutes.  
 
2.6.4 Detection 
Following transfer, the membranes were blocked in 5% Marvel/TBS-T (marvel milk 
powder in 1X TBS-T, 20mM Tris-HCl, pH 7.6, 150mM NaCl, 0.1% Tween20) for 40 
minutes to 1 hour with gentle shaking to block unspecific antibody binding sites. 
For detection of phosphorylated proteins, phos-block (Cambridge Bioscience, 
Cambridge, UK) was used in place of marvel, as marvel milk contains casein, which 
is a phospho-protein, and therefore would interfere with antibodies which are 
designed to detect a phosphorylated protein, leading to unspecific binding 
(Mahmood & Yang, 2012). Following blocking, the membrane is incubated with the 
appropriate primary antibody (Table 2.1) at the appropriate dilution made up in 
blocking buffer at 4°C overnight. The following morning the membranes were 
93 
 
washed 3 times for 5 minutes in 1X TBS-T. Licor Alexa-Fluor conjugated secondary 
antibodies (Licor Odyssey, Nebraska, USA) (Table 2.2) were added in blocking 
buffer at 1 : 5000 dilution and incubated for 1 hour at room temperature. 
Membranes were washed as before then visualised. Bound antibody was detected 
by Licor Odyssey scanner (Licor Odyssey, Nebraska, USA) which detects the 
fluorescence within the secondary antibody. Densitometry of the image was 
performed using Odyssey software (Licor Odyssey, Nebraska, USA). The level of a 
particular protein in a sample was always measured relative to the level of a 
'housekeeping' protein, namely glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).  
 
Table 2.1Primary Antibodies 
 
Name Supplier Catalogue 
Number 
Dilution 
His-HRP Abcam ab1187 1:5000 
GFP Abcam ab6556 1:1000 
HA Cell Signalling 2367 1:1000 
GAPDH Abcam ab8245 1:1000 
Phos β2AR (PKA) 
345-346 
Santa Cruz sc-16718 1:1000 
Phos PKA 
Substrate 
Cell Signalling 9621 1:1000 
Phos ERK Cell Signalling 9101 1:1000 
ERK Cell Signalling 9102 1:1000 
UBC9 Santa Cruz sc-271057 1:1000 
Phos β2AR (GRK) 
355-356 
Santa Cruz sc-16719 1:1000 
Ubiquitin K48 Abcam ab140601 1:1000 
SUMO-2/3 Abcam ab22654 1:1000 
SUMO-1 Abcam ab11672 1:1000 
PIASy Abcam ab58416 1:1000 
β2AR Thermofisher PA5-18423 1:1000 
β2AR Santa Cruz Sc-569 1:1000 
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Table 2.2 Secondary Antibodies 
 
Name Supplier Catalogue 
Number 
Dilution 
IRDye® 800 Goat 
anti-Rabbit IgG 
Licor P/N 925-32211 1:5000 
IRDye® 680 
Donkey anti-
Mouse IgG 
Licor P/N 925-68022 1:5000 
Anti-rabbit IgG 
HRP-linked 
Antibody 
Cell Signalling 7074 1:1000-5000  
Anti-mouse IgG 
HRP-linked 
Antibody 
Cell Signalling 7076 1:1000-5000  
 
2.7 Peptide Array 
The peptide array technique involves the spotting of sequences of amino acids as 
various spots on a cellulose membrane support. In this thesis, this technique has 
been used in two different ways; 
 
• Chapter 3 - Production of a SUMO-β2AR Specific Polyclonal Antibody. 
Peptide arrays were used to determine the ability of the SUMO-β2AR 
antibody to recognise the epitope against which it was raised.   
 
• Chapter 4 - In Vitro SUMOylation of the β2AR. Peptide arrays were used to 
determine the points of interaction between the SUMOylation enzymes 
UBC9 and PIASγ with the β2AR.  
 
2.7.1 Solid Phase Peptide Synthesis (SPPS) 
The standard method for synthesizing peptides is solid phase peptide synthesis 
(SPPS). Peptides are synthesised by the coupling of the carboxyl group on one 
amino acid to the amino group on another. Since peptides have side chain 
functional groups which could interact with carboxyl or amino groups, these 
functional groups must be chemically protected during synthesis. An important 
protection group is Fmoc (9-fluorenylmethyloxycarbonyl), which protects the 
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amino group from interaction with carboxyl groups. This is important as it isolates 
only the carboxyl group on the amino acid for further interaction, meaning 
interactions can be chosen and not random.  
 
An example of the coupling of two amino acids (Figure 2.1) (SigmaAldrich, 2017) 
could occur as follows; 
 
1. Amino acid 1 (AA1) could be coupled to a solid resin support via its carboxyl 
group, while its amino group is protected by Fmoc. This resin is the solid 
support which the chain of peptides can be built upon.  
 
2. Amino acid 2 (AA2) has its amino group protected by Fmoc, but its carboxyl 
group must be activated before coupling to AA1 can occur. Activation 
means the carboxyl group becomes more susceptible to nucleophilic attack 
by the amino group on AA1.  
 
3. Before the amino group on AA1 can attack the activated carboxyl group the 
Fmoc group which protects the amimo group on AA1 must be removed. 
Fmoc can be removed using the base piperidine in DMF 
(dimethylformamide).  
 
4. Coupling can then occur with the carboxyl group from AA2 and amino group 
from AA1. This chain can continue to be built upon in a similar manner by 
unblocking appropriate groups.  
 
5. The final steps involve removing additional protecting groups from side 
chains and cleaving the peptide from resin.  
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Figure 2.1 Schematic of solid phase peptide synthesis. AA1 coupled to a solid 
resin support via carboxyl group, while amino group is protected by Fmoc. AA2 
amino group protected by Fmoc, but carboxyl group must be activated before 
coupling to AA1 can occur. Fmoc removed from AA1. Coupling can then occur with 
the carboxyl group from AA2 and amino group from AA1. The final steps involve 
removing additional protecting groups (P1 and P2) from side chains and cleaving 
the peptide from resin  (SigmaAldrich, 2017). AA1 (amino acid 1), AA2 (amino acid 
2), A (activator), P1 (protecting group 1), P2 (protecting group 2) Fmoc (9-
fluorenylmethyloxycarbonyl).  
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The peptide arrays used within this thesis were synthesized on either Whatman 50 
cellulose membranes (Sigma-Aldrich, Dorset, UK), or on cellulose membranes 
immobilised on glass slides (Intavis, Köln, Germany) by automatic spot synthesis 
using Autospot Robot ASS 222 (Intavis, Köln, Germany) (Frank, 2002). Either a 
domain within a protein, or the full-length protein can be spotted as overlapping 
25-mer or shorter peptides, each shifted by 5 amino acids to increase the 
reliability of the screen.  
 
2.7.2 Peptide Array – Overlay 
Cellulose membrane peptide arrays spotted with the amino acid sequence of the 
β2AR were used to elucidate interactions between β2AR and enzymes of the 
SUMOylation cascade, UBC9 and PIASγ (Chapter 4 – In Vitro SUMOylation of the 
β2AR).  
 
The array was bathed in 100% ethanol for 30 seconds and then equilibrated in 1X 
TBS-T for 10 minutes before blocking in 5% TBS-T/phospho-block (Cambridge 
Bioscience, Cambridge, UK) to prevent unspecific binding for 2 hours. The array 
was then incubated with 400-1000μg/μl of HEKβ2 lysate overexpressing the 
enzyme of interest - either UBC9 or PIASγ - in 1% TBS-T/phospho-block at 4ºC 
overnight. As control, standard HEKβ2 lysate, in which no enzyme was 
overexpressed, was incubated on a separate array to determine unspecific 
binding, and treated exactly the same as the PIASγ/UBC9 lysate array. The 
following morning arrays were washed 3 times in 1X TBS-T for 10 minutes and 
incubated in 1% TBS-T/phospho-block with primary antibody (specific for the 
enzyme of interest) (Table 2.1) overnight at 4ºC. The following morning, arrays 
were then washed three times in 1X TBS-T and the appropriate secondary antibody 
(Table 2.2) was applied at the appropriate dilution in 1% TBS-T/phospho-block at 
room temperature for 1 hour. After a further 3 washes the array was exposed to 
Pierce ® ECL (enhanced chemiluminescence) western blotting substrate 
(ThermoFisher Scientific, Paisley, UK). The array was then placed in a developing 
cassette for developing in the dark room with X-OMAT (Kodak, London, UK). X-ray 
film (Kodak, London, UK) was placed in the cassette alongside the array for various 
exposure times before development in the X-OMAT.  
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2.7.3 Peptide Array – SUMOylation Assay 
Glass slide cellulose membrane peptide arrays were spotted with truncations of 
the epitope against which the SUMO-β2AR antibody was raised, to allow SUMO-
β2AR antibody specificity testing (Chapter 3 – Production of a SUMO-β2AR Specific 
Polyclonal Antibody). The array was blocked in 5% BSA (bovine serum albumin) in 
1X TBS-T for 1 hour at room temperature with gentle rocking. SUMO kit (Enzo Life 
Sciences, Exeter UK) was used to SUMOylate peptide array. The kit contains 
purified recombinant His (histidine) tagged human SUMO-1, SUMO-2, SUMO-3 
proteins, activating E1 enzyme, E2 enzyme, and ATP (required co factor for SUMO 
conjugation). This kit provides a means of generating SUMOylated proteins in 
vitro, by covalent linkage of the carboxy-terminal of SUMO-1, -2 or -3 to specific 
lysine residues on the target protein via isopeptide bonds. A reaction mixture was 
prepared with all the above kit components and made up to 1ml with sterile PBS. 
The array was incubated at 37°C for 60 min with the SUMO reaction mixture. The 
array was then washed three times in 1X TBS-T for 5 minutes followed by probing 
with His-HRP conjugated antibody (Table 2.1) 1 : 5000 dilution overnight at 4ºC to 
allow detection of SUMOylation. This antibody is capable of detecting 
SUMOylation, as it identifies the His tag on the SUMO paralogues. Slides are then 
washed 3 times for 5 minutes in 1X TBS-T. The array was developed via ECL as 
described for array in section 2.7.2 “Peptide Array Overlay”.  
 
2.8 UniProt Sequence Analysis of β2AR  
To assess the aptness of the SUMOylation sites within the β2AR identified by the 
Baillie lab using peptide array (Figure 1.13, Chapter 1 – Introduction), a 
comparison was made with a SUMO-site finding algorithm, sp2.0 SUMOylation site 
identification software (GPS-SUMO, Guangzhou, China). The four identified sites 
(60, 227, 232 and 235) were examined in the following species; human, rat, 
mouse, rhesus monkey, cow. This was completed using the UniProt website 
(www.unitprot.org).  
2.9 Immunoprecipitation (IP) 
To assess the influence of SUMOylation on β2AR ubiquitination the extent of 
ubiquitination was assessed using immunoprecipitation (IP). This allowed 
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evaluation of the interaction between the β2AR and ubiquitin proteins. Following 
cell lysis and determination of protein concentration, samples were equilibrated 
to 400μg/μl in 3T3 lysis buffer per IP. A “mock” IP involving antibody conjugate 
beads (ThermoFisher, Paisley, UK) which will not bind to the target molecule 
within the lysate was completed alongside the test IP (antibody conjugate beads 
which will bind the target molecule) to act as a control. 100μl of IP beads or mock 
IP beads were added to an eppendorf and then beads were washed twice with 
500μl of 3T3 lysis buffer via brief centrifugation. Supernatant was removed leaving 
beads alone, which were diluted with 100μl of 3T3 lysis buffer and vortex mixed 
to provide both mock IP and IP bead stock. 75μl of the appropriate bead stock was 
added to the appropriate lysate, both a mock set of lysate (incubated with mock 
beads) and an IP set of lysate (incubated with test beads). Beads and samples 
were incubated for 1-2 hours at 4ºC with end over end rotation to allow proteins 
within the lysate to bind to the beads. Beads were then washed twice via brief 
centrifugation with 500μl of 3T3 lysis buffer. Supernatant was removed and 100μl 
of 5x lamaelli sample buffer (Bio-rad, Hertfordshire, UK) was added to the beads 
then heated to 90°C for 5 minutes. This caused bound proteins to denature 
releasing them from the beads. Proteins that associated with the immunopurified 
subject protein were detected via immunoblotting. 
2.10 ArrayScan High Content Analysis of Internalisation 
The ArrayScan system was used to determine the influence of β2AR SUMOylation 
on isoprenaline-mediated receptor internalisation. The ArrayScan® (Cellomics, 
Pittsburgh, USA) is a microtiter plate imaging system that allows both cellular and 
subcellular quantification of fluorescence in cells. Within the HEKβ2 cell line 
(McLean & Milligan, 2000) (Mclean, et al., 1999) (described in section 2.2.2 - HEKβ2 
Cells) the β2AR is GFP labelled, and therefore isoprenaline-mediated 
internalisation of the β2AR was visualised as fluorescent green spots enclosed 
within the cell. An algorithm has been developed that identifies and collects 
information about these spots, allowing quantification of the internalisation 
process (Conway, et al., 1999). 
HEKβ2 cells were seeded into a poly-D-lysine (1:20 dilution in phosphate buffered 
saline (PBS), 40μl/well) coated 96 well plate at a density of 35,000 cells/well. 
HEKβ2 cells were subject to this assay with prior mock transfection with empty 
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transfection reagent or transfection with the E3 ligase PIASγ, which promotes 
SUMOylation of the β2AR (Figure 4.4) (described in section 2.3.2 – Transient 
Transfection of Plasmid DNA). After 24 hours, cells were washed 2X with Hanks 
balanced salt solution (HBSS) and incubated with 10μM isoprenaline for the 
following time points: - 10, 20, 40, 60, 90 minutes. Cells were then washed 3X 
with PBS and fixed with 4% paraformaldehyde (PFA)/PBS. Cells were then 
incubated for 30 minutes with 10μg/ml Hoechst nuclear stain (ThermoFisher, 
Paisley, UK) which binds to nucleic acids at 37°C. Images were acquired 
immediately by using a Cellomics ArrayScan II high content imager and internalised 
receptors were quantified by using the proprietary algorithm designed to identify 
the number of endosomal recycling compartments per cell (Conway, et al., 1999). 
 
2.11 Bioluminescence Resonance Energy Transfer 
(BRET)  
The bioluminescence resonance energy transfer (BRET) assay was used to 
determine the influence of β2AR SUMOylation on the relationship between the 
β2AR and β-arrestin. BRET is similar to FRET and was originally discovered in 
marine organisms. This is a naturally occurring non-radiative energy transfer from 
a donor enzyme to a suitable acceptor molecule after substrate oxidation. Renilla 
luciferase (RLuc), isolated from the sea pansy Renilla reniformis, is traditionally 
used as a bioluminescence donor in conjugation with a fluorescent acceptor, 
which for this work is YFP (yellow fluorescent protein) (Ward & Cormier, 1979). 
This enzyme generates bioluminescence through oxidation of its substrate 
coelenterazine-h, and thus excites the fluorescence acceptor YFP. BRET was used 
to determine if the SUMOylation of the β2AR influenced the interaction between 
the receptor and β-arrestin. The constructs used for this project were kindly 
provided by Professor Graeme Milligan of University of Glasgow. The β2AR was 
attached to RLuc and β-arrestin was attached to YFP.  Binding of isoprenaline to 
β2AR induces recruitment of β-arrestin to the receptor. The interaction brings 
RLuc and YFP into close proximity, therefore bioluminescent resonance energy 
transfer occurs in the presence of co-elentrazine h (Figure 2.2A) (Hattori & Ozawa, 
2015). The effectiveness of energy transfer between RLuc and YFP is 
demonstrated in the ratio of acceptor energy emission relative to the donor 
emission. This is also referred to as the BRET ratio and is a degree for proximity 
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of YFP to RLuc. For this project, the BRET ratio was monitored in the presence of 
increasing concentrations of isoprenaline, RLuc emitting at 480nm and YFP at 
527nm (Figure 2.2B) (Hattori & Ozawa, 2015). 
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Figure 2.2 Principle of BRET. (A) β2AR attached to RLuc, β-arrestin attached to 
YFP.  Binding of isoprenaline to β2AR induces recruitment of β-arrestin to β2AR. 
The interaction brings RLuc and YFP into close proximity therefore bioluminescent 
resonance energy transfer occurs. (B) BRET ratio can be monitored in the presence 
of increasing concentrations of isoprenaline, Rluc emitting at 480nm and YFP at 
527nm. At higher concentrations, greater BRET will be observed (Hattori & Ozawa, 
2015). BRET (bioluminescence resonance energy transfer) YFP (yellow fluorescent 
protein), RLuc (renilla luciferase), GPCR (G protein-coupled receptor).  
A.
B.
Log [Isoprenaline] M
Log [Isoprenaline] M
Log [Isoprenaline] M
Log [Isoprenaline] M
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HEK293 cells were transfected with β2AR tagged with YFP and β-arrestin2 tagged 
with RLuc 6 (Lorenz, et al., 1991) (ratio 4:1) in addition to mock transfection with 
empty transfection reagent or transfection with the E3 ligase PIASγ, which 
promotes SUMOylation of the β2AR (Figure 4.4) (described in section 2.3.2 – 
Transient Transfection of Plasmid DNA). An additional transfection was performed 
with only the RLuc construct to measure background from RLuc alone. From 10cm 
dishes, cells were seeded into a poly-D-lysine (1 : 20 dilution in phosphate 
buffered saline (PBS), 40μl/well) coated 96 well plate at a density of 50,000 
cells/well. After 24 hours, cells were washed 2X with HBSS and 5mM 
coelentrazine-h (Promega, Southampton, UK) was added. Cells were incubated in 
darkness for 10 min at 37°C before addition of isoprenaline (1ρM-10μM). Cells 
were incubated for a further 5 min at 37°C before reading on a Mithras LB940 
plate reader (Berthold Technology, Bad Wildbad, Germany), that allows 
sequential reading of emission signals detected at 480nm and 527nm, for RLuc and 
YFP, respectively. Net BRET was defined as the 527nm : 480nm ratio of cells co-
expressing RLuc and YFP minus the BRET ratio of cells expressing only the RLuc 
construct in the same experiment. This value was multiplied by 1000 to obtain 
mBRET units. This gives a degree of proximity of YFP to RLuc in response to 
isoprenaline concentration allowing quantification of the relationship between 
β2AR-β-arrestin.   
 
2.12 Fluorescence Resonance Energy Transfer (FRET)  
Fluorescence resonance energy transfer (FRET) was used to determine how long 
after β2AR isoprenaline-mediated stimulation the cAMP levels within the cell 
interior remain elevated, and if SUMOylation of the β2AR influences this 
timeframe. FRET is a non-radiative process of energy transfer from an excited 
donor fluorophore to an acceptor fluorophore. This phenomenon can only occur 
when the two fluorophores are in close proximity to one another. This technique 
has been exploited to generate genetically-encoded sensors to visualise cAMP 
dynamics in intact living cells (Zaccolo, et al., 2000). A FRET-based indicator of 
cAMP is usually composed of a cAMP-binding domain and the cyan and yellow 
variants of the green fluorescent protein, CFP and YFP respectively. Excitation of 
CFP, by 430nm wavelength, results in the transfer of excited state energy to YFP, 
which will emit a signal at 545nm.  Both emissions from CFP (480nm) and YFP 
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(545nm) are collected for analysis. Binding of cAMP to the sensor induces a 
conformational change which alters the distance between the two fluorophores 
thereby affecting the energy transfer between them. When this occurs only the 
CFP emission (480nm) is detected as no energy is transferred to YFP. FRET changes 
can be expressed as changes in the ratio between CFP emission (480 nm)/YFP 
emission (545 nm) (Figure 2.3). Changes in FRET can be used in real-time imaging 
experiments as variations in FRET efficiency correlates with changes in cAMP 
intracellular concentration. An elevation in cAMP binding to the FRET probe results 
in less FRET from CFP to YFP therefore the ratio will be reduced. 
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Figure 2.3 Principle of FRET.  Excitation of CFP (430 nm) results in the transfer 
of energy to YFP (emitting a signal at 545 nm). Binding of cAMP to the sensor 
induces a conformational change which alters the distance between the two 
fluorophores, thereby affecting the energy transfer between them. When this 
occurs only the CFP emission (480nm) is detected if the wavelength selected for 
excitation is 430nm as this excites only the CFP donor and no energy is transferred 
to YFP. FRET changes can be expressed as changes in the ratio between CFP 
emission (480 nm)/YFP emission (545 nm). Image adapted from original in the 
thesis of Dr Ashleigh Fields “Local cAMP signalling and phosphodiesterase activity 
in an in vitro model of cardiac hypertrophy” http://theses.gla.ac.uk/4755/. CFP 
(cyan fluorescent protein), YFP (yellow fluorescent protein), FRET (fluorescence 
resonance energy transfer), EPAC (exchange protein activated by cAMP), cAMP 
(cyclic adenosine monophosphate).  
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HEKβ2 cells were seeded onto glass coverslips at a density of 700,000 cells per 
coverslip. Targeted FRET sensor - EPAC cAMPs-1 which is a cytosolic cAMP sensor 
- was transiently transfected in addition to mock transfection with empty 
transfection reagent or transfection with the E3 ligase PIASγ, which promotes 
SUMOylation of the β2AR (Figure 4.4) (described in section 2.3.2 – Transient 
Transfection of Plasmid DNA). Cells were imaged 24-48 hours following 
transfection. Cells were stimulated in real time with 1nM isoprenaline on an 
Olympus IX71 inverted microscope with a 100x oil immersion objective (Zeiss, 
London, UK) in the presence of 10μM rolipram. Rolipram was used to inhibit 
phosphodiesterase-4 (PDE-4) as this enzyme will normally degrade cAMP. The 
sample was exposed to excitation at 430nm, and CFP and YFP signals acquired. 
FRET changes were measured following background subtraction by dividing the 
intensity of emissions at 480nm and 545nm, to give a FRET ratio.  
 
2.13 Radioligand Binding Studies 
Radioligand binding studies were used to determine if the SUMOylated β2AR 
interacts differently with ligand. These studies provided information on the 
interaction between the β2AR and both radioligand and isoprenaline.  
2.13.1 Cell Membrane Preparations  
Cell membrane preparations were used to isolate the β2AR. Pellets of cells were 
frozen at −80°C for a minimum of 1 hour, thawed, and re-suspended in ice-cold 
10 mM Tris, 0.1 mM EDTA, pH 7.4 (Tris-EDTA buffer) supplemented with complete 
protease inhibitors cocktail (Roche, West Sussex, UK) and N-ethylmaleimide (NEM) 
(25mM) (Sigma-Aldrich, Dorset, UK) to inhibit deSUMOylation. Cells were 
homogenized on ice by 40 strokes of a glass-on-Teflon homogenizer followed by 
centrifugation at 1000g for 5 minutes at 4°C to remove unbroken cells and nuclei. 
The supernatant fraction was removed and passed through a 25-gauge needle 10X 
before being transferred to ultracentrifuge tubes and subjected to centrifugation 
at 50,000 x g for 45 minutes at 4°C. The resulting pellets were re-suspended in 
ice-cold Tris-EDTA buffer. Protein concentration was assessed via Bradford assay 
(described in section 2.5 – Protein Quantification by the Bradford Assay) and 
membranes were stored at −80°C until required. The membrane preparations 
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were prepared from HEKβ2 cells which had been mock transfected with empty 
transfection reagent or transfected with the E3 ligase PIASγ, which promotes 
SUMOylation of the β2AR (Figure 4.4) (described in section 2.3.2 – Transient 
Transfection of Plasmid DNA). 
 
2.13.2 Saturation Ligand Binding  
Saturation radioligand binding studies are performed using several concentrations 
of a radioligand to allow determination of the dissociation constant (Kd) and the 
number of binding sites in the assay (Bmax) for the radioligand. Kd is indicative of 
the receptor affinity for the radioligand – it is the concentration at which the 
ligand binds to half of its binding sites, the ligand’s affinity for the receptor is 
small when its Kd is large. Conversely, ligands with a high affinity have small Kd 
values. The Bmax is representative of the number of binding sites in the assay for 
the radioligand – indicative of receptor density (Figure 2.4) (Hein, et al., 2005). 
Saturation binding isotherms were established after the addition of 5µg of 
membrane protein both with and without the SUMOylated form of the β2AR - 
mediated via PIASγ transfection - to assay buffer (TEM: Tris 75mM, EDTA 1mM, 
MgCl2 12.5mM) containing varying concentrations of 3H-dihydroalprenolol (DHA) 
(Tocris, Bristol, UK) (0.1nM-10nM). This is a common radioligand used to assess 
βARs. Nonspecific binding was determined in the presence of 50μM propranolol 
(βAR antagonist). Reactions were incubated for 60 min at 25°C, and bound ligand 
was separated from free by vacuum filtration through GF/C filters (Brandel Inc., 
Gaithersburg, Maryland). The filters were washed 2X with PBS, and bound ligand 
was estimated by liquid scintillation counting. For this the filters are mixed with 
a scintillator solution, which will fluoresce upon interaction with a particle 
emitted by radioactive decay – meaning it has been irradiated by the sample. The 
light emitted in response to this irradiation is taken as a measure of the amount 
of radioactivity in the sample (Diagnostics, 2004). This allowed determination if 
SUMOylation of the β2AR influences the receptor Kd or Bmax for the radioligand. 
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Figure 2.4 Saturation ligand binding schematic. Kd is indicative of the receptor 
affinity for the radioligand – it is the concentration at which the ligand binds to 
half its binding sites. The Bmax is representative of the number of binding sites in 
the assay for the radioligand – indicative of receptor density  (Hein, et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bmax
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2.13.3 Competition Ligand Binding 
To assess the interaction between the β2AR and isoprenaline in both its 
SUMOylated and non SUMOylated format a competition binding assay was used. A 
single concentration of radioligand, 3H-DHA (Tocris, Bristol, UK), competes for 
receptor site occupation with multiple concentrations of a non-radioactively 
labelled compound, isoprenaline. Competition studies primarily yield the 
concentration of the inhibitor causing 50% inhibition of radioligand binding (IC50), 
which can be converted into the inhibitor constant (Ki) using appropriate equations 
(Figure 2.5)  (Hein, et al., 2005). Saturation binding isotherms were established 
after the addition of 5µg of membrane protein both with and without the 
SUMOylated form of the β2AR - mediated via PIASγ transfection -  to assay buffer 
(TEM: Tris 75mM, EDTA 1mM, MgCl2 12.5mM) containing 0.7nM 3H-DHA. 
Nonspecific binding was determined in the presence of 50μM propranolol. The 
radioligand 3H-DHA was competed for receptor occupation with isoprenaline (1nM-
100μM).  Reactions were incubated for 60 min at 25°C, and bound ligand was 
separated from free by vacuum filtration through GF/C filters (Brandel Inc., 
Gaithersburg, Maryland). The filters were washed 2X with PBS, and bound ligand 
was estimated by liquid scintillation counting. This allowed us to determine if 
SUMOylation of the β2AR influences its interaction with isoprenaline, the ligand 
used within our studies to promote β2AR signalling.  
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Figure 2.5 Competition ligand binding schematic. A single concentration of 
radioligand is competed for by multiple concentrations of a non-radioactively 
labelled compounds, namely isoprenaline. Competition studies primarily yield the 
concentration of the inhibitor causing 50% inhibition of radioligand binding (IC50), 
which can be converted into the inhibitor constant of the inhibitor (K i) using 
appropriate equations (Hein, et al., 2005). 
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2.14 Systemic Protein Affinity Strength Modulation 
(SPASM) Sensor  
The Systemic Protein Affinity Strength Modulation (SPASM) sensor was used to 
determine the influence of β2AR SUMOylation on the interaction between the β2AR 
and different G proteins. The SPASM sensors used in this project were BRET sensors 
which are based on a recently developed technique that involves the fusion of a 
native peptide from the C-terminus of a Gα subunit to the C-terminus of the intact 
GPCR (Sivaramakrishnan & Spudich, 2011). Upon activation of the GPCR, the C 
terminus of the Gα subunit slots itself into a cytosolic groove on the GPCR (Choe, 
et al., 2011) (Rasmussen, et al., 2011) (Chung, et al., 2011). Therefore, mimicking 
this peptide will allow the mimic to slot into this same area on the GPCR as the 
native C-terminus of the Gα subunit. For our work, SPASM sensors within a Flp-In 
T-Rex ® HEK293 system were used to investigate the relationship between Gs-β2AR 
and Gi-β2AR. These cells were kindly provided by Dr Brian Hudson from the group 
of Professor Graeme Milligan of University of Glasgow. This system allows 
induction of the gene for the Gs-β2AR and Gi-β2AR sensors by the addition of 
doxacycline (Ward, et al., 2011). Each SPASM sensor contains, from N to C-
terminus: a GPCR joined to mCitrine (BRET acceptor); ER/K linker which is a 
polypeptide motif joining acceptor to donor; a peptide which is designed for G iα 
or Gsα subunit (G-pep) joined to NLuc (BRET donor). When the β2AR is stimulated 
with isoprenaline the G peptide mimic will interact with the GPCR giving BRET 
signal due to interaction between mCitrine and NLuc (Figure 2.6).   
 
 
 
 
 
112 
 
 
Figure 2.6 Principle of SPASM sensor. When the β2AR is stimulated with 
isoprenaline (ligand addition) the G-pep will interact with the GPCR giving BRET 
signal seen with stimulation by agonist in a dose-dependent manner. Image 
designed by Dr Brian Hudson of University of Glasgow. NLuc (NanoLuc Luciferase).  
 
 
 
Ligand Addition
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2.14.1 SPASM Sensor Protein Expression and Cell 
Preparation 
HEK293 Flp-In T-Rex ® cells (ThermoFisher, Paisley, UK) which stably expressed 
either Gi-β2AR or Gs-β2AR SPASM sensors were cultured in culture medium and 
incubated at 37°C in DMEM 41695 with 10% fetal bovine serum, 1% 
penicillin/streptomycin. Cells were plated into 10cm dishes and both sets of 
SPASM sensor cells were either mock transfected with empty transfection reagent 
or transfected with the E3 ligase PIASγ, which promotes SUMOylation of the β2AR 
(Figure 4.4) (described in section 2.3.2 – Transient Transfection of Plasmid DNA).  
24 hours later the plate was coated with poly-D-lysine (1 : 20 dilution in phosphate 
buffered saline (PBS), 40μl/well) at a density of 40,000 cells/well. The medium 
was refreshed to contain 1µg/ml doxacycline to promote induction of the gene for 
the Gs-β2AR and Gi-β2AR sensors. 24 hours later cells were washed with twice with 
HBSS and Nanoglo luciferase (Promega, Wisconsin, USA) substrate was added to 
the cells and incubated for 10 minutes. Isoprenaline was then added for 10 
minutes for either concentration response experiments (1ρM-10μM), or kinetics 
experiments (10μM). Cells were read either on PheraStar FS (kinetics) (BMG 
LabTech, Buck, UK) or Clariostar (concentration response) (BMG LabTech, Buck, 
UK) that allows sequential reading of emission signals detected at 485nm and 
530nm, for NLuc and mCitrine, respectively. Net BRET was defined as the 530nm 
: 485nm ratio of cells co-expressing NLuc and mCitrine. This gives a degree of 
proximity of NLuc and mCitrine in response to isoprenaline concentration, 
allowing quantification of the relationship between β2AR and the respective G 
protein-dependent upon with set of Flp-In T-Rex ® cells were being assessed, Gs-
β2AR and Gi-β2AR.  
 
2.15 Minimally Invasive TAC Pressure Overload Model in 
Mice 
2.15.1 Ethical Approval 
Animal experiments were performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986. These experiments were approved by institutional ethical 
review committees and conducted under authority of project licenses held at the 
University of Glasgow.  
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2.15.2 C57BL/6J Mice 
C57BL/6J mice (25–30 g) were purchased from Harlan (Bicester, UK) and group 
housed in standard conditions of a 12h-12h light–dark cycle with ad libitum feeding 
(Rat and Mouse Chow, Special Diet Services, Witham, UK) and water. Only male 
mice were used for these experiments. 
2.15.3 Surgical Procedure  
The surgical protocol was an adaptation of the minimally invasive TAC technique 
described by Martin et al (2012). Mice were anaesthetized in a perspex chamber 
with 3% isofluorane in oxygen delivered at 2 l minute−1 for induction. After 2–3 
minutes, mice were placed supine on a heating pad – to maintain body 
temperature at 37°C – and visualised under an operating microscope (Zeiss, 
Stuttgart, Germany). Anaesthesia was maintained at 1.5% isofluorane in 1 l 
minute−1 oxygen via a specially designed facemask which orients the animal in an 
optimal surgical position. Fur was removed from the neck and upper chest area 
using hair removal cream (Veet ®) and the area was wiped with betadine to 
prevent infection at the surgical site. A sterile adhesive patch (Tegaderm, 3M, 
Warks) was placed over the surgical area to aid in preventing infection. A small 
horizontal 1cm skin incision was made at the level of the suprasternal notch, 
allowing location of the trachea. Using the trachea for anatomical placement the 
thymus was located and retracted allowing location of the aortic arch. A 5–0 silk 
suture was snared with a hooked needle and passed under the aortic arch before 
tying between brachiocephalic and left carotid artery (Figure 5.1). This hooked 
needle had been blunted under a surgical microscope to prevent any damage to 
the blood vessels when passing under the arch. A 27G needle was used to control 
the tightness of the suture by laying the needle alongside the aortic arch during 
the suture tying. Following aortic arch ligation, the skin was sutured and the 
animal was left to recover in a heated box until fully conscious. SHAM operated 
animals were subjected to the same procedure, with the exception of the aortic 
arch ligation. In these animals, the hooked needle was passed underneath the 
aortic arch and then removed. Immediately after surgery, 0.5ml saline was 
administered subcutaneously if necessary due to blood loss. Rimadyl (carprofen) – 
a non-steroidal anti-inflammatory drug - was administered post-surgery for 
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analgesia, at a dose of 5mg/kg. Animals were housed individually following surgery 
for 8 weeks to allow subsequent cardiac remodelling (Figure 2.7).  
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Figure 2.7. Minimally invasive TAC study timeline. Animals underwent pre-TAC 
transthoracic echocardiography to assess baseline cardiac function prior to TAC 
surgery. At 3 weeks, cardiac function was assessed again by transthoracic 
echocardiography. At 8 weeks, cardiac function was assessed a final time and then 
animals were sacrificed. TAC (transverse aortic constriction), Echo 
(echocardiography).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Week 0 Week 3 Week 8
Pre TAC Echo
TAC Surgery
Post TAC Echo Pre Sacrifice Echo
Sacrifice
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2.15.4 Transthoracic Echocardiography  
Transthoracic echocardiographic assessment of LV function was performed both 3 
and 8 weeks after surgery, as well as before surgery (Figure 2.7). Animals were 
anaesthetized with isofluorane and oxygen as described for surgical procedure 
(section 2.15.3 – Surgical Procedure). Two-dimensional short-axis views and M-
mode images of the LV were recorded at the level of the papillary muscle using a 
Siemens Acuson Sequoia 512 ultrasound machine and a 15L8 probe set to a 
frequency of 14Hz (Siemens, Surrey, UK). The measurements taken include LV end 
systolic diameter (LVESD), LV end diastolic diameter (LVEDD), posterior wall 
thickness during systole (PWTs), posterior wall thickness during diastole (PWTd), 
anterior wall thickness during systole (AWTs), anterior wall thickness during 
diastole (AWTd). An average of 3 measurements of each variable was taken from 
each image (Figure 2.8). At the time of echocardiography both body weight and 
tibia length were also recorded.  
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Figure 2.8 Transthoracic echocardiography parameters. Animals underwent 
transthoracic echocardiography to assess cardiac function. The measurements 
taken include LVESD, LVEDD, PWTs, PWTd, AWTs, AWTd. LVESD (LV end systolic 
diameter), LVEDD (LV end diastolic diameter), PWTs (posterior wall thickness 
during systole), PWTd (posterior wall thickness during diastole), AWTs (anterior 
wall thickness during systole), AWTd (anterior wall thickness during diastole).  
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2.15.5 Organ Harvesting 
Mice were anaesthetised with isofluorane and oxygen as described above for 
surgical procedure (section 2.15.3 – Surgical Procedure) only maintenance 
remained at 5% isofluorane in oxygen delivered at 2 l min−1 as the animals were 
non-recovery. Mice were immobilised on a surgical pad before a vertical incision 
was made to expose the internal organs. Mice were culled via exsanguination, with 
blood being drawn from the LV. Aorta, heart, lungs, epidydimal fat, kidneys, brain 
and plasma were then collected. Samples for protein analysis were snap frozen in 
liquid nitrogen, while samples reserved for immunohistochemistry were placed in 
4% paraformaldehyde overnight before being transferred to 50% ethanol. At the 
time of sacrifice, both body weight and tibia length were also recorded. 
2.16 Histology 
Paraformaldehyde treated tissue was transferred into Shandon biopsy cassettes 
(ThermoFisher Scientific, Paisley, UK) and then processed in a Shandon Excelsior 
tissue processor (ThermoFisher Scientific, Paisley, UK) (Table 2.3).  
Table 2.3 Processing sequence for Shandon Excelsior tissue processor  
 
Solvent  Time (minutes) 
70% Ethanol 30 
95% Ethanol 30 
100% Ethanol 30 
100% Ethanol 30 
100% Ethanol 45 
100% Ethanol 45 
100% Ethanol 60 
Xylene 30 
Xylene 30 
Xylene 30 
Paraffin Wax 30 
Paraffin Wax 30 
Paraffin Wax 45 
 
After infiltration in wax, the tissue was embedded on a Shandon Histocentre 3 
(ThermoFisher Scientific, Paisley, UK).  For sectioning, heart tissue blocks were 
chilled overnight in the freezer and then sectioned on a Shandon Finesse 325 
microtome (ThermoFisher Scientific, Paisley, UK). Initially, tissue blocks were 
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sectioned at 15μm until the entire cardiac section could be visualised, from which 
point on 5μm sections were taken for staining. After cutting, sections were 
transferred to a 40°C waterbath to remove wrinkles before mounting on Tissue-
Tek silanized microscope slides (Sakura Finetek, Thatcham, UK) and placing at 
60°C overnight to dry. Prior to histological staining, sections were de-paraffinised 
and re-hydrated by passing through histoclear and an alcohol gradient (Table 2.4).   
Table 2.4 De-paraffinisation and rehydration sequence   
 
Solution Time (minutes) 
Histoclear 7 
Histoclear 7 
100% Ethanol 7 
90% Ethanol 7 
70% Ethanol 7 
Water 5 
 
2.16.1 Picrosirius Red 
Picrosirius red is used to assess collagen deposition. This stain consists of a solution 
of yellow picric acid and sirius red. With picric acid being small and hydrophobic, 
whereas sirius acid being large and hydrophilic, the acids penetrate the fixed 
tissue at different rates. This leads to the collagenous tissue staining bright red, 
and the remaining tissue staining yellow.  
Sections were de-paraffinised and re-hydrated, as described previously (Table 2.4) 
After re-hydration, sections were placed into Weigert’s haematoxylin (TCS 
Bioscience, Buckingham, UK) for 10 minutes to stain the nuclei before washing in 
running tap water for 10 minutes. Slides were then stained in a 0.1 % sirius red 
solution in saturated picric acid (Picrosirius red (F3BA)) (Sigma-Aldrich, Dorset, 
UK) in the dark for 90 minutes. Slides were washed in 2 changes of 0.01 N HCl 
(acidified water) by submerging 3 times before de-hydration in 2 changes of 100 
% ethanol for 3 minutes and 2 changes in histoclear for 7 minutes. Sections were 
then mounted in DPX mountant (Sigma-Aldrich, Dorset, UK) and dried overnight at 
room temperature. Slides were imaged on Life Technologies EVOS microscope 
(ThermoFisher Scientific, Paisley, UK). 10 images were taken per slide for 
quantification by Image J (NIH, Maryland, USA).  
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2.16.2 Wheat Germ Agglutinin (WGA) 
Wheat Germ Agglutinin (WGA) is a plant lectin found in Triticum vulgaris (wheat), 
which binds to sugars with N-acetylglucosamine and N‐ acetylneuraminic acid 
residues. These residues are found in membrane glycoproteins, including those of 
the cardiomyocyte membrane (Wright, 1984). Therefore, fluorescently labelled 
WGA staining can be used to visualise the cardiomyocyte membrane (Savio-
Gamilberti, et al., 2008) (Tsukamoto, et al., 2013) (Bueno, et al., 2000). 
Sections were de-paraffinised and re-hydrated as described previously (Table 2.4) 
before sodium citrate-mediated antigen retrieval. This is an essential step, as 
during fixation methylene bridges are formed which cross link proteins and mask 
antigenic sites. The sodium citrate retrieval process breaks these bridges and 
exposes the antigenic sites, allowing for antibodies to bind (Abcam, 2017). 
Retrieval involves boiling the slides for 10 minutes in a pre-heated sodium citrate 
solution, and then allowing them to cool for 20 minutes to giving time for antigen 
refolding.  Slides were then washed in running tap water for 5 minutes followed 
by 5 minutes in PBS. Sections were blocked in PBS with 1 % BSA and 5 % goat serum 
(VectorLabs, Peterborough, UK) for 1 hour at room temperature, before being 
incubated with 10 μg/mL Alexa Fluor 555 conjugated WGA (ThermoFisher 
Scientific, Paisley, UK) prepared in the blocking solution for 1 hour. WGA allowed 
visualisation of the cell membrane. Following incubation, sections were washed 
twice in PBS for 5 minutes and mounted in Prolong Gold+DAPI (ThermoFisher 
Scientific, Paisley, UK). DAPI is a nuclear stain which allows visualisation of the 
nucleus in the cardiomyocytes. Slides were protected from light and allowed to 
dry overnight prior to imaging by epifluorescence confocal microscopy. 10 Images 
were taken per slide, and were analysed in Image J (NIH, Maryland, USA) to assess 
cardiomyocyte cross-sectional area. All cardiomyocytes were measured per 
image.  
2.17 Tissue Homogenisation 
Tissue homogenisation is similar to preparation of cell lysate, where the tissue 
must be broken down to release cellular contents. Both cardiac tissue samples 
from the mouse TAC surgical study and LAD artery balloon occlusion pigs, kindly 
provided by the Hajjar group, were prepared in this manner to allow assessment 
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of proteins via immunoblotting. 50mg of tissue was placed in a 2ml RNAse free 
tube alongside 5mm stainless steel beads (QIAgen, Manchester, UK).  700μl of RIPA 
buffer (Sigma-Aldrich, Dorset, UK) substituted with appropriate inhibitors; 
protease cocktail inhibitor (Roche, West Sussex, UK), phos-stop tablets (Roche, 
West Sussex, UK)  and 25mM N-ethylmaleimide (NEM) (Sigma-Aldrich, Dorset, UK)  
was added to the tubes and the tubes were then placed in the homogenizer 
(QIAgen, Manchester, UK). The protease cocktail inhibitor tablets inhibited a 
broad spectrum of proteases which would normally break down proteins, phos-
stop tablets inhibited phosphatases which prevented phosphorylated proteins 
from becoming de-phosphorylated, and NEM inhibited enzymes which promote de-
SUMOylation. The tubes were pulsed for 45 seconds with a 3 minute rest period in 
between to prevent excess heat. This was repeated 3 times. After homogenisation 
samples were centrifuged for 12 minutes at 13,000rpm at 4°C. The supernatant 
was collected and subject to protein quantification by Bradford assay (described 
in section 2.5 – Protein Quantification by the Bradford Assay). Samples were 
assessed via immunoblotting (described in section 2.6 – Immunoblotting).  
 
2.18 Statistical Analysis  
Data are expressed as mean ± standard error of the mean (SEM) unless otherwise 
stated. Statistical analysis was performed using GraphPad Prism Version 6 
(GraphPad Prism, California, USA). For comparisons of a continuous variable 
between 2 experimental groups, paired and unpaired Student's t-tests were 
applied as appropriate. For statistical comparisons in data sets with more than 
two groups, repeated measures analysis of variance (ANOVA) was applied, 
followed by the Dunnett's or Tukey’s post-tests, comparing all samples groups 
against a designated control group or for comparisons between the groups. For 
the majority of data derived from immunoblotting raw data was normalised and 
expressed as a percentage of control values. In each instance, statistical 
significance was denoted as follows; * when p <0.05, ** when p<0.01, *** when 
p<0.001, **** when p < 0.0001. 
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Chapter 3 Production of a SUMO-β2AR Specific 
Polyclonal Antibody 
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3.1 Introduction 
3.1.1 Post-Translational Modification (PTM) Antibodies  
A post-translational modification (PTM) is a chemical change experienced by a 
protein as a result of the covalent attachment of functional groups or smaller 
proteins. This can occur at any point within the life cycle of a protein ranging from 
directly after ribosomal translation up until the protein has relocated to a specific 
cellular location. These chemical changes can alter the structure of the protein 
and therefore can impact on protein stability, activity, localisation and protein-
protein interactions (Rockland-Inc, 2017). As discussed in Chapter 1 - Introduction, 
the β2AR, is subject to various PTMs including phosphorylation, glycosylation, 
palmitoylation, and ubiquitination (Rands, et al., 1990) (Sadeghi & Birnbaumer, 
1999) (Ovchinnikov, et al., 1988) (Benovic, et al., 1987) (Daaka, et al., 1997) 
(Hausdorff, et al., 1989) (Vaughan, et al., 2006) (Shenoy, et al., 2001). Since PTMs 
play a key role in regulating both function and activity of proteins in response to 
environmental stimuli, they are important determinants of cellular signalling, and 
therefore it is imperative to have biochemical techniques which allow us to 
quantify these modifications.  
Developing antibodies that specifically recognise the PTM modified residue and 
the surrounding amino acids within a protein, but not the non-modified sequence 
is an advancing area (Arur & Schedl, 2014) (Hattori, et al., 2013). This type of 
antibody is challenging to generate, but multiple companies now produce highly 
specific PTM antibodies that can be used in a wide range of in vitro and in vivo 
studies. The most common PTM examined via specific antibodies is 
phosphorylation – a PTM in which a phosphate group is added to either a serine, 
threonine or tyrosine residue by a kinase (Rockland-Inc, 2017). Many companies 
offer a diverse range of phospho-specific antibodies that successfully detect the 
phospho-modified sequence with great precision but this is not true for the other 
mentioned PTMs such as ubiquitination, palmitoylation, glycosylation, and the 
focus of our work SUMOylation.  
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3.1.1.1 SUMO Specific Antibody Development  
This thesis concentrates on SUMOylation of the β2AR, in which a small SUMO 
protein is covalently linked to a lysine residue on the substrate. The Baillie group 
confirmed putative SUMOylation sites on the β2AR using both software sequence 
analysis and peptide array (Figure 1.13, Chapter 1 - Introduction). Traditional 
identification of SUMOylation is mediated via the presence of a “ghost” band – a 
band which is apparent via immunoblotting at approximately 12-25kDa larger than 
the original protein band – indicative of the addition of the SUMO molecule. 
Although the SUMO protein itself only has an approximate weight of 11kDa – often 
larger shift sizes are observed due to the formation of SUMO chains, in which 
multiple SUMO molecules are added to either one lysine residue as a chain, or 
multiple lysine residues throughout the protein (Park-Sarge & Sarge, 2005). These 
band shifts are not always easily observed next to the non-modified protein 
therefore we aimed to develop a SUMO-site specific antibody for the β2AR. To 
produce such an antibody, we worked in conjunction with cardiovascular life 
science company Badrilla ® (Badrilla, Leeds, UK) to produce a panel of novel 
SUMO-specific antibodies against modified cardiac signalling proteins, starting 
with the β2AR. To my knowledge, this is the first time a SUMO-site specific 
antibody has been successfully raised. 
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3.2 Aims  
We aimed to: 
1. Validate the SUMOylation site at lysine 235 using peptide array 
2. Develop a polyclonal antibody which specifically identifies the SUMOylated 
form of the β2AR 
3. Validate the specificity of the SUMO-β2AR antibody to the epitope against 
which it was raised 
4. Determine the capability of the SUMO-β2AR antibody to detect the 
SUMOylated form of the β2AR in cell and tissue samples 
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3.3 Methods  
General materials and methods can be found in Chapter 2 – General Materials and 
Methods. The methods discussed below are specific to this chapter. In addition to 
these methods, immunoblotting was used (previously described in Chapter 2 - 
General Materials and Methods). Immunoblotting was used to assess protein 
expression. 
3.3.1 Polyclonal Antibody Purification Overview 
The first step in polyclonal antibody production is to design an antigen for 
injection into an animal. The second step is to choose a host animal for antibody 
production. The choice of animal is based on two factors; 1) the volume of 
antibody required to be produced, as a larger animal will produce a greater 
volume of antibody, and 2) the phylogenetic link between the immunised animal 
and the source of the antigen, as a more distant phylogenetic relationship will 
lead to a more immunogenic antigen. After primary immunisation and additional 
booster injections, the blood was collected and centrifuged to remove both blood 
cells and clotting factors. In serum, 1% of the total antibody population consists 
of antibodies specific to the antigen used for animal immunisation (Uhlen & 
Ponten, 2005). To isolate this 1% there are various purification strategies, one of 
which is affinity chromatography. The principles of affinity chromatography 
depend on the reversible interaction between a binding protein – the antibody - 
and a ligand – the antigen. One of these interacting molecules can be coupled to 
a solid support, known as an affinity chromatography column. When sera 
containing antibodies is passed through a column which has been packed with 
antigen, the antibodies become bound on the column via numerous non-covalent 
interactions including van der Waals forces, ionic bonds, hydrogen bonds and/or 
hydrophobic interactions. Antibodies can then be eluted by changing buffer 
conditions such as pH, ionic strength or polarity, to disrupt the interaction 
between antibody and column (GEHealthcare, 2014). 
 
3.3.2 Epitope Design  
Although the initial data (Figure 1.13) indicates the lysines at 60 and 235 to be 
the dominant SUMOylation sites, this may not reflect the case in real life due to 
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the proximity of position 60 to the cell membrane, as this lysine emerges from the 
membrane into the first intracellular loop. In this position, access of SUMO 
machinery to this site may prove problematic. Further analysis utilising alanine 
scans reveals that both lysines 232 and 235 are susceptible to SUMOylation (Figure 
3.6). For this reason, the SUMO-specific antibody epitope was designed against 
the first site in the sequence, 232. However, we do not expect the antibody to be 
capable to distinguish between SUMO conjugation on lysines which are only 3 
amino acids apart.   
The epitope, which is the antigen for immunisation, is chemically synthesised via 
standard solid phase methodology and purified by preparative reversed phase 
high-performance liquid chromatography (HPLC) (Anderson, et al., 1984). The 
peptide epitope was attached covalently to an immunogenic carrier protein, 
which in this case was keyhole limpet hemocyanin (KLH), a mollusc protein, to 
promote a more immunogenic response. A cysteine next to the acetyl (Ac) group 
on the antigen epitope was incorporated into the sequence and used for carrier 
protein attachment.  
The peptides in Table 3.1 are the antigens which were used to immunise rabbits. 
The antigens are a partial sequence of the β2AR with lysine 232 modified by either 
SUMO-1 or SUMO-2/3. Two rabbits were injected with the upper peptide against 
the SUMO-1 modified antigen and two injected with the lower peptide against the 
SUMO-2/3 modified antigen (Table 3.2). 
 
Table 3.1 Antigens for immunisation 
 
SUMO-1-β2AR KRQLQK (GGTQEQY)IDKSEGRF 
SUMO-2/3-β2AR KRQLQK(GGTQQQ)IDKSEGRF 
 
Amino acid abbreviations in appendix. 
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Table 3.2 Rabbits immunised against SUMO-1 or SUMO-2/3-β2AR 
 
RABBIT 23 SUMO-2/3-β2AR 
RABBIT 24 SUMO-2/3-β2AR 
RABBIT 25 SUMO-1-β2AR 
RABBIT 26 SUMO-1-β2AR 
 
Amino acid abbreviations in appendix. 
The epitope consists of partial sequence of receptor KRQLQKIDKSEGRF with 
covalent attachment of either SUMO-1 or SUMO-2/3 sequences, YQEQTGG or 
QQQTGG, respectively at lysine 232 (Figure 3.1A). The epitope was designed with 
the intention to detect the interaction point between β2AR and the SUMO protein, 
as opposed to either SUMO or β2AR alone (Figure 3.1B).  
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Figure 3.1 Epitope design schematic. (A) Epitope used for rabbit immunisation 
against SUMOylated β2AR. Consisted of partial sequence of β2AR KRQLQKIDKSEGRF 
with addition of either SUMO-1 or SUMO-2/3 sequences, YQEQTGG or QQQTGG, 
respectively. (B) Our antibody was designed to detect the interaction point 
between β2AR and SUMO not β2AR only or SUMO only. Amino acid abbreviations in 
appendix. 
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3.3.3 Rabbit Immunisation Protocol  
Rabbits received an initial immunisation via intradermal injection. After this, at 
monthly intervals, the animals underwent further antigen booster injections 
(Figure 3.2). The initial immunisation promotes production of immunoglobulin M 
(IgM) by B cells, which is the first antibody to be produced in response to first-
time antigen exposure (Alberts, et al., 2002). Booster injections promote a switch 
from the production of IgM to immunoglobulin G (IgG), the most dominant 
immunoglobulin found within the circulation, making up 75% of serum antibodies 
in humans (Alberts, et al., 2002). These bleeds contained the IgG against the 
injected antigens, but combined with a mixture of other blood proteins. To isolate 
the antibodies against SUMO-β2AR, the contaminating serum proteins and non-
specific antibodies were removed by affinity chromatography.  
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Figure 3.2. Rabbit immunisation protocol. A pre-immune bleed was taken 
initially prior to injection with antigen. After immunisation, a boost injection was 
given at monthly intervals. Bleeds were taken from the rabbit after each boost. 
The final bleed was larger in volume since the animal was sacrificed via 
exsanguination. The initial peak prior to boost 1 was IgM response to antigen, but 
after boost 1 this switches to IgG. IgM (immunoglobulin M), IgG (immunoglobulin 
G), P.I (pre-immune).  
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3.3.4 Immunoglobulin G (IgG) Isolation  
The blood samples were dialysed with binding buffer (20mM NaHPO4, 150mM NaCl 
pH 7) and left at 4°C overnight. The dialysed serum was passed through the AKTA 
chromatography system (GE Healthcare, Buckinghamshire, UK) using a protein A 
epoxy activated sepharose 6B column (GE Healthcare, Buckinghamshire, UK). 
Staphylococcal protein A (SpA), is a naturally occurring protein found in the cell 
wall of staphylococcus aureus which has affinity for IgG, and therefore, is often 
used in antibody purification (Hjelm, et al., 1972). Approximately 5ml of dialysed 
serum was passed through the column using AKTA affinity chromatography 
equipment in one load, as excess of 5ml compromised function of the column. All 
IgG was bound to the protein A column with non-IgG passing through the column 
as “flow through”. The column was then washed and IgG was eluted using low pH 
eluting buffer (100mM glycine HCl pH 3) which disrupted the interaction between 
the column and IgG. The eluted product was collected in 2ml segments and 
monitored by UV absorption at 280nm, with the output displayed graphically 
(Figure 3.3). This allowed identification of the segments containing IgG. The 
segments containing IgG for further purification ranged from B2 to B12 (Figure 
3.3). These segments were then pooled for treatment with neutralisation buffer 
(1.0M Tris HCl pH9) to prevent damage from the acidic low eluting pH. Further 
chromatographic procedures were required to isolate IgG which identified 
SUMOylated β2AR antigen from the complete pool of IgG.  
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Figure 3.3 IgG isolation. 5ml of dialysed serum purified via affinity 
chromatography on protein A epoxy activated sepharose 6B column. Large pink 
peak represents the 280 UV absorption (amino acid detection) by the initial “flow 
through” material which does not bind to column. Low pH was applied to elute 
bound fraction producing the second pink peak. This peak indicates segments 
which contain the eluent; B2-B12. The eluent contained all IgG from the sera. Blue 
peak absorbance 280nm. Pink peak absorbance at 280nm. Red peak absorbance 
260nm. Brown peak representative of conductivity. Green peak representative of 
concentration.   
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3.3.5 Specific SUMO-β2AR IgG Isolation 
Following total IgG isolation, IgG which specifically recognised the SUMOylated 
form of the β2AR was isolated. The specific SUMO-β2AR IgG was isolated from the 
pool of IgG using custom peptide affinity columns. For these columns, the affinity 
ligand that is immobilised on the column is custom designed. To immobilise 
affinity ligand on the columns, 1.2g of freeze dried sepharose powder (GE 
Healthcare, Buckinghamshire, UK) was suspended in dH2O giving matrix volume of 
3.6ml. This was washed via 500 x g centrifugation for 60 seconds. The affinity 
ligands which were peptides either recognising β2-SUMO-1/ β2-SUMO-2/3 or β2 
alone (Table 3.3) were dissolved in coupling buffer (phosphate buffered saline) to 
a concentration of 0.5mg-10mg/ml and reduced using TCEP (tris(2-
carboxylethyl)phosphine)) before addition to the matrix.  
 
Table 3.3 Affinity ligand peptides 
 
SUMO-1-β2AR KRQLQK (GGTQEQY)IDKSEGRF 
SUMO-2/3-β2AR KRQLQK(GGTQQQ)IDKSEGRF 
β2AR alone KRQLQKIDKSEGRF 
 
Amino acid abbreviations in appendix. 
 
The columns were known as column 1) designed to recognise SUMO-β2AR either 
against the SUMO-2/3 or SUMO-1 paralogue dependent upon which rabbit sera was 
being purified, and column 2) designed to recognise β2AR alone (Figure 3.4). The 
IgG binding to column 1 included IgG specific for β2AR, SUMO-β2AR and SUMO. The 
reason IgG against SUMO and β2AR could interact with this column, as well as IgG 
against SUMO-β2AR, is due to epitope design – it is probable that the column had 
enough points of interaction with both these types of IgG that an interaction is 
feasible, even although it is not completely specific like IgG against SUMO-β2AR. 
Total IgG was loaded onto column 1 using a peristaltic pump. This column was 
then slotted into position on the AKTA chromatography equipment and the eluent 
obtained. This eluent was of value as it contained IgG which can bind SUMO, SUMO-
β2AR and β2AR, separated from the total portion of IgG (Figure 3.5A). To isolate 
the SUMO and SUMO-β2AR IgG from the β2AR IgG, column 2 was used. The eluent 
was passed down column 2 which recognised IgG specific for β2AR alone. Here the 
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fraction that was retained was the flow through, as it contained the bulk of SUMO-
β2AR IgG which was not masked by β2AR alone IgG (Figure 3.5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
 
 
Figure 3.4 Peptide affinity columns for isolation of specific SUMO-β2AR IgG. (A) 
Total IgG was applied to column 1 which recognised SUMO-β2AR. This bound IgG 
specific for β2AR, SUMO-β2AR and SUMO. The eluent from this column was passed 
down column 2 which recognised β2AR alone. This column would interact with IgG 
for β2AR alone and therefore our flow through contained IgG which recognised 
SUMO-β2AR and SUMO (B) Peptides similar to epitope were used to produce 
columns and schematic identifies anticipated IgG-column interactions. 
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Figure 3.5 Peptide affinity columns - affinity chromatography. (A) SUMO-β2AR 
column. Eluent loaded onto the column using a peristaltic pump. Eluent processed 
via AKTA affinity chromatography equipment producing pink peak. This eluent was 
of value as it contains IgG which can bind SUMO, SUMO-β2AR and β2AR. (B) β2AR 
column. Eluent from SUMO-β2AR column was passed down this column. The 
important area was the flow through as the pink peak contained β2AR alone IgG. 
Flow through contained IgG against SUMO-β2AR which was not swamped by IgG 
against β2AR alone. Blue peak absorbance 280nm. Pink peak absorbance at 280nm. 
Red peak absorbance 260nm. Brown peak representative of conductivity. Green 
peak representative of concentration.   
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3.3.6 Antibody Testing 
We tested the custom antibodies described above for the ability: 
 
1) To specifically recognise the SUMOylated epitope against which it was 
raised 
2) To detect the SUMOylated form of the β2AR in cell and tissue samples 
To evaluate the success of these antibodies in recognising their epitope, a peptide 
array SUMOylation assay was used (described in Chapter 2 - General Materials and 
Methods). The procedure was followed as before, with four sets of slides consisting 
of truncated versions of the antigen epitope which were: - 
 
1) Pre-SUMOylated and probed with commercially available His HRP 
conjugated antibody detecting SUMOylation promoted by an in vitro 
SUMOylation kit, which modifies with a His-SUMO protein  
 
2) Pre-SUMOylated and probed with novel SUMO-antibodies developed in 
conjunction with Badrilla ® 
 
3) Pre-SUMOylated and probed with novel SUMO-antibodies developed in 
conjunction with Badrilla ® after a pre-incubation with an unSUMOylated 
“blocking” peptide of the full length unSUMOylated epitope  
 
4) UnSUMOylated and treated with antibodies either His-HRP conjugated or 
novel SUMO-β2AR antibodies to identify that in vitro SUMOylation has been 
successful.  
 
The antibody was then tested in cell and tissue lysate samples via immunoblot 
analysis (described in Chapter 2 - General Materials and Methods). 
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3.4 Results 
3.4.1 Identification of Key Amino Acid Residues Required 
for β2AR SUMOylation 
The Baillie group identified four possible SUMOylation sites on the β2AR using sp2.0 
SUMOylation site identification software at positions 60, 227, 232 and 235. 
Following further validation, the two most robustly SUMOylated lysines were at 
position 60 and position 235 (Figure 1.13, Chapter 1 - Introduction). As mentioned 
in section 3.3.2 – Epitope Design although, the lysine found at position 60 was 
susceptible to SUMOylation using an in vitro peptide array technique; this may not 
reflect the case in real life because of its proximity to the cell membrane. 
Therefore, the aim was to identify the SUMO-susceptibility of site 235. Due to the 
close proximity of lysines 232 and 235, both were mutated for alanine scanning 
peptide arrays.  
Peptide array slides consisting of the sequence of the proposed cardiac 
SUMOylation site plus alanine scans of the sequence were developed. The slides 
were SUMOylated using an in vitro SUMOylation kit, which consists of the enzymes 
essential for SUMOylation and SUMO paralogues 1, 2 and 3 which are His tagged. 
This tag allows visualisation of SUMOylation using the His-HRP antibody. Peptide 
array data suggests that the receptor can be SUMOylated at two non-consensus 
lysines - 232 and 235. In both cases, mutation of lysine to alanine results in a 75% 
reduction in β2AR SUMOylation in comparison to native control peptide (Figure 
3.6) (N=3) (*p<0.05). Control coomassie stained slides demonstrated that the 
slides contained equal amounts of peptide spots (Figure 3.6) and control non-
SUMOylated slides identified that the SUMOylation process was successful as the 
His-HRP antibody did not detect SUMOylation on these control arrays (Figure 3.6). 
It is notable that both lysines 235 and 232 are required for maximal SUMOylation, 
as substitution of either attenuates the signal significantly. Earlier data had 
suggested that 235 was the single non-consensus SUMO site. This probably stems 
from the close proximity of lysines as SUMOylation of one site alone is difficult to 
visualise in a peptide array format that uses 25-mer peptides. As discussed in 
section 3.3.2 – Epitope Design, SUMO-specific antibody epitope was designed 
against the first site in the sequence, 232. However, we do not expect the 
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antibody to be capable to distinguish between SUMO conjugation on lysines which 
are only 3 amino acids apart.  
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Figure 3.6 Lysines 232 and 235 are essential for SUMOylation of β2AR. (A&B) 
β2AR peptide arrays contained wild type sequences and alanine substitutions of 
crucial lysine residues 232 and 235. These were SUMOylated in vitro. Mutation of 
essential residues resulted in significant ablation of SUMO modification in β2AR. 
Control coomassie slides demonstrated that the slides contained peptide spots. 
Non-SUMOylated slides identified that the SUMOylation process was successful as 
the His-HRP antibody did not detect SUMOylation on this array (N=3) (*p<0.05). 
Primary concentration 1 : 5000.  (A) Representative peptide array spots shown. 
Amino acid abbreviations in appendix. 
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3.4.2 Conservation of β2AR SUMOylation Lysines 232 and 
235  
Another way to emphasize the importance of the SUMO consensus motif is via 
examination of motif conservation throughout various species as was done for 
SERCA2a (Kho, et al., 2011).  Through comparison of the SUMOylation sites of 
SERCA2a Kho et al examined the conservation of lysine 480 and 585 in mouse, rat, 
pig and human showing conservation of the sequence in all species. Often 
sequences of amino acids which play a functional role are conserved throughout 
multiple species. Indeed, the β2AR SUMOylation sites at position 60, 227, 232 and 
235 which were identified from the sp2.0 SUMOylation site identification software 
are conserved throughout human, rat, mouse, rhesus monkey and cow (Figure 
3.7).  
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Figure 3.7 β2AR SUMOylation sites are conserved between species. β2AR 
SUMOylation sites 60 (consensus) and 227, 232 and 235 (non-consensus) are 
conserved throughout species. Amino acid abbreviations in appendix. 
 
 
Position 60 (consensus)
HUMAN LVITAIAKFERLQTV
RAT LVITAIAKFERLQTV
MOUSE LVITAIAKFERLQTV
RHESUS MONKEY LVITAIAKFERLQTV
COW LVITAIAKFERLQTV
Position 227 (non consensus)
HUMAN SRVFQEAKRQLQKID
RAT SRVFQVAKRQLQKID
MOUSE SRVFQVAKRQLQKID
RHESUS MONKEY SRVFQEAKRQLQKID
COW SRVFQVAKRQLQKID
Position 232 (non consensus)
HUMAN EAKRQLQKIDKSEGR
RAT VAKRQLQKIDKSEGR
MOUSE VAKRQLQKIDKSEGR
RHESUS MONKEY EAKRQLQKIDKSEGR
COW VAKRQLQKIDKSEGR
Position 235 (non consensus)
HUMAN RQLQKIDKSEGRFHV
RAT RQLQKIDKSEGRFHV
MOUSE RQLQKIDKSEGRFHV
RHESUS MONKEY RQLQKIDKSEGRFHV
COW RQLQKIDKSEGRFHV
Position 60 (consensus)
HUMAN LVITAIAKFERLQTV
RAT LVITAIAKFERLQTV
MOUSE LVITAIAKFERLQTV
RHESUS MONKEY LVITAIAKFERLQTV
COW LVITAIAKFERLQTV
Position 227 (non consensus)
HUMAN SRVFQEAKRQLQKID
RAT SRVFQVAKRQLQKID
MOUSE SRVFQVAKRQLQKID
RHESUS MONKEY SRVFQEAKRQLQKID
COW SRVFQVAKRQLQKID
Position 232 (non consensus)
HUMAN EAKRQLQKIDKSEGR
RAT VAKRQLQKIDKSEGR
MOUSE VAKRQLQKIDKSEGR
RHESUS MONKEY EAKRQLQKIDKSEGR
COW VAKRQLQKIDKSEGR
Position 235 (non consensus)
HUMAN RQLQKIDKSEGRFHV
RAT RQLQKIDKSEGRFHV
MOUSE RQLQKIDKSEGRFHV
RHESUS MONKEY RQLQKIDKSEGRFHV
COW RQLQKIDKSEGRFHV
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3.4.3 Epitope Recognition Testing – Peptide Array 
All antibodies produced at Badrilla ® were shown to be non-specific for the 
SUMOylated epitope as they recognised the non SUMOylated β2AR sequence as well 
as the SUMOylated epitope (Figure 3.8 and 3.9) (N=3).  For control experiments to 
confirm successful array SUMOylation, antigen epitope arrays, both SUMOylated 
and unSUMOylated, were incubated with the His tag antibody which detects 
SUMOylation mediated via the in vitro SUMOylation kit (Figure 3.10) (N=3). This 
provided evidence of successful in vitro SUMOylation. These findings confirmed 
the commercial antibody can decipher between the SUMOylated and non 
SUMOylated epitopes but the 4 custom antibodies cannot.   
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Figure 3.8 Testing of SUMO-2/3-β2AR antibody – derived from rabbits 23 and 
24. SUMO-β2AR antibody from rabbit 23 (A) and 24 (B). Peptide array slides 
consisting of truncations of epitope highlighted in red. Peptide arrays SUMOylated 
via ENZO in vitro SUMOylation kit per manufacturers’ instruction. Control array 
does not undergo in vitro SUMOylation therefore remains unSUMOylated. Antibody 
incubated overnight on both control and SUMOylated slide (N=3). Primary 
concentration 1 : 500, secondary concentration 1 : 1000.  Representative peptide 
array spots shown. Amino acid abbreviations in appendix. 
 
1. VSFYVPLVIMVFVYSRVFQEAKRQL
2. VPLVIMVFVYSRVFQEAKRQLQKID
3. VFVYSRVFQEAKRQLQKIDKSEGRF
4. VFQEAKRQLQKIDKSEGRFHVQNLS
5. KRQLQKIDKSEGRFHVQNLSQVEQD
6. QKIDKSEGRFHVQNLSQVEQDGRTG
7. SEGRFHVQNLSQVEQDGRTGHGLRR
8. HVQNLSQVEQDGRTGHGLRRSSKFC
SUMOYLATED 
CONTROL
(UNSUMOYLATED) 
1.
2.
3.
4.
5.
6.
7.
8.
1:200 primary 
1:2000 secondary
Rabbit 23
A.
1.
2.
3.
4.
5.
6.
7.
8.
1. VSFYVPLVIMVFVYSRVFQEAKRQL
2. VPLVIMVFVYSRVFQEAKRQLQKID
3. VFVYSRVFQEAKRQLQKIDKSEGRF
4. VFQEAKRQLQKIDKSEGRFHVQNLS
5. KRQLQKIDKSEGRFHVQNLSQVEQD
6. QKIDKSEGRFHVQNLSQVEQDGRTG
7. SEGRFHVQNLSQVEQDGRTGHGLRR
8. HVQNLSQVEQDGRTGHGLRRSSKFC
B.
SUMOYLATED 
CONTROL
(UNSUMOYLATED) 
1:200 primary 
1:2000 secondary
Rabbit 24
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Figure 3.9 Testing of SUMO-1-β2AR antibody – derived from rabbits 25 and 26. 
SUMO-β2AR antibody from rabbits 25 (A) and 26 (B). Peptide array slides consisting 
of truncations of epitope highlighted in red. Peptide arrays SUMOylated via ENZO 
in vitro SUMOylation kit per manufacturers’ instruction. Control array does not 
undergo in vitro SUMOylation therefore remains unSUMOylated. Antibody 
incubated overnight on both control and SUMOylated slide (N=3). Primary 
concentration 1 : 500, secondary concentration 1 : 1000.  Representative peptide 
array spots shown. Amino acid abbreviations in appendix.  
 
1. VSFYVPLVIMVFVYSRVFQEAKRQL
2. VPLVIMVFVYSRVFQEAKRQLQKID
3. VFVYSRVFQEAKRQLQKIDKSEGRF
4. VFQEAKRQLQKIDKSEGRFHVQNLS
5. KRQLQKIDKSEGRFHVQNLSQVEQD
6. QKIDKSEGRFHVQNLSQVEQDGRTG
7. SEGRFHVQNLSQVEQDGRTGHGLRR
8. HVQNLSQVEQDGRTGHGLRRSSKFC
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A.
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Figure 3.10 Testing of SUMO-β2AR antibody – His-HRP antibody control. Peptide 
array slides consisting of truncations of epitope highlighted in red. Peptide arrays 
SUMOylated via ENZO in vitro SUMOylation kit per manufacturers’ instructions. 
Control array does not undergo in vitro SUMOylation therefore remains 
unSUMOylated. His-HRP Antibody incubated overnight on both control and 
SUMOylated slide (N=3). Primary concentration 1 : 5000.  Representative peptide 
array spots shown. Amino acid abbreviations in appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTROL 
(UNSUMOYLATED) SUMOYLATED 
1.
2.
3.
4.
5.
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1. VSFYVPLVIMVFVYSRVFQEAKRQL
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4. VFQEAKRQLQKIDKSEGRFHVQNLS
5. KRQLQKIDKSEGRFHVQNLSQVEQD
6. QKIDKSEGRFHVQNLSQVEQDGRTG
7. SEGRFHVQNLSQVEQDGRTGHGLRR
8. HVQNLSQVEQDGRTGHGLRRSSKFC
A.
His-HRP Antibody Control
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As all the custom designed SUMOylation-specific antibodies recognised the 
unmodified form of the β2AR, the testing process was redesigned to include pre-
incubation (for approximately 1 hour) of the antibody with 10μM blocking peptide 
of the full length unSUMOylated epitope peptide (KRQLQKIDKSEGRF) prior to 
incubation with peptide arrays. For this, we selected 1 from the 4 rabbit antibody 
sets; rabbit 25. This decision was made on the basis that rabbits 23 and 24 showed 
excessive non-specific binding of the unSUMOylated slides compared to the 
SUMOylated slides. Rabbit 26 derived antibody showed high variability in the 
control slide in comparison to other animals – therefore the rabbit selected for 
further testing was rabbit 25 – as the antibody derived from the sera of this animal 
showed a similar profile in both the SUMOylated and non SUMOylated slides. This 
technique proved successful in quenching unspecific binding leading to recognition 
of the SUMOylated epitope alone (Figure 3.11) (N=3). This represents the first time 
a SUMOylated epitope has been recognised specifically using immunoblot-peptide 
array technique, validating the antibody derived from rabbit 25 sera for further 
testing. 
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Figure 3.11 Testing of SUMO-1-β2AR antibody from derived from rabbit 25 – 
blocking peptide. Peptide array slides consisting of truncations of epitope 
highlighted in red. Peptide arrays SUMOylated via ENZO in vitro SUMOylation kit 
per manufacturers’ instruction. Control array does not undergo in vitro 
SUMOylation therefore remains unSUMOylated. Antibody incubated overnight on 
both control and SUMOylated slide after 1 hour pre incubation with 10μM non-
SUMOylated epitope blocking peptide (N=3). Primary concentration 1 : 500, 
secondary concentration 1 : 1000.  Representative peptide array spots shown. 
Amino acid abbreviations in appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. VSFYVPLVIMVFVYSRVFQEAKRQL
2. VPLVIMVFVYSRVFQEAKRQLQKID
3. VFVYSRVFQEAKRQLQKIDKSEGRF
4. VFQEAKRQLQKIDKSEGRFHVQNLS
5. KRQLQKIDKSEGRFHVQNLSQVEQD
6. QKIDKSEGRFHVQNLSQVEQDGRTG
7. SEGRFHVQNLSQVEQDGRTGHGLRR
8. HVQNLSQVEQDGRTGHGLRRSSKFC
1.
2.
3.
4.
5.
6.
7.
8.
1:500 primary 
1:2000 secondary
Peptide 10μM pre incubate
Rabbit 25
SUMO ANTIBODY + 
PEPTIDE 
CONTROL (SUMO 
ANTIBODY ALONE)
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3.4.4 SUMO-β2AR Recognition in Cells 
In Chapter 4 – In Vitro SUMOylation of the β2AR,  I have shown that the E3 ligase 
PIASγ – the final enzyme of the SUMOylation cascade - plays an important role in 
the SUMOylation of the β2AR. Many of the findings within this thesis are based on 
this premise. For further evidence to support the notion that PIASγ mediates 
SUMOylation we wished to use the SUMO-β2AR specific antibody to determine if 
the SUMOylated form of the β2AR could be identified in cells, which overexpress 
PIASγ and the β2AR.  
To examine the SUMOylation of the β2AR in vitro in the presence of PIASγ, the 
HEKβ2 cell line was used. This is a stable HEK293 cell line which stably 
overexpresses the GFP/FLAG-tagged form of the β2AR (McLean & Milligan, 2000) 
(Mclean, et al., 1999). These cells were either transiently transfected with PIASγ-
HA tagged DNA constructs or mock transfected with empty transfection reagent. 
PIASy expression was confirmed via the expression of the HA tag (panel 4). 
Standard HEK293 cell lysate was probed using SUMO-β2AR antibody to provide 
evidence that the antibody was specific for the β2AR in the HEKβ2 stable cell line. 
GFP antibody identified the β2AR present within the HEKβ2 cell lysate but not in 
HEK293 cell lysate (panel 5). GAPDH was used as a loading control (panel 3). 
In agreement with the peptide array validation (Figure 3.8 - 3.11) above, SUMO-
β2AR antibody (without prior incubation with blocking peptide) was capable of 
detecting the receptor specifically within the HEKβ2 cell line (both with and 
without PIASγ expression) but not in native HEK293 cell lysate (panel 1). After 1 
hour pre-incubation of the SUMO-β2AR antibody with blocking peptide, the SUMO-
β2AR antibody selectively identifies the SUMOylated form of the β2AR which is 
promoted via overexpression of the E3 ligase PIASγ (panel 2) (Figure 3.12) (N=3). 
However, there are two important points two consider. Firstly, in the HEKβ2 lane 
(lanes 1 and 2) (panel 2) the SUMO-β2AR antibody still detects what would appear 
to be unSUMOylated β2AR, when the intention of the blocking peptide is to prevent 
unSUMOylated receptor detection. We cannot rule out unspecific binding to 
another protein of similar molecular weight, or the blocking peptide incubation 
time and/or concentration is not sufficient to abolish antibody-receptor 
interaction. Another option to consider is the antibody could be detecting 
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endogenous levels of β2AR SUMOylation, which we would expect to be lesser in 
lanes 1 and 2 (panel 2) when compared to HEKβ2+PIASγ lanes 3 and 4 (panel 2). 
This seems the more probable option as the HEK293 lane alone should account for 
any unspecific binding from proteins existing with the HEK cell lysate (lane 5 and 
6), and no bands are apparent in these lanes.  Secondly, the SUMOylated-β2AR 
band does not appear to be presenting at a 12-25kDa shift from the original 75kDa 
β2AR band, indicative of SUMOylation. However, as the upper molecular markers 
of the gel present closely together (see panel 5, 75kDa and 100kDa), it would be 
important to run the gel for longer leading to increased separation between higher 
molecular weights. This would allow determination of the band shift that may be 
present. This is the first time a SUMO-site specific antibody has been reported to 
monitor SUMOylation of a protein using cellular lysates, and the first validation 
that the β2AR gets modified by SUMO.  
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Figure 3.12 Testing of SUMO-β2AR specific antibody in cells. PIASγ used to 
promote SUMOylation of the β2AR. With SUMO-β2AR antibody alone antibody 
detected all forms of receptor as opposed to only SUMOylated forms (panel 1). 
SUMO-β2AR antibody detected SUMOylated form of the β2AR in the presence of 
blocking peptide, however protein detection in lanes 1&2 and band shift in lanes 
3&4 remain to be confirmed (panel 2). GAPDH identified protein in all lanes (panel 
3). HA identified expression of PIASγ indicating transfection success (panel 4). GFP 
identified β2AR receptor presence in the cells, blue arrow indicative of re-probing 
of blot from panel 2 (panel 5) (N=3). Representative blots are shown. 
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3.5  Discussion 
As eluded to above, the β2AR is subject to various PTMs. Since these modifications 
play a key role in regulating protein function or activity in response to 
environmental stimuli, they are important determinants of cellular signalling 
(Rands, et al., 1990) (Sadeghi & Birnbaumer, 1999) (Ovchinnikov, et al., 1988) 
(Benovic, et al., 1987) (Daaka, et al., 1997) (Hausdorff, et al., 1989) (Vaughan, et 
al., 2006) (Shenoy, et al., 2001). Hence, it is imperative to have biochemical 
techniques which allow us to quantify these modifications. I aimed to develop an 
antibody which would recognise the SUMOylated form of the β2AR. This is novel 
on two counts as firstly, it is previously unknown that the β2AR can be SUMOylated 
and secondly, a SUMO-site specific antibody has never before been reported on.  
The data here shows that the β2AR can be SUMOylated at lysines 232 and 235, and 
that the novel SUMO-β2AR antibody is capable of 1) identifying the epitope against 
which it was raised and 2) identifies the SUMOylated form of the β2AR in cell and 
tissue samples.  
PTM antibodies of the β2AR have been utilised in the past to assess β2AR 
phosphorylation at distinct sites. As discussed in Chapter 1 - Introduction, the β2AR 
is susceptible to phosphorylation by PKA and GRK, therefore antibodies are 
commercially available which decipher between post-translational modification 
by these kinases. Shenoy et al (2006) utilised antibodies from Santa Cruz 
Biotechnology; phospho-β2AR at serines 345/346 (PKA-mediated phosphorylation) 
and phospho-β2AR at serines 355/356 (GRK-mediated phosphorylation). This group 
utilised the phospho-β2AR serines 345/346 antibody to confirm the susceptibility 
of a β2AR mutant to PKA phosphorylation. This mutant was functionally uncoupled 
from Gs, therefore did not produce cAMP elevation in response to isoprenaline, 
and via PTM antibody detection, it was confirmed the mutant was unable to be 
phosphorylated by PKA. This same group used the partner phospho β2AR antibody 
by Santa Cruz - serines 355/356 - to reveal that the same β2AR mutant, although 
unsusceptible to PKA-mediated phosphorylation, was subject to phosphorylation 
in the presence of GRK5/6 but not GRK2. This work exposed the fact that the β2AR 
can induce activation of the ERK MAPK in a β-arrestin-dependent manner, that is 
independent of the PKA-mediated Gs to Gi switch (Shenoy, et al., 2006)  
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In the quest to understand how PTMs impinge on cellular signalling processes, the 
advancement in site-specific PTM antibodies has been rapid in the last 10 years. 
For example, Hattori et al (2013) recently produced a novel PTM antibody against 
methylated histones and Arur and Schedl (2014) reported that 4 rounds of affinity 
chromatography purification were required to produce a phospho-specific 
antibody which was not available commercially for the RNA helicase, CGH-1. In 
contrast to the work presented in this chapter, when the phospho-CGH-1 specific 
antibody was shown to be ineffective in determining between phosphorylated and 
unmodified protein, the antibody was subject to further rounds of affinity 
purification. This continued until the antibody was capable of identifying only the 
phospho-modified form of the RNA helicase and not the non-modified form. This 
would have been a suitable alternative to the blocking peptide testing procedure 
used here, however the suitable equipment was within Badrilla ® at Leeds 
University and the testing procedure was completed within the University of 
Glasgow, where the blocking peptide was readily available, and therefore was the 
first option to be assessed. By quenching unspecific total protein binding using 
pre-incubation with a full-length epitope blocking peptide, the antibody described 
in this chapter was proven to be capable of detecting the SUMOylated form of the 
β2AR in a specific fashion.  
However, two features of the antibody remain to be solved; unspecific binding 
and the expected SUMO band shift. Although the antibody is selectively identifying 
the SUMOylated form of the β2AR promoted via overexpression of PIASγ, the 
binding in HEKβ2 cells alone lanes implies that the antibody is possibly detecting 
endogenous levels of β2AR SUMOylation, or the unSUMOylated receptor is still 
being detected by the antibody. We believe the possibility of unspecific binding 
to another protein of a similar molecular weight is unlikely, as the HEK293 lysate 
should account for the antibody binding to proteins within the HEKβ2 cell line 
which are not the β2AR, and no bands are present in these lanes. Furthermore, 
SUMOylation is traditionally associated with a 12-25kDa ghost band shift which is 
not apparent in Figure 3.12 as both the SUMO-β2AR band and the β2AR band 
present between the 75kDa and 100kDa markers, which are spaced closely 
together. Further antibody validation should involve repeating these experiments 
with longer gel running times to promote further protein separation at these 
higher molecular weights. 
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There are different SUMO paralogues which can be conjugated to a substrate 
protein to mediate SUMOylation; SUMO-1 or SUMO-2/3  (Hay, 2013) (Varadaraj, et 
al., 2014). Although the immunisation peptide for rabbit 25 was designed to 
produce an antibody against SUMO-1-β2AR, the testing procedure involved using 
an in vitro SUMOylation kit, which mediated SUMO modification by SUMO-1 and 
SUMO-2/3 equally. I did not determine whether the custom antibody is capable of 
deciphering between different SUMO paralogues that modify the β2AR. The “TGG” 
residue of SUMO-1 and SUMO-2/3 is the same, and this is the area which is 
important for the bond between SUMO and the essential lysine. Therefore, as the 
desired sequence for identification was the link between the β2AR and SUMO this 
made it complex to produce an antibody which is specific for the SUMO-1-β2AR 
and SUMO-2/3-β2AR, when the areas which distinguish SUMO-1 and SUMO-2/3 from 
each other are not those which are directly involved with the lysine interaction. 
For the purpose of our work we did not intend to decipher between the forms and 
therefore testing was stopped at the stages described here, but it would be 
possible to determine the specificity of the antibody by using similar techniques 
of in vitro SUMOylated arrays using only one SUMO paralogue at a time. If the 
antibody purified from rabbit 25 was specific for the SUMO-1-β2AR form then 
continuation of the testing procedure for all other samples may have produced a 
panel of antibodies which could distinguish between the SUMO paralogue 
responsible for SUMO modification of the β2AR. 
As mentioned in Chapter 1 – Introduction, SUMOylation shares similarities with the 
PTM ubiquitination. Both SUMOylation and ubiquitination can form chains of SUMO 
and ubiquitin molecules, respectively. Similarly to poly-SUMO chains, a poly-
ubiquitin chain is formed when the lysine residue on the ubiquitin is linked to the 
carboxy-terminal of another ubiquitin. This linkage can be mediated by different 
lysines within ubiquitin, two of which are K48 and K63. K48 linked chains mainly 
target proteins for proteasomal degradation and K63 linked chains regulate 
protein function, subcellular localisation or protein-protein interactions 
(Komander, 2009). Commercial antibodies are available which distinguish 
between these poly-ubiquitin chains. During the assessment of proteasomal 
phosphorylation, the K48 poly-ubiquitin chain antibody was used to assess a build-
up in poly-ubiquitinated proteins, giving an indication of proteasome activity  
(Guo, et al., 2016). The K63 poly-ubiquitin chain antibody has also been used to 
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assess the reduction of K63 poly-ubiquitin chain formation in yeast Saccharomyces 
cerevisiae in states of oxidative stress (Silva, Finley, & Vogel, 2015).This is a 
similar approach which could be utilised for poly-SUMO chains to reveal the 
purpose of these chain formations.   
In addition to differing SUMO paralogues which can mediate SUMOylation, there 
are also different sites within the β2AR which can be subject to SUMO 
modification. The custom SUMO-β2AR antibody was designed to detect 
SUMOylation at lysine 232 on the β2AR. Alternative lysines which can be 
SUMOylated include 227 and 235 (Figure 1.13, Chapter 1 - Introduction), which are 
close to our lysine of interest. Due to the close proximity of the three lysines (227, 
232 and 235) it is probable that the antibody may also be detecting SUMOylation 
at those sites. Further work with β2AR mutant peptide arrays with mutations at 
these neighbouring lysines may reveal a new level of antibody specificity, but 
various points of contact required between antibody and epitope recognition 
would even make this challenging to determine, as single lysine mutation may not 
be enough to prevent antibody detection of epitope.  
Further research into the role of individual SUMO sites is important, as specific 
antibodies could be used to determine the functional output of specific lysine 
SUMOylation. For example, it is known when PKA phosphorylates the β2AR this 
mediates a switch in signalling from Gs to Gi, therefore antibodies are designed 
which detect phosphorylation by this kinase alone (Daaka, et al., 1997). In a 
similar manner, it would be important to identify if SUMOylation of specific lysines 
initiated tailored signalling changes, and therefore antibodies could be designed 
to examine this. Another alternative, is the design of an epitope which is based 
upon the consensus motif γKxE/D (where γ is a large hydrophobic residue often 
consisting of 3-4 aliphatic residues, K is the lysine SUMO acceptor and x is any 
residue, D/E an acidic residue)  (Hay, 2005)  (Rodriguez, et al., 2001) (Bernier-
Villamor, et al., 2002). The drawback with this work lies with the fact that some 
lysines which can be SUMOylated lie out with a consensus motif, and therefore 
SUMOylation at these sites would be undetected by an antibody designed in this 
manner  (Impens, et al., 2014).  
In conclusion, I have developed an antibody to recognise the SUMOylated form of 
the β2AR which is the first of its kind. I have proven this antibody is capable of 1) 
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identifying the SUMOylated epitope against which it was raised and 2) identifying 
the SUMOylated form of the β2AR promoted via PIASγ transfection. This provides 
evidence to support our prior conclusion that PIASγ promotes SUMOylation of the 
β2AR. We will use this important new reagent to probe β2AR SUMOylation in 
Chapter 5 – Analysis of β2AR SUMOylation in Animal Models of HF.  
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Chapter 4 In Vitro SUMOylation of the β2AR 
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4.1 Introduction 
4.1.1 Post-Translational Modifications (PTMs) of the β2AR  
Like many GPCRs, the β2AR is susceptible to multiple post-translational 
modifications (PTMs), which can alter how the β2AR orchestrates downstream 
intracellular signals. The β2AR can transduce signals via stimulatory G protein (Gs) 
to activate adenylyl cyclase (AC). AC catalyses the conversion of adenosine 
triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), which then 
activates cAMP effectors such as protein kinase A (PKA) (Hausdorff, et al., 1989) 
(Strulovici, et al., 1984). PKA can phosphorylate a large number of proteins 
leading to tailored physiological responses. This is the most common mechanism 
by which the β2AR signals, but it can also mediate effects through Gi proteins 
which, have an opposite inhibitory influence on AC (Daaka, et al., 1997). The 
switch between Gs and Gi signalling is mediated by direct PKA-mediated 
phosphorylation of β2AR. Other PTMs have also been shown to play a role in β2AR 
signalling namely ubiquitination, palmitoylation and glycosylation.  β2AR 
ubiquitination tags the receptor for degradation by the 26S proteasome and is 
therefore vital for receptor down-regulation in response to excessive agonist 
exposure (Shenoy, et al., 2001); glycosylation has been shown to be involved in 
β2AR internalisation (Rands, et al., 1990); palmitoylation promotes the interaction 
between Gs and the β2AR allowing AC activation (O'Dowd, et al., 1989).  
4.1.2 SUMOylation of the β2AR 
SUMOylation is a PTM much like ubiquitination in which a small SUMO protein is 
covalently linked to a lysine residue on the substrate protein (Hay, 2005). 
SUMOylation can occur on either a lysine within a consensus motif or a non-
consensus lysine. This consensus motif consists of γKxE/D (where γ is a large 
hydrophobic residue often consisting of 3-4 aliphatic residues, K is the lysine SUMO 
acceptor and x is any residue, D/E an acidic residue) (Hay, 2005)  (Rodriguez, et 
al., 2001) (Bernier-Villamor, et al., 2002). 
To date there are five GPCRs which are identified as substrates for SUMOylation; 
metabotropic glutamate receptors, a cannabinoid receptor, a serotonin receptor 
and smo (Tang, et al., 2005) (Dutting, et al., 2011) (Gowran, et al., 2009) (Li & 
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Muma, 2013) (Zhang, et al., 2017). In addition to GPCRs, other cardiac signalling 
proteins have also been shown to be susceptible to SUMOylation, such as SERCA2a. 
SERCA2a has been shown to be modified by SUMO-1, resulting in preserved ATPase 
activity of the protein (Kho, et al., 2011) (Tilemann, et al., 2013).  
The purpose of this chapter is to assess the outcome of β2AR SUMOylation using in 
vitro functional signalling assays. 
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4.2 Aims  
I hypothesise that SUMOylation of the β2AR influences receptor signalling and 
stability. The aims of this chapter are the following: - 
1) Promote β2AR SUMOylation in the HEKβ2 cell line by overexpressing a SUMO 
E3 ligase, namely PIASγ, to allow a model in which to probe function of the 
modification   
2) Determine the influence of β2AR SUMOylation on receptor signalling in the 
model HEKβ2 cell line using a variety of in vitro functional signalling assays 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
4.2.1 HEKβ2 Cell Line  
To monitor the effects of β2AR SUMOylation on receptor signalling in vitro, the 
HEKβ2 cell line was used. This is a stable HEK293 cell line which stably 
overexpresses the GFP/FLAG-tagged form of the β2AR (McLean & Milligan, 2000) 
(Mclean, et al., 1999). The stable expression of the receptor within this cell line 
allows us to examine the influence of SUMOylation on β2AR signalling as HEKβ2 is 
a robust and proven model for examining cellular effects of β2AR signalling 
(Bolger, et al., 2006) (Baillie, et al., 2003) (Perry, et al., 2002) .  
Initial experiments using isoprenaline were undertaken to ensure the HEKβ2 cells 
were responding as expected upon activation of the β2AR. HEKβ2 cells were 
stimulated with 10μM isoprenaline for 5 and 10 minutes, and as expected I 
observed a 50% increase in PKA-mediated phosphorylation of the β2AR by PKA by 
(Figure 4.1) (N=4) (*p<0.05) and an approximate 1-fold increase in PKA-mediated 
phosphorylation of other target proteins (Figure 4.2) (N=4) (**p<0.01)(*p<0.05) as 
measured using a phospho-PKA consensus site antibody. Also, as expected, 
isoprenaline treatment promoted a 4-fold increase in phosphorylation of ERK MAP 
kinase (Figure 4.3) (N=4) (p=0.058/p=0.0550) in comparison to control. Previous 
work had shown that PKA-mediated phosphorylation of the β2AR by PKA switches 
Gs to Gi signalling to promote the increase in active ERK (Daaka, et al., 1997). All 
of these results indicated the β2AR was functional in the stable cell line. 
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Figure 4.1 Phosphorylation of β2AR-mediated by isoprenaline. (A&B) HEKβ2 cells 
were stimulated with 10µM isoprenaline (ISO) for 5 and 10 minutes. This 
significantly increased phosphorylation of the β2AR by PKA in comparison to 
control (N=4) (*p<0.05). Primary concentration 1 : 1000, secondary concentration 
1 : 5000.  (A) Representative blots shown.  
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Figure 4.2 Increased activity of PKA-mediated by isoprenaline. (A&B) HEKβ2 
cells were stimulated with 10µM isoprenaline (ISO) for 5 and 10 minutes. This 
significantly increased activity of protein kinase A (PKA) to phosphorylate 
substrates in comparison to control (N=4) (*p<0.05) (**p<0.01). Primary 
concentration 1 : 5000, secondary concentration 1 : 1000. (A) Representative blots 
shown. 
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Figure 4.3 Phosphorylation of ERK mediated by isoprenaline. (A&B) HEKβ2 cells 
were stimulated with 10µM isoprenaline (ISO) for 5 and 10 minutes. This showed 
a trend to increase phosphorylation of ERK in comparison to control (N=4) (control 
vs 5 min  p=0.0558 control vs 10 min p=0.0550). Primary concentration 1 : 1000, 
secondary concentration 1 : 5000. (A) Blue arrow indicative of quantification 
lanes. Representative blots shown. 
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4.2.2 SUMOylation of the β2AR In Vitro  
Following validation of β2AR signalling in the HEKβ2 cell line, the next step was to 
promote SUMOylation of the β2AR within these cells and evaluate whether this 
modification altered signalling. To induce SUMOylation of the β2AR, PIASγ  was 
transiently transfected into HEKβ2 cells. PIASγ is a SUMO E3 ligase, a family of 
enzymes which facilitates the conjugation of SUMO to substrates (Meulmeester, 
et al., 2008). Often the E2 enzyme UBC9 alone can be enough to encourage protein 
SUMOylation but many proteins require additional enzymatic support by E3 ligases 
which add fidelity to the process – one of which is PIASγ (Yunus & Lima, 2009). 
Therefore, over-expression of PIASγ was utilised as a route to increase the 
probability that the β2AR would be SUMOylated. 
In optimising PIASγ transfection into HEKβ2 cells, proof of successful transfection 
was shown by immunoblotting for the presence of the HA tag on PIASγ (Figure 
4.4A). At maximal PIASγ expression, there was a trend for β2AR expression 
(analysed via GFP tag expression) to be enhanced 1-fold when normalised to 
GAPDH control (Figure 4.4B) (N=3) (p=0.0709). Traditional identification of 
SUMOylation is mediated via the presence of a “ghost” band – a band which is 
apparent via immunoblotting at approximately 12-25kDa larger than the original 
protein – indicative of covalent attachment of the SUMO protein. Although the 
SUMO protein itself only has an approximate weight of 11kDa – often larger shift 
sizes are observed due to the formation of SUMO chains, in which multiple SUMO 
molecules are added to either one lysine residue as chains, or multiple lysine 
residues throughout the protein (Park-Sarge & Sarge, 2005). Following PIASγ 
expression a “ghost” band is observed above the β2AR, which I believe to be the 
SUMOylated form of the β2AR (Figure 4.4A). At maximal PIASγ expression there is 
a significant 1-fold increase in the SUMO-β2AR band shift when normalised to 
GAPDH control (Figure 4.4C) (N=3) (*p<0.05). Detection of this ghost band and its 
increase in line with PIASγ expression suggests the discovery of a means by which 
to enhance SUMO modification of the β2AR. Increased β2AR expression following 
PIASγ expression may also suggest that SUMOylation of the β2AR may prevent 
degradation of the receptor. SUMOylation of other proteins on lysine residues 
known to be ubiquitination sites can protect such proteins from degradation by 
the proteasome  (Desterro, et al., 1998)  (Meek & Knippschild, 2003) (Kim, et al., 
168 
 
2008) (Mooney, et al., 2010). To my knowledge, this work is the first to support 
the notion that the β2AR can be directly modified by SUMOylation. 
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Figure 4.4 Amplifying PIASγ in HEKβ2 cells promotes SUMOylation of β2AR. 
(A&C) HEKβ2 cell transfection with PIASγ (E3 ligase) provokes SUMO band shift 
which could be indicative of SUMOylation of β2AR (N=3) (*p<0.05). (A&B) In 
addition to band shift, promotion of SUMOylation appears to enhance expression 
of β2AR (N=3) (p=0.0709). Primary concentration 1 : 1000, secondary 
concentration 1 : 5000. (A) Representative blots shown. 
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4.2.3 Interaction between β2AR and SUMOylation Enzymes 
PIASγ/UBC9 
Although overexpression of PIASγ mediates a band shift indicative of SUMOylation 
of the β2AR, further evidence is required to support this hypothesis. To this end, 
the putative interaction between the β2AR and the enzymes involved in the 
SUMOylation cascade, namely PIASγ and UBC9, were examined using peptide array 
overlay. 
4.2.3.1 Peptide Array Overlay Assessment of β2AR-PIASγ/UBC9 Interaction  
The peptide array overlay can predict the regions of interaction between the 
proteins down to the amino acid level. The interaction between the receptor and 
SUMOylation enzymes was examined by overlaying cellular lysate prepared from 
cells overexpressing the desired enzyme onto peptide arrays corresponding to the 
intra-cellular portions of the β2AR. Interaction sites were identified using 
overnight incubation with appropriate antibody and ECL detection the following 
day. HA-tag antibody was used to identify the interaction points between PIASγ 
and β2AR since PIASγ was HA tagged, whereas UBC9 had no tag and therefore a 
UBC9 antibody raised against UBC9 protein was used. The latter antibody produced 
more non-specific sites due to direct interaction with peptide array peptides 
(Figure 4.6). 
Putative interaction sites between PIASγ and β2AR were detected at three 
different areas within the receptor; intracellular loop 2 (spot 2), intracellular loop 
3 (spots 3, 4, 6, 8 and 9) and the cytoplasmic tail (spots 13 and 20) (Figure 4.5) 
(Figure 4.7) (N=1). Interaction sites between UBC9 and β2AR occurred at two 
different areas within the receptor; intracellular loop 3 (spots 4 and 6), and 
cytoplasmic tail (spots 12, 22 and 23) (Figure 4.6) (Figure 4.7) (N=1). As expected 
interactions with both enzymes occurred near the identified SUMO sites, 232 and 
235 within the third intracellular loop, as traditionally these enzymes mediate 
their interactions via the amino acids which surround the SUMO consensus motif 
(Bernier-Villamor, et al., 2002) (Duval, et al., 2003) (Yunus & Lima, 2009) 
(Hochstrasser, 2001).The interactions found within the other areas of the β2AR 
could imply that further SUMOylation sites exist within the receptor that have not 
been recognised by the sequence analysis prediction software or that there is a 
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more extensive binding of UBC9 with β2AR than was previously imagined. For 
future work, immunoprecipitations and visualisation of β2AR and SUMOylation 
enzymes co-localisation using microscopy should be done to verify the interaction. 
Sites of interaction could be verified by undertaking IP experiments with mutants 
of the β2AR that contain substitutions shown to ablate interactions between the 
enzymes and the receptor (Figure 4.5 & 4.6). The UBC9 overlay on β2AR peptide 
array should also be completed with a tag expression construct of the enzyme to 
compensate for unspecific binding. 
In conclusion, the data suggest that interactions exist between vital SUMOylation 
enzymes and β2AR, a conclusion that supports the identification of SUMO 
modification of the β2AR for the first time.  
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Figure 4.5. β2AR–PIASγ interaction assessed by peptide array overlay. β2AR 
peptide array on cellulose incubated overnight with either HEKβ2 lysate or HEKβ2 
lysate overexpressed with PIASγ. Following overnight incubation with appropriate 
antibody and ECL detection the following day, the point of interaction was 
identified with  black spots. The text is displayed in red for the positive back spots 
(N=1). Ponceau identifies all spots within array as control. Primary concentration 
1 : 1000, secondary concentration 1 : 1000. Amino acid abbreviations in appendix.  
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Figure 4.6 β2AR–UBC9 interaction assessed by peptide array overlay. β2AR 
peptide array on cellulose incubated overnight with either HEKβ2 lysate or HEKβ2 
lysate overexpressed with UBC9. Following overnight incubation with appropriate 
antibody and ECL detection the following day, the point of interaction was 
identified with black spots. The text is displayed in red for the positive back spots 
(N=1). Ponceau identifies all spots within array as control. Primary concentration 
1 : 1000, secondary concentration 1 : 1000. Amino acid abbreviations in appendix. 
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Figure 4.7 β2AR–PIASγ/UBC9 interaction sites identified near SUMOylation 
sites. The interaction sites for PIASγ and UBC9 were found to be near SUMOylation 
sites 232 and 235 within the third intracellular loop. They were also identified in 
intracellular loop 2 and the cytoplasmic tail.  
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4.2.4 Influence of β2AR SUMOylation on Receptor Function.  
4.2.4.1 β2AR SUMOylation Alters Receptor Signalling 
The HEKβ2 cell line was used to examine the influence of β2AR SUMOylation on 
receptor signalling. Cells underwent mock transfection with empty transfection 
reagent or transfection with the E3 ligase PIASγ, which promotes SUMOylation of 
the β2AR (Figure 4.4) (described in Chapter 2 – General Materials and 
Methods).These cells were then stimulated with 10µM isoprenaline for both 5 and 
10 minutes. Stimulation of HEKβ2 cells by isoprenaline leads to an elevation in 1) 
phosphorylation of β2AR by PKA, 2) ERK activation, and 3) PKA cytosolic activity 
(Figures 4.1 - 4.3). The next step was to evaluate the effects of β2AR SUMOylation 
on these downstream signals. In comparison to cells that did not have PIASγ 
transfected into them, the SUMOylated β2AR exhibited approximately 25% less 
direct phosphorylation by PKA (Figure 4.8) (N=4) (*p<0.025), approximately 25% 
reduced PKA activity as measured indirectly by monitoring general PKA substrates 
(Figure 4.9) (N=4) (*p<0.025) (**p<0.01), as well as an approximate 65% reduction 
in ERK activation (Figure 4.10) (N=4) (***p<0.001) (**p<0.01). In addition, there is 
an approximate 25% increase in total β2AR at the 10 minute time point in the 
SUMOylated β2AR cell compared to unSUMOylated β2AR control (Figure 4.11) (N=4) 
(*p<0.05). Normally when the β2AR is chronically stimulated with agonist it will 
down regulate to prevent excessive agonist exposure – this down-regulation begins 
with the receptor becoming internalised and at longer time points degraded by 
lysosomal degradation  (Shenoy, et al., 2001) (Moore, et al., 1999). The data here 
suggests that there is less internalisation or degradation of the receptor in 
response to isoprenaline for the SUMOylated β2AR compared with wild-type (WT) 
β2AR. 
 
In addition to PKA, the β2AR can also be phosphorylated by other kinases, for 
example G protein-coupled receptor kinases (GRKs). GRKs phosphorylate multiple 
serine and threonine residues within the C-terminus of the receptor (Ferguson, et 
al., 1996) (Mak, et al., 2002) (Collins, et al., 1991) (Vaughan, et al., 2006) and in 
doing so promote β-arrestin1/2 recruitment to the membrane (Violin, et al., 2006) 
(Vaughan, et al., 2006). This is vital for receptor desensitisation. In light of this, 
the effect of SUMOylation on β2AR phosphorylation by GRK using a site-specific 
antibody was examined. An approximate 40% reduction in GRK phosphorylation of 
176 
 
the β2AR at basal levels was observed following PIASγ transfection in comparison 
to mock transfected cells (Figure 4.12) (N=3) (*p<0.05). No significant difference 
in GRK phosphorylation existed between unSUMOylated and SUMOylated β2AR 
following 5 and 10 minutes of isoprenaline treatment (Figure 4.12) (N=3). However 
the detection of total β2AR via the GFP-tag antibody is not as clear as prior western 
blots, and therefore to confirm the influence of receptor SUMOylation on β2AR 
phosphorylation by GRK, this western blot would need to be repeated.  
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Figure 4.8. β2AR SUMOylation reduces isoprenaline-mediated PKA 
phosphorylation of β2AR. (A&B) HEKβ2 cells transfected with PIASγ to promote 
β2AR SUMOylation and HEKβ2 mock transfected cells were stimulated with 10µM 
isoprenaline (ISO) for 5 and 10 minutes. SUMOylation of the β2AR caused a 
significant reduction in phosβ2 expression after 5 minutes isoprenaline treatment 
in comparison to control (N=4) (*p<0.05). Primary concentration 1 : 1000, 
secondary concentration 1 : 5000.  (A) Representative blots shown. 
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Figure 4.9 β2AR SUMOylation reduces isoprenaline-mediated PKA cytosolic 
activity. (A&B) HEKβ2 cells transfected with PIASγ to promote β2AR SUMOylation 
and HEKβ2 mock transfected cells were stimulated with 10µM isoprenaline (ISO) 
for 5 and 10 minutes. SUMOylation of the β2AR caused a significant reduction in 
PKA activity after 5 and 10 minutes 10μM isoprenaline treatment in comparison 
to control (N=4) (*p<0.05) (**p<0.01). Primary concentration 1 : 1000, secondary 
concentration 1 : 5000. (A) Representative blots shown. 
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Figure 4.10 β2AR SUMOylation reduces isoprenaline-mediated phosphorylation 
of ERK. (A&B) HEKβ2 cells transfected with PIASγ to promote β2AR SUMOylation 
and HEKβ2 mock transfected cells were stimulated with 10µM isoprenaline (ISO) 
for 5 and 10 minutes.  SUMOylation of the β2AR caused a significant difference in 
phosERK expression at basal levels and  after 5 minutes isoprenaline treatment in 
comparison to control. At basal level PIASγ causes an elevation in phosERK 
expression in comparison to control (N=4) (***p<0.001). At 5 minutes PIASγ causes 
a reduction in phosERK expression in comparison to control (N=4) (**p<0.01). 
Primary concentration 1 : 1000, secondary concentration 1 : 5000. (A) 
Representative blots shown. 
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Figure 4.11 β2AR SUMOylation reduces isoprenaline-mediated reduction in 
total β2AR. (A&B) HEKβ2 cells transfected with PIASγ to promote β2AR SUMOylation 
and HEKβ2 mock transfected cells were stimulated with 10µM isoprenaline (ISO) 
for 5 and 10 minutes.  SUMOylation of the β2AR caused a significant difference in 
total β2AR expression after 10 minutes isoprenaline treatment in comparison to 
control cells (N=4) (*p<0.05). Primary concentration 1 : 1000, secondary 
concentration 1 : 5000. (A) Representative blots shown. 
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Figure 4.12 β2AR SUMOylation influence on isoprenaline-mediated GRK 
phosphorylation of β2AR is inconclusive. (A&B) HEKβ2 cells transfected with 
PIASγ to promote β2AR SUMOylation and HEKβ2 mock transfected cells were 
stimulated with 10µM isoprenaline (ISO) for 5 and 10 minutes. SUMOylation of the 
β2AR caused a significant reduction in phosβ2 expression in basal signalling. There 
was no difference after isoprenaline treatment in comparison to control (N=3) 
(*p<0.05). However the detection of total β2AR via the GFP-tag antibody is not as 
clear as prior western blots, and therefore to confirm the influence of receptor 
SUMOylation on β2AR phosphorylation by GRK, this western blot would need to be 
repeated.  Primary concentration 1 : 1000, secondary concentration 1 : 5000. (A) 
Representative blots shown. 
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4.2.4.2 β2AR SUMOylation Reduces Receptor Internalisation 
Chronic isoprenaline treatment is known to promote β2AR internalisation as a 
medium-term desensitisation mechanism. When the β2AR is internalised, it is 
moved away from the cell surface and isolated within clathrin coated vesicles 
preventing it from further signalling via the G proteins (Goodman, et al., 1996). 
There is now evidence for endosomal signalling by the β2AR. Irranejad et al (2013) 
revealed that in HEK293 cells isoprenaline-promoted cAMP production at the 
plasma membrane via the β2AR as expected, but also in the early endosome. 
Furthermore, inhibition of endocytosis led to a reduction in cAMP production 
mediated via the β2AR (Irannejad, et al., 2013). This group propose that β2AR-Gs 
coupling occurs in the early endosome, promoting a discrete phase of cAMP 
production (Irannejad & Von Zastrow, 2014). 
The Cellomics ® ArrayScan ® was used to examine the influence of SUMOylation 
of the β2AR on receptor internalisation in response to agonist. HEKβ2 cells 
underwent mock transfection with empty transfection reagent or transfection 
with the E3 ligase PIASγ, which promotes SUMOylation of the β2AR (Figure 4.4) 
(described in Chapter 2 – General Materials and Methods). These cells were then 
stimulated with 10µM isoprenaline for various time points to 90 minutes and 
internalisation of the β2AR was monitored using the Cellomics ® ArrayScan ®.  
Analysis of data from procedure above suggested that SUMOylation of the β2AR 
significantly reduces β2AR internalisation in response to isoprenaline by 
approximately 60% in comparison to control (Figure 4.13) (N=3) (*p<0.05) 
(**p<0.01).  
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Figure 4.13 β2AR SUMOylation delays receptor internalisation. (A&B) HEKβ2 
cells overexpressing PIASγ via transfection and HEKβ2 mock transfected cells were 
stimulated with 10µM isoprenaline (ISO) for various time points from basal to 90 
minutes. SUMOylation of β2AR significantly reduces β2AR internalisation in 
response to isoprenaline approximately 60% in comparison to control (N=3) 
(*p<0.05) (**p<0.01). (B) Representative images from one experiment shown.  
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4.2.4.3 β2AR SUMOylation Influence on Receptor Half-Life is Inconclusive  
The β2AR has a relatively long half-life with the longest reported being up to 30 
hours (Mahan & Insel, 1986) (Fraser & Venter, 1980). HEKβ2 cells underwent mock 
transfection with empty transfection reagent or transfection with the E3 ligase 
PIASγ, which promotes SUMOylation of the β2AR (Figure 4.4) (described in Chapter 
2 – General Materials and Methods). These cells were then treated with 50μg/ml 
cycloheximide for 3, 5, 8, and 24 hours. This drug acts by preventing protein 
synthesis therefore allowing us to monitor receptor turnover rate by monitoring 
the decline of β2AR over time.  Cycloheximide treatment produced an approximate 
50% reduction in β2AR expression at the 24 hour time point - in both cells 
transfected with PIASγ and those mock transfected – in comparison to the 0 hour 
time point, indicative that the β2AR was being degraded (Figure 4.14) (N=3) 
(***p<0.001) (****p<0.0001). No significant difference existed between SUMOylated 
and non SUMOylated β2AR in total β2AR population at any time point. In conclusion, 
SUMOylation of β2AR does not influence receptor turnover rate under basal 
conditions. However the detection of total β2AR via the GFP-tag antibody is not 
as clear as prior western blots and therefore to confirm the influence of receptor 
SUMOylation on β2AR half-life this western blot would need to be repeated. 
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Figure 4.14 β2AR SUMOylation influence on receptor half-life is inconclusive. 
(A&B) HEKβ2 cells overexpressing PIASγ via transfection and HEKβ2 mock 
transfected cells were stimulated with 50μg/ml cycloheximide for 3, 5, 8 and 24 
hours.  Cycloheximide treatment produced a significant reduction in β2AR at the 
24 hour time point - in both cells transfected with PIASγ and those mock 
transfected – in comparison to 0 hour time point, indicative that the β2AR was 
being degraded in these cells (N=3) (***p<0.0001) (****p<0.0001). No significant 
difference existed between SUMOylated and non SUMOylated β2AR in total β2AR 
population at any time point (N=3). However the detection of total β2AR via the 
GFP-tag antibody is not as clear as prior western blots and therefore to confirm 
the influence of receptor SUMOylation on β2AR half-life this western blot would 
need to be repeated. Primary concentration 1 : 1000, secondary concentration 1 
: 5000. (A) Representative blots shown. 
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4.2.4.4 β2AR SUMOylation Reduces Ubiquitination  
Ubiquitination is a PTM in which a ubiquitin protein is attached to a lysine on the 
target protein. Ubiquitination is essential for β2AR internalisation (Shenoy, et al., 
2001). When β2AR is internalised, it can either be recycled back to the surface or 
it can be degraded. The extent of ubiquitination on the internalised β2AR 
determines if its degradation is undertaken by both the 26S proteasome and 
lysosomal degradation (Gagnon, et al., 1998) (Moore, et al., 1999). HEKβ2 cells 
underwent mock transfection with empty transfection reagent or transfection 
with the E3 ligase PIASγ, which promotes SUMOylation of the β2AR (Figure 4.4) 
(described in Chapter 2 – General Materials and Methods). Cells were then treated 
with 20µM MG132, a proteasome inhibitor, which prevents the degradation of 
ubiquitinated proteins allowing them to build up within the cell. A 3 hour MG132 
timepoint was used to assess ubiquitination at basal levels. Shenoy et al (2001) 
have previously reported that receptor activation influences ubiquitination, 
therefore these experiments were also carried out with isoprenaline stimulation 
in which the protocol was changed to 1 hour 20µM MG132 followed by 10 minutes 
10μM isoprenaline stimulation.  
Immunoprecipitation of the β2AR was undertaken using FLAG beads to isolate 
receptor and GST beads used as control. Immunoblotting with antibody to detect 
ubiquitin chains allowed examination of β2AR ubiquitination. As expected, MG132 
treatment produced a significant increase in β2AR ubiquitination after 3 hours - in 
both cells transfected with PIASγ (1.5-fold increase) and those without (2.5-fold 
increase) – in comparison to the 0 hour time point, indicating that the β2AR was 
being ubiquitinated at basal levels (Figure 4.15) (N=3) (*p<0.05). No significant 
difference existed between SUMOylated and non SUMOylated β2AR in the extent 
of ubiquitination at basal levels. After treatment of 20μM MG132 for 1 hour 
followed by 10μM isoprenaline for 10 minutes SUMOylated β2AR was approximately 
70% less ubiquitinated in comparison to unSUMOylated β2AR (Figure 4.16) (N=3) 
(*p<0.05). In conclusion, SUMOylation of β2AR reduces receptor susceptibility to 
ubiquitination but only after β2AR activation. The outcome of our MG132 studies 
correlates with work by Shenoy et al (2001) in which proteasomal inhibition 
mediated a significant increase in ubiquitinated β2AR in an agonist-dependent 
manner. Similarly to other proteins in which the PTMs SUMOylation and 
187 
 
ubiquitination compete  (Desterro, et al., 1998)  (Meek & Knippschild, 2003) (Kim, 
et al., 2008) (Mooney, et al., 2010), this may also be the case for the β2AR.  
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Figure 4.15 β2AR SUMOylation does not influence receptor ubiquitination at 
basal levels. (A&B) HEKβ2 cells overexpressing PIASγ via transfection and HEKβ2 
mock transfected cells were stimulated with 20μM MG132 for 3 hours. MG132 
treatment caused a significant elevation in β2AR ubiquitination in both control and 
transfected cells at 3 hours in comparison to the 0 time point. No significant 
difference existed between SUMOylated and non SUMOylated β2AR (N=3) 
(*p<0.05). Primary concentration 1 : 1000, secondary concentration 1 : 5000. (A) 
Representative blots shown. 
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Figure 4.16 β2AR SUMOylation reduced isoprenaline-mediated receptor 
ubiquitination. (A&B) HEKβ2 cells overexpressing PIASγ via transfection and HEKβ2 
mock transfected cells were stimulated with 20μM MG132 for 1 hour followed by 
either 10μM isoprenaline (ISO) for 10 minutes or non-treated. Isoprenaline caused 
a significant elevation in β2AR ubiquitination in control cells in comparison to non-
treated cells. SUMOylation of the β2AR significantly reduces isoprenaline-
mediated ubiquitination in comparison to control unSUMOylated β2AR (N=3) 
(*p<0.05). Primary concentration 1 : 1000, secondary concentration 1 : 5000. (A) 
Representative blots shown.  
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4.2.4.5 β2AR SUMOylation Does Not Influence β2AR-β-arrestin Interaction  
β-arrestins play a dual regulatory role in β2AR signalling. Firstly, they sterically 
uncouple the receptor from the Gαs subunit therefore preventing further cAMP 
production. Secondly, they serve as a scaffolding protein, which links the β2AR to 
further trafficking machinery such as the ubiquitin, E3 ligase MDM2 which 
promotes ubiquitination of the β2AR (Ferguson, et al., 1996), and PDE4 to 
attenuate cAMP signalling (Perry, et al., 2002). Additionally, they also allow G 
protein independent signalling (McDonald, et al., 2000). 
β2AR interaction with β-arrestin is vital for internalisation. Stimulation with 
isoprenaline mediates an interaction between β2AR and β-arrestin following GRK 
phosphorylation of the receptor. Using the BRET assay, HEK293 cells were 
transfected with β2AR tagged with YFP and β-arrestin2 tagged with RLuc 6 (Lorenz, 
et al., 1991) (ratio 4:1), in addition to  mock transfection with empty transfection 
reagent or transfection with the E3 ligase PIASγ, which promotes SUMOylation of 
the β2AR (Figure 4.4) (described in Chapter 2 - General Materials and Methods). 
These cells were then stimulated with isoprenaline and subjected to the BRET 
assay. This assay is designed to assess the interaction between the β2AR and β-
arrestin using the fluorescent tags YFP and RLuc 6. To assess the receptor’s 
interaction with β-arrestin the EC50 was quantified from these experiments. This 
is the concentration of isoprenaline that was required to cause 50% of the maximal 
BRET response – a response that is indicative of the β2AR-β-arrestin interaction.  
This technique revealed that there was no significant difference in EC50 between 
SUMOylated β2AR and control indicating SUMOylation does not influence how the 
β2AR interacts with β-arrestin (Figure 4.17) (N=3). In conclusion, SUMOylation of 
the β2AR does not influence the capability of the receptor to interact with β-
arrestin. This was as expected based upon two reasons; firstly, GRK-mediated 
phosphorylation – the initiating step for β-arrestin translocation – does not appear 
to be influenced by receptor SUMOylation, and secondly, the suspected 
SUMOylation sites on the β2AR are within the third intracellular loop, not the 
cytoplasmic tail where the β-arrestin interaction occurs (Krasel, et al., 2005). 
Therefore β-arrestin agonist-dependent translocation would not be expected to 
change following receptor modification by SUMO.  
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Figure 4.17 β2AR SUMOylation does not influence β2AR-β-arrestin interaction. 
(A&B) BRET assay was used to ascertain the relationship between β2AR and β-
arrestin by tagging proteins with YFP and RLuc 6, respectively.  In HEK293 cells 
these proteins were expressed either with or without PIASγ to promote 
SUMOylation of the β2AR. Cells were stimulated with isoprenaline to mediate β2AR- 
β-arrestin binding and BRET was measured to quantify interaction. No significant 
difference existed in EC50 between unSUMOylated and SUMOylated β2AR therefore 
SUMOylation of the receptor does not influence the interaction between β2AR-β-
arrestin (N=3). (A) Representative graph from one experiment shown. 
A.
B.
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4.2.4.6 β2AR SUMOylation Prolongs Cellular Response to cAMP 
The β2AR signals via stimulatory G protein (Gs) and as mentioned previously Gs 
activates AC. When Gαs stimulates the catalytic domain, AC catalyses the 
conversion of ATP to cAMP. cAMP FRET was used to determine how long after β2AR 
isoprenaline-mediated stimulation, the cAMP levels within the cell interior remain 
elevated, and whether SUMOylation of the β2AR influences this timeframe. HEKβ2 
cells were transfected with the EPAC cAMPs-1 FRET sensor, in addition to mock 
transfection with empty transfection reagent or transfection with the E3 ligase 
PIASγ, which promotes SUMOylation of the β2AR (Figure 4.4) (described in Chapter 
2 - General Materials and Methods). These cells were stimulated with 10μM 
isoprenaline and subjected to cAMP FRET. The representative examples 
demonstrate the time taken for isoprenaline to induce stimulation of cAMP and 
the subsequent switching off of AC / hydrolysis of cAMP by PDEs during 
desensitisation. The data generated by the cAMP FRET probes suggest that cAMP 
degradation/desensitisation is significantly different in cells overexpressing PIASγ 
in comparison to mock transfected. Following stimulation with isoprenaline both 
cells over expressing PIASγ and mock transfected show an increase in FRET ratio, 
which is indicative of a rise in cAMP. In mock transfected control cells the FRET 
ratio falls at approximately 12 minutes after isoprenaline stimulation indicating 
that less cAMP is produced due to desensitisation mechanisms. In contrast, cAMP 
degradation does not occur until approximately 17 minutes following isoprenaline 
stimulation in cells transfected with PIASγ (Figure 4.18) (Control N=19, PIASγ 
N=28) (***p<0.001). In conclusion, SUMOylation of the receptor significantly 
prolongs the time for which cAMP is elevated within the cytosol. This may be due 
to the delayed desensitisation of the receptor in the SUMO modified form, 
exemplified by less agonist-mediated PKA phosphorylation of the β2AR (Figure 
4.8), and delayed receptor internalisation (Figure 4.13). In conclusion, the 
SUMOylated form of the β2AR mediates prolonged cAMP signalling due to lessened 
desensitisation and internalisation. However, as the probe utilised within these 
experiments was cytosolic, it would be important to repeat these experiments 
using a membrane tethered probe in the vicinity of the β2AR.  
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Figure 4.18 β2AR SUMOylation prolongs isoprenaline-mediated cellular levels 
of cAMP. (A&B) Isoprenaline mediates β2AR signalling which results in cAMP 
formation. HEKβ2 either mock transfected or transfected with PIASγ to promote 
SUMOylation of the β2AR were stimulated with isoprenaline and subject to FRET.  
SUMOylation of the receptor significantly prolongs the time to cAMP degradation 
within the cell in response to isoprenaline (Control N=19, PIASy N=28)  
(***p<0.001). (A) Representative traces from one experiment shown above bar 
graph. 
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4.2.4.7 β2AR SUMOylation Does Not Influence β2AR-Ligand Interaction 
As the results suggest a desensitisation phenotype is induced following PIASγ 
transfection, radioligand binding studies were used to ascertain if β2AR 
SUMOylation influences the ligand-receptor interaction. Once again, HEKβ2 cells 
were transfected with PIASγ to promote SUMOylation of the β2AR (described in 
Chapter 2 - General Materials and Methods) or mock transfected, and membrane 
preparations made for radioligand binding studies. Saturation radioligand binding 
studies were performed to reveal how the receptor interacts with the radioligand, 
namely 3H-DHA. This was assessed from two parameters; Kd and Bmax. Kd is the 
dissociation constant indicative of the β2AR affinity for 3H-DHA and Bmax is the 
number of binding sites available for 3H-DHA. There was no significant difference 
in Kd and Bmax between SUMOylated β2AR and control indicating SUMOylation does 
not influence how the β2AR interacts with3H-DHA (Figure 4.19) (N=3). This was 
expected as the areas which are important for β2AR-ligand interaction – 
asparagines 113 and 293, serines 203 and 207  -  are found within the 
transmembrane domains, distinct from the suspected SUMOylation sites in the 
third intracellular loop (Liggett, 2002) (Strader, et al., 1988) (Strader, et al., 
1989) (Wieland, et al., 1996). 
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Figure 4.19 β2AR SUMOylation does not influence Kd or Bmax. (A&B)HEKβ2 
transfected either with PIASγ to promote SUMOylation of the β2AR or mock 
transfected were used to make membrane preparations for saturation binding 
studies. SUMOylation of the receptor does not influence Kd or Bmax therefore 
SUMOylation of the receptor does not influence how the receptor binds to 
radioligand (N=3).  (A) Representative traces from one experiment shown above 
bar graphs. 
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Competition binding studies, also known as displacement studies, were used to 
assess if β2AR SUMOylation influences the isoprenaline binding pocket. Here a 
single concentration of radioligand 3H-DHA was competed for by multiple 
concentrations of non-radioactively labelled isoprenaline. To assess the receptor’s 
interaction with isoprenaline, the IC50 was quantified from these competition 
experiments. This is the concentration of isoprenaline that was required to cause 
50% inhibition in 3H-DHA binding. These experiments revealed that there was no 
significant difference in IC50 between SUMOylated β2AR and control indicating 
SUMOylation does not influence how the β2AR interacts with isoprenaline (Figure 
4.20) (N=3). This was expected due to distinct locations of ligand interaction sites 
and SUMO susceptible lysines.  
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Figure 4.20 β2AR SUMOylation does not influence IC50. (A&B) HEKβ2 transfected 
either with PIASγ to promote SUMOylation of the β2AR or mock transfected were 
used to make membrane preparations for saturation binding studies. SUMOylation 
of the receptor does not influence IC50 therefore SUMOylation of the receptor does 
not influence how the receptor binds to isoprenaline (N=3). (A) Representative 
trace from one experiment shown above bar graph. 
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4.2.4.8 β2AR SUMOylation Does Not Influence β2AR-G Protein Interaction 
The β2AR signals via stimulatory G protein (Gs), which activates AC to produce 
cAMP. Although this is the classical mechanism by which the β2AR signals, the β2AR 
can also mediate negative effects through Gi proteins (Daaka, et al., 1997). The 
switch between stimulatory Gs signalling and inhibitory Gi signalling occurs 
following direct PKA phosphorylation of the receptor (Hausdorff, et al., 1989) 
(Strulovici, et al., 1984). To determine if SUMOylation of the β2AR influences G 
protein interaction, SPASM sensor experiments were used. SPASM sensors are BRET 
sensors, which are based on a recently developed technique termed systemic 
protein affinity strength modulation (SPASM) and involve the fusion of a native 
peptide from the C-terminus of a Gα subunit to the C-terminus of the intact GPCR 
(Sivaramakrishnan & Spudich, 2011). Upon activation of the GPCR, the C-terminus 
of the Gα subunit slots itself into a cytosolic groove on the GPCR (Choe, et al., 
2011) (Rasmussen, et al., 2011) (Chung, et al., 2011). Therefore, a mimic of this 
peptide will slot into this same area on the GPCR as the native C-terminus of the 
Gα subunit. Hence the β2AR SPASM sensors responded to stimulation with 
isoprenaline causing BRET to occur when the receptor is activated. SPASM sensors 
were designed to assess the interaction between the β2AR-Gs and β2AR-Gi.  
Two types of experiment were completed with the SPASM sensors; dose response 
experiments and kinetics experiments. Dose response experiments examined the 
interaction between the β2AR and the G protein in response to increasing 
isoprenaline concentrations, whereas the kinetics experiments assessed the 
interaction produced from one concentration of isoprenaline over time. The 
SPASM sensors were stably expressed in HEK293 cells using the Flp-In T-Rex ® 
system with mock transfection with empty transfection reagent or transfection 
with the E3 ligase PIASγ, which promotes SUMOylation of the β2AR (Figure 4.4) 
(described in Chapter 2 - General Materials and Methods). For dose response 
experiments to assess the interaction between β2AR and the G protein the EC50 
was quantified. This is the concentration of isoprenaline that was required to 
cause 50% of the maximal BRET, indicative of β2AR-G protein interaction. 
Following stimulation by isoprenaline the G protein mimic peptide interacts with 
the receptor initiating an increase in BRET dependent upon isoprenaline 
concentration. Using the dose response approach, I observed no significant 
difference in EC50 between SUMOylated β2AR and control indicating that 
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SUMOylation does not influence interaction between β2AR and either of the G 
proteins, Gi or Gs (Figure 4.21) (N=3). This was unexpected as the third 
intracellular loop which is known to contain the SUMO sites, is also known to be 
important for G protein coupling, and therefore we would expect a change to be 
observed (O'Dowd, et al., 1988).  
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Figure 4.21 Dose response SPASM sensor experiment - β2AR SUMOylation does 
not influence β2AR-Gs/Gi interaction. (A&B) Flp-In T-Rex ® HEK293 cells 
expressing SPASM sensors were either mock transfected or transfected with PIASγ 
to promote SUMOylation of the β2AR.  SUMOylation of the receptor does not 
influence EC50 therefore SUMOylation of the receptor does not influence how the 
receptor interacts with G proteins (N=3). (A) Representative traces from one 
experiment shown above bar graphs. 
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For kinetics experiments to assess the interaction between β2AR and the G 
proteins, a comparison was made at various time points following isoprenaline 
stimulation. Following stimulation with isoprenaline, no significant difference 
between transfected and mock transfected cells was observed for interactions 
with Gi. In fact, the interaction with Gi following isoprenaline was slight, just 
above the detection sensitivity of the assay. In contrast, the interaction between 
β2AR and Gs showed a marked increase but again no significant difference between 
cells with and without PIASγ.   There was no significant difference in the BRET 
mediated by isoprenaline at any time point for either G protein, therefore 
SUMOylation does not influence interaction between β2AR and either G protein, Gi 
or Gs (Figure 4.22) (N=3). As mentioned above, this was unexpected as the third 
intracellular loop is known to be the site for both SUMOylation and G protein 
coupling (O'Dowd, et al., 1988). However, these experiments are the first to use 
the SPASM sensor probes donated by the Milligan group of University of Glasgow, 
and further probe optimisation, specifically for the β2AR-Gi probe which lacked 
response in kinetics experiments, is required.  
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Figure 4.22 Kinetics SPASM sensor experiment - β2AR SUMOylation does not 
influence β2AR-Gs/Gi interaction. (A&B) Flp-In T-Rex ® HEK293 cells expressing 
SPASM sensors were either mock transfected or transfected with PIASγ to promote 
SUMOylation of the β2AR. SUMOylation of the receptor does not influence how the 
receptor interacts with G proteins at any time point following isoprenaline 
stimulation (N=3). (A) Representative traces from one experiment shown above 
bar graphs. 
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4.3 Discussion 
The β2AR is susceptible to multiple post-translational modifications (PTMs) which 
are implicated in receptor signalling: phosphorylation by both PKA and GRK, which 
is vital in the desensitisation process (Bouvier, et al., 1989) (Vaughan, et al., 2006) 
(Nobles, et al., 2011); ubiquitination mediated by NEDD4, which is essential for 
receptor degradation (Shenoy, et al., 2008); glycosylation which has been 
implicated in β-arrestin recruitment, receptor internalisation, receptor dimer 
formation and membrane insertion, however the exact function remains unclear 
(Rands, et al., 1990)  (Li, et al., 2017) (Mialet-Perez, et al., 2004); and 
palmitoylation which has been shown to influence phosphorylation of the 
receptor, in addition to adequate Gs coupling (Ovchinnikov, et al., 1988) (Moffett, 
et al., 2001) (De Lean, et al., 1980) (O'Dowd, et al., 1988).  The data within this 
chapter describes a novel and never before reported  PTM of the β2AR, namely 
SUMOylation. In a similar manner to the other PTMs, SUMOylation influences the 
signalling of the β2AR including desensitisation, internalisation and downstream 
signalling.  
To promote β2AR SUMOylation in order to characterise the modification 
biochemically, the E3 ligase PIASγ was overexpressed using transient liposomal 
transfection. A similar approach of enhancing the components of the SUMOylation 
cascade has been used for other proteins (Sachdev, et al., 2001) (Leight, et al., 
2005) (Kho, et al., 2011). In all cases, this was shown to promote SUMOylation of 
the respective protein, evident by the presence of the “ghost band” at 
approximately 12-22kDa higher than the original protein band assessed via 
immunoblotting (Park-Sarge & Sarge, 2005). 
The SUMOylation of SERCA2a  (Kho, et al., 2011) was the basis for our hypothesis 
that other cardiac signalling proteins, namely the β2AR, could also be SUMOylated. 
The susceptibility of SERCA2a to SUMOylation was discovered via a proteomics 
screen which identified an interaction between SUMO-1 and SERCA2a. Additional 
evidence was provided by in vivo interactions discovered between SERCA2a-UBC9 
and SERCA2a-SUMO-1. SUMOylated lysines within SERCA2a – K480 and K585 - were 
conserved between four different species. These sites are located within the ATP 
binding domain of SERCA2a, and therefore SUMOylation was speculated to 
influence the intrinsic ATPase activity of SERCA2a. Kho et al (2011) reported that 
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SERCA2a SUMOylation acts to increase ATPase activity of the protein, and 
therefore would promote Ca2+ uptake into the SR. SUMOylation of SERCA2a also 
influences the stability of the protein as the lysines susceptible to SUMOylation 
are also susceptible to ubiquitination. This has been observed for other proteins 
also. For example, IĸBα can be modified by ubiquitin and SUMO on the same lysine 
residue (Desterro, et al., 1998). Degradation of proteins is normally mediated by 
ubiquitination, which has been implicated in both proteasomal and lysosomal 
degradation (Naujokat & Hoffman, 2002) (Moore, et al., 1999). Therefore, 
SUMOylation of SERCA2a inhibits ubiquitin-mediated degradation of this important 
cardiac protein.  
Unlike SERCA2a SUMOylation, SUMOylation of the β2AR was not associated with 
any specific SUMO isoform - paralogue 1 or 2/3. Initial peptide array data, 
indicative of β2AR SUMOylation, was generated using an ENZO in vitro SUMOylation 
kit. The paralogues within this kit are His tagged and therefore a His antibody 
detects all SUMO paralogues without deciphering between them. To assess 
paralogue specificity two methods could be used; paralogue specificity 
SUMOylation arrays or SUMO-specific antibody immunoprecipitation. In vitro 
SUMOylation of the β2AR peptide array could be mediated using individual His 
tagged SUMO paralogues to determine which isoform is responsible for β2AR 
SUMOylation. SUMO specific agarose beads linked to either SUMO-1 or SUMO-2/3 
antibodies could be incubated with HEKβ2 lysate overexpressing PIASγ to mediate 
β2AR SUMOylation, with subsequent probing of the immunoprecipitate for the 
receptor to determine if an interaction occurred between β2AR-SUMO-1, β2AR-
SUMO-2/3 or both.  
In a similar fashion to SERCA2a, the stability of β2AR was influenced by 
SUMOylation. Following prolonged ligand activation, the receptor is down 
regulated to prevent excessive agonist exposure – this was observed at 10 minutes 
of isoprenaline stimulation (10μM). However, SUMOylation of the β2AR, mediated 
by the overexpression of PIASγ, delayed receptor down-regulation. Unlike 
SERCA2a SUMOylation, SUMOylation of the β2AR did not influence receptor half-
life, however it did impact on receptor ubiquitination following isoprenaline 
treatment. Ubiquitination of the β2AR occurs within two areas; the third 
intracellular loop (K263 and K270) and the cytoplasmic tail (K348, K372 and K375) 
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(Shenoy, et al., 2008). The third intracellular loop is also the location of the 
confirmed SUMOylation sites K232 and K235. Although SUMOylation does not occur 
on the ubiquitin lysines, the presence of the bulky SUMO modification within the 
same intracellular loop at a 30 amino acid proximity to the ubiquitination sites 
could act to sterically hinder the process.  For example, Syntaxin-1A (Stx1A) 
SUMOylation at lysines 252, 253 and 256 acts to influence interactions within the 
SNARE domain (amino acids 191-235) of the protein (Craig, et al., 2015). 
Furthermore, steric hindrance via SUMOylation has been reported before for DNA 
binding to both hepatoma-derived growth factor (HDGF) and Rad1 (a cell cycle 
checkpoint protein) (Thakar, et al., 2008) (Sarangi & Zhao, 2015). Based upon 
these observations it is possible to speculate that SUMO modification could 
sterically hinder ubiquitination by preventing the ubiquitin machinery such as 
NEDD4 (Shenoy, et al., 2008) from accessing the lysines within the third 
intracellular loop. Additionally, the ubiquitin susceptible lysines within the 
cytoplasmic tail may also be subject to SUMOylation. The initial identification of 
the SUMO sites via sequence analysis software has been reported to miss certain 
SUMO specific sites. This was the case for caveolin-3 SUMOylation. The 
preferential solo SUMO site identified via sequence software analysis was K38, 
however if K38 was mutated then SUMOylation was possible at sites 15, 20, 30, 
69, 108 and 144  (Fuhs & Insel, 2011). Furthermore, the initial identification of 
the β2AR sites by software sequence analysis and subsequent peptide array was 
completed in the Baillie group in 2010. Since then, advancement in the 
SUMOylation consensus motifs to reveal both HCSMs and inverted motifs (Matic, 
et al., 2010)  (Impens, et al., 2014) means that SUMO susceptible lysines could 
have remained unidentified in these screens.  
 
SUMOylation of the β2AR also influences trafficking of the receptor. SUMOylation 
has been reported in the trafficking of other proteins: DISC1 SUMOylation 
promotes nuclear translocation  (Tankou, et al., 2016); LEF-1 SUMOylation targets 
the protein to nuclear bodies (Sachdev, et al., 2001); SUMOylation of the GluK2 
subunit at K886 promotes internalisation dependent upon PKC phosphorylation at 
site 868 (Chamberlain, et al., 2012). The β2AR is internalised in response to 
isoprenaline stimulation and data presented within this chapter demonstrates that 
SUMOylation of the β2AR causes a reduction in receptor internalisation in response 
to isoprenaline stimulation. Therefore, in line with the novel concept of β2AR 
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endosomal signalling (Irannejad, et al., 2013) (Irannejad & Von Zastrow, 2014), 
we would expect SUMOylation of the receptor to inhibit β2AR-Gs mediated cAMP 
production within the endosome. This hypothesis could be assessed by utilising 
FRET probes which detect endosomal cAMP levels. To internalise the β2AR there 
are various steps which are essential: GRK phosphorylation at sites 355/356 in the 
cytoplasmic tail  (Vaughan, et al., 2006); β2AR-β-arrestin2 interaction (Krasel, et 
al., 2005); β2AR-β-arrestin2 complex interaction with AP-2 of clathrin to initiate 
the formation of the endosome (Laporte, et al., 2000); β-arrestin2 ubiquitination 
(Shenoy, et al., 2001). The data presented within this chapter suggests that 
receptor SUMOylation mediates no significant change to isoprenaline-dependent 
GRK phosphorylation of the receptor. However the detection of total β2AR via the 
GFP-tag antibody is not as clear as prior western blots, and therefore to confirm 
the influence of receptor SUMOylation on β2AR phosphorylation by GRK, this 
western blot would need to be repeated. SUMOylation has previously been shown 
to alter the outcome of phosphorylation, not phosphorylation susceptibility. In 
this case PDE4D5 – an enzyme which degrades cAMP - is susceptible to SUMOylation 
and phosphorylation. Although SUMOylation does not prevent the enzyme from 
becoming phosphorylated, it does change the confirmation of PDE4D5 therefore 
changing the output of phosphorylation (Li, et al., 2010). However, the outcome 
of GRK-mediated phosphorylation of the receptor is promoting the interaction 
between β2AR-β-arrestin and the data within this chapter utilising the BRET 
technique implies there is no significant change in this interaction following 
receptor SUMOylation.  
β-arrestin is one of many proteins that has been reported to be a SUMO substrate 
following  overexpression of SUMO-1  (Xiao, et al., 2015). SUMOylation prevents 
β-arrestin from binding to TRAF6 gene, a gene which encodes for the TNF receptor 
associated family. This leads to TRAF6 oligomerisation and auto ubiquitination, 
and consequently leads to TRAF6-mediated activation of NF-κB/AP-1. It is 
unknown if β-arrestin SUMOylation can also be mediated by PIASγ and therefore 
this could be a contributing factor in β2AR internalisation. If the SUMOylation and 
ubiquitination compete for lysines within the same area of β-arrestin  as has been 
reported for other proteins including SERCA2a  (Kho, et al., 2011), IĸBα (Desterro, 
et al., 1998) MDM2,  (Meek & Knippschild, 2003) NEMO  (Huang, et al., 2003), axin 
(Kim, et al., 2008), and RNA helicases p68 and p72  (Mooney, et al., 2010), then 
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SUMOylation of β-arrestin may alter  the stoichiometry of the scaffold. 
Additionally if the arrestin were SUMOylated it would raise questions in the 
following areas; firstly would the SUMOylated arrestin sterically hinder 
internalisation as has been seen for other proteins (Thakar, et al., 2008) (Sarangi 
& Zhao, 2015), or secondly, could SUMOylation of the arrestin mediate a 
conformational change of the protein causing a change in arrestin function, similar 
to PDE4D5  (Li, et al., 2010). 
The β2AR traditionally signals via the Gs protein mediating PKA activation with the 
kinase capable of phosphorylating multiple substrates, one of which is the 
receptor itself (Daaka, et al., 1997). The consensus sequences for PKA-mediated 
phosphorylation are within the C-terminus of intracellular loop 3 (serines 261 and 
262) and in proximal cytoplasmic tail (serines 345 and 346) (Bouvier, et al., 1989). 
Phosphorylation results in reduced coupling between the β2AR and Gs, switching 
it to Gi, with a mutant β2AR lacking these phospho-sites incapable of signalling via 
Gi (Hausdorff, et al., 1989) (Strulovici, et al., 1984) (Daaka, et al., 1997). 
SUMOylation of the β2AR mediates a reduction in isoprenaline-dependent PKA-
mediated phosphorylation of the β2AR at serines 345/346. As mentioned above it 
is possible that all SUMOylation sites on the β2AR have not been identified and 
therefore sites within the cytoplasmic tail could be SUMOylated. An interaction 
between the PTMs phosphorylation and SUMOylation has been reported before. 
This was first identified in heat shock factors, in which stress-induced 
phosphorylation, resulted in increased levels of SUMO modification  (Hietakangas, 
et al., 2003). By contrast, phosphorylation can also negatively regulate SUMO 
modification. For example, phosphorylation of ELK1 (transcription factor which 
regulates early gene expression) results in a reduction in ELK1 SUMO modification 
(Yang, et al., 2003). Additionally, if additional SUMOylation sites were to exist in 
the cytoplasmic tail, this could act to sterically hinder phosphorylation.  
The SUMO susceptible lysines 232 and 235 could influence the dynamics of the 
third intracellular loop. The traditional signalling pathway via Gs begins with 
receptor agonist binding initiating PKA activation via production of cAMP. The 
receptor undergoes a conformational change to allow activation of the signal 
transduction pathway. Glutamine 268 within the intracellular loop interacts with 
arginine 131 from the third transmembrane helix to constitute an ionic lock in the 
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resting β2AR – which must be disrupted upon receptor activation (Ballesteros, et 
al., 2001) (Yao, et al., 2006). It is possible the bulky SUMO modification within 
this region could hinder lock disruption resulting in dampened, downstream 
signalling. The data within this chapter suggests that the SUMOylated receptor 
mediates no change in β2AR-G protein interaction and no change in β2AR-ligand 
interaction therefore it is probable that SUMO modification may interfere with the 
helical movements of the receptor. However, the experiments assessing the β2AR-
G protein interaction  are the first to use the SPASM sensor probes and further 
probe optimisation, specifically for the β2AR-Gi probe which lacked response in 
kinetics experiments, is required. 
The final aspect of β2AR signalling that SUMOylation was shown to influence was 
cAMP dynamics. SUMOylation of the receptor causes an increase in the time taken 
for cytosolic cAMP levels to fall following receptor activation. Traditionally, 
PDE4D5 is recruited to the receptor following activation via it’s interaction with 
β-arrestin (Perry, et al., 2002) This enzyme mediates downregulation of cAMP and 
therefore a reduction in PKA activity, which leads to less phosphorylation of the 
β2AR. It has been shown that PDE4D5 is susceptible to SUMOylation via PIASγ at 
lysine 232. Normally PDE4D5 activity would be enhanced by PKA phosphorylation 
and reduced by ERK phosphorylation, however when the PDE is SUMOylated it 
becomes more susceptible to PKA activation and less susceptible to ERK inhibition 
– leading to a more active PDE4D5. In our set up, it is probable that overexpression 
of PIASγ in addition to SUMOylating the receptor would also be promoting 
SUMOylation of the PDE  (Li, et al., 2010). With cAMP levels being maintained at 
a low level by the enhanced activity of PDE4D5, there will be less activation of 
PKA, and therefore less PKA phosphorylation of the receptor and other substrates.  
Therefore, it is possible that PIASγ overexpression has both promoted SUMOylation 
of the β2AR and PDE4D5. Further experiments will need to be conducted to 
determine the functional outcomes of each individual SUMOylation event. In 
contrast to what is observed with reduced PKA activity, cAMP levels are elevated 
following SUMOylation of the β2AR. Further cAMP assays will need to be completed 
to determine the outcome of cAMP dynamics mediated by receptor SUMOylation. 
Indeed, the answer to this contradiction may lie in the compartmentalisation of 
signalling components. As the cAMP reporter constructs are cytosolic the only pick 
up “global” bulk changes in the cyclic-nucleotide. Spatially targeted cAMP probes 
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that locate to the plasma membrane are more likely to report on cAMP changes in 
the vicinity of the β2AR. 
For future work, the SUMOylation of the β2AR should be assessed in a 
physiologically relevant model. A more appropriate cell type would be the 
cardiomyocyte which expresses both β1AR and β2AR, at 75-80% and 20-25% 
respectively (Madamanchi, 2007). Liposomal transfection utilised in this chapter 
to promote β2AR SUMOylation is not the optimum method to enhance PIASγ in 
cardiomyocyte. Neonatal cardiomyocytes transfection rates of only up to 15% are 
reported, with adult cardiomyocytes proving even more difficult to transfect than 
neonatal cardiomyocytes (Djurovic, et al., 2004). In comparison with transfection, 
viral based techniques enable much more efficient and stable gene transfer for 
cardiac cells (Louch, et al., 2011). Therefore, future experiments will utilize a 
PIASγ adenovirus.  
In conclusion, I have validated the SUMOylation sites 232 and 235 on the β2AR and 
successfully promoted SUMOylation of the β2AR in vitro via the use of the E3 ligase 
PIASγ. SUMOylation of the β2AR has been shown to influence downstream 
signalling, internalisation and down-regulation of the receptor. These changes 
could be associated to steric hindrance of the bulky SUMO modification, 
speculative unidentified SUMOylation sites, and ubiquitin-SUMOylation 
competitions.  
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Chapter 5 Analysis of β2AR SUMOylation in 
Animal Models of Heart Failure (HF) 
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5.1 Introduction 
5.1.1 The Need for Animal Models of HF  
Heart failure (HF) is often regarded as the inadequacy of cardiac output resulting 
in the metabolic needs of organs and tissues being unmet. The primary symptoms, 
which present clinically, include dyspnea, fatigue, exercise intolerance, and 
retention of fluid in the lungs and peripheral tissues (Houser, et al., 2012). HF can 
be managed by multiple approaches ranging from lifestyle changes and 
pharmacological therapies, to more extreme approaches, such as implantable 
devices and cardiac surgery. However, the prognosis is poor with average life 
expectancy around three years post diagnosis (Dickstein, et al., 2008). Although 
the current standard of care improves outcomes, the syndrome continues to 
progress and there is a need for novel therapies that can prevent, inhibit 
progression, and/or reverse the structural and functional defects of the failing 
heart. Research to identify novel targets for HF therapy usually requires 
preclinical testing in appropriate animal models. The two models presented in this 
thesis are the transverse aortic constriction (TAC) pressure overload HF model in 
mice and the left anterior descending (LAD) artery balloon occlusion ischemic HF 
model in pigs.   
5.1.2 Minimally Invasive TAC Pressure Overload HF Model in 
Mice   
The TAC model is based on HF mediated by aortic stenosis (AS). Common causes 
of AS include atherosclerotic disease, calcification and aortic valve 
malformations. All of these result in a stiffness of the aortic valve and reduce the 
orifice area. The increased resistance to LV (left ventricular) ejection results in 
an increased LV afterload, which is the pressure which the LV must develop to 
propel blood across the reduced aortic orifice  (Houser, et al., 2012). The TAC 
model mimics LV pressure overload, which allows the study of compensated 
hypertrophy of the heart with progression to HF  (Lompre, et al., 1979) (Mercadier, 
et al., 1981) (Izumo, et al., 1987). A silk suture around the aortic arch acts to 
create a greater LV afterload (Figure 5.1). Mice undergoing SHAM surgery are 
treated in the exact same surgical manner – only no suture is used to tie off the 
aorta.   
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Figure 5.1 Location of aortic ligation during TAC surgery. The constriction is 
made at the aortic arch with 5-0 silk suture under the guidance of a 27G needle 
to provide a 0.4mm diameter passage (Ardehali, et al., 2013). 
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In the model, there is an initial compensatory phase, in which the elevated wall 
stress mediates myocardial growth creating a thicker and “stronger” LV that is 
capable of maintaining ejection fraction into the aorta. However, this phase 
becomes maladaptive with increased fibrosis occurring due to elevated cardiac 
fibroblast proliferation and collagen synthesis in response to the growing 
myocardium (Diez, et al., 2007). The stiffening of the LV leads to diastolic 
dysfunction – a structural milestone in the transition from the compensated state 
to HF (Krayenbuehl, et al., 1989) (Heyman, et al., 2005) (Monrad, et al., 1988). 
This leads to the manifestation of HF symptoms, where the heart is in a state of 
both LV systolic and diastolic dysfunction (Houser, et al., 2012) (Peske, 2004).  
Kho et al (2011) used the TAC model in mice to study the influence of SERCA2a 
SUMOylation on HF and reported that around 2 months post TAC surgery mice were 
in a state of HF. These mice had a fractional shortening of below 50%, in which 
fractional shortening is a reduction in the diastolic dimensions of the heart that 
occurs by the end of systole. For example, when the healthy heart contracts to a 
state of systole, the diastolic dimensions should become smaller therefore forcing 
blood out, but in a stiffened state the heart will be limited in its contractility and 
the diastolic dimensions will remain constant leading to a lower fractional 
shortening percentage. This means less blood will be expelled with each beat. In 
addition to changes in fractional shortening these mice had a reduced LV ejection 
fraction, elevated LV pressure and an increased LV end diastolic diameter, 
indicative of LV dilation. This provides further evidence these mice are in HF, as 
both LV end systolic and diastolic diameter become increased in this condition 
(Peske, 2004). Further evidence of cardiac remodelling came from an increase in 
heart-to-body weight ratio in comparison to the appropriate SHAM control. The 
HF mice displayed reduced SUMOylated SERCA2a levels, but restoration of 
SUMOylated SERCA2a by SUMO-1 gene transfer led to improved LV function, as 
well as stabilising the heart-to-body weight ratios (Kho, et al., 2011).   
The traditional TAC model requires thoracotomy to gain access to the aortic arch 
along with mechanical ventilation, but this can be time consuming and technically 
complex. Mechanical ventilation is essential due to the partial thoracotomy and 
sternum retraction required for the surgery. This process increases the time the 
animal is under anaesthesia, as intubation is required both prior to and following 
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surgery, but only when the animal begins to breathe spontaneously during 
recovery (deAlmeida, et al., 2010). Martin et al (2012) reported findings on a 
minimally invasive model of the TAC procedure, which circumvents these 
requirements, making the surgery both quicker and easier. In the minimally 
invasive procedure a small horizontal skin incision of about 1cm at the level of the 
suprasternal notch allows trachea location, and using the trachea for anatomical 
placement the aortic arch is located. Access to the arch is then optimised using a 
5mm cut in the sternum. As the thoracotomy is no longer required, the animal can 
breathe without support of mechanical ventilation throughout the entire 
procedure. This procedure is therefore less invasive than traditional TAC surgery, 
making both pre-surgical preparation and recovery quicker. The minimally 
invasive TAC model displayed similar results to traditional TAC surgery, with 
cardiac hypertrophy being indicated by increased LV wall thickness, elevated 
systolic pressure, increased individual cardiomyocyte size and increased heart-to-
body weight ratio, in comparison to SHAM control. In addition, sacrifice data 
identified that TAC animals had elevated cardiac fibroblast proliferation and 
collagen production, as well as elevated activity in inflammatory signalling 
pathways in comparison to SHAM animals.  
5.1.3 LAD Artery Balloon Occlusion Ischemic HF Model in 
Pigs 
The LAD artery balloon occlusion model is an ischemia/reperfusion model that 
acts to mimic an acute myocardial infarction (MI) (Koudstaal, et al., 2014). The 
LAD artery provides the blood supply for over half the myocardium, and is often 
the largest coronary artery, therefore a major blockage in this artery can be 
detrimental to the heart (Ahmed, 2015) (Figure 5.2). This model is based on 
occluding the LAD for ninety minutes to initiate a period of myocardial ischaemia. 
During this period, an “ischemic cascade” is triggered, in which the heart cells 
which are supplied by the LAD become necrotic and die with a collagen scar 
forming in their place. After ninety minutes, the myocardium is re-perfused by 
removing the blockage in the LAD artery, but this in itself can promote problems 
as although re-perfusion saves viable myocytes, it also accelerates the 
degradation of injured myocytes and permits infarct scar growth. After an MI, the 
scar tissue deleteriously affects the function of the heart by making it stiffer and 
disrupting communication between cardiomyocytes (Simonis, et al., 2012). The 
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LAD artery balloon occlusion model promotes an infarct size of approximately 10-
15% of the LV, increases LV end diastolic diameter and reduces LV ejection 
fraction by approximately 35-45% 4 weeks post-surgery (Koudstaal, et al., 2014).   
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Figure 5.2 Location of the LAD artery for balloon occlusion. This model is based 
on occluding the LAD for 90 minutes to initiate a period of myocardial ischaemia 
(www.hopkinsmedicine.org, 2017). LAD (left anterior descending).  
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The Hajjar group also examined the SUMOylation of SERCA2a in the LAD artery 
balloon occlusion ischemic HF model in pigs  (Tilemann, et al., 2013). This was 
the next step following their study in rodents (Kho, et al., 2011), as pigs are 
increasingly being used in cardiovascular research due to their similarity in cardiac 
function and anatomy with the human heart (Crick, et al., 1998) (Stubhan, et al., 
2008). For instance, pig heart-to-body weight ratio, cardiac size and coronary 
artery anatomy distribution have all shown to have a high degree of similarity to 
man (Crick, et al., 1998). Moreover, cardiomyocyte metabolism, 
electrophysiological properties and response to an ischemic insult, such as MI, 
have been reported to match the human situation (Heusch, et al., 2011) 
(Skychally, et al., 2009). In the pig LAD artery balloon occlusion ischemic HF 
model, the Hajjar group found that HF mediates a reduction in SUMOylated 
SERCA2a, but when this modified protein was restored via SUMO-1 gene transfer 
there was an increase in cardiac contractility, improved LV ejection fraction and 
an alleviation of deteriorating LV volumes  (Tilemann, et al., 2013). With regards 
to the HF phenotype Tilemann et al (2013) reported similar findings to Koudstaal 
et al (2014), with a reduction in LV ejection fraction and cardiac output, in 
conjunction with LV end systolic and diastolic diameter becoming increased, all 
indicative of the animal being in a state of HF.  
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5.2 Aims 
As HF has been shown to result in a decreased expression of SUMO protein, I 
hypothesise that SUMOylation of the β2AR is reduced in HF in a similar fashion to 
SERCA2a.  
The aims of this chapter are to: - 
1. Establish and characterise the minimally invasive TAC pressure overload 
model of HF in mice  
2. Evaluate SUMOylation of the β2AR in the minimally invasive TAC pressure 
overload model of HF in mice and the LAD artery balloon occlusion ischemic 
HF model in pigs 
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5.3 Results  
5.3.1 Minimally Invasive TAC Pressure Overload Model in 
Mice 
I aimed to establish a minimally invasive TAC model of HF in C57BL/6 mice with 
the intention of creating a model in which we could investigate the role of β2AR 
SUMOylation in the HF phenotype. The following results relate to this model.  
5.3.1.1 The Influence of TAC Surgery on Echocardiographic Parameters    
Echocardiographic assessment of left ventricular (LV) function was performed 
before and after TAC surgery (Figure 2.7). Through this method we were able to 
determine the following parameters; cardiac output, stroke volume, fractional 
shortening, ejection fraction and relative wall thickness by assessing the 
echocardiographic parameters discussed in section 2.15.4 – Transthoracic 
Echocardiography (Figure 2.8 & 5.3A). These parameters were assessed in relation 
to body weight and tibia length over the 8-week time period. Both tibia length 
and body weight were assessed throughout the study as at the beginning of the 
study it was not known if TAC surgical intervention would influence the body 
weight of the animal, and therefore taking both measurements was appropriate 
to ensure reliable comparisons between groups.  
Throughout the study there was no significant difference observed in body weight 
and tibia length between TAC and SHAM groups (Figure 5.3B) (TAC N=17, SHAM 
N=9). At both 3 and 8 weeks post TAC, there was an approximate 40-50% reduction 
in cardiac output and an approximate 35-40% reduction in stroke volume in TAC 
mice in comparison to SHAM mice, but a significant increase in relative wall 
thickness by approximately 60% in TAC mice in comparison to SHAM mice (Figure 
5.4) (TAC N=17, SHAM N=9) (**p<0.01) (***p<0.001) (****p<0.0001). There was no 
significant difference observed in fractional shortening or ejection fraction in TAC 
mice in comparison to SHAM mice (Figure 5.4) (TAC N=17, SHAM N=9).  
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Figure 5.3 Echocardiographic representative images and physical body 
measurements used to determine cardiac remodelling and function. (A) 
Echocardiographic assessment of left ventricular (LV) function was performed 
both 3 and 8 weeks after surgery, as well as before surgery. The measurements 
taken include LVESD, LVEDD, PWTs, PWTd, AWTs, AWTd. Representative traces 
from one echocardiogram shown above bar graphs. (A&B) Cardiac parameters 
were assessed in relation to BW and TL. Throughout the study no significant 
difference in BW or TL was observed between the TAC and SHAM groups. (TAC 
N=17, SHAM N=9). LVESD (LV end systolic diameter), LVEDD (LV end diastolic 
diameter), PWTs (posterior wall thickness during systole), PWTd (posterior wall 
thickness during diastole), AWTs (anterior wall thickness during systole), AWTd 
(anterior wall thickness during diastole), BW (body weight), TL (tibia length), TAC 
(transverse aortic constriction).  
  
 
 
A.
B.
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Figure 5.4 Cardiac function and remodelling assessed following TAC surgery. 
At both 3 and 8 weeks post TAC, there was a significant reduction in cardiac output 
and stroke volume in TAC mice in comparison to SHAM mice, but an increase in 
relative wall thickness (TAC N=17, SHAM N=9) (**p<0.01) (***p<0.001) 
(****p<0.0001). There was no difference observed in fractional shortening or 
ejection fraction in TAC mice in comparison to SHAM mice (TAC N=17, SHAM N=9). 
TAC (transverse aortic constriction). 
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5.3.1.2 The Influence of TAC Surgery on Left Ventricular Mass  
Echocardiographic assessment of the measurements discussed in section 2.15.4 – 
Transthoracic Echocardiography (Figure 2.8) and comparing them to physical body 
measurements of weight and tibia length allowed assessment of the following 
ratios: LV mass-to-body weight and LV mass-to-tibia length. These measurements 
allowed the assessment of heart size in comparison to the size of the animal 
throughout the time course of the study. An increase in LV mass-to-body weight 
and LV mass-to-tibia length ratios would be expected in TAC animals in comparison 
to SHAM animals as this surgical intervention initiates a hypertrophic response  
(Kho, et al., 2011) (Martin, et al., 2012).  
The data showed that there was a trend for an increased LV mass-to-body weight 
and LV mass-to-tibia length ratio in TAC mice in comparison to SHAM mice at the 
3 and 8 week time point, however significant changes were only observed at the 
three week time point, 35% increase in LV mass : body weight and 50% increase in 
LV mass : tibia length from SHAM to TAC (Figure 5.5) (TAC N=17, SHAM N=9). This 
indicates that the TAC surgical intervention has initiated a hypertrophic response.  
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Figure 5.5 Left ventricular mass indices assessed following TAC surgery. There 
was an increased LV mass-to-body weight and LV mass-to-tibia length ratio in TAC 
mice in comparison to SHAM mice at the 3 and 8 week time point, however this 
was only significant at the 3 week time point (*p<0.05) (TAC N=17, SHAM N=9). 
TAC (transverse aortic constriction), LV (left ventricle).  
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5.3.1.3 The Influence of TAC Surgery on Whole Heart Mass  
In addition to echocardiographic assessment of heart size, physical assessment of 
whole heart mass was assessed following TAC surgery. Animals were sacrificed at 
8 weeks post TAC surgery and organs were harvested. Organ weight was compared 
to both body weight and tibia length. An increase in whole heart mass would be 
expected in TAC animals in comparison to SHAM animals as this surgical 
intervention initiates a hypertrophic response  (Kho, et al., 2011) (Martin, et al., 
2012).  
There was a significant increase of approximately 20% in TAC mice in comparison 
to SHAM mice in the following ratios; heart-to-body weight, LV-to-body weight 
and heart weight-to-tibia length (Figure 5.6) (TAC N=17, SHAM N=9) (*p<0.05) 
(***p<0.001). There was a trend for LV weight-to-tibia length to increase in TAC 
mice, in comparison to SHAM mice, however no significant changes were observed 
(Figure 5.6) (TAC N=17, SHAM N=9). Similarly, to the echocardiographic data, 
physical assessment of the heart revealed that the TAC surgical intervention has 
initiated a hypertrophic response.  
 
 
 
 
 
 
 
225 
 
 
 
Figure 5.6 Heart weight is increased by TAC surgery. (A) There was a significant 
increase in TAC mice in comparison to SHAM mice in the following ratios; heart-
to-body weight, LV-to-body weight and heart weight-to-tibia length.  There was a 
trend for LV weight-to-tibia length to increase in TAC mice in comparison to SHAM 
mice (TAC N=17, SHAM N=9) (*p<0.05) (**p<0.01). (B) Representative hearts from 
TAC and SHAM animals shown. TAC (transverse aortic constriction), LV (left 
ventricle).  
A.
B.
SHAM TAC
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5.3.1.4 The Influence of TAC Surgery on Other Organs  
To determine that the TAC surgical intervention only initiated a cardiac response, 
the other organs of the body were physically examined.  The weights of other 
organs were normalised against both body weight and tibia length. No differences 
would be expected to be observed in the kidney and liver, however some groups 
report an increase in lung mass following TAC surgery (Lu, et al., 2010) (Xu, et 
al., 2011) (Lu, et al., 2010) (Takimoto, et al., 2005). 
No significant differences were observed in body weight or tibia length (Figure 
5.7) (TAC N=17, SHAM N=9) or in the ratios lung-to-body weight, liver-to-body 
weight, kidney-to-body weight, lung-to-tibia length, liver-to-tibia length, kidney-
to-tibia length between TAC and SHAM groups at point of sacrifice (Figure 5.8) 
(TAC N=17, SHAM N=9). This indicates that the TAC surgical intervention only 
mediated effects on the heart.  
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Figure 5.7 TAC surgery does not influence body weight or tibia length. No 
significant differences were observed in body weight or tibia length between TAC 
and SHAM groups at point of sacrifice (TAC N=17, SHAM N=9). TAC (transverse 
aortic constriction).  
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Figure 5.8 TAC surgery does not influence other organs. No significant 
differences were observed between TAC and SHAM groups at point of sacrifice in 
the following ratios; lung-to-body weight, liver-to-body weight, kidney-to-body 
weight, lung-to-tibia length, liver-to- tibia length, kidney-to- tibia length (TAC 
N=17, SHAM N=9). TAC (transverse aortic constriction).  
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5.3.1.5 Identification of TAC Mice with the Strongest Hypertrophic Response 
The TAC surgery can mediate variable response between animals. The success of 
this model can be dependent on the tightness of the suture around the aortic arch, 
as this will determine the degree of hypertrophic development, and therefore the 
time frame in which HF and cardiac dilatation develops (deAlmeida, et al., 2010). 
Although the aortic constriction is standardised by a needle aligned against the 
vessel when tying off the suture, constriction does vary between mice with some 
animals having tighter banding than others. This variability is even more 
pronounced in the minimally invasive TAC model due to the lack of thoracotomy, 
and therefore there is a limited view of the aortic arch when the suture is being 
tied. This can result in different anatomical placement in every animal, since the 
aortic arch may be more easily accessed in some mice. Regardless of the 
thoracotomy giving better access in the standard TAC model, Kho et al. (2011) 
still used isolation criteria to identify animals which displayed a stronger HF 
phenotype for further study. Parameters used were pressure gradient greater than 
30mmHg, in addition to fractional shortening of less than 50%. In the TAC 
establishment study the animals that displayed the greatest changes in relative 
wall thickness were identified to have the strongest hypertrophic phenotype.  
Using this isolation criteria, the echocardiographic parameters (fractional 
shortening and ejection fraction) were re-examined (Table 5.1). Despite the 
significant hypertrophic changes observed, fractional shortening and ejection 
fraction, which are normally reduced by aortic banding models (Martin, et al., 
2012), were unchanged in the TAC establishment study (TAC N=6, SHAM N=6). This 
strongly suggested that the mice have not yet progressed to HF and are still in a 
state of compensatory hypertrophy.  
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Table 5.1 Echocardiographic data from RWT criterion animals 
  
 0 Weeks 3 Weeks 8 Weeks 
Parameter TAC SHAM TAC SHAM TAC SHAM 
Fractional 
Shortening 
(%) 
Mean±SEM  39.73 
±1.92 
39.64 
±1.51 
41.12 
±2.90 
40.90 
±1.93 
42.41 
±3.14 
35.50 
±2.10 
P Value 0.9725 0.9693 0.0972 
Ejection 
Fraction 
(ml) 
Mean±SEM  77.78 
±2.11 
77.8 
±1.74 
78.87 
±2.79 
79.12 
±2.09 
80.06 
±3.21 
72.74 
±2.59 
P Value 0.992 0.9449 0.1016 
 
 
 
5.3.1.6 The Influence of TAC Surgery on Cardiomyocyte Cross Sectional 
Area  
Considering the variability observed in response to the TAC surgery in the study 
animals, the decision was made to examine cardiomyocyte hypertrophy and 
fibrosis only in those animals displaying the greatest response to surgical 
intervention based on criterion described in section 5.3.1.5 - Identification of TAC 
Mice with the Strongest Hypertrophic Response. Using wheat germ agglutinin 
(WGA) staining – a membrane stain to ascertain cell size – the cardiomyocyte cross 
sectional area was measured. Using this method, I observed a significant increase 
of approximately 35% in cardiomyocyte cross sectional area in the TAC animals in 
comparison to SHAM animals (Figure 5.9) (TAC N=6, SHAM N=6) (*p<0.05). This is 
indicative of increased hypertrophy in these animals, as would be expected 
following TAC surgical intervention  (Kho, et al., 2011) (Martin, et al., 2012).  
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Figure 5.9 TAC surgery increases cardiomyocyte size. (A&B) There was a 
significant increase in cardiomyocyte cross sectional area in the TAC animals in 
comparison to the SHAM animals (TAC N=6, SHAM N=6) (*p<0.05). TAC (transverse 
aortic constriction). (A) Representative images of WGA staining are shown above 
bar graph. 
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5.3.1.7 The Influence of TAC Surgery on Cardiac Fibrosis  
Using picrosirius red staining – a stain which recognises collagen deposition – the 
volume of fibrotic tissue within cross sections of the hearts was assessed. Fibrosis 
was assessed both perivascularly and interstitially. The measurements from these 
individual areas were combined to give total fibrosis. There was a 1-fold 
significant increase in fibrotic tissue area in the TAC mice in comparison to the 
SHAM (Figure 5.10) (TAC N=6, SHAM N=6) (**p<0.01) (***p<0.001). This increase in 
fibrosis is associated with cardiac remodelling and hypertrophy, as would be 
expected following TAC surgery  (Kho, et al., 2011) (Martin, et al., 2012). 
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Figure 5.10 TAC surgery increases cardiac fibrosis. (A&B) There was a significant 
increase in fibrotic tissue area in the TAC mice in comparison to SHAM both 
perivascularly, interstitial and total (***p<0.001) (**p<0.01) (TAC N=6, SHAM N=6). 
TAC (transverse aortic constriction). (A) Representative images of picrosirius red 
staining are shown above bar graph. 
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5.3.1.8 TAC Model Influences SUMOylation Pathway Machinery  
Intermediates within the SUMOylation pathway were examined in TAC in 
comparison to SHAM via immunoblot analysis. The SUMOylation pathway consists 
of the following components; the SUMO paralogues 1, 2 and 3 and the SUMOylation 
enzymes consisting of E1 activating enzyme, UBC9 E2 conjugating enzyme, and E3 
ligases, such as PIASγ. SUMO-1, SUMO-2/3, UBC9, and the E3 ligase PIASγ which 
we have shown promotes β2AR SUMOylation were examined in both TAC and SHAM 
mice tissue, in addition to examination of SUMOylated β2AR levels using the 
Badrilla ® custom designed antibody.  
There was no significant difference in SUMO-2/3 and expression between TAC and 
SHAM mice (Figure 5.11) (TAC N=6, SHAM N=6). PIASγ expression between TAC and 
SHAM animals was inconclusive due to poor quality of western blot (Figure 5.12) 
(TAC N=6, SHAM N=6). TAC animals display a significant reduction of 
approximately 30% in UBC9 expression in comparison to SHAM animals (Figure 
5.13) (TAC N=6, SHAM N=6) (**p<0.01). The impact of TAC surgery on SUMO-1 
expression was unable to be assessed in this study. No bands for SUMO-1 were 
detected in the mouse cardiac lysate (Figure 5.14A), although the SUMO-1 
antibody I used has been shown to be functional as SUMO-1 expression was 
identified at the correct molecular weight in both pig cardiac tissue and HEKβ2 
cell lysate (Figure 5.14B). No significant difference was observed in SUMO-β2AR 
expression between TAC and SHAM mice (Figure 5.15A) (TAC N=6, SHAM N=6). 
However, the appropriate quantification would involve normalising the SUMO-β2AR 
band to the total β2AR band, and a signal could not be detected using two total 
β2AR antibodies in the mouse lysate as the band was below the threshold of 
detection (Figure 5.15B). The capability of these antibodies was tested via the 
detection of β2AR present in the stable HEKβ2 cell line, in comparison to standard 
HEK cells. Both antibodies successfully detected β2AR (Figure 5.16). In this 
instance SUMO-β2AR was therefore quantified to GAPDH loading control (Figure 
5.15A).   
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Figure 5.11 TAC surgery does not influence SUMO-2/3 expression. (A&B) There 
is no significant change in SUMO-2/3 expression in the HF model in comparison to 
SHAM (TAC N=6, SHAM N=6). TAC (transverse aortic constriction). Primary 
concentration 1 : 1000, secondary concentration 1 : 5000. (A) Representative blots 
shown. 
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Figure 5.12 TAC surgery influence on PIASγ expression is inconclusive. (A&B) 
PIASy expression in the HF model in comparison to SHAM animals is inconclusive 
due to poor quality of western blot (TAC N=6, SHAM N=6). TAC (transverse aortic 
constriction). Primary concentration 1 : 1000, secondary concentration 1 : 5000. 
(A) Representative blots shown. 
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Figure 5.13 TAC surgery reduces UBC9 expression. (A&B) There is a significant 
reduction in UBC9 expression in the HF model in comparison to SHAM (TAC N=6, 
SHAM N=6) (**p<0.01). TAC (transverse aortic constriction). Primary concentration 
1 : 1000, secondary concentration 1 : 5000. (A) Representative blots shown. 
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Figure 5.14 TAC surgery influence on SUMO-1 expression is inconclusive. (A)  
Assessment of SUMO-1 expression in TAC model of HF is inconclusive due to lack 
of antibody detection. (B) SUMO-1 antibody is functional proven by detecting cell 
lysate and pig cardiac tissue (TAC N=6, SHAM N=6). TAC (transverse aortic 
constriction). Primary concentration 1 : 1000, secondary concentration 1 : 5000. 
(A&B) Representative blots shown. 
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Figure 5.15 TAC surgery does not influence SUMO-β2AR expression. (A) There 
is no significant change in SUMO-β2AR expression in the HF model in comparison 
to SHAM (TAC N=6, SHAM N=6). (B)  β2AR antibody displays no signal with cardiac 
lysate. TAC (transverse aortic constriction) β2AR (beta 2 adrenoceptor). Primary 
concentration 1 : 500, secondary concentration 1 : 5000. (A&B) Representative 
blots shown. 
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Figure 5.16 Testing of β2AR antibodies with cell lysate. The capability of the 
β2AR antibodies, Santa Cruz antibody (A) and Thermofisher antibody (B), was 
tested via the detection of β2AR present in the stable HEKβ2 cell line, in 
comparison to standard HEK cells. Both antibodies successfully detected β2AR.  
β2AR (beta 2 adrenoceptor). Primary concentration 1 : 1000, secondary 
concentration 1 : 5000. (A&B) Representative blots shown. 
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5.3.2 LAD Artery Balloon Occlusion Ischemic HF Model in 
Pigs 
A student placement within the Hajjar group (New York) allowed me to access pig 
cardiac tissue from the LAD artery balloon occlusion model of HF. This allowed 
the investigation of the β2AR SUMOylation in an animal model which is considered 
to be more relevant to the human cardiac system than rodents. The following 
results relate to the LAD artery balloon occlusion model.  
5.3.2.1 LAD Artery Balloon Occlusion Ischemic HF Model Influences 
SUMOylation Pathway Machinery  
Similarly to the TAC study, the SUMOylation pathway and SUMOylated- β2AR were 
examined in LAD artery balloon occlusion in comparison to SHAM via immunoblot 
analysis. 
On visualising SUMO-2/3 using western blotting, a band would be expected at 
approximately 12kDa, which is the case for the HEKβ2 control lysate (Figure 5.17). 
The only band present within the pig samples appears below 37kDa (Figure 5.17) 
but there is no information regarding this antibody having unspecific binding. It is 
probable that this band could indicate chains of SUMO-2/3 within the pig samples, 
or possibly a protein which SUMO-2/3 has modified. When the present band was 
quantified there was a significant reduction of approximately 30% in the LAD 
artery occlusion model in comparison to SHAM (Figure 5.17) (LAD artery occlusion 
N=3, SHAM N=3) (**p<0.01). There was no significant difference in SUMO-1 and 
PIASγ expression in the LAD artery occlusion model in comparison to SHAM (Figure 
5.18 & 5.19) (LAD artery occlusion N=3, SHAM N=3). There is a significant 1.5-fold 
increase in SUMOylated β2AR expression in the LAD artery occlusion model in 
comparison to SHAM (Figure 5.20) (LAD artery occlusion N=3, SHAM N=3) (*p<0.05). 
UBC9 expression shows a trend to be reduced by approximately 60% in the LAD 
artery occlusion model in comparison to SHAM (Figure 5.21) (LAD artery occlusion 
N=3, SHAM N=3). However, this blot shows high variability and to determine 
differences in UBC9 between healthy and diseased phenotypes more n numbers 
would be required.   
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Figure 5.17 LAD artery balloon occlusion reduces SUMO-2/3 expression. (A&B) 
There is a significant reduction in SUMO-2/3 expression in the HF model in 
comparison to SHAM (LAD artery occlusion N=3, SHAM N=3) (**p<0.01). HF (heart 
failure), LAD (left anterior descending). Primary concentration 1 : 1000, secondary 
concentration 1 : 5000. (A) Representative blots shown. 
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Figure 5.18 LAD artery balloon occlusion does not influence SUMO-1 
expression. (A&B) There is no significant difference in SUMO-1expression in the 
HF model in comparison to SHAM (LAD artery occlusion N=3, SHAM N=3). HF (heart 
failure), LAD (left anterior descending). Primary concentration 1 : 1000, secondary 
concentration 1 : 5000. (A) Representative blots shown. 
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Figure 5.19 LAD artery balloon occlusion reduces PIASγ expression. (A&B) 
There is a trend for PIASγ expression to be reduced in the HF model compared to 
SHAM, however no significant differences are observed (LAD artery occlusion N=3, 
SHAM N=3). HF (heart failure), LAD (left anterior descending). Primary 
concentration 1 : 1000, secondary concentration 1 : 5000. (A) Representative blots 
shown. 
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Figure 5.20 LAD artery balloon occlusion increases SUMO-β2AR expression. 
(A&B) There is a significant reduction in SUMO-β2AR expression in the HF model in 
comparison to SHAM (LAD artery occlusion N=3, SHAM N=3) (*p<0.05). HF (heart 
failure), LAD (left anterior descending). Primary concentration 1 : 500, secondary 
concentration 1 : 5000. (A) Representative blots shown. 
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Figure 5.21 LAD artery balloon occlusion reduces UBC9 expression. (A&B) 
There is a trend for UBC9 expression to be reduced in the HF model compared to 
SHAM, however no significant differences are observed. More n numbers would be 
required to account for variability (LAD artery occlusion N=3, SHAM N=3). HF 
(heart failure), LAD (left anterior descending). Primary concentration 1 : 1000, 
secondary concentration 1 : 5000. (A) Representative blots shown. 
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5.4 Discussion 
I aimed to establish the minimally invasive TAC model of pressure overload HF 
within our animal unit at University of Glasgow, as this model had not been used 
within our institute. I intended to use this model to assess the SUMOylation of the 
β2AR, in a similar manner to which the Hajjar group assessed the SUMOylation of 
SERCA2a (Kho, et al., 2011). This surgical intervention initially leads to 
compensated hypertrophy of the heart, but over time this response to the chronic 
hemodynamic load becomes maladaptive resulting in cardiac dilatation and HF 
(Heineke & Molkentin, 2006). Three weeks post TAC surgery the animals from my 
study experienced reduced cardiac output and stroke volume, indicative of 
reduced cardiac function. This was in conjunction with increased relative wall 
thickness in comparison to SHAM mice. This provides evidence cardiac remodelling 
had been initiated in these mice. However, despite the significant hypertrophic 
changes observed, echocardiographic data failed to demonstrate anticipated 
changes in two important cardiac function parameters; fractional shortening and 
ejection fraction. This provides evidence that the mice have not yet progressed 
to HF, and are still in a state of compensatory hypertrophy. 
Additional data to support the echocardiography data indicating hypertrophic 
response is illustrated at organ harvest. Both heart and LV-to body weight/tibia 
length were increased in the animals that underwent TAC surgery in comparison 
to SHAM. The heart was the only organ influenced by the TAC model, with no other 
organs showing differences between TAC and SHAM groups. Multiple TAC studies 
have reported elevated lung weight in relation to LV hypertrophy and dysfunction 
(Lu, et al., 2010) (Xu, et al., 2011) (Lu, et al., 2010) (Takimoto, et al., 2005), but 
this was not observed in the current TAC establishment study. The increase in lung 
weight is often believed to be associated with pulmonary oedema but Chen et al 
(2012) identified it was associated with massive lung fibrosis, leukocyte 
infiltration and vascular remodelling. The same group reported that the increase 
in lung weight and the lung-to-body weight ratio after TAC are significantly related 
to the increase of LV weight and the reduction in LV ejection fraction. In addition, 
when this group examined a group of mice regarded as severe HF phenotype, in 
comparison to moderate HF phenotype, the lung-to-body weight ratio was 
significantly greater in the severe group (Chen, et al., 2012). Neither Martin et al 
(2012) or Kho et al (2011) reported any changes to lung weight in their TAC studies. 
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The fact that this TAC establishment study did not identify changes in lung-to-
body weight ratio between TAC and SHAM animals supports the fact that the 
mouse model has not begun to develop HF in the time frame of this study, and the 
animals are in a state of cardiac hypertrophy.  
Although HF was not initiated in this study, the time frame of the surgical protocol 
– 8 weeks for HF development – was appropriate as this was based upon the TAC 
protocol utilised by both Martin et al (2012) and Kho et al (2011). Therefore, 
future studies should be extended to allow time for HF development. This outcome 
is further supported by the fact that the animals in this study did not appear to 
experience as severe a hypertrophic response as was observed in the similar 
minimally invasive TAC study (Martin, et al., 2012), in which the heart-to-body 
weight ratio was twice the value in the TAC animals as it was in SHAM.  
Further evidence to show that the current study model was successful in 
promoting cardiac remodelling, which could eventually progress to HF was 
histological analysis. TAC animals had significantly greater fibrotic tissue in their 
hearts in comparison to SHAM animals, as well as having larger individual 
cardiomyocytes – indicative of hypertrophy. There are drawbacks with assessing 
cardiomyocyte cross sectional area to consider; the cross-sectional area gives only 
a 2D picture of a 3D cell and ignores the length of the cardiomyocyte, which can 
vary considerably within the same heart (Bensley, et al., 2016). Alternate methods 
can be used to account for this, one such option includes using multiple thin serial 
sections to identify cell boundaries and then reconstruct the images to measure 
cell volume, but this is technically challenging to achieve (Bruel & Nyengaard, 
2005). Another approach is to use much thicker sections -approximately 40μm - 
and take multiple images at different focal planes, and then the entire sample 
volume can be reconstructed (Bensley, et al., 2016).  
A parameter that was not assessed in the TAC establishment study was blood 
pressure. Both Kho et al (2011) and Martin et al (2012) identified elevated systolic 
blood pressure in TAC animals in comparison to SHAM. I anticipate our animals 
would have displayed similar results, but this was not assessed for the reason that 
prior to the study I could not be certain how the C57BL/6 mice would respond to 
TAC surgical intervention. The decision was therefore made to minimalise 
handling of the animals following TAC surgery, and unlike echocardiography, blood 
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pressure would have been measured via the tail-cuff system with the animals 
conscious therefore initiating unnecessary stress. For future studies, blood 
pressure is an imperative parameter to assess. 
Although the mice failed to develop HF, the expression of the proteins of the 
SUMOylation pathway, as well as β2AR SUMOylation were examined, since ongoing 
changes mediated during cardiac remodelling could be important in the 
development of HF. Similarly to SERCA2a SUMOylation (Kho, et al., 2011), I 
hypothesised that SUMOylation of the β2AR would be diminished by HF and 
therefore could be changed during the cardiac remodelling process. However, in 
the TAC establishment study no significant changes in the expression of 
SUMOylated β2AR were observed between TAC and SHAM animals. Other 
components of the SUMOylation pathway were also assessed; namely SUMO, UBC9 
and PIASγ. The only SUMOylation pathway component that showed significant 
changes in a state of cardiac remodelling was the E2 conjugating enzyme UBC9. 
UBC9 was significantly reduced in TAC mice in comparison to SHAM mice. This is 
in contrast to what is reported by Kho et al (2011), in which no changes were 
observed in UBC9. However, the changes reported by Kho et al (2011) were in a 
state of HF and the changes within the TAC establishment study relate to cardiac 
hypertrophy. Changes in UBC9 have been reported before in disease. Increased 
UBC9 expression has been reported in both primary lung cancer tissue in 
comparison to premalignant and/or normal tissue (Li, et al., 2013), and in a mouse 
model of Alzheimer’s disease (Nistico, et al., 2014). Furthermore, elevating UBC9 
in mice suffering from cardiomyopathy resulted in decreased fibrosis, reduced 
hypertrophy and improved cardiac function and survival (Gupta, et al., 2016). 
Therefore the role of UBC9 in the development of HF still remains to be 
elucidated, with studies examining UBC9 expression at various time points 
following TAC surgery being an avenue to explore.  
To examine the SUMOylation pathway and SUMOylation of the β2AR within a HF 
model, tissue from the LAD artery balloon occlusion in the pig was provided by the 
Hajjar group (Tilemann, et al., 2013). 
Both paralogues SUMO-1 and SUMO-2/3 were difficult to assess, as although 
positive controls confirmed the antibody was functional, the signal was weak, 
regardless of the same amount of protein being loaded for pig tissue lysate 
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samples and the positive control HEKβ2 cell lysate sample. This is similar to what 
I observed in the mouse tissue lysate samples, where no SUMO-1 expression was 
observed. This would imply that there is a greater concentration of the SUMO 
paralogues within the cell lysate. The difference between these two lysate 
preparations is the lysis buffer. HEKβ2 cells were lysed via manual scraping of cells 
in 3T3 lysis buffer, whereas the pig and mouse tissue undergo lysis via 
homogenisation in RIPA buffer. RIPA buffer contains harsh denaturing ionic 
detergents whereas 3T3 lysis buffer only has milder, non-ionic detergents. These 
variations in lysis buffer could be responsible for the proteins showing different 
expression in the different tissue types (Advansta, 2014). 
Another contrast between cell lysate and animal tissue lysate existed with the 
SUMO-2/3 paralogue band presenting at a greater molecular weight in the pig 
tissue as what was seen in the HEKβ2 cells. One such reason for this could be the 
formation of SUMO paralogue chains, which is only feasible for the SUMO-2/3 
paralogue (Bylebyl, et al., 2003) (Tatham, et al., 2001)(Ulrich, 2008). In the pig 
tissues, the antibody could be identifying a series of SUMO-2/3 paralogues within 
a chain, which would therefore increase the molecular weight. This SUMO-2/3 
band indicates that SUMO-2/3 is significantly reduced in the HF animals in 
comparison to SHAM, but due to the unexpected band shift, further work is needed 
to confirm this. In support of this notion, SUMO-1 has been shown to be reduced 
in HF therefore SUMO-2/3 could also be reduced (Kho, et al., 2011) (Tilemann, et 
al., 2013). Although the SUMO-1 paralogue has a weak signal it does display at the 
correct molecular weight. No significant difference was identified between TAC 
and SHAM groups for this protein. This is in contrast to what is reported by Kho et 
al (2011) who have shown that SUMO-1 expression is reduced in HF. However with 
the low n numbers of this study (n=3) further assessment of the SUMO paralogues 
is necessary. 
Expression of the E2 conjugating enzyme UBC9 showed a trend to be reduced in 
HF in comparison to SHAM. This is in agreement to what was observed in the TAC 
establishment study, with UBC9 expression being significantly reduced in cardiac 
remodelling, however the immunoblots from the pig cardiac lysate showed a high 
degree of variability and further n numbers would be required to confirm this 
finding. Although Kho et al (2011) reported no changes in UBC9, the evidence from 
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both the TAC mouse study and LAD artery balloon occlusion pig study suggest UBC9 
levels could be altered in the development of HF. There was no significant 
difference observed between HF and SHAM groups for the E3 ligase PIASγ.  
In contrast to what is observed for SUMOylated-SERCA2a – HF reduces SUMOylated 
SERCA2a expression - the SUMOylated form of the β2AR shows a significant increase 
in HF animals in comparison to SHAM. Although unexpected - as our hypothesis 
expected β2AR SUMOylation to be compromised during HF - this finding does 
confirm that SUMOylation of other cardiac signalling proteins can be influenced 
by cardiac disease. It may also be the case that important cardiac proteins may 
be SUMOylated as a preventative response before HF is reached. 
SUMOylation can be positive or negative, dependent upon the protein being 
modulated. SUMO modification of transcription factors involved in cancer has been 
shown to have conflicting outcomes; for example, SUMOylation of Myc promotes 
oncogenesis whereas SUMOylation of MITF prevents it (Yang & Chiang, 2013). 
SUMOylation is also not limited to influencing one disease state. SERCA2a 
SUMOylation has been proven to be beneficial in restoring cardiac function during 
heart failure (Kho, et al., 2011) (Tilemann, et al., 2013), and in contrast 
SUMOylation of the nuclear receptor PPARγ promotes diabetes development (Yang 
& Chiang, 2013).The varying outcomes of protein SUMOylation can be attributed 
to the complexity of the signalling pathway: substrates can show SUMO paralogue 
preference  (Vertegaal, et al., 2006); PIAS enzymes can show substrate and 
isoform preference (Sachdev, et al., 2001) (Chun, et al., 2003) (Gocke, et al., 
2005); the capacity of SUMO chain formation may mean that similarly to 
ubiquitination, chains of SUMO molecules may influence protein fate (Wang & 
Dasso, 2009).It is therefore important to understand the components of the SUMO 
pathway which are involved in the SUMOylation of individual proteins. With 
regards to the β2AR, the work within this thesis suggests that E3 ligase PIASγ is 
vital to mediate receptor SUMOylation.  
In conclusion I have identified a significant increase in β2AR SUMOylation in the 
pig LAD artery balloon occlusion model of HF. Additionally the data presented 
within this chapter is evidence of a reduction in UBC9 expression during the 
development of HF. The long term aim is to lengthen the time of the TAC study 
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to promote HF development and thereby allow manipulation of β2AR SUMOylation 
using PIASγ adenovirus and determine the phenotypic outcome.  
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Chapter 6 General Discussion 
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Based on the work by Kho et al (2011) which identified the SUMOylation of 
SERCA2a and the subsequent protective role in heart failure (HF), the aims of this 
thesis were as follows: 
1) Determine the susceptibility of the β2AR to SUMOylation 
2) Develop a polyclonal antibody capable of detecting SUMOylated-β2AR 
3) Assess the outcome of β2AR SUMOylation on receptor signalling  
4) Examine the changes to β2AR SUMOylation in heart failure (HF)  
 
6.1 The Susceptibility of the β2AR to SUMOylation 
The β2AR is a well characterised receptor in terms of post-translational 
modifications (PTM). As discussed in Chapter 1 – Introduction, it has been shown 
to be susceptible to phosphorylation, ubiquitination, glycosylation and 
palmitoylation (Bouvier, et al., 1989) (Vaughan, et al., 2006) (Nobles, et al., 2011) 
(Shenoy, et al., 2008) (Rands, et al., 1990) (Li, et al., 2017) (Mialet-Perez, et al., 
2004) (Ovchinnikov, et al., 1988) (Moffett, et al., 2001) (De Lean, et al., 1980) 
(O'Dowd, et al., 1988) (Figure 6.1). The identification of SUMOylation of the 
cardiac signalling protein SERCA2a (Kho, et al., 2011), in addition to SUMOylation 
of 5 different GPCRs (Tang, et al., 2005) (Dutting, et al., 2011) (Gowran, et al., 
2009) (Li & Muma, 2013) (Zhang, et al., 2017) led us to believe that the β2AR, 
which is both a cardiac signalling protein and GPCR, may be a substrate for 
SUMOylation.  
We have confirmed the susceptibility of the β2AR to SUMOylation in three ways; 
firstly, by identifying the SUMO accepting lysines 232 and 235 via peptide array 
(Figure 3.6 & 6.1), secondly, following overexpression of the SUMO E3 ligase PIASγ 
we observed the ghost band shift (Figure 4.4) which is characteristic of 
SUMOylation (Park-Sarge & Sarge, 2005), and thirdly,  we have confirmed an 
interaction exists between the β2AR and the enzymes of the SUMOylation cascade 
UBC9 and PIASγ via peptide array (Figure 4.5, 4.6 & 6.1). However, the SUMO 
accepting lysines 232 and 235 may not be the only lysines within the β2AR which 
are capable of covalently binding to SUMO. As mentioned previously, the initial 
software sequence analysis of the β2AR was completed in 2010, and at this time 
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point the software accounted for amino acids which formed the traditional 
consensus motif γKxE/D, (Hay, 2005)  (Rodriguez, et al., 2001) (Bernier-Villamor, 
et al., 2002), phosphorylation-dependent SUMO motifs (PDSMs)  (Hietakangas, et 
al., 2003) (Yang, et al., 2003), and negatively charged amino acid-dependent 
SUMO motifs (NDSMs)  (Yang, et al., 2006). Further amino acid sequences, such as 
hydrophobic cluster-dependent SUMO motifs (HCSMs) and inverted SUMO motifs  
(Matic, et al., 2010) (Impens, et al., 2014), are now known to influence substrate 
susceptibility to SUMOylation, therefore the software sequence analysis for the 
β2AR should be repeated using software which accounts for the novel motifs, 
possibly leading to identification of further SUMOylation susceptible lysines.  
Further research into the role of individual SUMO sites is important. For example, 
it is known when PKA phosphorylates the β2AR this mediates a switch in signalling 
from Gs to Gi (Daaka, et al., 1997), therefore, in a similar manner, it would be 
important to identify if SUMOylation of specific lysines initiated tailored signalling 
changes. Kho et al (2011) determined the role of SUMOylation at lysines 480 and 
585 of SERCA2a by generating mutants in which the lysines were mutated to 
arginines.  This exposed SUMOylation at these specific lysines to be responsible 
for decreasing the ATPase activity of SERCA2a and preventing ubiquitination of 
the protein. A similar approach should be utilised for the β2AR to determine if the 
signalling changes observed with the SUMOylated receptor are lost when the 
SUMO-lysines are mutated.  
This thesis did not assess what drives the SUMOylation of the β2AR. In Chapter 5 – 
Analysis of β2AR SUMOylation in Animal Models of Heart Failure, we identified that 
in the LAD artery occlusion model of HF, SUMOylation of the receptor was 
increased in HF pigs in comparison to SHAM pigs. In the HF phenotype levels of 
circulating catecholamines are increased (Kaumann, et al., 1999), leading to β2AR 
agonist occupation, suggesting that agonist occupation could promote 
SUMOylation of the β2AR. This is a likely scenario, as other post-translational 
modifications such as phosphorylation and ubiquitination, are also driven by 
agonist occupation of the receptor (Bouvier, et al., 1989) (Vaughan, et al., 2006) 
(Nobles, et al., 2011) (Shenoy, et al., 2008). This assumption will be assessed in 
future cardiomyocyte studies utilising the SUMO-β2AR antibody following 
isoprenaline stimulation. Another avenue to explore is the possibility that 
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increased levels of oxidative stress associated with the HF phenotype (Keith, et 
al., 1998) have promoted SUMOylation of the β2AR in the HF mice in comparison 
to SHAM mice. Prior studies have reported that an increase in cellular oxidative 
stress leads to a global increase in protein SUMOylation identified by mass 
spectrometry  (Zhou, et al., 2004). This hypothesis could be assessed in the 
cardiomyocytes by enhancing oxidative stress in the cells via the addition of 
hydrogen peroxide (Ali, et al., 2013) and assessing SUMOylation of the β2AR using 
the SUMO-β2AR specific antibody.  
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Figure 6.1 Post Translational Modifications and SUMO-Enzyme Interactions of 
the β2AR. The β2AR is susceptible to phosphorylation, ubiquitination, glycosylation 
and palmitoylation. In this thesis, we have identified the susceptibility of the 
receptor to SUMOylation at lysines 232 and 235. Interaction sites have been 
identified between the receptor and enzymes of the SUMOylation cascade, PIASγ 
and UBC9. We hypothesise SUMOylation to be mediating β2AR signalling changes 
via sterically hindering the movements of TM5 and TM6, and inhibiting 
ubiquitination within intracellular loop 3. TM (transmembrane domain). Amino 
acid abbreviations in appendix.  
 
 
 
 
PIASy Interaction Points – Loop 2, 3 and C-tail
UBC9 Interaction Points – Loop 3 and C-tail
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6.2 SUMO- β2AR Polyclonal Antibody Development 
Following identification of receptor susceptibility, we aimed to produce a first-in-
class SUMO specific antibody against the SUMO-modified form of the β2AR. As 
discussed in Chapter 3 - Production of a SUMO-β2AR Specific Polyclonal Antibody, 
antibodies which have identified the phosphorylated forms of the receptor - 
phospho-β2AR at serines 345/346 (PKA-mediated phosphorylation) and phospho-
β2AR at serines 355/356 (GRK-mediated phosphorylation) - were vital in exposing 
β2AR signalling pathways (Shenoy, et al., 2006). We wished to produce such an 
antibody for the SUMOylated form of the receptor.  
The SUMO-β2AR antibody we have produced in conjunction with Badrilla ® is 
capable of detecting the epitope against which it was raised via peptide array 
(Figure 3.11), and also detecting the SUMOylated β2AR within HEKβ2 cells following 
transient transfection of the E3 ligase PIASγ (Figure 3.12), and in cardiac tissue 
lysate (Figure 5.15 & 5.20). This is the first antibody to be reported that is capable 
of detecting the SUMOylated form of a protein and therefore the antigen design, 
custom affinity chromatography and testing procedures could be used to allow the 
generation of a panel of SUMO-substrate specific antibodies. Future steps would 
involve further validation to assess the precise molecular weight at which SUMO- 
β2AR presents, in addition to modifying the testing procedure to determine 
whether the custom antibody is capable of deciphering between different SUMO 
paralogues which modify the β2AR. 
In addition to paving the way for the production of a panel of SUMO-substrate 
antibodies, this work also provides the first evidence that an antibody could be 
raised to recognise an interaction between two proteins. Although SUMOylation is 
a post-translational modification, the SUMO protein itself has an approximate 
weight of 11kDa, in contrast to modifications such as phosphorylation, which 
increase the molecular weight of the substrate by as little as 1kDa  (Park-Sarge & 
Sarge, 2005). This means that the SUMO-β2AR antibody production protocol could 
be utilised to assess protein-protein interactions or dimer formations which are 
suspected to play a role in disease states.  
In HF, there is an increased volume of circulating cTNI, and it has been shown that 
elevation of troponin within serum correlates with adverse outcomes in HF (Kociol, 
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et al., 2010) (Wettersten & Maisel, 2015) (Francis, et al., 1995) (Januzzi, et al., 
2012). With regards to a diagnostic approach using the SUMO-β2AR antibody, there 
is no evidence in the literature of the receptor being assessed in blood samples, 
therefore I do not believe the antibody could be used in this manner to assess 
SUMO- β2AR as a biomarker of HF. Based on the work within our study a more 
invasive approach would be required to assess modification of the receptor by 
SUMO, such as a myocardial biopsy.  
6.3 The Influence of β2AR SUMOylation on Receptor 
Signalling 
For many proteins SUMOylation has been shown to influence receptor signalling, 
and many of these similar changes were observed for the β2AR.  In Chapter 4 –  In 
Vitro SUMOylation of the β2AR, we report that SUMOylation of the receptor 
mediated via overexpression of the E3 ligase PIASγ was shown to reduce β2AR-
mediated activation of PKA and subsequent downstream signalling (Figure 4.8, 4.9 
& 4.10), inhibit β2AR ubiquitination and degradation (Figure 4.11 & 4.16), and 
delay β2AR internalisation (Figure 4.13).  
We predict the reduction in β2AR-mediated activation of PKA and subsequent 
downstream signalling (Figure 4.8, 4.9 &4.10) to be mediated by SUMO covalently 
binding to lysines 232 and 235 within the third intracellular loop, therefore 
sterically hindering helical movements in this area that are vital for receptor 
activation (Ballesteros, et al., 2001) (Yao, et al., 2006) (Figure 6.1). To confirm 
this hypothesis the crystal structure of the SUMO modified β2AR would be 
essential.  
The PTMs ubiquitination and SUMOylation have been reported to compete for 
lysine residues for many proteins, two examples including SERCA2a  (Kho, et al., 
2011), and IĸBα  (Desterro, et al., 1998), which in both cases SUMOylation causes 
a reduction in ubiquitination and protein degradation. This pattern was also 
observed for the β2AR (Figure 4.11 & 4.16). However, ubiquitination of the β2AR 
occurs at distinct lysines – K263, K270, K348, K372, K375 (Shenoy, et al., 2008) - 
from those identified as the SUMO susceptible lysines in this thesis - K232 and 
K235. However, we predict that the presence of the bulky SUMO modification 
within the same intracellular loop at a 30 amino acid proximity to the 
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ubiquitination sites could act to sterically hinder the process by preventing 
ubiquitin machinery such as NEDD4 (Shenoy, et al., 2008) from accessing the 
lysines (Figure 6.1). Furthermore, the cytoplasmic tail may contain lysines which 
are susceptible to both SUMO and ubiquitin modification, that were not identified 
in the initial software sequence analysis. Future work would assess the 
susceptibility of the β2AR to SUMOylation at lysines out with 232 and 235.  
 
SUMOylation of the β2AR was also shown to delay internalisation of the receptor 
(Figure 4.13), a pattern which was also reported for other proteins namely DISC1 
(Tankou, et al., 2016), LEF-1 (Sachdev, et al., 2001), and the GluK2 subunit 
(Chamberlain, et al., 2012). Although the interaction between β2AR and β-arrestin 
which is vital for internalisation was not influenced by SUMOylation of the β2AR 
(Figure 4.24), the β-arrestin itself has been shown to be susceptible to 
SUMOylation (Xiao, et al., 2015). It is therefore possible that in the internalisation 
experiments, transient transfection of the E3 ligase PIASγ may be leading to the 
modification of both the β2AR and β-arrestin, with the latter influencing the 
internalisation process.  It will be imperative to assess the SUMOylation status of 
β-arrestin in the presence of PIASγ.  
 
Although the work within this thesis focuses on cardiovascular disease the changes 
outlined above could be important for other disease states that are out with the 
scope of this thesis. In arthritis, β2AR signalling has conflicting outcomes, either 
promoting or inhibiting inflammation in autoimmunity. It has been discovered that  
time-dependent phosphorylation patterns of the β2AR after induction of arthritis 
in an animal model influenced the disease outcomes (Lorton, et al., 2017). As we 
have identified that SUMOylation of the receptor leads to a reduction in PKA-
mediated phosphorylation, and dampens downstream signalling, this could shed 
new light on arthritis research. Another area of research which could be impacted 
by our findings is work focussing on Alzheimer’s disease. Amyloid plaque is primary 
cause of Alzheimer’s disease and activation of the β2AR has been shown to lead to 
the production of amyloid plaque. This is dependent upon agonist-induced 
endocytosis of the β2AR, and as we have shown SUMOylation can influence the 
trafficking of the receptor, these finding could impact upon the ability of the β2AR 
to promote plaque formation (Ni, et al., 2006).  
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6.4 SUMOylation of the β2AR in HF 
Kho et al (2011) identified that cardiac signalling protein SERCA2a is modified by 
SUMO-1, and that this modification is reduced in the pathogenesis of HF. The group 
proved that restoring SUMO-1 expression via adenoviral gene transfer is beneficial 
as it improves cardiac function and also stabilizes heart weight to body weight 
ratio – indicative of reduced hypertrophic response. This work was pivotal in our 
belief that the β2AR SUMOylation may also be diminished in the HF phenotype and 
therefore could be changed during the cardiac remodelling process.   
In Chapter 5 – Analysis of β2AR SUMOylation in Animal Models of Heart Failure, we 
assessed SUMOylation of the β2AR and SUMOylation pathway components in two 
animal models of HF; transverse aortic constriction (TAC) pressure overload HF 
model in mice and the left anterior descending (LAD) artery balloon occlusion 
ischemic HF model in pigs. In the TAC pressure overload establishment study no 
significant changes in the expression of SUMOylated β2AR were observed between 
TAC and SHAM animals (Figure 5.15), however in the LAD artery balloon occlusion 
ischemic study the SUMOylated form of the β2AR shows a significant increase in 
HF animals in comparison to SHAM (Figure 5.20). Although unexpected - as our 
hypothesis expected β2AR SUMOylation to be compromised during HF - this finding 
does confirm that SUMOylation of other cardiac signalling proteins can be 
influenced by cardiac disease.  
It is important to consider why the β2AR may be SUMOylated in HF. In failing human 
hearts although the β1AR is downregulated, the abundance of β2AR remains 
unchanged (Bristow, et al., 1986) (Jensen, et al., 2009). In Chapter 1 – 
Introduction, the cardio-protective role for β2AR is discussed: in isolated myocytes 
β2AR stimulation protects against stress-induced apoptosis (Chelsey, et al., 2000); 
in a rat model of myocardial infarction-induced HF, selective activation of the 
β2AR improves cardiac function and reduces apoptosis (Ahmet, et al., 2004); and 
in HF there is enhanced signalling of β2AR via the Gi pathway, which reduces the 
positive inotropic effects of β1AR stimulation and activates cardio-protective 
signalling pathways (Bohm, et al., 1994) (Chelsey, et al., 2000) (Feldman, et al., 
1988) (Zhu, et al., 2001). With regards to the results presented within Chapter 4 
– In Vitro SUMOylation of the β2AR, SUMOylation of the receptor leads to a 
reduction in degradation of the receptor (Figure 4.11). This would therefore 
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promote cardio-protective effects of the receptor by maintaining receptor levels. 
However, in HF there is enhanced signalling of β2AR via the inhibitory Gi protein 
which is cardio-protective. In contrast to this notion, the data presented in 
Chapter 4 - In Vitro SUMOylation of the β2AR, reveals that SUMOylation of the 
receptor causes a reduction in the switch from Gs to Gi signalling, and therefore 
SUMOylation of the β2AR would inhibit this cardio-protective effect.  
In addition to the traditional opposing roles of the βARs - β2AR cardio-protective 
and β1AR cardio-toxic – the receptors also exist in distinct locations, described in 
detail in Chapter 1 – Introduction. The β2AR is exclusively localised to T-tubules 
whereas β1AR are present in both the domes and T-tubules of the cardiomyocyte 
(Nikolaev, et al., 2010). Furthermore, spatial compartmentation of the cAMP 
signal can influence the outcome of receptor stimulation, with β1AR stimulation 
promoting cAMP production which propagates throughout the entire cell, and β2AR 
stimulation leading to locally confined cAMP at the T-tubules (Nikolaev, et al., 
2006). However, this organisation is disrupted during HF leading to the β2AR signals 
now manifesting in a similar manner to that of the β1AR, contributing to the 
cardio-toxic effects (Xiao, 2001) (Engelhardt, et al., 1999) (Communal, et al., 
1999)(del Monte, et al., 1993) (Dorn, et al., 1999). However, as we have identified 
that the SUMOylated form of the β2AR displays depressed signalling, this 
modification which is increased in HF could be protective, to inhibit the 
deleterious switch to β1AR-like signalling.  
The role of β2AR SUMOylation in HF remains speculative. Idealistically the best 
way to examine the influence of β2AR SUMOylation would be to assess the impact 
of PIASγ adeno-associated viral gene transfer on animals which have undergone 
either the TAC surgery of LAD artery balloon occlusion, to determine if enhanced 
SUMOylation of the receptor worsens the HF phenotype or prevents its 
development. Following confirmation of the role of β2AR SUMOylation it would be 
possible to follow the route of the SERCA2a SUMOylation research. Kho et al (2015) 
identified a small molecule, N106, which promotes SUMOylation of SERCA2a by 
directly activating the SUMO E1 activating enzyme. In a mouse model of HF, this 
molecule improves ventricular function. Once the outcome of β2AR SUMOylation 
in HF is confirmed we could manipulate SUMOylation of the receptor in a similar 
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manner to this, possibly leading to a potential therapeutic strategy for HF 
treatment.  
6.5 Final Conclusion 
To conclude we present the first evidence that the β2AR is susceptible to 
SUMOylation and mediate this change in in vitro studies. We have uncovered that 
this novel post-translational modification acts to influence the receptors 
downstream signalling, desensitisation and degradation which could be important 
for a range of disease states. We have designed a first-in-class SUMO-β2AR 
antibody – which paves the way for a panel of SUMO specific antibodies and 
antibodies which can identify protein-protein interactions – and utilised it to 
assess SUMOylation of the β2AR in animal models of HF. In line with our hypothesis, 
SUMOylation does influence the β2AR in the HF phenotype, although not a decrease 
in SUMOylation as was expected, but an increase. Future work in animal models 
promoting SUMOylation of the receptor is vital to assess the role of this important 
post-translational modification of the β2AR, allowing us to harness this change as 
a therapeutic treatment for HF.   
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Chapter 7 Appendix 
Amino Acid 1 Letter Abbreviation 
Alanine A 
Arginine R 
Asparagine N 
Aspartic acid D 
Cysteine C 
Glutamic acid E 
Glutamine Q 
Glycine G 
Histidine H 
Isoleucine I 
Leucine L 
Lysine K 
Methionine M 
Phenylalanine F 
Proline P 
Serine S 
Threonine T 
Tryptophan W 
Tyrosine Y 
Valine V 
(i-base.info, 2017) 
265 
 
Chapter 8 References 
Abcam. (2017). www.abcam.com. Retrieved March 31, 2017, from 
http://www.abcam.com/protocols/ihc-antigen-retrieval-protocol 
Advansta. (2014). https://advansta.com. Retrieved April 12, 2017, from 
https://advansta.com/detergent-lysis-buffer/ 
AHA. (2016, March 25). Recognizing Advanced Heart Failure and Knowing Your 
Options. Retrieved April 14, 2017, from 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/Recognizing-
Advanced-Heart-Failure-and-Knowing-Your-
Options_UCM_441926_Article.jsp#.WPC2J2nyvcs 
Ahmed, M. (2015). http://myheart.net. Retrieved March 30, 2017, from 
http://myheart.net/articles/the-lad-artery/ 
Ahmet, I., Krawcyzk, M., Heller, P., Moon, C., Lakatta, E., & Talan, M. (2004). 
Beneficial effects of chronic pharmacological manipulation of beta-
adrenoreceptor subtype signaling in rodent dilated ischemic 
cardiomyopathy. Circulation, 1083-1090. 
Alberts, B., Johnson, A., Lewis, J., Walter, P., Raff, M., & Roberts, K. (2002). 
Chapter 24. In Molecular Biology of the Cell (4th ed.). . Routledge: ISBN. 
Ali, M., Kandasamy, A., Fan, X., & Schulz, R. (2013). Hydrogen peroxide-induced 
necrotic cell death in cardiomyocytes is independent of matrix 
metalloproteinase-2. Toxicol In Vitro, 1686-1692. 
Alousi, A., Jasper, J., Insel, P., & Motuski, H. (1991). Stoichiometry of receptor-
Gs-adenylate cyclase interactions. FASEB J(5), 2300-2303. 
Ambrosy, A., Fonarow, G., Butler, J., Chioncel, O., Greene, S., Vaduganathan, 
M., . . . Gheorghiade, M. (2014). The global health and economic burden 
of hospitalizations for heart failure: lessons learned from hospitalized 
heart failure registries. Journal of the American College of Cardiology 
(63), 1123-1133. 
Anderson, H., Galyean, R., McClintock, R., & Rivier, J. (1984). Reversed-phase 
high-performance liquid chromatography: preparative purification of 
synthetic peptides. J Chromatogr(288), 303-328. 
Angers, S., Salahpour, A., Joly, E., Hilairet, S., Chelsky, D., Dennis, M., & 
Bouvier, M. (2000). Detection of beta 2-adrenergic receptor dimerization 
in living cells using bioluminescence resonance energy transfer (BRET). 
Proc Natl Acad Sci U S A(97), 3684-3689. 
Angres, S., Salahpour, A., Joly, E., Hilairet, S., Chelsky, D., Dennis, M., & 
Bouvier, M. (2000). Detection of beta 2 adrenergic receptor dimerisation 
in living cells using bioluminescence resonance energy transfer (BRET). 
Proc Natl Acad Sci(97), 3684-3689. 
Annderson, R., Yanni, J., Boyett, M., Chandler, N., & Dobrzynski, H. (2009). The 
anatomy of the cardiac conduction system. Clinical Anatomy(22), 93-113. 
266 
 
Apionishev, S., Malhotra, D., Raghavachari, S., Tanda, S., & Rasooly, R. (2001). 
The Drosophila UBC9 homologue lesswright mediates the disjunction of 
homologues in meiosis I. Genes Cells(6), 215-224. 
Ardehali, H., Bolli, R., & Losordo, D. (2013). Transverse Aortic Constriction: a 
Model to Study Heart Failure in Small Animals. In S. Verma, P. 
Krishnamurthy, & R. Kishore (Eds.), Manual of Research Techniques in 
Cardiovascular Medicine (pp. 164-169). John Wiley & Sons, Ltd. 
Arur, S., & Schedl, T. (2014). Generation and purification of highly specific 
antibodies for detecting post-translationally modified proteins in vivo. 
Nature Protocols(9), 375-395. 
Asahi, M., Nakayama, H., Tada, M., & Otsu, K. (2003). Regulation of 
sarco(endo)plasmic reticulum Ca2+ adenosine triphosphatase by 
phospholamban and sarcolipin: implication for cardiac hypertrophy and 
failure. Trends in cardiovascular medicine(13), 152-157. 
Ayaydin, F., & Dasso, M. (2004). Distinct in vivo dynamics of vertebrate SUMO 
paralogues. Mol. Biol. Cell(15), 5208-5218. 
Bachant, J., Alacasabas, A., Blat, Y., Kleckner, N., & Elledge, S. (2002). The 
SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through 
SUMO-1 modification of DNA topoisomerase II. Mol Cell(9), 1169-1182. 
Baillie, G., Sood, A., McPhee, I., Gall, I., Perry, S., Lefkowitz, R., & Houslay, M. 
(2003). beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment 
regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci 
USA(100), 940-945. 
Ballesteros, J., Jensen, A., Liapakis, G., Rasmussen, S., Shi, L., Gether, U., & 
Javtich, A. (2001). Activation of the β2-Adrenergic Receptor Involves 
Disruption of an Ionic Lock between the Cytoplasmic Ends of 
Transmembrane Segments 3 and 6. Journal of Biological Chemistry(276), 
29171-29177. 
Bang, I., & Choi, H. (2015). Structural Features of β2 Adrenergic Receptor: 
Crystal Structures and Beyond. Mol Cells, 105-111. 
Bang, I., & Choi, H. (2015). Structural Features of 2 Adrenergic 
Receptor:Crystal Structures and Beyond. Mol. Cells(38), 105-111. 
Barak, L., Ferguson, S., Zhang, J., Martenson, C., Meyer, T., & Caron, M. (1997). 
Internal traficking and surface mobility of a functionally intact beta 2 
adrenergic receptor green fluorescent protein conjugate . Mol 
Pharmacol(51), 177-184. 
Bawa-Khalfe, T., & Yeh, E. (2010). SUMO losing balance: SUMO proteases disrupt 
SUMO homeostasis to facilitate cancer development and progression. 
Genes Cancer(1), 748-752. 
BCBST. (2016). BlueCross BlueShield of Tennessee Medical Policy Manual. 
Retrieved April 14, 2017, from 
http://www.bcbst.com/mpmanual/Surgical_Ventricular_Restoration.htm 
267 
 
Beckerman, J. (2016, October 6). Heart Disease and Diuretics. Retrieved April 
14, 2017, from http://www.webmd.com/heart-disease/guide/medicine-
diuretics#1 
Benovic, J., Kuhn, H., Weyand, I., Codina, J., Caron, M., & Lefkowitz, R. (1987). 
Functional desensitisation of the isolated beta adrenergic receptor by the 
beta adrenergic receptor kinase: potential role of an analog of the retinal 
protein arrestin (48kDa protein). PNAS(84), 8879-8882. 
Benovic, J., Mayor, F., Staniszewski, C., Lefkowitz, R., & Caron, M. (1987). 
Purification and characterisation of the beta adrenergic receptor kinase . 
J Biol Chem(262), 9026-9032. 
Bensley, J., Matteo, R., Harding, R., & Black, M. (2016). Three-dimensional 
direct measurement of cardiomyocyte volume, nuclearity, and ploidy in 
thick histological sections. Scientific Reports (6), 23756-23766. 
Benya, R., Kusui, T., Katsuno, T., Tsuda, T., Mantey, S., Battey, J., & Jensen, R. 
(2000). Glycosylation of the gastrin releasing peptide receptor and its 
effect on expression, G protein coupling, and receptor modulatory 
processes. Mol Pharmacol(58), 1490-1501. 
Bergelson, J., Cunningham, J., Droguett, G., Kurt-Jones, E., Krivthivas, A., 
Hong, J., . . . Finberg, R. (1997). Isolation of a common receptor for 
coxsackie B viruses and adenoviruses 2 and 5. Science(275), 1320-1323. 
Bernier-Villamor, V., Sampson, D., Matunis, M., & Lima, C. (2002). Structural 
basis for E2-mediated SUMO conjugation revealed by a complex between 
ubiquitin conjugating enzyme UBC9 and RanGAP1. Cell(108), 345-356. 
Bernstein, D., Fajardo, G., Zhao, M., Urashima, T., Powers, J., Berry, G., & 
Kobilka, B. (2005). Differential cardioprotective/cardiotoxic effects 
mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ 
Physiol, 2441-2449. 
Bers, D. (2002). Cardiac excitation-contraction coupling. Nature(415), 198-205. 
Bers, D. (2002). Cardiac Na/Ca exchange function in rabbit, mouse and man: 
what's the difference? J Mol Cell Cardiol(34), 369-373. 
Bettermann, K., Benesch, M., Weis, S., & Haybaeck, J. (2012). SUMOylation in 
carcinogenesis. Cancer Letters(316), 113-125. 
Beuckelmann, D., Nabauer, M., Kruger, C., & Erdmann, E. (1995). Altered 
diastolic [Ca2+]i handling in human ventricular myocytes from patients 
with terminal heart failure. American Heart Journal(129), 684-689. 
BHF. (2015). Heart Statistics. Retrieved April 14, 2017, from 
https://www.bhf.org.uk/research/heart-statistics 
Billington, C., & Penn, R. (2003). Signaling and regulation of G protein coupled 
receptors in airway smooth muscle. Resp Res(4), 2. 
Black, J., Crowther, A., Shanks, R., Smith, L., & Dornhorst, A. (1964). A new 
adrenergic betareceptor antagonist. The Lancet, 1080-1081. 
268 
 
Bodi, I., Mikala, G., Koch, S., Akhter, S., & Schwartz, A. (2005). The L-type 
calcium channel in the heart: the beat goes on. J Clin Invest(115), 3306-
3317. 
Bodor, G., Oakeley, A., Allen, P., Crimmins, D., Ladensons, J., & Anderson, P. 
(2001). Troponin I phosphorylation in the normal and failing adult human 
heart. Circulation Research(104), 1424-1429. 
Bohm, M., Eschenhagen, T., Gierschlik, P., Larisch, K., Lensche, H., Mende, 
U., . . . Steinfath, M. (1994). Radioimmunochemical quantification of Gi 
alpha in right and left ventricles from patients with ischaemic and dilated 
cardiomyopathy and predominant left ventricular failure. J Mol Cell 
Cardiol, 133-149. 
Bohren, K., Nadkami, V., Song, J., Gabbay, K., & Owerbach, D. (2004). A M55V 
polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat 
shock transcription factors and is associated with susceptibility to type 1 
diabetes mellitus. J Biol Chem(279), 27233-27238. 
Bolger, G., Baillie, G., Li, X., Lynch, M., Herzyk, P., Mohamaed, A., . . . 
Houslay, M. (2006). Scanning peptide array analyses identify overlapping 
binding sites for the signalling scaffold proteind, B-arrestin and RACK1, in 
cAMP specific phosphodiesterase PDE4D5. Biochemical Journal(398), 23-
36. 
Bouvier, M., Collins, S. O., Campbell, P., de Blasi, A., Kobilka, B., MacGregor, 
C., . . . Lefkowitz, R. (1989). Two distinct pathways for cAMP mediated 
down regulation of the B2 adrenergic receptor. Phosphorylation of the 
receptor and regulation of its mRNA level. J Biol Chem(264), 16786-
16792. 
Bradford, M. (1976). A rapid and sensitive method for the quantification of 
microgram quantities of protein utilizing the principle of protein-dye 
binding. Anal Biochem(72), 248-254. 
Bristow, M., Ginsrbug, R., Umans, V., Fowler, M., Minobe, W., Rasmussen, 
R., . . . Shah, P. (1986). Beta 1- and beta 2-adrenergic-receptor 
subpopulations in nonfailing and failing human ventricular myocardium: 
coupling of both receptor subtypes to muscle contraction and selective 
beta 1-receptor down-regulation in heart failure. Circ Res, 297-309. 
Bristow, M., Minobe, W., Raynolds, M., Port, J., Rasmussen, R., Ray, P., & 
Feldman, A. (1993). Reduced beta 1 receptor messenger RNA abundance 
in the failing human heart. J Clin Invest(92), 2737-2745. 
Bruce, D. (2014). Abcam p65 and the NF-κB inflammatory pathway. Retrieved 
July 4, 2017, from http://www.abcam.com/cancer/p65-and-the-nf-b-
inflammatory-pathway 
Bruel, A., & Nyengaard, J. (2005). Design-based stereological estimation of the 
total number of cardiac myocytes in histological sections. Basic Res 
Cardiol(4), 311-319. 
269 
 
Bueno, O., De Windt, L., Tymitz, K., Witt, S., Kimball, T., Klevitsky, R., . . . 
Molkentin, J. (2000). The MEK1-ERK1/2 signaling pathway promotes 
compensated cardiac hypertrophy in transgenic mice. EMBO J(19), 6341-
6350. 
Bylebyl, G. R., Belichenko, I., & Johnson, E. (2003). The SUMO isopeptidase Ulp2 
prevents accumulation of SUMO chains in yeast. J. Biol. Chem(278), 
44113-44120. 
Calebiro, D., Nikolaev, V., Gagliani, M., Fillippis, T., Dees, C., Tacchetti, 
C., . . . Lohse, M. (2009). Persistent cAMP-Signals Triggered by 
Internalized G-Protein–Coupled Receptors. PLOS Biology, 1371-1381. 
Calebiro, D., Rieken, F., Wagner, J., Sungakaworn, T., Zabel, U., Borzi, A., . . . 
Lohse, M. (2013). Single-molecule analysis of fluorescently labeled G-
protein-coupled receptors reveals complexes with distinct dynamics and 
organization. Proc Natl Acad Sci U S A(110), 743-748. 
Campbell, N., Reece, J., Urry, L., Cain, M., Wasserman, S., Minorsky, P., & 
Jackson, R. (2008). Circulation and Gas Exchange. In B. Wilbur (Ed.), 
Biology Eighth Edition (pp. 898-906). San Francisco: Pearson. 
Campbell, T., & MacDonald, P. (2003). Digoxin in heart failure and cardiac 
arrhythmias. Med J Aust(179), 98-102. 
Castelvecchio, S., Menincanti, L., & Donato, M. (2010). Surgical Ventricular 
Restoration to Reverse Left Ventricular Remodeling. Curr Cardiol 
Reviews(6), 15-23. 
Chamberlain, S., Gonzalez-Gonzalez, I., Wilkinson, K., Konopacki, F., 
Kantamneni, S., Henley, J., & Mellor, J. (2012). SUMOylation and 
phosphorylation of GluK2 regulate kainate receptor trafficking and 
synaptic plasticity. Nat Neurosci(15), 845-852. 
Chang, P., Fitzgerald, L., Geelen, A., Izumiya, Y., Ellison, T., Wang, D., . . . 
Kung, H. (2009). KRAB domain-associated protein-1 as a latency regulator 
for Kaposi's sarcoma-associated herpesvirus and its modulation by the viral 
protein kinase. Cancer Research(69), 5681-5689. 
Chelsey, A., Lundberg, M., Asai, T., Xiao, R., Ohtani, S., Lakatta, E., & Crow, M. 
(2000). The beta(2)-adrenergic receptor delivers an antiapoptotic signal 
to cardiac myocytes through G(i)-dependent coupling to 
phosphatidylinositol 3'-kinase. Circ Res, 1172-1179. 
Chen, M., & Malbon, C. (2009). G protein coupled receptor associated A-kinase 
anchoring proteins AKAP5 and AKAP12: differential trafficking and 
distribiution. Cell signal(21), 136-142. 
Chen, Y., Guo, H., Xu, D., Xu, X., Wang, H., Hu, X., . . . Weir, K. (2012). Left 
ventricular failure produces profound lung remodeling and pulmonary 
hypertension in mice: heart failure causes severe lung disease. 
Hypertension(59), 1170-1178. 
270 
 
Chen, Y., Li, Z., Zhu, M., & Cao, Y. (2012). Effects of exercise training on left 
ventricular remodelling in heart failure patients: an updated meta-
analysis of randomised controlled trials. Int J Clin Pract(66), 782-791. 
Chen, Z., Stokes, D., & Jones, L. (2005). Role of Leucine 31 of Phospholamban in 
Structural and Functional Interactions with the Ca2+ Pump of Cardiac 
Sarcoplasmic Reticulum. The Journal of Biological Chemistry(280), 10530-
10539. 
Cherevoz, V., Rosenbaum, D., Hanson, M., Rasmussen, S., Thian, F., Kobilka, 
T., . . . Stevens, R. (2007). High resolution crystal structure of an 
engineered human β2 adrenergic G protein coupled receptor. 
Science(318), 1258-1265. 
Chistiakov, D., Ashwell, K., Orekhov, A., & Bobryshev, Y. (2015). Innervation of 
the arterial wall and its modification in atherosclerosis. Autonomic 
Neuroscience, 7-11. 
Choe, H. W., Kim, Y., Park, J., Morizumi, T., Pai, E., Krauss, N., . . . Ernst, O. 
(2011). Crystal structure of metarhodopsin II. Nature(471), 651-655. 
Choi, J., Park, J., Park, S., Lee, H., Han, S., Park, K., & Suh, Y. (2015). 
Regulation of mGluR7 Trafficking by SUMOylation in Neurons. 
Neuropharmacology(102), 229-235. 
Chun, T., Itoh, H., Subramanian, L., Iniquez-Lluhi, J., & Nakao, K. (2003). 
Modification of GATA-2 transcriptional activity in endothelial cells by the 
SUMO E3 ligase PIASy. Circ Res(92), 1201-1208. 
Chung, K., Rasmussen, S., Liu, T., Li, S., Devree, B., Chae, P., . . . Sunahara, R. 
(2011). Conformational changes in the G protein Gs induced by the β2 
adrenergic receptor. Nature(477), 611-615. 
Cleland, J., Swedberg, K., Follath, F., Komajda, M., Cohen-Solal, A., Aguilar, 
J., . . . Mason, J. (2003). The EuroHeart Failure survey programme—a 
survey on the quality of care among patients with heart failure in Europe . 
European Heart Journal(24), 442-463. 
Clevland, J., Gemmell, I., Khand, A., & Boddy, A. (1999). Is the prognosis of 
heart failure improving? European Journal of Heart Failure(1), 229-241. 
Collins, S., Lohse, M., O'Dowd, B., Caron, M., & Lefkowitz, R. (1991). Structure 
and regulation of G protein coupled receptors: the beta 2 adrenergic 
receptor as a model. Vitam Horm(46), 1-39. 
Colucci, W. (2016, July 12). Hydralazine plus nitrate therapy in patients with 
heart failure with reduced ejection fraction. Retrieved April 14, 2017, 
from http://www.uptodate.com/contents/hydralazine-plus-nitrate-
therapy-in-patients-with-heart-failure-with-reduced-ejection-fraction 
Coman, O., Paunescu, H., Ghita, I., Coman, L., Badararu, A., & Fulga, I. (2009). 
Beta 3 adrenergic receptors: molecular, histological, functional and 
pharmacological approaches . Romanian Journal of Morphology and 
Embryology, 169-179. 
271 
 
Communal, C., Singh, K., Sawyer, D., & Colucci, W. (1999). Opposing effects of 
beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : 
role of a pertussis toxin-sensitive G protein. Circulation(22), 2210-2212. 
Communal, C., Singh, K., Sawyer, D., & Colucci, W. (1999). Opposing effects of 
beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: 
role of a pertussis toxin-sensitive G protein. Circulation, 2210-2212. 
Cong, M., Perry, S., Hu, L., Hanson, P., Claing, A., & Lefkowitz, R. (2001). 
Binding of the beta 2 adrenergic receptor to N ethylmaleimide-sensitive 
factor regulates receptor recycling. J Biol Chem(276), 45145-41152. 
Conway, B., Minor, L., Xu, J., Gunnet, J., DeBiasio, R., D'Andrea, M., . . . 
Demarest, K. (1999). Quantification of G-Protein Coupled Receptor 
Internatilization Using G-Protein Coupled Receptor-Green Fluorescent 
Protein Conjugates with the ArrayScantrade mark High-Content Screening 
System. J Biomol Screen(4), 75-86. 
Cooper, G. (2000). Protein Degradation. In G. Cooper (Ed.), The Cell: A 
Molecular Approach. Sunderland: Sinauer Associates. 
Cowie, M., Lacey, L., & Tabberer, M. (2005). Heart Failure After Myocardial 
Infarction: A Neglected Problem? British Journal of Cardiology (12), 205-
208. 
Craig, T., Anderson, D., Evans, A., Girach, F., & Henley, J. (2015). SUMOylation 
of Syntaxin1A regulates presynaptic endocytosis. Scientific Reports (5), 1-
11. 
Crick, S., Sheppard, M., Ho, S., Gebstein, L., & Anderson, R. (1998). Anatomy of 
the pig heart : comparisons with normal human cardiac structure. J 
Anat(193), 105-119. 
Daaka, Y., Luttrell, L., & Leflowitz, R. (1997). Switching of the coupling of the 
adrenergic receptor to different G-proteins by protein kinase A. 
Nature(390), 88-91. 
Day, S., Westfall, M., & Metzger, J. (2007). Tuning cardiac performance in 
ischemic heart disease and failure by modulating myofilament function. 
Mol Med(9), 911-921. 
De Lean, A., Stadel, J., & Lefkowitz, R. (1980). A ternary complex model 
explains the agonist specific binding properties of the adenylate cyclase 
coupled beta adrenergic receptor. J Biol Chem(255), 7108-7117. 
deAlmeida, A., van Oort, R., & Wehrens, X. (2010). Transverse Aortic 
Constriction in Mice. J Vis Exp(38), 1729-1734. 
del Monte, F., Kaumann, A., Poole-Wilson, P., Wynne, D., Pepper, J., & Harding, 
S. (1993). Coexistence of functioning beta 1- and beta 2-adrenoceptors in 
single myocytes from human ventricle. Circulation(88), 854-863. 
Demarque, M., Naverddine, K., Neyret-Kahn, H., Andrieux, A., Danenberg, E., 
Jouvion, G., . . . Dejean, A. (2011). Sumoylation by Ubc9 regulates the 
272 
 
stem cell compartment and structure and function of the intestinal 
epithelium in mice. Gastroenterology(140), 286-296. 
Denolin, H., Kuhn, H., Krayenbuehl, H., Loogen, F., & Reale, A. (1983). The 
definition of heart failure. European Heart Journal(4), 445-448. 
Desterro, J., Rodriguez, M. K., & R.T, H. (1999). Identification of the enzyme 
required for the activation of the small ubiquitin like proteon SUMO-1. J 
Biol Chem(274), 10618-10624. 
Desterro, J., Rodriguez, M., & Hay, R. (1998). SUMO-1 modification of 
IkappaBalpha inhibits NF-kappaB activation. Mol Cell(2), 233-239. 
Desterro, J., Thomson, J., & Hay, R. (1997). Ubch9 conjugates SUMO but not 
ubiquitin . FEBS letters(417), 297-300. 
DeWire, S., Ahn, S., Lefkowitz, R., & Shenoy, S. (2007). β-arrestins and cell 
signaling. Annu Rev Physiol(69), 483-510. 
Diagnostics, N. (2004). http://ehs.psu.edu. Retrieved March 16, 2017, from 
http://ehs.psu.edu/sites/ehs/files/lsc_theory_of_operation_part_1.pdf 
Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J., Ponikowski, P., 
Poole-Wilson, P., . . . Swedberg, K. (2008). ESC guidelines for the 
diagnosis and treatment of acute and chronic heart failure 2008. 
European Society of Cardiology (29), 2388-2442. 
Diez, J., Lopez, B., Gonzalez, A., & Querejeta, R. (2007). The role of myocardial 
collagen network in hypertensive heart disease. Curr Hyperten Rev(3), 1-
7. 
Djurovic, S., Iversen, N., Jeansson, S., Hoover, F., & Christensen, G. (2004). 
Comparison of nonviral transfection and adeno-associated viral 
transduction on cardiomyocytes. Mol Biotechnol(28), 21–32. 
Doerks, T., Copley, R., Schultz, J., Ponting, C., & Bork, P. (2002). Systematic 
identification of novel proten domain families associated with nuclear 
functions. Genome Res(12), 47-56. 
Dorn, G., Tepe, N., Lorenz, J., Koch, W., & Liggett, S. (1999). Low- and high-
level transgenic expression of beta2-adrenergic receptors differentially 
affect cardiac hypertrophy and function in Galphaq-overexpressing mice. 
PNAS(11), 6400-6405. 
Dorval, V., & Fraser, P. (2006). Small ubiquitin-like modifier (SUMO) 
modification of natively unfolded proteins tau and α-synuclein. Journal of 
Biological Chemistry(281), 9919-9924. 
Downes, G., & Gautam, N. (1999). The G protein subunit gene families . 
Genomics(62), 544-552. 
Dumitru, I. (2016, January 11). Heart Failure Treatment & Management. 
Retrieved April 14, 2017, from 
http://emedicine.medscape.com/article/163062-treatment#d1 
273 
 
Dutting, E., Schroder-Kress, N., Sticht, H., & Enz, R. (2011). SUMO E3 ligases are 
expressed in the retina and regulate SUMOylation of the metabotropic 
glutamate receptor 8b. BioChem J(435), 365-371. 
Duval, D., Duval, G., Kedinger, C., Poch, O., & Boeuf, H. (2003). The 'PINIT' 
motif, of a newly identified conserved domain of the PIAS protein family, 
is essential for nuclear retention of PIAS3L. FEBS Letters(554), 111-118. 
Eisner, D., & Trafford, A. (2002). Heart Failure and the Ryanodine Receptor. Circ 
Res(91), 979-981. 
Engelhardt, S., Hein, L., Wiesmann, F., & Lohse, M. (1999). Progressive 
hypertrophy and heart failure in beta1-adrenergic receptor transgenic 
mice. PNAS(12), 7059-7064. 
Espinoza-Fonesca, L., Autry, J., & Thomas, D. (2015). Sarcolipin and 
phospholamban inhibit the calcium pump by populating a similar metal 
ion-free intermediate state. Biochem Biophys Res Commun. (463), 37-41. 
Fajardo, G., Zhao, M., Urashima, T., Kobilka, B., & Bernstein, D. (2007). β-
adrenergic receptor subtypes mediate a temporal switch between 
cardiotoxic and cardioprotective signaling in doxorubicin cardiomyopathy. 
Pediatr Res, abstract. 
Fan, G., Shumay, E., Wang, H., & Malbon, C. (2001). The scaffold protein gravin 
(cAMP dependent protein kinase anchoring protein 250) binds the beta 2 
adrenergic receptor via the receptor cytoplasmic Arg-329 to Leu-413 
domain and provides a mobile scaffold during desensitisation. J Biol 
Chem(276), 24005-24014. 
Felce, J., Knox, R., & Davis, S. (2014). Type-3 BRET, an improved competition-
based bioluminescence resonance energy transfer assay. Biophys J(12), 
L41-L43. 
Feldman, A., Cates, A., Veazey, W., Hershberger, R., Bristow, M., Baughman, 
K., . . . Van Dop, C. (1988). Increase of the 40,000-mol wt pertussis toxin 
substrate (G protein) in the failing human heart. J Clin Invest, 189-197. 
Felgner, P., Gadek, T., Holm, M., Roman, R., Chan, H., Wenz, M., . . . 
Danielsen, M. (1987). Lipofection: a highly efficient, lipid-mediated DNA-
transfection procedure. PNAS(84), 7413-7417. 
Ferguson, S., Downey, W., Colapietro, A., Barak, L., Menard, L., & Caron, M. 
(1996). Role of beta arrestin in mediating agonist promoted G protein 
coupled receptor internalisation. Science(271), 363-366. 
Ferrandon, S., Feinstein, T., Castro, M., Wang, B., Bouley, R., Potts, J., . . . 
Vilardaga, J. (2009). Sustained cyclic AMP production by parathyroid 
hormone receptor endocytosis. Nature Chemical Biology, 734-742. 
Fischmeister, R., Castro, L., Abi-Gerges, A., Rochais, F., Jurevicius, J., Leroy, 
J., & Vandecasteele, G. (2006). Compartmentation of cyclic nucleotide 
signaling in the heart: the role of cyclic nucleotide phosphodiesterases. 
Circ Res(99), 816-828. 
274 
 
Francis, G., McDonald, K., Chu, C., & Cohn, J. (1995). Pathophysiologic aspects 
of endstage heart failure. Am J Cardiol(75), 11A-16A. 
Frank, R. (2002). The SPOT-synthesis technique. Synthetic peptide arrays on 
membrane supports--principles and applications. J Immunol 
Methods(267), 13-26. 
Fraser, C., & Venter, J. (1980). Regulation of beta adrenergic receptors density 
in the control of adrenergic responsiveness. Prog Clin Biol Res(42), 127-
144. 
Freedman, N., & Lefkowitz, R. (1996). Desensitization of G protein-coupled 
receptors. Recent Prog Horm Res(51), 319-351. 
Fuhs, S., & Insel, P. (2011). Caveolin-3 undergoes SUMOylation by the SUMO E3 
ligase PIASy: sumoylation affects G-protein-coupled receptor 
desensitization. J Biol Chem(286), 14830-14841. 
Furst, J., Sutton, R., Chen, J., Brunger, A., & Grigorieff, N. (2003). Electron 
cryomicroscopy structure of N-ethyl maleimide sensitive factor at 11 A 
resolution. The EMBO Journal(17), 4365-4374. 
Futter, C., Pearse, A., Hewlett, L., & Hopkins. (1996). Multivesicular endosomes 
containing internalized EGF-EGF receptor complexes mature and then 
fuse directly with lysosomes. The Journal of Cell Biology (132), 1011-
1023. 
Gagnon, A., Kalla, L., & Benovic, J. (1998). Role of clathrin mediated 
endocytosis in agonist induced down regulation of the beta 2 adrenergic 
receptor. J Biol Chem(273), 6976-6981. 
Gareau, J., & Lima, C. (2010). The SUMO pathway: emerging mechanisms that 
shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol(11), 
861-871. 
Gareau, J., Reverter, D., & Lima, C. (2012). Determinants of small ubiquitin-like 
modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 
binding activities of nucleoporin RanBP2. Journal of Biological 
Chemistry(287), 4740-4751. 
GEHealthcare. (2014). http://www.gelifesciences.com. Retrieved February 3, 
2017, from 
/webapp/wcs/stores/swww.gelifesciences.comervlet/CategoryDisplay?cat
egoryId=3301626&catalogId=126109&productId=&top=Y&storeId=12751&la
ngId=-1 
Gocke, C., Yu, H., & Kang, J. (2005). Systematic identification and analysis of 
mammalian small ubiquitin-like modifier substrates. Journal of Biological 
Chemistry(280), 5004-5012. 
Gomez, A., Valdivia, H., Cheng, H., Lederer, M., Santana, L., Cannell, M., . . . 
Lederer, W. (1997). Defective excitation contraction coupling in 
experimental cardiac hypertrophy and heart failure . Science(276), 800-
806. 
275 
 
Gong, L., Millas, S., Maul, G., & Yeh, E. (2000). Differential regulation of 
sentrinized proteins by a novel sentrin specific proteases. J Biol 
Chem(275), 3355-3359. 
Goodman, O. J., Krupnick, J., Santini, F., Gurevich, V., Penn, R., Gagnon, 
A., . . . Benovic, J. (1996). Beta arrestin acts as a clathrn adaptor in 
endocytosis of the beta 2 adrenergic receptor. Nature(383), 447-450. 
Gowran, A., Murphy, C., & Campbell, V. (2009). Δ9‐Tetrahydrocannabinol 
regulates the p53 post‐translational modifiers Murine double minute 2 
and the Small Ubiquitin MOdifier protein in the rat brain. FEBS 
letters(583), 3412-3418. 
Graham, F., Smiley, J., Russel, W., & Nairu, R. (1977). Characteristics of a 
human cell line transformed by DNA from human adenovirus type 5. J Gen 
Virol(36), 59-72. 
Green, S., Cole, G., Jacinto, M., Innis, M., & Liggett, S. (1993). A polymorphism 
of the human beta 2 adrenergic receptor within the fourth 
transmembrane domain alters ligand binding and functional properties of 
the receptor. J Biol Chem(268), 23116-23121. 
Green, S., Turki, J., Bejarano, P., Hall, I., & Liggett, S. (1995). Influence of beta 
2 adrenergic receptor genotypes on signal transduction in human airway 
smooth muscle cells. Am Respir Cell Mol Biol(13), 25-33. 
Green, S., Turki, J., Innis, M., & Liggett, S. (1994). Amino terminal 
polymorphisms of the human beta 2 adrenergic receptor impact distinct 
agonist promoted regulatory properties . Biochemistry(33), 9414-9419. 
Greenberg, B., Butler, J., Felker, G., Ponikowski, P., Voors, A., Desai, A., . . . 
Zsebo, K. (2016). Calcium upregulation by percutaneous administration of 
gene therapy in patients with cardiac disease (CUPID 2): a randomised, 
multinational, double-blind, placebo-controlled, phase 2b trial. 
LANCET(387), 1178-1186. 
Greenberg, B., Yaroshinsky, A., Zsebo, K., Butler, J., Felker, G., Voors, A., . . . 
Hajjar, R. (2014). Design of a phase 2b trial of intracoronary 
administration of AAV1/SERCA2a in patients with advanced heart failure: 
the CUPID 2 trial (calcium up-regulation by percutaneous administration 
of gene therapy in cardiac disease phase 2b). JACC Heart Failure(1), 84-
92. 
Gunasekaran, K., Tsai, C., Kumar, S., Zanuy, D., & Nussinov, R. (2003). Extended 
disordered proteins: targeting function with less scaffold. Trends Biochem 
Sci(2), 81-85. 
Guo, X., Wang, X., Wang, Z., Banerjee, S., Yang, J., Huang, L., & Dixon, J. 
(2016). Site-specific Proteasome Phosphorylation Controls Cell 
Proliferation and Tumorigenesis. Nat Cell Biol, 202-212. 
Gupta, M., McLendon, P., Gulick, J., James, J., Khalili, K., & Robbins, J. (2016). 
UBC9-Mediated Sumoylation Favorably Impacts Cardiac Function in 
Compromised Hearts. Circ Res(118), 1894-1905. 
276 
 
Gurevich, V., & Gurevich, E. (2003). The new face of active receptor bound 
arrestin attracts new partners. Structure(11), 1037-1042. 
Haberland, M., Montgomery, R., & Olson, E. (2009). The many roles of histone 
deacetylases in development and physiology: implications for disease and 
therapy. Nature Reviews Genetics (10), 32-42. 
Hadcock, J., Wang, H., & Malbon, C. (1989). Agonist induced destabilisation of 
beta adrenergic receptor mRNA. Attenuation of glucocorticoid induced up 
regulation of beta adrenergic receptors. J Biol Chem(264), 19928-19933. 
Hajjar, R., Kang, J., Gwathmey, J., & Rosenzweig, A. (1997). Physiological 
Effects of Adenoviral Gene Transfer of Sarcoplasmic Reticulum Calcium 
ATPase in Isolated Rat Myocytes. Circulation(95), 423-429. 
Hamm, H. (1998). The many faces of G protein signaling. J Biol Chem(273), 669-
672. 
Hannoun, Z., Greenhough, S., Jaffray, E., Hay, R., & Hay, D. (2010). Post-
translational modification by SUMO. Toxicology (278), 288-293. 
Hartz, P. (2005). TOPOISOMERASE I-BINDING ARGININE/SERINE-RICH PROTEIN; 
TOPORS . Retrieved April 20, 2017, from 
http://www.omim.org/entry/609507 
Hasenfuss, G., Schilinger, W., Lehnart, S., Preuss, M., Pieske, B., Maier, L., . . . 
Just, H. (1999). Relationship between Na+-Ca2+-exchanger protein levels 
and diastolic function of failing human myocardium. Circulation(99), 641-
648. 
Hattori, M., & Ozawa, T. (2015). Bioluminescent tools for the analysis of G-
protein-coupled receptor and arrestin interactions. Royal Society of 
Chemistry Advances(5), 12655-12663. 
Hattori, T., Taft, J., Swist, K., Luo, H., Witt, H., Slattery, M., . . . Koide, S. 
(2013). Recombinant antibodies to histone post-translational 
modifications. Nature Methods(10), 992-995. 
Hausdorff, W., Bouvier, M., O'Dowd, B., Irons, G., Caron, M., & Lefkowitz, R. 
(1989). Phosphorylation sites on two domains of the beta 2-adrenergic 
receptor are involved in distinct pathways of receptor desensitization. J 
Biol Chem(264), 12657-12665. 
Hawkins, G., Tantisira, K., Meyers, D., Ampleford, E., Moore, W., Klanerman, 
B., . . . Bleecker, E. (2006). Sequence, haplotype and association analysis 
of ADRB2 in a multiethnic ashtma case control study. Am J Respir Crit 
Care Med(174), 1101-1109. 
Hay, R. (2005). SUMO: a history of modification . Molecular Cell(18), 1-12. 
Hay, R. (2013). Decoding the SUMO signal. Biochemical Society Transactions(41), 
463-473. 
277 
 
Hayashi, T., Seki, M., Maeda, D., Wang, W., Kawabe, Y., Seki, T., . . . Enomoto, 
T. (2002). Ubc9 is essential for viability of higher eukaryotic cells. Exp 
Cell Res(280), 212-221. 
Hebert, T., Moffett, S., Morello, J., Loisel, T., Bichet, D., Barret, C., & Bouvier, 
M. (1996). a peptide derived from a beta 2 adrenergic receptor 
transmembrane domain inhibits both receptor dimerisation and 
activation. J Biol Chem(271), 16384-16392. 
Hedaya, M., Mahmoudi, M., Rose, N., & Rezaei, N. (2010). Proinflammatory 
cytokines in heart failure: double-edged swords. Heart Fail Rev(15), 543-
562. 
Hein, P., Michel, M., Leineweber, K., Wieland, T., Wettschureck, N., & 
Offermanns, S. (2005). Practical Methods in Cardiovascular Research: 
Receptor and binding studies (Dhein, S; Mohr, F; Delmar, M ed.). Berlin: 
Springer. 
Hein, P., Rochais, F., Hoffmann, C., Dorsch, S., Nikolaev, V., Enfelhardt, S., . . . 
Bunemann, M. (2006). GS Activation Is Time-limiting in Initiating 
Receptor-mediated Signaling. The Journal of Biological Chemistry(281), 
33345-33351. 
Heineke, J., & Molkentin, J. (2006). Regulation of cardiac hypertrophy by 
intracellular signaling pathways. Nat. Rev. Mol. Cell. Biol. (7), 589-600. 
Henley, J., Craig, T., & Wilkinson, K. (2014). Neuronal SUMOylation mechanisms, 
physiology and roles in neuronal dysfunction. Physiological reviews(94), 
1249-1285. 
Hertel, C., & Staehelin, M. (1983). Reappearance of beta-adrenergic receptors 
after isoproterenol treatment in intact C6-cells. The Journal of Cell 
Biology (216), 1538-1543. 
Heusch, G., Skychally, A., & Schulz, R. (2011). The in-situ pig heart with 
regional ischemia/reperfusion - ready for translation. J Mol Cell 
Cardiol(50), 951-963. 
Heyman, S., Schroen, B., Vermeersch, P., Milting, H., Gao, F., Kassner, A., . . . 
Janssens, S. (2005). Increased cardiac expression of tissue inhibitor of 
metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related 
to cardiac fibrosis and dysfunction in the chronic pressure-overloaded 
human heart. Circulation(112), 1136-1144. 
Hickey, C., Wilson, N., & Hochstrasser, M. (2012). Function and regulation of 
SUMO proteases. Nature Reviews Molecular Cell Biology(13), 755-766. 
Hietakangas, V., Ahlskog, J., Jakobsson, A., Hellesuo, M., Sahlberg, N., 
Holmberg, C., . . . Sistonen, L. (2003). Phosphorylation of serine 303 is a 
prerequisite for the stress-inducible SUMO modification of heat shock 
factor 1. Mol Cell Biol(23), 2953-2968. 
278 
 
Hill, S., Ganellin, C., Timmerman, H., Schwartz, J., Shankley, N., Young, J., . . . 
Haas, H. (1997). International Union of Pharmacology. XIII. Classification 
of histamine receptors. Pharmacological Reviews(49), 253-278. 
Hjelm, H., Hjelm, K., & Sjoquist, J. (1972). Protein A from Staphylococcus 
aureus. Its isolation by affinity chromatography and its use as an 
immunosorbent for isolation of immunoglobulins. FEBS Lett(28), 73-76. 
Hochstrasser, M. (2001). SP-RING for SUMO. New Functions Bloom for a 
Ubiquitin-like Protein. Cell(107), 5-8. 
Hochstrasser, M. (2001). SP-RING for SUMO: new functions bloom for a ubiquitin-
like protein. Cell(107), 5-8. 
Hoege, C., Pfander, B., Moldovan, G., Pyrowolakis, G., & Jentsch, S. (2002). 
RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin 
and SUMO. Nature(419), 135-141. 
Houser, S., Marguiles, K., Murphy, A., Spinale, F., Francis, G., Prabhu, S., . . . 
Koch, W. (2012). Animal Models of Heart Failure. Circulation 
Research(111), 131-150. 
Huang, T., Wuerzberger-Davis, S., Wu, Z., & Miyamoto, S. (2003). Sequential 
modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB 
activation by genotoxic stress. Cell(115), 565-576. 
Hunt, S., Abraham, W., Chin, M., Feldman, A., Francis, G., Ganiats, T., . . . al, 
e. (2005). ACC/AHA 2005 Guideline Update for the Diagnosis and 
Management of Chronic Heart Failure in the Adult. Circulation(112), e154-
e235. 
i-base.info. (2017, August 17). appendix-3-list-of-amino-acids-and-their-
abbreviations. Retrieved from http://i-base.info: http://i-
base.info/appendix-3-list-of-amino-acids-and-their-abbreviations/ 
Ibrahaim, M., Masri, A., Navaratnarajah, M., Siedlecka, U., Soppa, G., Moshkov, 
A., . . . Terraciano, C. (2010). Prolonged mechanical unloading affects 
cardiomyocyte excitation-contraction coupling, transverse-tubule 
structure, and the cell surface. FASEB(9), 3321-3329. 
Ikonnikov, G., & Yelle, D. (2016). Physiology of cardiac conduction and 
contractility. Retrieved June 20, 2017, from 
http://www.pathophys.org/physiology-of-cardiac-conduction-and-
contractility/ 
Impens, F., Radoshevich, L., Cossart, P., & Ribet, D. (2014). Mapping of SUMO 
sites and analysis of SUMOylation changes induced by external stimuli. 
PNAS(111), 12432-12437. 
Impens, F., Radoshevich, L., Cossart, P., & Ribet, D. (2014). Mapping of SUMO 
sites and analysis of SUMOylation changes induced by external stimuli. 
PNAS(111), 12432-12437. 
Irannejad, R., & Von Zastrow, M. (2014). GPCR signaling along the endocytic 
pathway. Current Opinion in Cell Biology, 109-116. 
279 
 
Irannejad, R., Tomshine, J., Tomshine, J., Chevalier, M., Mahoney, J., Steyaert, 
J., . . . von Zastrow, M. (2013). Conformational biosensors reveal GPCR 
signalling from endosomes. Nature, 534-538. 
Izumo, S., Lompre, A., Matsuoka, R., Koren, G., Schwartz, K., Nadal-Ginard, B., 
& Mahdavi, V. (1987). Myosin heavy chain mRNA and protein isoform 
transitions during cardiac hypertrophy. Interaction between 
haemodynamic and thyroid hormone-induced signals. J Clin Invest(79), 
970-977. 
Januzzi, J., Filippatos, G., Nieminen, M., & Gheorghiade, M. (2012). Troponin 
Elevation in Patients With Heart Failure. European Heart Journal(33), 
2265-2271. 
Jaski, B., Jessup, M., Mancini, D., Cappola, T., Pauly, D., Greenberg, B., . . . 
Hajjar, R. (2009). Calcium Upregulation by Percutaneous Administration 
of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 
1/2 Clinical Trial. Journal of Cardiac Failure(15), 170-181. 
Jensen, C., Swigart, P., De Marco, T., Hoopes, C., & Simpson, P. (2009). 
{alpha}1-Adrenergic receptor subtypes in nonfailing and failing human 
myocardium. Circ Heart Fail, 654-663. 
Johnson, E., & Blobel, G. (1997). Ubc9p is the conjugating enzyme for the 
ubiquitin like protein Smt3p. Journal of biological chemistry(272), 26799-
26802. 
Johnson, M. (1998). The Beta Adrenoceptor. Am J Respir Crit Care Med(158), 
S146-S153. 
Jones, D., Crowe, E., Stevens, T., & Candido, E. (2002). Functional and 
phylogenetic analysis of the ubiquitylation system in caenorhabditis 
elegans: ubiquitin conjugating enzymes, ubiquitin activating enzymes, and 
ubiquitin like proteins. Genome Biol(3), 1-0002. 
Joseph, J., Tan, S., Karpova, T., McNally, J., & Dasso, M. (2002). SUMO-1 targets 
RanGAP1 to kinetochores and mitotic spindles. J Cell Biol(156), 595-602. 
Kadambi, V., & Kranias, E. (1997). Phospholamban: a protein coming of age. 
Biochem Biophys Res Commun(239), 1-5. 
Kallal, L., Gagnon, A., Penn, R., & Benovic, J. (1998). Visualization of agonist-
induced sequestration and down-regulation of a green fluorescent 
protein-tagged β2-adrenergic receptor. J. Biol. Chem.(273), 322-328. 
Katragadda, M., Maciejewski, M., & Yeagle, P. (2004). Structural studies of the 
putative helix 8 in the human β2 adrenergic receptor: an NMR study. 
Biochim Biophys Acta(1663), 74-81. 
Katritch, V., Reynolds, K., Cherezov, V., Hanson, M., Roth, C., Yeager, M., & 
Abagyan, R. (2009). Analysis of Full and Partial Agonists Binding to β2-
Adrenergic Receptor Suggests a Role of Transmembrane Helix V in 
Agonist-Specific Conformational Changes. J Mol Recognit, 307-318. 
280 
 
Kaumann, A., Bartel, S., Molenaar, P., Sanders, L., Burrell, K., Vetter, D., . . . 
Krause, E. (1999). Activation of beta 2 adrenergic receptors hastes 
relaxation and mediates phosphorylation of phospholamban, troponin I, 
and C-protein in ventricular myocardium from patients with terminal 
heart failure . Circulation(99), 65-72. 
Kaur, K., Park, H., Pandey, N., Azuma, Y., & Guzman, R. (2017). Identification 
of a New SUMO-Interacting Motif in PIASy. JBC, 1-18. 
Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, 
H., . . . Ikeda, U. (2011). Inflammasome activation of cardiac fibroblasts 
is essential for myocardial ischemia/reperfusion injury. Circulation(123), 
594-604. 
Kawano, K., Yano, Y., Omae, K., Matsuzaki, S., & Matsuzaki, K. (2013). 
Stoichiometric analysis of oligomerization of membrane proteins on living 
cells using coiled-coil labeling and spectral imaging. Anal Chem(85), 3454-
3461. 
Kawase, Y., & Hajjar, R. (2008). The cardiac sarcoplasmic/endoplasmic 
reticulum calcium ATPase: a potent target for cardiovascular diseases. 
Nature Clinical Practice Cardiovascular Medicine(5), 554-565. 
Keith, M., Geranmayegan, A., Sole, M., Kurian, R., Robinson, A., Omran, A., & 
Jeejeebhoy, K. (1998). Increased Oxidative Stress in Patients With 
Congestive Heart Failure. Journal of American Cardiology, 1352-1356. 
Kerscher, O. (2007). SUMO junction-what’s your function? New insights through 
SUMO-interacting motifs. EMBO Rep(8), 550-555. 
Kessler, J., Kahle, K., Sun, T., Meerbrey, K., Schlabach, M., Schmitt, E., . . . al, 
e. (2012). A SUMOylation-dependent transcriptional subprogram is 
required for Myc-driven tumorigenesis. Science(335), 348-353. 
Kho, C., Lee, A. J., Oh, J., Gorski, P., Fish, K., Sanchez, R., . . . Hajjar, R. 
(2015). Small-molecule activation of SERCA2a SUMOylation for the 
treatment of heart failure. Nature Communications(6), 1-11. 
Kho, C., Lee, A., Jeong, D., Oh, J., Chaanine, A., Kizana, E., . . . Hajjar, R. 
(2011). SUMO-1 dependent modulation of SERCA2a in heart failure. 
Nature(477), 601-605. 
Kho, C., Lee, A., Jeong, D., Oh, J., Chaanine, A., Kizana, E., . . . Hajjar, R. 
(2011). SUMO1-dependent modulation of SERCA2a in heart failure. 
Nature(477), 601-605. 
Kim, M., Chia, I., & Constantini, F. (2008). SUMOylation target sites at the C 
terminus protect Axin from ubiquitination and confer protein stability. 
FASEB J(11), 3785-3794. 
Kobilka, B., Dixon, R., Friella, H., Dohlman, M., Bolanowski, I., & Sigal, I. 
(1987). cDNA for the human β2 adrenergic receptor: a protein with 
multiple spanning domains and encoded by a gene whose chromosomal 
281 
 
location is shared with that of a receptor for platelet growth factor. Proc 
Natl Acad Sci U S A(84), 46-50. 
Kociol, R., Pang, P., Gheorghiade, M., Fonarow, G., O'Connor, C., & Felker, G. 
(2010). Troponin elevation in heart failure prevalence, mechanisms, and 
clinical implications. J Am Coll Cardiol (56), 1071-1078. 
Kohout, T. L., Perry, S., Conner, D., & Lefkowitz, R. (2001). Beta arrestin 1 and 
2 differentially regulate heptahelical receptor signalling and trafickking. 
Proc Natl Acad Sci(98), 1601-1606. 
Komander, D. (2009). The emerging complexity of protein ubiquitination. 
Biochem Soc Trans, 937-953. 
Konerman, M., & Hummel, S. (2014). Sodium Restriction in Heart Failure: 
Benefit or Harm? Curr Treat Options Cardiovasc Med(16), 286-288. 
Konturek, S., Konteruk, J., Pawlik, T., & Brzozowski, T. (2004). Brain gut axis 
and its role in the control of food intake. Journal of Physiology and 
Pharmacology, 137-154. 
Koss, K., & Kranias, E. (1996). Phospholamban: a prominent regulator of 
myocardial contractility. Circ Res(79), 1059-1063. 
Kotaja, N., Karvonen, U., Janne, O., & Palvimo, J. (2002). PIAS proteins 
modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell 
Biol(22), 5222-5234. 
Koudstaal, S., Jansen of Lorkeers, S., Gho, J., van Hout, G., Jansen, M., 
Grunderman, P., . . . Chamuleau, S. (2014). Myocardial Infarction and 
Functional Outcome Assessment in Pigs. J Vis Exp(86), 51269-51279. 
Kovesdi, I., & Hedley, S. (2010). Adenoviral Producer Cells. Viruses(8), 1681-
1703. 
Kranias, E. (1985). Regulation of calcium transport by protein phosphatase 
activity associated with cardiac sarcoplasmic reticulum. J Biol Chem(260), 
11006-11010. 
Kranias, E., & Solaro, R. (1982). Phosphorylation of troponin I and 
phospholamban during catecholamine stimulation of rabbit heart. 
Nature(298), 182-184. 
Krasel, C., Bunemann, M., Lorenz, K., & Lohse, M. (2005). Beta arrestin binding 
to the beta 2 adrenergic receptor requires both receptor phosphorylation 
and receptor activation. J Biol Chem(280), 9528-9535. 
Krayenbuehl, H., Hess, O., Monrad, E., Schneider, J., Mall, G., & Turina, M. 
(1989). Left ventricular myocardial structure in aortic valve disease 
before, intermediate, and late after aortic valve replacement. 
Circulation(79), 744-755. 
Krueger, K., Daaka, Y., Pitcher, J., & Lefkowitz, R. (1997). The role of 
sequestration in G protein coupled receptor resensitisation. Regulation of 
282 
 
beta 2 adrenergic receptor dephosphorylation by vesicular acidification. J 
Biol Chem(272), 5-8. 
Lan, T., Liu, Q., Li, C., Wu, G., Steyaert, J., & Lambert, N. (2015). BRET 
evidence that β2 adrenergic receptors do not oligomerize in cells. 
Scientific Reports (5), 1-12. 
Laporte, S., Oakley, R., Holt, J., Barak, L., & Caron, M. (2000). The interaction 
of beta arrestin with the AP-2 adaptor is required for the clustering of 
beta 2 adrenergic receptor into clathrin coated pits. J Biol Chem(275), 
23120-23126. 
Lavoie, C., Mercier, J., Salahpour, A., Umapathy, D., Breit, A., Villeneuve, 
L., . . . Hebert, T. (2002). Beta 1/Beta 2 adrenergic receptor 
heterodimerisation regulates beta 2 adrenergic receptor internalisation 
and ERK signaling efficacy. J Biol Chem(277), 35402-35410. 
Le Peuch, C., Guilleux, J., & Demaille, J. (1980). Phospholamban 
phosphorylation in the perfused rat heart is not solely dependent on beta-
adrenergic stimulation. FEBS Letter(114), 165-168. 
Lee, A., Dongtak, J., Shinichi, M., Gyun, O., Lifan, L., Yoshiyuki, I., . . . Kho, C. 
(2014). The Role of SUMO-1 in Cardiac Oxidative Stress and Hypertrophy . 
Antioxidants & Redox Signaling(21), 1986-2001. 
Lee, J., & Thorgeirsson, S. (2004). Genome-scale profiling of gene expression in 
hepatocellular carcinoma: classification, survival prediction, and 
identification of therapeutic targets. Gastroenterology(127), S51-S55. 
Lefkowitz, R., & Shenoy, S. (2005). Transduction of receptor signals by beta-
arrestins. Science(308), 512-517. 
Lefkowitz, R., Rajagopal, K., & Whalen, E. (2006). New Roles for β-Arrestins in 
Cell Signaling: Not Just for Seven-Transmembrane Receptors. Molecular 
Cell(5), 643-652. 
Leight, E., D, G., & Kornfeld, K. (2005). Sumoylation of LIN-1 promotes 
transcriptional repression and inhibition of vulval cell fates. 
Development(132), 1047-1056. 
Li, H., Niu, H., Peng, Y., Wang, J., & He, P. (2013). Ubc9 promotes invasion and 
metastasis of lung cancer cells. Oncology Reports(29), 1588-1594. 
Li, Q., & Muma, N. (2013). Estradiol potentiates 8-OH-DPAT-induced sumoylation 
of 5-HT 1A receptor: Characterization and subcellular distribution of 
sumoylated 5-HT 1A receptors. Psychoneuroendocrinology(38), 2542-2553. 
Li, X., Vadrevu, S., Dunlop, A., Day, J., Advant, N., Troeger, J., . . . Baillie, G. 
(2010). Selective SUMO modification of cAMP-specific phosphodiesterase-
4D5 (PDE4D5) regulates the functional consequences of phosphorylation 
by PKA and ERK. Biochem J(428), 55-65. 
Li, X., Zhou, M., Huang, W., & Yang, H. (2017). N-glycosylation of the β2AR 
regulates receptor function by modulating dimerisation. FEBS(10), 1-15. 
283 
 
Liggett, S. (2002). Update on current concepts of the molecular basis of β2-
adrenergic receptor signalling. J Allergy Clin Immunol(110), S223-S228. 
Lin, D., Tatham, M., Yu, B., Kim, S., Hay, R., & Chen, Y. (2002). Identification of 
a substrate recognition site on UBC9. J Biol Chem(277), 21740-21748. 
Litalien, C., & Beaulieu, P. (2011). Molecular Mechanisms of Drug Actions: From 
Receptors to Effectors. In B. Fuhrman, J. Zimmerman, J. Carcillo, R. 
Clark, M. Relvas, A. Rotta, . . . J. Tobias, Pediatric Critical Care (pp. 
1553-1568). Philadelphia: Elsevier. 
Liu, Y., Lagowski, J., Gao, S., Raymond, J., White, C., & Kulesz-Martin, M. 
(2010). Regulation of psoriatic chemokine CCL20 by E3 ligases Trim32 and 
Piasy in keratinocytes. J Invest Dermatol(130), 1384-1390. 
Lokuta, A., Rogers, T., Lederer, W., & Valdivia, H. (1995). Modulation of cardiac 
ryanodine receptors of swine and rabbit by a phosphorylation-
dephosphorylation mechanism. J Physiol (Lond)(487), 609-622. 
Lompre, A. S., d'Albis, A., Lacombe, G., Thiem, N., & Swynghedauw, B. (1979). 
Myosin isoenzyme redistribution in chronic heart overload. Nature(282), 
105-107. 
Lorenz, W., McCann, R., Longiaru, M., & Cormier, M. (1991). Isolation and 
expression of a cDNA encoding Renilla reniformis luciferase. Proc Natl 
Acad Sci USA, 88, 4438-4442. 
Lorton, D., Lubahn, C., Molinaro, C., & Bellinger, D. (2017). Beta2-Adrenergic 
Receptor Regulates Inflammation in Autoimmune Arthritis: Inhibit or 
Promote? – Depends on Timing, Immune Organ and Posttranslational 
Receptor Modifications. FASEB Journal, 31, 1. 
Louch, W., Sheehan, K., & Wolska, B. (2011). Methods in Cardiomyocyte 
Isolation, Culture, and Gene Transfer. J Mol Cell Cardiol(51), 288-298. 
Louis, N., Evelgh, C., & Graham, F. (1997). Cloning and sequencing of the 
cellular-viral junctions from the human adenovirus type 5 transformed 293 
cell line. Virology(233), 423-429. 
Lu, Z., Xu, X., Hu, X., Fassett, J., Zhu, G., Tao, Y., . . . Chen, Y. (2010). PGC-1α 
regulates expression of myocardial mitochondrial antioxidants and 
myocardial oxidative stress after chronic systolic overload. Antioxid Redox 
Signal(13), 1011-1022. 
Lu, Z., Xu, X., Hu, X., Lee, S., Traverse, J., Zhu, G., . . . Chen, Y. (2010). 
Oxidative stress regulates left ventricular PDE5 expression in the failing 
heart. Circulation(121), 1474-1483. 
Luttrel, L., & Gesty-Palmer, D. (2010). Beyond desensitization: Physiological 
relevance of arrestin-dependent signaling. Pharmacol Rev(62), 305-330. 
Luttrell, L., Ferguson, S., Daaka, Y., Miller, W., Maudsley, S., Rocca, D., . . . 
Lefkowitz, R. (1999). Beta-arrestin-dependent formation of beta2 
adrenergic receptor-Src protein kinase complexes. Science(29), 655-661. 
284 
 
Lyon, A., MacLeod, K., Zhang, Y., Garcia, E., Kanda, G., Lab, M., . . . Gorelik, J. 
(2009). Loss of T-tubules and other changes to surface topography in 
ventricular myocytes from failing human and rat heart. PNAS(106), 6854-
6859. 
MacLannan, D., & Kranias, E. (2003). Phospholamban: a crucial regulator of 
cardiac contractility. Nature (4), 565-577. 
Macon, B., Yu, W., & Reed-Guy, L. (2015). Healthline. Retrieved December 1, 
2016, from http://www.healthline.com/health/acute-myocardial-
infarction#Overview1 
Madamanchi, A. (2007). β-Adrenergic receptor signaling in cardiac function and 
heart failure. McGill Journal of Medicine(10), 99-104. 
Mahan, L., & Insel, P. (1986). Expression of beta adrenergic receptors in 
synchronous and asynchronous S49 lymphoma cell. Receptor metabolism 
after irreversible blockade of receptors in cells transversing the cell 
division cycle. Mol Pharm(29), 7-15. 
Mahmood, T., & Yang, P. (2012). Western Blot: Technique, Theory, and Trouble 
Shooting. N Am J Med Sci(9), 429-434. 
Mak, J., Hisada, T., Salmon, M., Barnes, P., & Chung, K. (2002). Glucocorticoids 
reverse IL-1 beta induced impairment of beta adrenoceptor mediated 
relaxation and up regulation of G protein coupled receptor kinases . Br J 
Pharmacol(135), 987-996. 
Malave, H., Taylor, A., Nattama, J., Deswal, A., & Mann, D. (2003). Circulating 
levels of tumour necrosis factor correlate with indexes of depressed heart 
rate variability: a study in patients with mild to moderate heart failure. 
Chest(123), 716-724. 
Manurung, D., & Trisnohadi, H. (2007). Beta Blockers for Congestive Heart 
Failure. Acta Med Indones-Indones J Intern Med, 44-48. 
Marantz, P., Tobin, J., Wassertheil-Smoller, S., Steingart, R., Wexler, J., 
Budner, N., . . . Wachspress, J. (1988). The relationship between left 
ventricular systolic function and congestive heart failure diagnosed by 
clinical criteria. Circulation(77), 607-612. 
Marks, A. (2000). Cardiac intracellular calcium release channels: role in heart 
failure. Circ Res(87), 8-11. 
Martin, T., Robinson, E., Harvey, A., MacDonald, M., Grieve, D., Paul, A., & 
Currie, S. (2012). Surgical optimization and characterization of a 
minimally invasive aortic banding procedure to induce cardiac 
hypertrophy in mice. Experimental Physiology(97), 822-832. 
Marvin, H. (1964). Diseases of the heart and blood vessels: Nomenclature and 
criteria for diagnosis. Arch Intern Med(113), 906-907. 
Matic, I., Schimmel, J., Hendriks, I. v., van de Rijke, F., van Dam, H., Gnad, 
F., . . . Vertegaal, A. (2010). Site-specific identification of SUMO-2 targets 
285 
 
in cells reveals an inverted SUMOylation motif and a hydrophobic cluster 
SUMOylation motif. Mol Cell(39), 641-652. 
Matic, I., van Hagen, M., Schimmel, J., Macek, B., Ogg, S., Tatham, M., . . . 
Vetegaal, A. (2008). In vivo identification of human small ubiquitin like 
modifier polymerisation sites by high accuracy mass spectometry and an 
in vitro in vivo strategy. Mol. Cell. Proteomics (7), 132-144. 
Matsuzaki, K., Minami, T., Tojo, M., Honda, Y., Uchimara, Y., Saitoh, H., . . . 
Nakao, M. (2003). Serum response factor is modulated by the SUMO-1 
conjugation system. Biochem Biophys Res Commun(306), 32-38. 
McDonald, P., Chow, C., Miller, W., LaPorte, S., Field, M., Lin, F. D., & 
Lefkowitz, R. (2000). β-arrestin 2: A receptor-regulated MAPK scaffold for 
the activation of JNK3. Science(290), 1574-1577. 
McGraw, D., Forbes, S., Kramer, L., & Liggett, S. (1998). Polymorphisms of the 5' 
leader cistron of the human beta 2 adrenergic receptor regulate receptor 
expression. J Clin Invest(102), 1927-1932. 
McGraw, D., Mihbachler, K., Schwarb, M., Rahman, F., Small, K., & Liggett, S. 
(2006). Airway smooth muscle prostaglandin-Ep1 receptors directly 
modulate beta 2 adrenergic recerptors within a unique heterodimeric 
complex. J Clin Invest(116), 1400-1409. 
McLean, A., & Milligan, G. (2000). Ligand regulation of green fluorescent 
protein-tagged forms of the human beta(1)- and beta(2)-adrenoceptors; 
comparisons with the unmodified receptors. Br J Pharmacol(130), 1825-
1832. 
Mclean, A., Bevan, N., Rees, S., & Milligan, G. (1999). Visualizing Differences in 
Ligand Regulation of Wild-Type and Constitutively Active Mutant β2-
Adrenoceptor-Green Fluorescent Protein Fusion Proteins. Molecular 
Pharmacology (56), 1182-1191. 
Meek, D., & Knippschild, U. (2003). Post-translational modification of MDM2. Mol 
Cancer Research(1), 1017-1026. 
Mercadier, J., Lompre, A., Wisnewsky, C., Samuel, J., Bercovici, J., 
Swynghedauw, B., & Schwartz, K. (1981). Myosin isoenzmic changes in 
several models of rat cardiac hypertrophy. Circ Res(49), 525-532. 
Mercier, J., Salahpour, A., Angers, S., Breit, A., & and Bouvier, M. (2002). 
quantitative assessment of B1 and B2 adrenergic receptor homo and 
heterodimerisation by bioluminscence resonance energy transfer. J Biol 
Chem(277), 44925-44931. 
Mercier, J., Salahpour, A., Angers, S., Breit, A., & Bouvier, M. (2002). 
Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- 
and heterodimerization by bioluminescence resonance energy transfer. J 
Biol Chem(47), 44925-44931. 
286 
 
Metzger, J., & Westfall, M. (2004). Covalent and noncovalent modification of 
thin filament action: the essential role of troponin in cardiac muscle 
regulation. Circ Res(94), 146-158. 
Meulmeester, E., Kunze, M., Hsiao, H., Urlaub, H., & Melchior, F. (2008). 
Mechanism and consequences for paralog-specific sumoylation of 
ubiquitin-specific protease 25. Mol Cell(30), 610-619. 
Mialet-Perez, J., Green, S., Miller, W., & Liggett, S. (2004). A primate dominant 
third glycosylation site of the beta 2 adrenergic receptor routes receptors 
to degradation during agonist regulation. J Biol chem(279), 38603-38607. 
Miller-Davis, C., Marden, S., & Leidy, N. (2006). The New York Heart 
Association.Classes and functional status: What are we really measuring? 
Heart and Lung: The Journal of Acute and Critical Care(35), 217-224. 
Millman, E., Rosenfield, J., Vaughan, D., Nguyen, J., Dai, W., Alpizar-Foster, 
E., . . . Knoll, B. M. (2004). Endosome sorting of β2-adrenoceptors is GRK5 
independent. Brit Journal Pharmacol(141), 277-284. 
Miyamoto, M., del Monte, F., Schmidt, U., DiSalvo, T., Kang, Z., Matsui, T., . . . 
Hajjar, R. (2000). Adenoviral gene transfer of SERCA2a improves left-
ventricular function in aortic-banded rats in transition to heart failure. 
Proc Natl Acad Sci USA(97), 793-798. 
Moffett, S., Rousseau, G., Lagace, M., & Bouvier, M. (2001). The palmitoylation 
state of the β2AR regulates the synergistic action of cyclic AMP dependent 
protein kinase and βARK involved in its phosphorylation and 
desensitisation. Journal of neurochemistry(76), 269-279. 
Mohideen, F., Capili, A., Bilimoria, P., Yamada, T., Bonni, A., & Lima, C. (2009). 
A molecular basis for phosphorylation-dependent SUMO conjugation by the 
E2 UBC9. Nat Struc Mol Biol(16), 945-952. 
Molinoff, P. (1984). Alpha- and beta-adrenergic receptor subtypes properties, 
distribution and regulation. Drugs, 1-15. 
Monrad, E., Hess, O., Murakami, T., Nonogi, H., Corin, W., & Krayenbuehl, H. 
(1988). Time course of regression of left ventricular hypertrophy after 
aortic valve replacement. Circulation(77), 1345-1355. 
Mooney, S., Grande, J., Salisbury, J., & Janknecht, R. (2010). Sumoylation of 
p68 and p72 RNA helicases affects protein stability and transactivation 
potential. Biochemistry(49), 1-10. 
Moore, R., Tuffana, A., Millman, E., Dai, W., Hall, H., Dickey, B., & Knoll, B. 
(1999). Agonist induced sorting of human beta 2 adrenergic receptors to 
lysosomes during down regulation. J Cell Sci(112), 329-338. 
Morrison, K., Moore, R., Carsrud, N., Trial, J., Millman, E., Tuvim, M., . . . Knoll, 
B. (1996). Repetitive endocytosis and recycling of the beta 2-adrenergic 
receptor during agonist-induced steady state redistribution. Molecular 
Pharmacology(50), 692-699. 
287 
 
Mukhopadhyay, D., Ayaydin, F., Koli, N., Tan, S., Anan, T., Kametaka, A., . . . 
Dasso, M. (2006). SUSP1 antagonizes formation of highly SUMO2/3-
conjugated species . J Cell Biol(174), 939-949. 
Murakami, P., Pungor, E., Files, J., Do, L., van Rijnsoever, R., Vogels, R., . . . 
McCaman, M. (2002). A single short stretch of homology between 
adenoviral vector and packaging cell line can give rise to cytopathic 
effect-inducing, helper-dependent E1-positive particles. Hum Gene 
Ther(13), 909-920. 
Naujokat, C., & Hoffman, S. (2002). Role and Function of the 26S Proteasome in 
Proliferation and Apoptosis. Nature Lab Invest(82), 965-980. 
NHS. (2016). Treatments for heart failure. Retrieved April 14, 2017, from 
http://www.nhs.uk/Conditions/Heart-failure/Pages/Treatment.aspx 
Ni, Y., Zhao, X., Bao, G., Zou, L., Teng, L., Wang, Z., . . . Pei, G. (2006). 
Activation of β2-adrenergic receptor stimulates γ-secretase activity and 
accelerates amyloid plaque formation. Nature Medicine, 1390-1396. 
NIH. (2011). Your Heart's Electrical System. Retrieved April 19, 2017, from 
https://www.nhlbi.nih.gov/health/health-topics/topics/hhw/electrical 
Nikolaev, V., Bunemann, M., Schmitteckert, E., Lohse, M., & Egelhardt, S. 
(2006). Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching 
beta1-adrenergic but locally confined beta2-adrenergic receptor-
mediated signaling. Circ Res(10), 1084-1091. 
Nikolaev, V., Moshkov, A., Lyon, A., Miragoli, M., Novak, P., Paur, H., . . . 
Gorelik, J. (2010). Beta2-adrenergic receptor redistribution in heart 
failure changes cAMP compartmentation. Science(327), 1653-1657. 
Nishida, T., & Yasuda, H. (2002). PIAS1 and PIASxα function as SUMO-E3 ligases 
toward androgen receptor and repress androgen receptor-dependent 
transcription. Journal of Biological Chemistry(277), 41311-41317. 
Nistico, R., Ferraina, C., Marconi, V., Blandini, F., Negri, L., Egebjerg, J., & 
Feligioni, M. (2014). Age-related changes of protein SUMOylation balance 
in the AβPP Tg2576 mouse model of Alzheimer's disease. Frontiers 
Pharmacology(5), 1-9. 
Nobles, K., Xiao, K., Ahn, S., Shukla, A., Lam, C., Rajagopal, S., . . . Lefkowitz, 
R. (2011). Distinct phosphorylation sites on the β(2)-adrenergic receptor 
establish a barcode that encodes differential functions of β-arrestin. Sci 
Signal(4), 1-22. 
Oakley, R., Laporte, S., Holt, J., Caron, M., & Barak, L. (2000). Differential 
Affinities of Visual Arrestin, βArrestin1, and βArrestin2 for G Protein-
coupled Receptors Delineate Two Major Classes of Receptors. The Journal 
of Biological Chemistry(275), 17201-17210. 
O'Dowd, B., Hnatowich, M., Caron, M., Lefkowitz, R., & Bouvier, M. (1989). 
Palmitoylatyion of the human B2-adrenergic receptor. Mutation of Cys341 
288 
 
in the carboxyl tail leads to an uncoupled non palmitoylated form of the 
receptor. J Biol Chem(264), 7564-7569. 
O'Dowd, B., Hnatowich, M., Regan, J., Leader, W., Caron, M., & Lefkowitz, R. 
(1988). Site directed mutagenesis of the cytoplasmic domains of the 
human beta 2 adrenergic receptor. Localisation of regions involved in G 
protein receptor coupling. J Biol Chem(263), 15986-15992. 
Olesen, C., Sorensen, T., Nielsen, R., Moller, J., & Nissen, P. (2004). 
Dephosphorylation of the calcium pump coupled to counterion occlusion. 
Science(306), 2251-2255. 
Ostrom, R., Post, S., & Insel, P. (2000). Stoichiometry and compartmentalisation 
in G protein coupled receptor signaling: implications for therapeutic 
interventions involving Gs. Perspectives in Pharmacol(294), 407-412. 
Ovchinnikov, Y., Abdulaev, N., & Bogachuk, A. (1988). Two adjacent cysteine 
residues in the C terminal cytoplasmic fragment of bovine rhodopsin are 
palmitylated . FEBS Letters(230), 1-5. 
Pai, R., & Hetherington, M. (2015, February 20). Beta-Blockers for Heart 
Failure. Retrieved April 14, 2017, from http://www.webmd.com/heart-
disease/heart-failure/beta-blockers-for-heart-failure 
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C., Motoshima, H., Fox, B., . . . 
Miyano, M. (2000). Crystal structure of rhodopsin: a G protein coupled 
receptor. Science(289), 739-945. 
Pandey, D., Chen, F., Patel, A., Patel, V., Rudic, D., Wang, C., . . . Fulton, D. 
(2011). SUMOylation of NADPH Oxidases Negatively Regulates Reactive 
Oxygen Species Production. The FASEB Journal(25), 1093-1094. 
Park-Sarge, O., & Sarge, K. (2005). Detection of Sumoylated Proteins. Methods 
Mol Biol, 329-338. 
Parmar, V., Grinde, E., Mazurkiewicz, J., & Herrick-Davis, K. (2016). Beta2-
adrenergic receptor homodimers: Role of transmembrane domain 1 and 
helix 8 in dimerization and cell surface expression. Biochimica et 
Biophysica Acta (BBA) - Biomembranes(12), 1-11. 
Pathak, A., del Monte, F., Zhao, W., Schultz, J., Lorenz, J., Bodi, I., . . . 
Kranias, E. (2005). Enhancement of Cardiac Function and Suppression of 
Heart Failure Progression By Inhibition of Protein Phosphatase 1. 
Circulation(96), 756-766. 
Pelaia, G., & Marsico, S. (1994). Regulation of beta 2-adrenergic receptors and 
the implications for bronchial asthma: an update. Monaldi Arch Chest 
Dis(49), 125-130. 
Perry, J., Tainer, J., & Boddy, M. (2008). A SIM-ultaneous role for SUMO and 
ubiquitin. Trends Biochem Sci(33), 201-208. 
Perry, S., Baillie, G., Kohout, T., McPhee, I., Magiera, M., Ang, K., . . . 
Lefkowitz, R. (2002). Targeting of cyclic AMP degradation to beta 2-
adrenergic receptors by beta-arrestins. Science(298), 834-836. 
289 
 
Perry, S., Baillie, G., Kohout, T., McPhee, I., Magiera, M., Ang, K., . . . 
Leflowitz, R. (2002). Targetting of cyclic AMP degradation to beta 2 
adrenergic receptors by beta-arrestins. Science(298), 834-836. 
Peske, B. (2004). Reverse remodeling in heart failure – fact or fiction? Eur Heart 
J Suppl(5), 66-78. 
Pichler, A., & Melchior, F. (2002). Ubiquitin-related modifier SUMO1 and 
nucleocytoplasmic transport. Traffic(3), 381-387. 
Pipping, S., Andexinger, S., & Lohse, M. (1995). Sequestration and recycling of 
beta 2-adrenergic receptors permit receptor resensitization. Molecular 
Pharmacology(47), 666-676. 
Qing, F., Rahman, S., Rhodes, C., Hayes, M., & Ind, P. H. (1997). β-adrenergic 
receptors in vivo and lung function in drug-free asthmatic subjects. Am J 
Respir Crit Care Med(155), A885. 
Rabe, K., Tenor, H., Dent, G., Schudt, C., Liebig, S., & Magnussen, H. (1993). 
Phosphodiesterase isoenzymes modulating inherent tone in human 
airways: identification and characterisation. Am J Physiol Lung Cell Mol 
Physiol(264), L458-L464. 
Rands, E., Candelore, M., Cheung, A., Hill, W., Strader, C., & Dixon, R. (1990). 
Mutational analysis of beta adrenergic receptor glycosylation. Journal of 
Biological Chemistry(265), 10759-10764. 
Rasmussen, S., Choi, H., Fung, J., Pardon, E., Casarosa, P., Chae, P., . . . 
Kobilka, B. (2011). Structure of a nanobody-stabilized active state of the 
β(2) adrenoceptor. Nature(469), 175-180. 
Rasmussen, S., Choi, H., Rosenbaum, D., Kobilka, T., Thian, F., Edwards, 
P., . . . Kobilka, B. (2007). Crystal structure of the human beta2 
adrenergic G-protein-coupled receptor. Nature(450), 383-387. 
Rasmussen, S., DeVree, B., Zou, Y., Kruse, A., Chung, K., Kobilka, T., . . . 
Kobilka, B. (2011). Crystal structure of the b2 adrenergic receptor–Gs 
protein complex. Nature(477), 1-9. 
Rasmussen, S., Devree, B., Zou, Y., Kruse, A., Chung, K., Kobilka, T., . . . 
Sunahara, R. e. (2011). Crystal structure of the β2 adrenergic receptor-Gs 
protein complex. Nature(477), 549-555. 
Raul, A., Baker, A., & Nicklin, S. (2012). Vector Systems for Prenatal Gene 
Therapy: Principles of Adenovirus Design and Production. In C. C. 
Waddington (Ed.), Methods in Molecular Biology (pp. 1-32). New York: 
Springer Science+Business Media. 
Reihause, E., Innis, M., MacIntyre, N., & Liggett, S. (1993). Mutations in the gene 
encoding for the beta 2 adrenergic receptor in normal and asthamtic 
subjects. Am J Respir Cell Mol Biol(8), 334-339. 
Renwick, J., Kerr, C., McTaggart, R., & Yeung, J. (1993). Cardiac 
electrophysiology and conduction pathway ablation. Can J Anaesth(40), 
1053-1064. 
290 
 
Reverter, D., & Lima, C. (2005). Insights into E3 ligase activity revealed by a 
SUMO-RanGAP1-Ubc9-Nup358 complex. Nature(435), 687-692. 
Ribet, D., Hamon, M., Gouin, E., Nahori, M., Impens, F., Neyret-Kahn, H., . . . 
Cossart, P. (2010). Listeria monocytogenes impairs SUMOylation for 
efficient infection . Nature(464), 1192-1195. 
Riobi, N., & Manning, D. (2005). Receptors coupled to heterotrimeric G proteins 
of the G12 family. Trends Pharm Sci(26), 146-154. 
Rissanen, T., & Yla-Herttuala, S. (2007). Current status of cardiovascular gene 
therapy. Mol Ther(15), 1233-1247. 
Rockland-Inc. (2017, February 20). Post-Translational Modification (PTM) 
Antibodies. Retrieved from www.rockland-inc.com: 
http://www.rockland-inc.com/post-translational-modification-
antibodies.aspx 
Rodriguez, M., Dargemont, C., & Hay, R. (2001). SUMO-1 conjugation in vivo 
requires both a consensus modification motif and nuclear targetting. J 
Biol Chem(276), 12654-12659. 
Roger, V. (2013). Epidemiology of heart failure. Circulation Research, 646-
659(113). 
Rogers, R., Horvath, C., & Matunis, M. (2003). SUMO modification of STAT1 and 
its role in PIAS-mediated inhibition of gene activation. Journal of 
Biological Chemistry(278), 30091-30097. 
Rosas, P., Liu, Y., Abdalla, M., Thomas, C., Kidwell, D., Dusio, G., . . . Tong, C. 
(2015). Phosphorylation of Cardiac Myosin-Binding Protein-C Is a Critical 
Mediator of Diastolic Function. Circulation Heart Failure(8), 582-594. 
Rosenbaum, D., Cherezov, V., Hanson, M., Rasmussen, S., Thian, F., Kobilka, 
T., . . . Kobilka, B. (2007). GPCR engineering yields high-resolution 
structural insights into beta2-adrenergic receptor function. Science(5854), 
1266-1273. 
Sachdev, S., Bruhn, L., Sieber, H., Pichler, A., Melchior, F., & Grosschedl, R. 
(2001). PIASy, a nuclear matrix–associated SUMO E3 ligase, represses LEF1 
activity by sequestration into nuclear bodies. Genes and 
Development(15), 3088-3103. 
Sachdev, S., Bruhn, L., Sieber, H., Pichler, A., Melchoir, F., & Grosschedl, R. 
(2001). PIASy, a nuclear matrix–associated SUMO E3 ligase, represses LEF1 
activity by sequestration into nuclear bodies. Genes Dev(15), 3088-3103. 
Sadeghi, H., & Birnbaumer, M. (1999). O-Glycosylation of the V2 vasopressin 
receptor. Glycobiology(9), 731-737. 
Saitoh, H., & Hinchey, J. (2000). Functional heterogeneity of small ubiquitin 
related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem(275), 
6252-6258. 
291 
 
Saitoh, H., & Hinchey, J. (2000). Functional heterogeneity of small ubiquitin 
related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem(275), 
6252-6258. 
Salahpour, A., Angers, S., Mercier, J., Lagace, M., Marullo, S., & Bouvier, M. 
(2004). Homodimerisation of the beta 2 adrenergic receptor as a 
prerequisite for cell surface targetting . J Biol Chem(279), 33390-33397. 
Sampson, D., Wang, M., & Matunis, M. (2001). The small ubiquitin like modifier 
(SUMO-1) consensus sequence mediates UBC9 binding and is essential for 
SUMO-1 modification. J Biol Chem(276), 21664-21669. 
Sarangi, P., & Zhao, X. (2015). SUMO-mediated regulation of DNA damage repair 
and responses. Trends Biochem Sci(40), 233-242. 
Savio-Gamilberti, E., Frank, J., Inoue, M., Goldhaber, J., Cannell, M. B., Bridge, 
J., & Sachse, F. (2008). Novel features of the rabbittransverse tubular 
system revealed by quantitative analysis of three-dimensional 
reconstructions from confocal images. Biophys J(95), 2053-2062. 
Scherer, W., Syverton, J., Gey, G., & Syverton, G. (1953). Studies on the 
propagation in vitro of poliomyelitis viruses IV. Viral multiplication in a 
stable strain of human malignant epithelial cells (strain HeLa) derived 
from an epidermoid carinoma of the cervix. J Exp Med(97), 695-710. 
Schmidt, U., Hajjar, R., Helm, P., Kim, C., Doye, A., & Gwathmey, J. (1998). 
Contribution of Abnormal Sarcoplasmic Reticulum ATPase Activity to 
Systolic and Diastolic Dysfunction in Human Heart Failure . Journal of 
Molecular and Cellular Cardiology(30), 1929-1937. 
Schrier, R. (1990). Body fluid volume regulation in health and disease: A unifying 
hypothesis. Ann Intern Med(113), 155-159. 
Schroder, F., Handrock, R., Beuckelmann, D., Hirt, S., Hullin, R., Priebe, L., . . . 
Herzig, S. (1998). Increased Availability and Open Probability of Single L-
Type Calcium Channels From Failing Compared With Nonfailing Human 
Ventricle. Circulation(98), 969-976. 
Schwinger, R., Bohm, M., Schmidt, U., Karczewski, P., Bavendiek, U., Flesch, 
M., . . . Erdmann, E. (1995). Unchanged protein levels of SERCA II and 
phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of 
cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients 
compared with patients with nonfailing hearts. Circulation(92), 3220-
3228. 
Seeler, J., & Dejean, A. (2003). Nuclear and unclear functions of SUMO. Nature 
Reviews Molecular Cell Biology(4), 690-699. 
Seeler, J., & Dejean, A. (2003). Nuclear and unclear functions of SUMO. Nature 
Reviews Molecular Cell Biology(4), 690-699. 
Seidah, N., & Prat, A. (2012). The biology and therapeutic targeting of the 
proprotein convertases. Nature Reviews Drug Discovery (11), 367-383. 
292 
 
Selektor, Y., & Weber, K. (2008). The salt-avid state of congestive heart failure 
revisited. Am J Med Sci(335), 209-218. 
Shannon, T., & Bers, D. (2004). Integrated Ca2+ management in cardiac 
myocytes. Ann N Y Acad Sci(1015), 28-38. 
Shen, L., Dong, C., Liu, H., Naismith, J., & Hay, R. (2006). The structure of 
SENP1-SUMO-2 complex suggests a structural basis for discrimination 
between SUMO paralogues during processing. Biochem J(397), 279-288. 
Shen, L., Geoffroy, M., Jaffray, E., & Hay, R. (2009). Characterisation of SENP7, 
a SUMO-2/4 specific isopeptidase. Biochem J(421), 223-230. 
Shenoy, S., Drake, M., Nelson, C., Houtz, D., Xiao, K., Madabushi, S., . . . 
Lefkowitz, R. (2006). β-Arrestin-dependent, G Protein-independent 
ERK1/2 Activation by the β2 Adrenergic Receptor. The Journal of 
Biological Chemistry, 1261-1273. 
Shenoy, S., McDonald, P., Kohout, T., & Lefkowitz, R. (2001). Regulation of 
receptor fate by ubiquitination of activated beta 2 adrenergic receptor 
and beta arrestin. Science(294), 1307-1313. 
Shenoy, S., Xiao, K., Venkataramanan, V., Snyder, P., Freedman, N., & 
Weissman, A. (2008). Nedd4 Mediates Agonist-dependent Ubiquitination, 
Lysosomal Targeting, and Degradation of the β2-Adrenergic Receptor. The 
Journal of Biological Chemistry(283), 22166-22176. 
Shuai, K., & Liu, B. (2005). Regulation of gene-activation pathways by PIAS 
proteins in the immune system. Nature Reviews Immunology(5), 593-605. 
SigmaAldrich. (2017). www.sigmaaldrich.com. Retrieved April 10, 2017, from 
http://www.sigmaaldrich.com/life-science/custom-oligos/custom-
peptides/learning-center/solid-phase-synthesis.html 
Silva, G., Finley, D., & Vogel, C. (2015). K63 polyubiquitination is a new 
modulator of the oxidative stress response. Nat Struc Mol Biol, 116-123. 
Simmerman, H., Collins, J., Theibert, J., Wegener, A., & Jones, L. (1986). 
Sequence analysis of phospholamban. Identification of phosphorylation 
sites and two major structural domains. J Biol Chem(261), 13333-13334. 
Simonis, G., Strasser, R., & Ebner, B. (2012). Reperfusion injury in acute 
myocardial infarction. Critical Care(16), A22-A27. 
Singh, M., & Anderson, M. (2011). Is CaMKII a link between inflammation and 
hypertrophy in heart? J Mol Med(89), 537-543. 
Sivaramakrishnan, S., & Spudich, J. (2011). Systematic control of protein 
interaction using a modular ER/K α-helix linker. Proc. Natl. Acad. Sci. 
U.S.A.(108), 20467–20472. 
Skychally, A., van Caster, P., Iliodromitis, E., Schulz, R., Kremastinos, D., & 
Heusch, G. (2009). Ischemic postconditioning: experimental models and 
protocol algorithms. Basic Res Cardiol(104), 469-483. 
293 
 
Smith, C. (2013, January 3). Stable vs. Transient Transfection of Eukaryotic 
Cells. Retrieved April 10, 2017, from www.biocompare.com: 
http://www.biocompare.com/Editorial-Articles/126324-Transfection/ 
Song, J., Zhang, Z., Hu, W., & Chen, Y. (2005). Small ubiquitin-like modifier 
(SUMO) recognition of a SUMO binding motif: a reversal of the bound 
orientation. J Biol Chem(280), 40122-40129. 
Stewart, S., MacIntyre, K., MacLeod, M., Bailey, A., Capewell, S., & McMurray, 
J. (2001). Trends in hospitalization for heart failure in Scotland, 1990-
1996 An epidemic that has reached its peak? European Journal of Heart 
Failure(22), 209-217. 
Strader, C., Candelore, M., Hill, W., Sigal, I., & Dixon, R. (1989). Identification 
of two serine residues involved in agonist activation of the β-adrenergic 
receptor. J Biol Chem(264), 13572-13578. 
Strader, C., Sigal, I., Candelore, M., Rands, E., Hill, W., & Dixon, R. (1988). 
Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor 
have different roles in receptor function. J Biol Chem(263), 10267-10271. 
Strosberg, A. (1993). Structure, function, and regulation. Protein Science, 1198-
1209. 
Strulovici, B., Cerione, R., Kilpatrick, B., Caron, M., & Lefkowitz, R. (1984). 
Direct demonstration of impaired functionality of a purified desensitized 
beta-adrenergic receptor in a reconstituted system. Science(225), 837-
840. 
Stubhan, M., Markert, M., Mayer, K., Trautmann, T., Klumpp, A., Henke, J., & 
Guth, B. (2008). Evaluation of cardiovascular and ECG parameters in the 
normal, freely moving Göttingen Minipig. Journal of Pharmacological and 
Toxicological Methods(57), 202-211. 
Subramaniam, S., Sixt, K., Barrow, R., & Snyder, S. (2009). Rhes, a striatal 
specific protein, mediates mutant-huntingtin cytotoxicity. Science(324), 
1327-1330. 
Takimoto, E., Champion, H., Li, M., Belardi, D., Ren, S., Rodriguez, E., . . . 
Kass, D. (2005). Chronic inhibition of cyclic GMP phosphodiesterase 5A 
prevents and reverses cardiac hypertrophy. Nat Med(11), 214-222. 
Tang, W., & Gilman, A. (1992). Adenylyl Cyclases. Cell(70), 869-872. 
Tang, Z., El Far, O., Betz, H., & Scheschonka, A. (2005). Pias1 interaction and 
sumoylation of metabotropic glutamate receptor 8. J Biol Chem(280), 
38153-38159. 
Tank, A., & Wong, D. (2015). Peripheral and central effects of circulating 
catecholamines. Comprehensive Physiology, 1-15. 
Tankou, S., Ishii, K., Elliott, C., Yalla, K., Day, J., Furukori, K., . . . Sawa, A. 
(2016). SUMOylation of DISC1: A Potential Role in Neural Progenitor 
Proliferation in the Developing Cortex. Molecular Neuropsychiatry(2), 20-
27. 
294 
 
Tatham, M., Jaffray, E., Vaughan, O., Desterro, J., Botting, C., Naismith, J., & 
Hay, R. (2001). Polymeric chains of SUMO-2 and SUMO-3 are conjugated to 
protein substrates by SAE1/SAE2 and UBC9. J. Biol. Chem(276), 35368-
35374. 
Tesmer, J., Sunahara, R., Gilman, A., & Sprang, S. (1997). Crystal structure of 
the catalytic domains of adenylyl cyclase in a complex with Gsalpha:GTP 
gammaS. Science(278), 1907-1916. 
Tesmer, J., Sunahara, R., Gilman, A., & Sprang, S. (1997). Crystal structure of 
the catalytic domains of adenylyl cyclases in a complex with Gs 
alpha:GTPgammaS. Science(278), 1907-1916. 
Thakar, K., Niedenthal, R., Okaz, E., Franken, S., Jakobs, A., Gupta, S., . . . 
Dietz, F. (2008). SUMOylation of the hepatoma-derived growth factor 
negatively influences its binding to chromatin. FEBS(7), 1411-1426. 
ThermofisherScientific. (2017, April 10). HA Tag Antibodies. Retrieved April 10, 
2017, from www.thermofisher.com: 
https://www.thermofisher.com/uk/en/home/life-
science/antibodies/primary-antibodies/epitope-tag-antibodies/ha-tag-
antibodies.html# 
Thorp, A., & Schlaich, M. (2015). Relevance of sympathetic nervous system 
activation in obesity and metabolic syndrome. Journal of Diabetic 
Research, 1155-1163. 
Thygesen, K., Alpert, J., & White, H. (2007). Universal Definition of Myocardial 
Infarction. Journal of the American College of Cardiology (22), 2173-
2195. 
Tilemann, L., Lee, A., Ishikawa, K., Aguero, J., Rapti, K., Santos-Gallego, 
C., . . . Hajjar, R. (2013). SUMO-1 Gene Transfer Improves Cardiac 
Function in a Large-Animal Model of Heart Failure. Sci Transl Med(211), 
211ra159. 
Tomko, R., Xu, R., & Philipson, L. (1997). HCAR and MCAR: the human and 
mouse cellular receptors for subgroup C adenoviruses and group B 
coxsackieviruses. PNAS(94), 3352-3356. 
Tong, C., Stelzer, J., Greaser, M., Powers, P., & Moss, R. (2008). Acceleration of 
crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin 
binding protein C modulates cardiac function. Circ Res(103), 974-982. 
Toyoshima, C., & Mizutani, T. (2004). Crystal structure of the calcium pump with 
a bound ATP analogue. Nature(430), 529-535. 
Toyoshima, C., Nakasako, M., Nomura, H., & Ogawa, H. (2000). Crystal structure 
of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. 
Nature(405), 647-655. 
Tran, T., Friedman, J., Qunaidi, E., Baameur, F., Moore, R., & Clark, R. (2004). 
Characterization of agonist stimulation of cAMP-dependent protein kinase 
and G protein-coupled receptor kinase phosphorylation of the β2-
295 
 
adrenergic receptor using phosphoserine-specific antibodies. Mol 
Pharmacol(65), 196-206. 
Trester-Zedlitz, M., Burlingame, A., Kobilka, B., & von Zastrow, M. (2005). Mass 
spectrometric analysis of agonist effects on posttranslational 
modifications of the β2-adrenoceptor in mammalian cells. 
Biochemistry(44), 6133-6143. 
Tsukamoto, Y., Mano, T., Sakata, Y., Ohtani, T., Takeda, Y., Tamaki, S., . . . 
Komuru, I. (2013). A novel heart failure mice model of hypertensive heart 
disease by angiotensin II infusion, nephrectomy, and salt loading. Am J 
Physiol Heart Circ Physiol(305), 1658-1667. 
Tuteja, N. (2009). Signaling through G protein coupled receptors. Plant Signal 
Behav(10), 942-947. 
Uberti, M., Hague, C., Oller, H., Minneman, K., & Hall, R. (2005). 
Heterodimerisation with beta 2 adrenergic receptors promotes surface 
expression and functional activity of alpha 1D adrenergic receptors. J 
Pharm Exp Ther(313), 16-23. 
Uhlen, M., & Ponten, F. (2005). Antibody-based Proteomics for Human Tissue 
Profiling. Molecular and Cellular Proteomics(4), 384-393. 
Ulrich, H. (2008). The fast growing business of SUMO chains. Molecular Cell(32), 
301-305. 
Varadaraj, A., Mattoscio, D., & Chiocca, S. (2014). SUMO Ubc9 enzyme as a viral 
target. IUBMB Life(66), 27-33. 
Vaughan, D., Millman, E., Godines, V., Friedman, J., Tran, T., Dai, W., . . . 
Moore, R. (2006). Rile of the G protein coupled receptor kinase site serine 
cluster in beta 2 adrenergic receptor internalisation, desensitisatio and 
beta arrestin translocation. J Biol Chem(281), 7684-7692. 
Vertegaal, A., Andersen, J., Ogg, S., Hay, R., Mann, M., & Lamond, A. (2006). 
Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins 
revealed by quantitative proteomics . Mol. Cell Proteomics (5), 2298-
2310. 
Violin, J., DiPilato, L., Yildirim, N., Elston, T., Zhang, J., & Lefkowitz, R. (2008). 
β2-Adrenergic Receptor Signaling and Desensitization Elucidated by 
Quantitative Modeling of Real Time cAMP Dynamics. The Journal of 
Biological Chemistry(283), 2949-2961. 
Violin, J., Ren, X., & Lefkowitz, R. (2006). G protein coupled receptor kinase 
specificity for beta arrestin recruitment to the beta 2 adrenergic receptor 
revealed by fluorescence resonance energy transfer . J Biol Chem(281), 
20577-20588. 
Wang, H., Tao, J., Shumay, E., & Malbon, C. (2006). G protein coupled receptor 
associated A kinase anchoring proteins: AKAP79 and AKAP250 (gravin). Eur 
J Cell Biol(85), 643-650. 
296 
 
Wang, J., & Schwartz, R. (2010). Sumoylation and regulation of cardiac gene 
expression. Circ Research(107), 19-29. 
Wang, P., Gao, H., Ni, Y., Wang, B., Wu, Y., Ji, L., . . . Pei, G. (2003). β-
Arrestin 2 Functions as a G-Protein-coupled Receptor-activated Regulator 
of Oncoprotein Mdm2. The Journal of Biological Chemistry(278), 6363-
6370. 
Wang, Y., & Dasso, M. (2009). SUMOylation and deSUMOylation at a glance. J. 
Cell. Sci(122), 4249-4252. 
Ward, R., Alvarez-Curto, E., & Milligan, G. (2011). Using the Flp-In™ T-Rex™ 
System to Regulate. In Receptor Signal Transduction Protocols: Third 
Edition (pp. 21-37). Springer. 
Ward, W., & Cormier, M. (1979). An energy transfer protein in coelenterate 
bioluminescence. Characterization of the Renilla green-fluorescent 
protein. The Journal of biological chemistry(254), 781-788. 
Warne, T., Serrano-Vega, M., Baker, J., Moukhametzianov, R., Edwards, P., 
Henderson, R., . . . Schertler, G. (2008). Structure of a β1-adrenergic G 
protein-coupled receptor. Nature(454), 486-491. 
Watari, K., Nakaya, M., & Kurose, H. (2014). Multiple functions of G protein-
coupled receptor kinases. J Mol Signal(9), 1-10. 
Wenger, N., & Greenbaum, L. (1984). From adrenoceptor mechanisms to clinical 
therapeutics: Raymond Ahlquist, Ph.D., 1914-1983. Journal of the 
American College of Cardiology, 419-421. 
Wettersten, N., & Maisel, A. (2015). Role of Cardiac Troponin Levels in Acute 
Heart Failure. CFR(2), 102-106. 
Wieland, K., Zuurmond, H., Krasel, C., Izjerman, A., & Lohse, M. (1996). 
Involvement of Asn-293 in stereospecific agonist recognition and in 
activation of the β2-adrenergic receptor. Proc Natl Acad Sci USA(93), 
9276-9281. 
Wilkinson, K., & Henley, J. (2011). Analysis of metabotropic glutamate receptor 
7 as a potential substrate for SUMOylation. Neuroscience letters(491), 
181-186. 
Wold, W., Tollefson, A., & Hermiston, T. (1993). E3 transcription unit of 
adenovirus. In P. Bohm, & W. Doerfler (Eds.), The Molecular Repertoire of 
Adenoviruses (pp. 237-278). Berlin: Springer-Verlag. 
Wright, P., & Dyson, J. (2015). Intrinsically Disordered Proteins in Cellular 
Signaling and Regulation. Nat Rev Mol Cell Biol(16), 18-29. 
www.hopkinsmedicine.org. (2017). http://www.hopkinsmedicine.org. Retrieved 
March 31, 2017, from 
http://www.hopkinsmedicine.org/healthlibrary/GetImage.aspx?ImageId=3
22243 
297 
 
Xiao, N., Li, H., Mei, W., & Cheng, J. (2015). SUMOylation Attenuates Human β-
Arrestin 2 Inhibition of IL-1R/TRAF6 Signaling. The Journal of Biological 
Chemistry(290), 1927-1935. 
Xiao, R. (2001). Beta-adrenergic signaling in the heart: dual coupling of the 
beta2-adrenergic receptor to G(s) and G(i) proteins. Sci STKE(104), 1-15. 
Xu, D., Guo, H., Xu, X., Lu, Z., Fassett, J., Hu, X., . . . Chen, Y. (2011). 
Exacerbated pulmonary arterial hypertension and right ventricular 
hypertrophy in animals with loss of function of extracellular superoxide 
dismutase. Hypertension(58), 303-309. 
Yang, S., Galanis, A., Witty, J., & Sharrocks, A. (2006). An extended consensus 
motif enhances the specificity of substrate modification by SUMO. EMBO 
J(25), 5083-5093. 
Yang, S., Jaffray, E., Hay, R., & Sharrocks, A. (2003). Dynamic interplay of the 
SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol 
Cell(12), 63-74. 
Yang, X., & Chiang, C. (2013). Sumoylation in gene regulation, human disease, 
and therapeutic action. F1000Prime Rep(5), 5-45. 
Yao, X., Parnot, C., Deupi, X., Ratnala, V., Swaminath, G., Farrens, D., & 
Kobilka, B. (2006). Coupling ligand structure to specific conformational 
switches in the β2-adrenoceptor. Nature Chemical Biology(2), 417-422. 
Yu, A., & Malek, T. (2000). The Proteasome Regulates Receptor-mediated 
Endocytosis of Interleukin-2. The Journal of Biological Chemistry, 381-
385. 
Yuan, N., Friedman, J., Whaley, B., & Clark, R. (1994). cAMPdependent protein 
kinase and protein kinase C consensus site mutations of the β-adrenergic 
receptor. Effect on desensitization and stimulation of adenylyl cyclase. J 
Biol Chem(269), 23032-23038. 
Yunus, A., & Lima, C. (2009). Structure of the Siz/PIAS SUMO E3 ligase Siz1 and 
determinants required for SUMO modification of PCNA. Molecular 
Cell(35), 669-682. 
Zaccolo, M., De Giorigi, F., Cho, C., Feng, L., Knapp, T., Negulescu, P., . . . 
Pozzan, T. (2000). A genetically encoded, fluorescent indicator for cyclic 
AMP in living cells. Nature Cell Biology(2), 25-29. 
Zakhary, D., Moravec, C., & Bond, M. (2000). Regulation of PKA binding to AKAPs 
in the heart: alterations in human heart failure. Circulation(12), 1459-
1464. 
Zhang, J., Barak, L., Winkler, K., Caron, M., & Ferguson, S. (1997). A Central 
Role for β-Arrestins and Clathrin-coated Vesicle-mediated Endocytosis in 
β2-Adrenergic Receptor Resensitization. The Journal of Biological 
Chemistry(272), 27005-27014. 
298 
 
Zhang, J., Liu, Y., Jiang, K., & Jia, J. (2017). SUMO regulates the activity of 
Smoothened and Costal-2 in Drosophila Hedgehog signaling. Scientific 
Reports (7), 4279-4285. 
Zhang, X., Goeres, J., Zhang, H., Yen, T., Porter, A., & Matunis, M. (2008). 
SUMO-2/3 modification and binding regulate the association of CENP-E 
with kinetochores and progression through mitosis. Mol. Cell. (29), 729-
741. 
Zheng, M., Zhu, W., Han, Q., & Xiao, R. (2005). Emerging concepts and 
therapeutic implications of beta-adrenergic receptor subtype signaling. 
Pharmacol Therapy, 257-268. 
Zhou, W., Ryan, J., & Zhou, H. (2004). Global analyses of SUMOylated proteins in 
saccharomyces cerevisiae. Induction of protein SUMOylation by cellular 
stresses. J Biol Chem(279), 32262-32268. 
Zhu, W., Wang, S., Chakir, K., Yang, D., Zhang, T., Brown, J., . . . Xiao, R. 
(2003). Linkage of beta1-adrenergic stimulation to apoptotic heart cell 
death through protein kinase A-independent activation of 
Ca2+/calmodulin kinase II. J Clin Invest, 617-625. 
Zhu, W., Zheng, M., Koch, W., Lefkowitz, R., Kobilka, B., & Xiao, R. (2001). Dual 
modulation of cell survival and cell death by beta(2)-adrenergic signaling 
in adult mouse cardiac myocytes. Proc Natl Acad Sci USA, 1607-1612. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
